TSCA HEALTH & SAFETY STUDY COVER SHEET - revised 6/25/96

TSCA CBI STATUS:

☐ CHECK IF THIS PAGE CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI)

Clearly mark the confidential information with bracketing and check the box in the appropriate section (☐ *Contains CBI*). Submit a sanitized cover sheet with CBI deleted. Mark the sanitized copy, "Public Display Copy" in the heading.

1.0 SUBMISSION TYPE ☐ *Contains CBI* Submission date: November 18, 1996

☐ 8(d) X 8(e) ☐ FYI ☐ 4 ☐ Other: specify

☐ Initial submission ☐ Follow-up submission X Final report submission

Previous EPA Submission or Title if Update or Follow-up: Docket Number, if any: #8EHQ-91-1157

DCN 8891000007

☐ continuation sheet attached

RECEIVED

2.1 SUMMARY/ABSTRACT ATTACHED	2.2 SUBMITTER TRACKING NUMBER OR INTERNAL ID	2.3 FOR EPA USE ONLY
X Yes ☐ No	8E-96-2	

3.0 CHEMICAL/TEST SUBSTANCE IDENTITY ☐ *Contains CBI*

Reported Chemical Name (specify nomenclature if other than CAS name):

CAS #: 117-81-7 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester

Purity: >99%

X Single Ingredient

☐ Commercial/Technical Grade

☐ Mixture

8EHQ-1196-13805 (A)

nmon Name: DEHP, "DOP"

Other chemical(s) present in tested mixture

% WEIGHT

8EHQ-96-13805

☐ continuation sheet atta

Contains No CBI

4.0 REPORT/STUDY TITLE

Oncogenicity Study in Rats with Di(2-ethylhexyl) Phthalate Including Anc[illegible] Hepatocellular Proliferation and Biochemical Analysis

☐ continuation sheet attached

5.1 STUDY/TSCATS INDEXING TERMS

[CHECK ONE]

HEALTH EFFECTS (HE): X ENVIRONMENTAL EFFECTS (EE): ENVIRONMENTAL FATE (EF):

5.2 STUDY/TSCATS INDEXING TERMS (see instructions for 4-digit codes)

STUDY TYPE: CARC	SUBJECT ORGANISM (HE, EE only): Rats	ROUTE OF EXPOSURE (HE only): Oral	VEHICLE OF EXPOSURE (HE only): Food
Other:	*Other:*	*Other:*	*Other:*

6.0 REPORT/STUDY INFORMATION ☐ *Contains CBI* *X Study is GLP*

Laboratory: Corning Hazelton Incorporated Report/Study Date: 9/27/96

9200 Leesburg Pike, Vienna, VA 22181

Source of Data/Study Sponsor (if different than submitter) Number of Pages: 3519

☐ continuation sheet attached

7.0 SUBMITTER INFORMATION ☐ *Contains CBI*

Submitter: Marc G. Schurger Title: Manager, Product Safety and Regulatory Programs Phone: (423) 229-5921

Company Name: Eastman Chemical Company Company Address: P. O. Box 1994, Kingsport TN 37664-5394

Submitter Address (if different):

Technical Contact: W. M. Dyer, Jr., M.D. Phone: (423) 229-3538

☐ continuation sheet attached

8.0 ADDITION *ns CBI*

See attached pag

X continuation sl

88970000055

96 NOV 22 AM 11:15

RECEIVED

Submitter Signature: [signature] Date:

Page 1 of 2

CSRAD: OPPT (SOC)

1-27-97

9.0 CONTINUATION SHEET

TSCA CBI STATUS:

☐ CHECK IF THIS PAGE CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI)

Clearly mark the confidential information with bracketing and check the box in the appropriate section (☐ *Contains CBI*). Submit a sanitized cover sheet with CBI deleted. Mark the sanitized copy, "Public Display Copy" in the heading.

Submitter Tracking Number/Internal ID

8E 96-2

Summary

This study was designed to evaluate the oncogenic potential of di(2-ethylhexyl) phthalate (DEHP) when administered to rats in the diet for at least 104 weeks and to provide information on the ability of DEHP to cause hepatocellular proliferation and peroxisomal proliferation.

DEHP was administered daily to F-344 rats in the diet for at least 104 weeks at dietary concentrations of 0, 100, 500, 2,500 and 12,500 ppm (Groups 1, 2, 3, 4, and 5, respectively). Rats in Group 6 were administered the 12,500 ppm DEHP diet admixture for 78 weeks, followed by a 26-week recovery period during which they were fed the basal diet alone. Parameters evaluated were mortality; clinical observations; body weight, food consumption, and compound consumption data; clinical pathology parameters, organ weight data; and necropsy and histopathology findings. Analyses were also conducted at weeks 1, 2, 13, 79, and study termination to evaluate chemically-induced cell proliferation and peroxisome proliferation in the livers of the appropriate dose groups.

The no-observable-effect-level (NOEL) and no-adverse-effect-level (NOAEL) for systemic effects and carcinogenic potential was 500 ppm (Group 3) in males and females. The dietary concentration of 500 ppm (Group 3) did not produce any treatment-related effects, including no significant changes in organ weights at weeks 1, 2, 13, and study termination; no treatment-related histopathological abnormalities; and no detectable indication of DEHP-induced liver peroxisome proliferation. The dietary concentration of 2,500 ppm (Group 4) induced gross and microscopic evidence of liver effects in males and females, with an increased incidence of liver neoplasms in males; evidence of kidney effects in males and females; and an increased incidence of monocellular leukemia in males. The dietary concentration of 12,500 ppm also induced gross and microscopic evidence of liver effects in males and females, including an increased incidence of liver neoplasms in each sex; evidence of kidney effects in each sex; an increased incidence of monocellular leukemia in males; evidence of testis effects; and an increased incidence of males exhibiting increased numbers of castration cells in the pituitary. In Group 6, administration of a dietary concentration of 12,500 ppm for 78 weeks, followed by a 26-week recovery period, indicated that effects of DEHP in the liver, including the induction of neoplasms, were reversible. However, DEHP effects in the kidney, testis, and pituitary were not reversible; and the incidence of monocellular leukemia in Group 6 males was not decreased compared to Group 5 males.

RECEIVED
96 NOV 22 AM 11:16

CORNING Hazleton

Sponsor:

Eastman Chemical Company
First American Center
P.O. Box 1994
Kingsport, Tennessee 37662-5394

FINAL REPORT

Study Title:

Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including Ancillary Hepatocellular Proliferation and Biochemical Analyses

Author:

Michael R. Moore, Ph.D., D.A.B.T.

Study Completion Date:

September 27, 1996

Performing Laboratory:

Corning Hazleton Incorporated (CHV)
9200 Leesburg Pike
Vienna, Virginia 22182-1699

Laboratory Study Identification:

CHV 663-134

Sponsor's Project Identification:

HAEL No. 90-0079;KAN 904099

Volume 1 of 7

THIS PAGE LEFT BLANK

COMPLIANCE STATEMENT
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including Ancillary Hepatocellular Proliferation and Biochemical Analyses

This study, as performed by Corning Hazleton, was conducted in compliance with the Good Laboratory Practice Standards as set forth in Title 40 of the U.S. Code of Federal Regulations Part 792, issued November 29, 1983 (effective December 29, 1983), and with any applicable amendments. Deviations from the protocol are listed in Appendix 12. There were no deviations from the aforementioned regulations which affected the quality or integrity of the study or the interpretation of the results in the report.

Study Director:

Michael R. Moore — September 27, 1996

Michael R. Moore, Ph.D., D.A.B.T.
Department of Toxicology

Date

CLIENT GLP COMPLIANCE STATEMENT
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including Ancillary Hepatocellular Proliferation and Biochemical Analyses

An independent auditor was retained by the Sponsor to perform periodic reviews during this study to help assure that it was conducted in accordance with Good Laboratory Practice Standards. Reports of these audits are on file with the Sponsor.

Sponsor's Representative:

W. Mills Dyer Jr., M.D. — October 11, 1996

W. Mills Dyer, Jr., M.D. — Date
Eastman Chemical Company

THIS PAGE LEFT BLANK

QUALITY ASSURANCE STATEMENT
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including Ancillary Hepatocellular Proliferation and Biochemical Analyses

Quality Assurance inspections and reviews of this study were conducted according to the standard operating procedures of the Quality Assurance Unit and according to the Good Laboratory Practice regulations of the Environmental Protection Agency (EPA - TSCA), Title 40 of the U.S. Code of Federal Regulations Part 792, issued November 29, 1983 (effective December 29, 1983) and with any applicable amendments. These inspections and reviews were performed and findings were reported to the Study Director and management as follows:

Dates of Inspection/Review	Dates Findings Reported	Inspector/Reviewer
Protocol Review:		
6/2/92	6/2/92	K. Butler
Inspection and/or Data Review:		
6/10/92	6/10/92	D. Wallace
6/11; 7/6,7,13,28/92	8/4/92	P. Tillotson
9/9,11-15,30; 10/8/92	10/23/92	S. Ballenger
12/3,16,18,21-23/92	1/11/93	P. Lacy/B. Mullett
3/10,11,12,16/93	4/1/93	K. Butler/L. Cassell
6/2,4,15/93	6/15/93	B. Wingard
6/14-16/93	6/16/93	S. Ballenger
9/24,27,28,29,30/93	10/1/93	D. Wilson/L. Cassell
12/7,8,10,13,14/93	12/14/93	L. Cassell
3/1,3,4,15-17/94	3/21/94	L. Cassell
6/7,24,27,29/94	6/30/94	L. Cassell
Report and Data Review:		
8/7,9,11,12,15,18-22/95	8/23/95	B.Wingard/S.Weymouth/L.Cassell S.Ballenger/M.Grissinger/D.Bland
8/23/95	8/23/95	S. Ballenger
9/24,25,26,27/96	9/27/96	B. Wingard/S. Weymouth

Blair Wingard 9/27/96
Blair Wingard Date Released
Quality Assurance Unit

STUDY IDENTIFICATION
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including Ancillary Hepatocellular Proliferation and Biochemical Analyses

CHV Study No.:	663-134
Test Material:	Di(2-ethylhexyl)phthalate[a]
Sponsor's Representative:	W. Mills Dyer, Jr., M.D. Eastman Chemical Company Product Safety & Environmental Affairs P.O. Box 1994 Eastman Road Kingsport, Tennessee 37662-5394
Sponsor's Study Monitor:	Raymond M. David, Ph.D., D.A.B.T. Corporate Health and Environment Laboratories Eastman Kodak Company Building 320, Kodak Park 1100 Ridgeway Avenue Rochester, New York 14652-6272
Study Directors:	James L. Ivett, Ph.D. Gary W. Wolfe, Ph.D., D.A.B.T. (effective June 15, 1992) Michael R. Moore, Ph.D., D.A.B.T. (effective February 12, 1993) Corning Hazleton Incorporated (CHV)[b] 9200 Leesburg Pike Vienna, Virginia 22182-1699 (703) 893-5400

[a] May also be referred to in this report as DEHP.
[b] As of April 1, 1995, the company name, Hazleton Washington, Inc., was legally changed to Corning Hazleton Incorporated. Modifications are currently underway to reflect the company name change. Both designations for the company (HWA and CHV) may be used in this report.

STUDY TIMETABLE

Study Timetable

Study Initiation:	March 25, 1992
Initiation of Dosing:	June 11, 1992 (Males)
	June 12, 1992 (Females)
First Interim Necropsy:	June 14/15, 1992
Second Interim Necropsy:	June 24/25, 1992
Third Interim Necropsy:	September 9, 1992
Fourth Interim Necropsy:	December 10/11, 1993
Terminal Necropsy:	June 9/10 and June 13-17, and 20, 1994

STUDY PERSONNEL
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including Ancillary Hepatocellular Proliferation and Biochemical Analyses

Study Directors:	James L. Ivett, Ph.D. Gary W. Wolfe, Ph.D., D.A.B.T. (effective June 15, 1992) Michael R. Moore, Ph.D., D.A.B.T. (effective February 12, 1993)
Associate Toxicologist:	Marcia Rodwin, B.A.
Study Coordinator:	Denise Doyle, LATg
Veterinarian:	Mark D. Walker, D.V.M.
Clinical Pathologist:	Renée C. Pearson, M.S., D.V.M., Diplomate, American College of Veterinary Pathologists
Pathologist:	Richard W. Voelker, D.V.M., Ph.D., Diplomate, American College of Veterinary Pathologists
Biostatistician:	Ajit K. Thakur, Ph.D.
Analytical Chemistry Supervisor:	Peggy L. Boehm, B.S.
Formulations Supervisor:	Danny L. Thomas, B.S., LAT
Laboratory Supervisor:	Howard D. Thornett, B.S., LATg
Laboratory Group Leader:	Charles F. Hatcher, B.S., LAT
Laboratory Head Technician:	Valerie G. Hardee, B.S., LAT Monica M. Vegarra, B.S.

CONTENTS

Page

SUMMARY 13

INTRODUCTION 18

TEST, POSITIVE CONTROL, AND VEHICLE/CONTROL MATERIALS 18

TEST ANIMALS AND HUSBANDRY 19

METHODS 20
Group Assignment and Dosage Levels 20
Compound Formulation and Administration 22
Analysis of Prepared Formulations 23
Observations and Records 24
Clinical Pathology 25
Terminal Studies 26
Postmortem Procedures - Hepatocellular Proliferation/Biochemical Analyses 29
Statistical Analyses 29
Record Retention 30

RESULTS 32
Ancillary Studies 32
Analytical Chemistry 33
In-life Observations 34
Clinical Pathology 40
Terminal Studies 42

DISCUSSION AND CONCLUSION 46

CLINICAL PATHOLOGY REPORT 56

PATHOLOGY REPORT 61

ANCILLARY STUDIES REPORT 71

FIGURES
1 - Flowchart of ANOVA and Related Methods 31
2 - Adjusted Percent Survival 35
3 - Mean Body Weights 37
4 - Mean Food Consumption 38
5 - Mean Compound Consumption 39

CONTENTS - CONTINUED

Page

TABLES
1 - Analytical Chemistry Results 90
2 - Animal Survival/Adjusted Survival Table 95
3 - Summary Incidence of Clinical Observations 114
4A - Body Weight Means and Standard Deviations 128
4B - Body Weight Change Means and Standard Deviations 140
5A - Food Consumption Means and Standard Deviations 142
5B - Mean Total Food Consumption and Standard Deviations 154
6 - Compound Consumption Means and Standard Deviations 156
7A - Summary of Clinical Hematology Data 167
7B - Summary of Clinical Chemistry Data 186
8A - Gross Pathology Incidence Summary - Unscheduled Deaths . . . 205
8B - Gross Pathology Incidence Summary - Interim Sacrifice - Week 79 230
8C - Gross Pathology Incidence Summary - Terminal Sacrifice . . . 248
9A - Complete Organ Weight Data - Liver Weights (Absolute and Relative-to-Body) Interim Sacrifices - Weeks 1, 2, and 13 . 273
9B - Complete Organ Weight Data - Interim Sacrifice - Week 79 . . 281
9C - Complete Organ Weight Data - Terminal Sacrifice 290
10A - Histopathology Incidence Summary - Unscheduled Deaths . . . 306
10B - Histopathology Incidence Summary - Interim Sacrifices - Weeks 1, 2, 13, and 79 339
10C - Histopathology Incidence Summary - Terminal Sacrifice . . . 354
10D - Expanded Histopathology Incidence Summary - Liver, Kidney, and Pituitary 372
10E - Histopathology Incidence Summary - All Deaths 388

APPENDICES
1 - Analytical Chemistry Method 412
2 - Individual Animal Disposition 422
3 - Individual Clinical Observations 447
4 - Individual Body Weights 701
5 - Individual Food Consumption 798
6 - Individual Compound Consumption 893
7A - Individual Clinical Hematology Data 982
7B - Individual Clinical Chemistry Data 1072
7C - Individual Clinical Urinalysis Data 1128
8 - Clinical Pathology and Statistical Analyses References . . . 1173

CONTENTS - CONTINUED

Page

APPENDICES - CONTINUED
9A - Individual Animal Summary Report - Unscheduled Deaths . . . 1182
9B - Individual Animal Summary Report - Interim Sacrifices - Weeks 1, 2, 13, and 79 1679
9C - Individual Animal Summary Report - Terminal Sacrifice - Males 2212
9C - Individual Animal Summary Report - Terminal Sacrifice - Females 2820
10 - Hepatocellular and Biochemical Analyses Data 3411
11 - Study Protocol and Amendments 3435
12 - Protocol Deviations 3517

SUMMARY

Di(2-ethylhexyl)phthalate (DEHP) was administered daily to F-344 rats in the diet for at least 104 weeks at dietary concentrations of 0, 100, 500, 2,500, and 12,500 ppm (Groups 1, 2, 3, 4, and 5, respectively). Rats in Group 6 were administered the 12,500 ppm DEHP diet admixture for 78 weeks, followed by a 26-week recovery period during which they were fed the basal diet alone. Parameters evaluated were mortality; clinical observations; body weight, food consumption, and compound consumption data; clinical pathology parameters; organ weight data; and necropsy and histopathology findings. Analyses were also conducted at Weeks 1, 2, 13, 79, and study termination to evaluate chemically-induced cell proliferation and peroxisome proliferation in the livers of the appropriate dose groups.

For Groups 2, 3, 4, and 5, the average daily consumed dose (based on target dietary concentrations) during Weeks 1 through 104 was 5.8, 28.9, 146.6, and 789.0 mg/kg/day, respectively, in the males; and 7.3, 36.1, 181.7, and 938.5 mg/kg/day, respectively, in the females. For Group 6, the average daily consumed dose (based on target dietary concentrations) during Weeks 1 through 78 was 679.3 and 808.2 mg/kg/day in males and females, respectively. Therefore, in each of the DEHP dose groups, the average daily dose (mg/kg/day) consumed by females was higher (range of 19 to 26%) than males administered the same dietary concentration of DEHP.

At the 100 ppm (Group 2) and 500 ppm (Group 3) dietary concentrations, there were no treatment-related effects, including no significant changes in organ weights at Weeks 1, 2, 13, and study termination; no treatment-related histopathological abnormalities; and no detectable indication of DEHP-induced liver peroxisome proliferation.

In the 2,500 ppm group (Group 4), survival at Week 104 in males and females was 70 and 76%, respectively, compared to 82 and 80% in the

control males and females, respectively. Males exhibited an increased incidence of clinical abnormalities reflecting a sustained depression of body weight gain and/or ante-mortem condition. Mean total body weight gain (Weeks 1 to 105) was 4% lower in the males compared to the control males. Mean serum albumin concentration was increased (significantly at most of the measurement intervals) in males and females at Weeks 26, 52, 78, and 104. Significantly increased mean liver weights (absolute and/or relative) occurred in both sexes at Weeks 1, 2, 13, 79, and study termination; with DEHP induction of liver peroxisome proliferation evident in both sexes at Week 104. Livers from Group 4 rats were remarkably free of treatment-related histologic findings, with the exception of an increased incidence of hepatocellular adenomas in the males. In rats killed at study termination, hepatocellular adenomas were detected in 16% and 2% of the Group 4 males and females, respectively, compared to 9% and 0% of the control males and females, respectively. At Week 79 and at study termination, kidney weights (absolute and relative) were increased in males and females of Group 4; but in the absence of treatment-related morphologic lesions. For all deaths, the total incidence of monocellular leukemia (a known spontaneous neoplasm in F-344 rats) was increased to 49% (32/65) in the Group 4 males compared to 23% in the control males (15/65).

In the 12,500 ppm group (Group 5), survival at Week 104 in males and females was 73 and 70%, respectively, compared to 82 and 80% in the control males and females, respectively. Males and females exhibited an increased incidence of clinical abnormalities reflecting a sustained depression of body weight gain and/or ante-mortem condition. Mean total body weight gain (Weeks 1 to 105) was 15% lower in the males, as well as the females, compared to the same sex controls. Associated with the depression of body weight gain, erythrocyte mass (erythrocyte count, hemoglobin, and hematocrit) was decreased in both sexes compared to the controls. Serum urea nitrogen was elevated in both sexes at Week 78 and at study termination. Mean serum albumin concentration was increased

(significantly at most of the measurement intervals) in males and females at Weeks 26, 52, 78, and 104. Significantly increased mean liver weights (absolute and relative) occurred in both sexes at Weeks 1, 2, 13, 79, and study termination; with DEHP induction of liver peroxisome proliferation evident in both sexes at Weeks 1, 2, 13, and 104. Histological findings in the liver of Group 5 (12,500 ppm) males and females were diffuse hepatocellular enlargement (first detected at Week 2); increased cytoplasmic eosinophilia (first detected at Week 2); increased pigment in Kupffer cells/hepatocytes (first detected at Week 79), and increased incidence of neoplasms (adenomas and carcinomas - first detected at Week 79). In rats killed at study termination, hepatocellular adenomas were detected in 45% and 8% of the Group 5 males and females, respectively, compared to 9% and 0% of the control males and females, respectively; and hepatocellular carcinomas were detected in 43% and 28% of the Group 5 males and females, respectively, compared to 2% and 0% of the control males and females, respectively. At Week 79 and at study termination, kidney weights (absolute and relative) were increased in males and females of Group 5; with an increase in the incidence and severity of mineralization of the renal papilla in males (but not females), an increased in incidence and/or severity of tubule cell pigment in both sexes; and increased severity of chronic progressive nephropathy in the males. Absolute and relative testis weights were significantly decreased, with associated increased incidence of bilateral aspermatogenesis, and decreased incidence of interstitial cell neoplasms. Increased castration cells in the pituitary was observed in 30/60 Group 5 males compared to 1/60 of the control males. For all deaths, the incidence of monocellular leukemia (a spontaneous neoplasm) was increased to 42% (27/65) in the Group 5 males compared to 23% (15/65) in the control males.

In Group 6 (12,500 ppm for 78 weeks, followed by a 26-week recovery period), there was evidence that some treatment-related findings

were reversible or did not progress after cessation of DEHP exposure. Compared to Group 5, depression of mean total body weight gain was less severe. Although there was no definitive evidence of improvement in erythrocyte mass, the Week 104 mean values for serum urea nitrogen in the Group 6 males and females approximated the mean values of the controls. Also at Week 104, mean values for serum albumin concentration in the Group 6 males and females approximated the mean values of the controls. Treatment-related liver enlargement appeared to be reversible; mean liver weights (absolute and relative) at study termination in the recovery group remained increased compared to control mean values, although the increase was less severe compared to Group 5. At the end of the 26-week recovery period, liver peroxisome proliferation activity in the Group 6 males and females, was comparable to the control group. In rats killed at study termination, treatment-related histological effects in the liver also appeared to be reversible in that diffuse hepatocellular enlargement and increased cytoplasmic eosinophilia were not evident in Group 6 animals, and the incidence of pigment in Kupffer cell/hepatocytes was decreased compared to Group 5. Most notable in livers of the recovery animals (Group 6) was a decreased incidence in liver neoplasms compared to Group 5. In rats killed at study termination, hepatocellular adenomas were detected in 25% and 13% of the Group 6 males and females, respectively, compared to 45% and 8% of the Group 5 males and females, respectively; and hepatocellular carcinomas were detected in 18% and 8% of the Group 6 males and females, respectively, compared to 43% and 28% of the Group 5 males and females, respectively. In contrast to the liver, there was no indication in rats killed at study termination that DEHP-related changes in the kidney, testis, and pituitary were reversible upon cessation of DEHP exposure. For all deaths, there was also no indication of reversibility in monocellular leukemia in males, with the incidence of 47% (29/55) being comparable to the incidence of 42% (37/65) observed in Group 5 males.

In conclusion, the no-observable-effect-level (NOEL) and no-adverse-effect-level (NOAEL) for systemic effects and carcinogenic potential was 500 ppm (Group 3) in males and females. The dietary concentration of 500 ppm (Group 3) did not produce any treatment-related effects, including no significant changes in organ weights at Weeks 1, 2, 13, and study termination; no treatment-related histopathological abnormalities; and no detectable indication of DEHP-induced liver peroxisome proliferation. The dietary concentration of 2,500 ppm (Group 4 induced gross and microscopic evidence of liver effects in males and females, with an increased incidence of liver neoplasms in males; evidence of kidney effects in males and females; and an increased incidence of monocellular leukemia in males. The dietary concentration of 12,500 ppm also induced gross and microscopic evidence of liver effects in males and females, including an increased incidence of liver neoplasms in each sex; evidence of kidney effects in each sex; an increased incidence of monocellular leukemia in males; evidence of testis effects; and an increased incidence of males exhibiting increased numbers of castration cells in the pituitary. In Group 6, administration of a dietary concentration of 12,500 ppm for 78 weeks, followed by a 26-week recovery period indicated that effects of DEHP in the liver, including the induction of neoplasms, were reversible. However, DEHP effects in the kidney, testis, and pituitary were not reversible; and the incidence of monocellular leukemia in Group 6 males was not decreased compared to Group 5 males.

INTRODUCTION

This study was designed to evaluate the oncogenic potential of Di(2-ethylhexyl)phthalate when administered to rats in the diet for at least 104 weeks and to provide information on the ability of Di(2-ethylhexyl)phthalate to cause hepatocellular proliferation and peroxisomal proliferation. Dosing began on June 11 (males) and June 12 (females), 1992, and interim sacrifices occurred on June 14/15, June 24/25, and September 9/10, 1992, and December 10/11, 1993. Terminal sacrifices were performed on June 9/10 and 13-17, and 20, 1994.

The protocol was designed in accordance with the applicable guidelines of the U.S. Environmental Protection Agency (Toxic Substances Control Act, 40 CFR Part 798.3300) and was conducted in accordance with the U.S. Environmental Protection Agency Good Laboratory Practice Standards (Toxic Substances Control Act, 40 CFR Part 792).

The protocol, in-life phase, and the final report was audited by the Quality Assurance Unit in accordance with CHV's Standard Operating Procedures.

The protocol was reviewed and approved by the Institutional Animal Care and Use Committee at CHV and is presented in Appendix 11. Deviations from the protocol are presented in Appendix 12.

TEST, POSITIVE CONTROL, AND VEHICLE/CONTROL MATERIALS

The test material, Di(2-ethylhexyl)phthalate (DEHP), lot No. 103, was received from the Sponsor on April 16, 1990 (used from prestudy analyses through Week 2), and June 17, 1992 (used Weeks 3-105). Both shipments were described as a clear liquid with a protocol-designated purity of 99% (assumed 100% for the purpose of dosage calculations) and were stored at room temperature. Methods of synthesis and stability,

composition, or other characteristics which define the test material are on file with the Sponsor.

The positive control material, WY 14,643; 4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio acetic acid (lot No. CSL-91-315-72-7), was received from ChemSyn Science Laboratories, Lenexa, Kansas, on May 5 (used for Week 1) and June 15 (used for Weeks 2-13), 1992, stored at room temperature, and handled as a suspected carcinogen. It was described as white powder with a reported purity of ≥98% and assumed 100% pure for formulation purposes.

Information on the methods of synthesis and stability, as well as data on composition or other characteristics which define the positive control, are on file with the manufacturer, ChemSyn Science Laboratories, Lenexa, Kansas.

Purina® Certified Rodent Chow® #5002 was used as the vehicle for administration of the test and positive control materials and as the control article.

Reserve samples (approximately 1 g) from each shipment of the test material and positive control material were taken prior to initiation of use and stored at room temperature. At the request of the Study Monitor, two additional 5-g samples of DEHP were taken during Weeks 10 and 85 and immediately sent to the Study Monitor.

TEST ANIMALS AND HUSBANDRY

A total of 1066 (541 male/525 female) approximately 4-week-old CDF®(F-344)CrlBR rats was received on May 26, 1992, from Charles River Laboratories, Inc., Raleigh, North Carolina. Upon arrival at the animal facility, the animals were housed apart from all other animals in the testing facility. Animals were assigned temporary numbers, acclimated to laboratory conditions for at least 2 weeks, and released for possible study use by a staff veterinarian.

Caging Conditions - Upon receipt, animals of the same sex were housed two/cage in suspended stainless-steel, wire-mesh cages (24.2 x 22.0 x 17.3 cm d x w x h). Cage racks were rotated at least every 2 weeks.

Feed and Water - Purina® Certified Rodent Chow® #5002 and tap water, via an automatic watering system, were available ad libitum during the acclimation and study periods, unless otherwise noted. The feed was analyzed by the manufacturer for concentrations of specified heavy metals and nutrients, aflatoxin, chlorinated hydrocarbons, and organophosphates; contaminants analyzed are presented in Attachment No. 1 of Appendix 11. Water samples are periodically analyzed for contaminants and specified microorganisms. Results of the feed and water analyses are periodically reviewed for compliance to specified limits and are on file at CHV.

No contaminants were reasonably expected to be present in the animal feed and water at levels sufficient to interfere with this study.

Environmental Conditions - Every attempt was made to maintain temperatures at 72 ± 6°F with a relative humidity of 50 ± 20%. A 12-hour light/12-hour dark cycle and 10 or greater air changes/hour was maintained in the room housing the animals.

Justification of Species - The rat was selected for use on this study because rats historically have been used in safety evaluation studies and are recommended by the appropriate regulatory agencies. The strain of rat was selected because of its unique sensitivity based on previous studies with this test substance.

METHODS

Group Assignment and Dosage Levels

Animals were initially accepted into the randomization pool based upon physical examinations and were randomized at least 1 week prior to initiation of dosing. A total of 915 animals (465 males and 450 females) were assigned to study using a computerized weight-randomization program,

which first eliminated the animals with extreme body weights, then selected the random assignment that produced homogeneity of variance and means by Bartlett's Test (1937) and One-Way Analysis of Variance (ANOVA). At randomization, the weight variation of the animals selected did not exceed ±2 standard deviations of the mean body weight for each sex, and the mean body weight for each group of each sex was not statistically different. Animals were assigned to groups as follows:

Group No.	Group	Dietary Levels ppm	Week of Sacrifice 1 M/F[a]	2 M/F[a]	13 M/F[a]	78 M/F[b]	104-106 M/F[a,b]	Total Number of Rats M/F
1	Control	0	5/5	5/5	5/5	15/15	55/55	85/85
2	Low	100	5/5	5/5	5/5	0	55/55	70/70
3	Mid-Low	500	5/5	5/5	5/5	0	55/55	70/70
4	Mid-High	2,500	5/5	5/5	5/5	15/15	55/55	85/85
5	High	12,500	5/5	5/5	5/5	15/15	55/55	85/85
6	Recovery-High[c]	12,500 (Weeks 1-78)	0	0	0	0	55/55	55/55
7	Positive Control	1,000	5/0	5/0	5/0	0	0	15/0

[a] Hepatocellular proliferation rates and biochemical analyses were measured during Weeks 1, 2, and 13 (for Groups 1, 5, and 7) and during Week 105 (on protocol-specified tissues of 5 animals/sex/group from Groups 1, 3, 4, 5, and 6). Only hepatocellular proliferation analysis was conducted on samples from Group 7.

[b] Five animals/sex/group were implanted with osmotic minipumps, sacrificed, and the tissues were collected and appropriately processed (hepatocellular prepared to the block stage) for possible hepatocellular proliferation and biochemical analyses (Groups 1, 3, 4, 5, and 6 were analyzed at Week 105). The remaining animals within each group were sacrificed for histomorphological evaluation.

[c] Animals assigned to Group 6 were removed from the test diet after 78 weeks of treatment and were placed on basal diet for the remainder of the study.

During the randomization process, each study animal was assigned a unique number and individually housed in a cage affixed with the animal's identification number. A tail tattoo of the last three digits was used to permanently identify each animal.

At initiation of dosing, the animals were approximately 6 weeks of age with body weights ranging from 101 to 140 g for the males and 83 to 112 g for the females.

Compound Formulation and Administration

Di(2-ethylhexyl)phthalate (DEHP) was assumed to be a 100% active compound for the purpose of dosage calculations. Purina® Certified Rodent Chow® #5002 was used as the vehicle for test and positive control material administration and as the control article.

For each dietary level, the test material was weighed on an appropriate balance (mg or kg). The weighed test material was added to a pocket of feed in an appropriate-sized glass beaker; the beaker contents then added to approximately 200 g of feed; and the test material/feed was then mixed in a Waring blender for approximately 2 minutes to ensure an apparent homogeneous mixture. Based on dietary level, multiple premixes were required. The premixes were added to approximately 5 kg of additional feed, mixed in a Hobart mixer for 15 minutes, then transferred to a Patterson-Kelley twin-shell mixer (fitted with an intensifier bar) that contained the remaining required amount of basal feed. The diets were mixed for 1 minute/kg. Fresh diets were prepared once each week and were stored in glass containers fitted with Teflon lids. No plastic came in contact with the test material. The formulated and basal diets were stored refrigerated (2-8°C) until presentation to the animals.

The positive control material, WY 14643, was assumed to be 100% active for the purpose of dosage calculations. The material was weighed on an appropriate balance (mg or kg), added to approximately 200 g of feed; and premixed in a Waring blender for approximately 2 minutes to ensure an apparent homogeneous mixture. The premix was added to required amount of additional feed, and mixed in a Hobart mixer for 1 minute/kg or a minimum of 5 minutes. As a suspected carcinogen, the positive control material was handled with care; it was maintained by the formulations department in their refrigerator and sent to the animal area preloaded in individual feeders.

Diets containing DEHP and WY 14643 were mixed weekly during the study. The DEHP was administered in the diet, 7 days per week for at

least 78 weeks for the Group 6 animals and up to 106 weeks for surviving animals in Groups 2-5. The Group 6 animals received the basal diet (Purina® Certified Rodent Chow® #5002) only after Week 78. The positive control males (Group 7) received WY 14,643 in the diet, 7 days per week for up to 13 weeks. The control animals were fed Purina® Certified Rodent Chow® #5002 in the same manner as the test animals for up to 106 weeks. All animals received the appropriate diet until the day prior to necropsy. Fresh diet was presented to the animals weekly (through Week 105).

One set of formulated samples from the pretest mix and Weeks 1, 13, 26, 52, 78, and 104 were sent to CHV's analytical chemistry department for analysis. Reserve samples (approximately 50 g) of the weekly mix for each dietary level were taken in duplicate, placed into glass containers with Teflon lids, and stored frozen, except for those protocol-specified weeks when one of the duplicate sets was analyzed for concentration verification. All reserve samples will be retained at CHV until issuance of the final report.

The dietary route was chosen because oral exposure is the customary procedure for evaluating the oncogenicity of plasticizers.

Analysis of Prepared Formulations

Homogeneity - The homogeneity of the test material in the dietary mixture was determined prior to the initiation of treatment (Groups 2, 5, and 6) and during Week 14 for Groups 2 and 5 and Week 80 for Groups 4 and 5. Analyses of homogeneity were conducted on duplicate samples obtained from the top, middle, and bottom of the test diets.

Stability - Duplicate samples from the low- and high-dose formulations of the test material (100 and 12,500 ppm, respectively) were analyzed to assess 0-, 7-, and 14-day stability at room temperature. (Due to staggered mix days, analyses for stability were actually performed 0, 8, and 15 days at room temperature for Group 2.)

Routine Concentration - The concentration of the test article at each dietary level was determined from the samples obtained during the pretest mix and from diet formulations for Weeks 1, 13, 26, 52, 78, and 104.

Analytical Method - The analytical method used to assay the level of test article in the diet involved extraction of the test article from the feed mixture and analysis using reverse-phase, high-performance liquid chromatography. The method, Method No. 391 (R2), is fully outlined in Appendix 1.

Observations and Records

Mortality and Clinical Observations - The rats were observed for mortality and moribundity twice daily. A thorough physical examination was conducted at each weighing interval. A careful cageside observation for obvious indications of toxic effects was performed once daily.

Physical Examinations - Detailed clinical observations were performed once each week. Special attention was paid to the development of tissue masses. The following information on each grossly visible or palpable mass was recorded:

time of onset
location
size
appearance
progression

Body Weight and Food Consumption - Body weights were recorded at randomization, prior to treatment, weekly for Weeks 1-17, and once every 4 weeks thereafter. Food consumption was measured and recorded weekly for Weeks 1-16 and once every 4 weeks thereafter. When obvious spillage or wastage of food was recorded for an animal during the detailed physical examination, the estimate of the food consumed by the animal was excluded from the group mean calculation for that particular interval.

Clinical Pathology

Prior to each clinical sampling, all designated animals were placed in urine collection racks and fasted overnight with water available. Blood samples for hematology and serum chemistry evaluations were obtained from 10 animals/sex/group (from the last ten surviving animals in the group) during Weeks 26, 52, 78, and 104. Myeloid/erythroid ratios were performed on samples from animals sacrificed at Week 79 (10/sex/group; Groups 1, 4, and 5) and all surviving animals sacrificed at Weeks 105/106 and when possible on smears from animals sacrificed in extremis. Samples were obtained via orbital sinus venipuncture from animals that were anesthetized with a gas mixture of 70% CO_2 and 30% O_2. The following parameters were determined:

Hematology

absolute reticulocyte count
corrected leukocyte count
erythrocyte count
hematocrit
hemoglobin
leukocyte differential and cellular morphology[a]
leukocyte count
mean cell hemoglobin
mean cell hemoglobin count
mean cell volume
platelet count
reticulocyte count
myeloid/erythroid ratios (at necropsy)

Serum Chemistry

albumin
calcium
chloride
creatinine
gamma glutamyltransferase
globulin
glucose
inorganic phosphorus
potassium
aspartate aminotransferase
alanine aminotransferase
sodium
total bilirubin
total protein
urea nitrogen

[a] The leukocyte differential and cellular morphology was performed for Groups 1, 5, and 6 only.

Urine Chemistry - presented with the Serum Chemistry

calcium	potassium
chloride	osmolality
creatinine	sodium
creatinine clearance	volume
phosphorus	

Urinalysis

appearance (color and turbidity)	occult blood
bilirubin	pH
glucose	protein
ketones	specific gravity
microscopic examination of sediment	urobilinogen

Clinical hematology analyses were performed using a Coulter Counter® Model S-Plus IV. Serum and urine chemistry analyses were performed using a BMD/Hitachi® 704/737 Chemistry Analyzer. Differential leukocyte counts and cellular morphology quantitations were manually determined from peripheral blood smears. M:E ratios were manually determined from bone marrow smears. Semiquantitative urinalysis determinations were performed using Ames™ Multistix® or equivalent. Specific gravity was determined with a refractometer.

Terminal Studies

Sacrifice and Gross Pathology - All animals which were found dead or sacrificed in extremis (using sodium pentobarbital and exsanguination) during the study were subjected to a gross postmortem examination. After at least 78 or 104 weeks of treatment, animals designated for histomorphological analysis of the tissues were food-fasted overnight, weighed the day of scheduled necropsy, given an intraperitoneal injection of sodium pentobarbital, and exsanguinated. Bone marrow smears were obtained from a femur in order to evaluate myeloid/erythroid ratios. Necropsies were performed on all animals by appropriately trained personnel using procedures approved by board-certified pathologists, and

all findings were recorded. A veterinary pathologist was readily available for consultation. Necropsies included examination of the following:

all orifices
carcass
cervical tissues and organs
cranial cavity
cut surfaces of the brain (at tissue trimming)
external surface of the body
external surface of the brain
external and cut surfaces of the spinal cord (at tissue trimming)
nasal cavity and paranasal sinuses
thoracic, abdominal, and pelvic cavities/viscera

Organ Weights - At the Weeks 79 and 105/106 sacrifices, the following organs (when present) were weighed after careful dissection and trimming of fat and other contiguous tissue:

brain with stem
spleen
kidneys (paired weight)
liver
testes with epididymides (paired weight)
lung
uterus

Organ-to-terminal-body-weight and organ-to-brain-weight ratios were calculated using the fasted terminal body weight recorded at necropsy.

Tissue Preservation - The following tissues (when present) from each animal were preserved in 10% neutral-buffered formalin:

adrenals
all gross lesions (including tissue masses)
aorta (thoracic)
brain with brainstem
esophagus
exorbital lacrimal glands[a]
eyes with optic nerves[a]
femur (bone marrow smear)[b]
femur with marrow and joint[a]
heart
kidneys

[a] These tissues were preserved for possible future examination if indicated by signs of toxicity or target organ involvement.
[b] Smear was fixed in methanol and appropriately stained for analysis of the M:E ratio. The bone used to obtain the smear was not the same femur used for histopathology.

large intestines (colon, cecum, rectum)
liver
lung
lymph nodes (mesenteric)
mammary gland[a]
ovaries
pancreas
peripheral nerve (sciatic)
pituitary
prostate
salivary glands (mandibular)
seminal vesicles
skeletal muscle (thigh)[a]
small intestines (duodenum, jejunum, ileum)
spinal cord (cervical, lumbar, thoracic)
spleen
stomach
testes with epididymides
thymus
thyroid with parathyroid
trachea
urinary bladder
uterus with vagina and cervix

Histopathology - All tissues (except those indicated for possible future examination) from the high-dose (Group 5) and control (Group 1) animals sacrificed after 78 or 104 weeks of treatment, and tissues from all animals that died or were sacrificed moribund during the study were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Gross lesions were examined microscopically from all animals.

The liver, testes with epididymides (males), uterus (females), spleen, and kidneys from all animals scheduled for sacrifice after treatment for at least 78 or 104 weeks (excluding those animals designated for analysis of hepatocellular proliferation, but including those animals that died or were sacrificed moribund during the study) were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Based on microscopic findings of the high-dose for animals killed at study termination, the pituitary was declared a target organ in males, and embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically for all males killed at study termination.

[a] These tissues were preserved for possible future examination if indicated by signs of toxicity or target organ involvement.

Postmortem Procedures - Hepatocellular Proliferation/Biochemical Analyses

Animal Selection - Hepatocellular proliferation evaluations were performed utilizing animals having the lowest identification numbers. At the appropriate harvest time, the liver weight was determined and the following tissues were preserved in 10% neutral-buffered formalin:

any gross lesion
liver (standard tissue samples from three lobes, left lateral, median, and right lateral lobes)
duodenum

The remainder of the liver was immediately frozen at approximately -70°C and stored frozen for biochemical analysis.

Hepatocellular Proliferation and Biochemical Analyses - The tissue samples from the three liver lobes (right and left lateral, and median), and the duodenum were processed for evaluation of hepatocellular proliferation and analysis of protein concentration, cyanide-insensitive palmitoyl-CoA oxidation, and DNA concentration from up to five animals/sex from Groups 1, 5, and 7 (only hepatocellular proliferation analysis was conducted on samples from Group 7) sacrificed during Weeks 1, 2, and 13, and from Groups 1, 3, 4, 5, and 6 at Week 105.

Histopathology - Liver tissue samples from each lobe were processed for histomorphological evaluation from those animals which were processed and scheduled for evaluation of hepatocellular proliferation.

Statistical Analyses

Cumulative survival data were analyzed using the National Cancer Institute Package.

Weekly/monthly mean body weights and food consumption, mean body weight change (Weeks 1-52 and 1-105), mean total food consumption (Weeks 1-52 and 1-104), clinical pathology data (except hemolysis and cellular morphology gradings and routine urinalysis data), fasted terminal body weights, and organ weight data of the control group were compared statistically to the data from the same sex of the treated groups.

Statistical analyses were performed as diagrammed in Figure 1. Statistical methods/references for the ancillary studies are addressed in the Ancillary Studies Report.

If variances of untransformed data were heterogeneous, a series of transformations was performed in an effort to achieve variance homogeneity. When the series of transformations was not successful in achieving variance homogeneity, analyses were performed on transformed data. Group comparisons were performed at the 5% two-tailed probability level.

Statistical significance is designated throughout the text of this report by the term *significant*. Data transformations are presented in the appropriate tables.

Record Retention

At the completion of the study, reserve samples, all tissues, blocks and slides as well as the raw data and a copy of the final report will be returned to the Sponsor for archival storage.

Figure 1
Flowchart of ANOVA and Related Methods



All parametric comparisons considered variance homogeneity/heterogeneity. All transformations indicated in the flowchart were done on untransformed data.

RESULTS

Ancillary Studies

Results of the hepatocellular proliferation and biochemical analyses are discussed in the Ancillary Studies Report. Data from these analyses are summarized in Text Table 1 of the Ancillary Studies Report.

DEHP induction of hepatocellular proliferation and/or liver peroxisome proliferation were evaluated at Weeks 1, 2, 13, and 104. At Weeks 1, 2, and 13, livers were collected from five rats/sex from Group 1 (0 ppm) and Group 5 (12,500 ppm), as well as males from the positive control (Group 7). At Week 104, livers were collected from 2-5 rats/sex from Group 1 (0 ppm), Group 3 (500 ppm), Group 4 (2,500 ppm), Group 5 (12,500 ppm) and Group 6 (12,500 ppm - Recovery Group). Hepatocellular proliferation was evaluated as the percentage of hepatocyte nuclei in S-phase (expressed as Labeling Index - LI); and the presence of peroxisome proliferation was evaluated by biochemical analyses (palmitoyl-CoA oxidase activity, DNA concentration, and protein concentration).

DEHP induction of hepatocellular proliferation occurred only during Week 1. Compared to the negative controls (Group 1), the Labeling Index was significantly increased (approximately 10-fold higher) in the Group 5 males and females at Week 1, but was not significantly increased at Week 2 or 13. At Week 104, the Labeling Index was not significantly increased in any of the DEHP dose groups compared to Group 1. In the positive control males, the Labeling Index was significantly increased at Weeks 1 and 13, and increased (not significantly) at Week 2, compared to Group 1.

DEHP induction of liver peroxisome proliferation, as indicated by significantly increased palmitoyl-CoA oxidase activity, was evident at Weeks 1, 2, and 13 in the Group 5 males and females; and at Week 104 in the Group 4 and 5 males and females, but not the Group 3 animals or the Group 6 animals. At Week 104, the significant increases of palmitoyl-CoA

oxidase activity in Groups 4 and 5 were dose-related. In Group 3 males and females, mean palmitoyl-CoA oxidase activity at Week 104 was comparable to Group 1 mean values, indicating that 500 ppm was a no-effect level for DEHP induction of liver peroxisome proliferation. In the Group 6 males and females, mean palmitoyl-CoA oxidase activity at Week 104 was also comparable to Group 1 mean values, indicating that the severity of peroxisome proliferation observed in Group 5 was reversible after 6 months of nonexposure to DEHP.

Liver weight data correlated with the intergroup differences in peroxisome proliferation. Compared to Group 1, mean absolute liver weights were significantly increased in the Group 5 males and females at Week 1, 2, 13, and 104, with the difference compared to the controls increasing with time. At Week 104, mean absolute liver weight was increased in the Group 4 males, and was significantly increased in the Group 4 females, as well as the Group 5 males and females; but was not significantly increased in the Group 3 males or females, or in the Group 6 males and females.

Analysis results for liver tissue DNA and protein concentration did not indicate any consistent intergroup differences or trends.

Analytical Chemistry

Results of analyses for homogeneity, stability, and routine concentration are presented in Table 1. The analytical method used is presented in Appendix 1.

Homogeneity analyses indicated that the test material was homogeneously mixed; relative standard deviation values were within 3.5%.

Results of stability analyses indicated that the formulations were stable for 14 days (Group 2 samples were stable for 15 days) at room temperature. All values were within 9% of initial concentration.

Results of routine concentration analyses indicated that all formulations were within 10% of target, except for the Group 2 mix at Week 13 that was within 11%.

In-life Observations

Mortality - Cumulative adjusted survival through Week 104 is presented in Table 2 and depicted graphically in Figure 2; individual animal disposition is presented in Appendix 2.

At Week 79 (the first week of the recovery period for Group 6), the percent survival in Groups 1-6 was 96, 96, 96, 93, 96, and 98%, respectively, for the males; and 96, 98, 96, 95, 95, and 96%, respectively, for the females. However, at the beginning of Week 104, the percent survival for Groups 1-6 was 82, 78, 78, 70, 73, and 73%, respectively, for the males; and 80, 86, 80, 76, 70, and 67%, respectively, for the females.

Statistical evaluation revealed no difference in survival between control and treated groups.

Clinical Observations - A summary of daily cageside and weekly physical observations is presented in Table 3. Individual observations are presented in Appendix 3.

The following clinical signs were observed during Weeks 1-105 in males and females of Groups 1-6 and incidences were proportional (in general) to treatment regimen: thin appearance (primarily seen in the females), hunched posture, hypoactivity, prostration, pale body appearance, few and/or no feces, and urine stains.

Other findings observed occurred sporadically and/or were of the type commonly observed in this species at this laboratory.

Figure 2
Adjusted Percent Survival



Body Weight, and Food and Compound Consumption - Mean body weight data are presented in Table 4A and depicted graphically in Figure 3; body weight change data are presented in Table 4B. Individual body weight data are presented in Appendix 4. Mean food consumption data are presented in Table 5A and depicted graphically in Figure 4; mean total food consumption data are presented in Table 5B; individual data are presented in Appendix 5. Mean compound consumption data are presented in Table 6 and depicted graphically in Figure 5; individual data are presented in Appendix 6.

Mean body weights were lower in the Group 4 males during Weeks 49 to 105, and were significantly lower at all measurement intervals in the Group 5 and 6 males from Week 1 to Week 105, compared to the control males (Group 1). Mean body weights in the Group 4 females were comparable to the control female mean values. Mean body weights in the Group 5 and 6 females were significantly lower, with few exceptions, at all measurement intervals compared to the control females (Group 1).

However, an improvement in body weight gain occurred in the Group 6 males and females during the recovery phase. At Week 77 (prior to the beginning of the recovery phase at Week 79), the mean body weight for Groups 5 and 6 was 8% lower and 8% lower, respectively, in the males; and 11% lower and 9% lower, respectively, in the females, compared to the same sex in Group 1. At Week 105 (end of the 26-week recovery phase for Group 6), the mean body weight for Groups 5 and 6 was 11% lower and 4% lower, respectively, in the males; and 9% lower and 2% lower, respectively, in the females, compared to the same sex in Group 1. The improvement in body weight gain that occurred in the Group 6 animals during the recovery phase is also apparent in the mean total body weight gain values. For Groups 5 and 6, mean total body weight gain for Weeks 1-52 was 13 and 14% lower, respectively, in the males; and 13 and 13% lower, respectively, in the females, compared to the same sex in Group 1. However, mean total body weight gain for Weeks 1-105 in Groups 5

Figure 3
Mean Body Weights



Figure 4
Mean Food Consumption



Figure 5
Mean Compound Consumption



and 6 was 15 and 4% lower, respectively, in the males; and 15 and 5% lower, respectively, in the females.

Throughout the study, mean weekly food consumption values for males and females exhibited sporadic intergroup differences (with occasional statistical significance) lacking any dose- or treatment-related pattern. In females, statistically significant lower mean food consumption values were noted most frequently in Groups 5 and 6. However, each of the significantly lower weekly mean food consumption values in the Group 5 and 6 females were within 10% deviation from the respective weekly mean value for the control females (Group 1). Additionally, even though Group 5 and 6 females were fed the same dietary concentration (12,000 ppm) of Di(2-ethylhexyl)phthalate, significantly lower mean weekly food consumption values were noted at 15/31 measurement intervals for Group 5, but only 10/31 intervals for Group 6 during Weeks 1-76.

For each sex in each DEHP dose group, there were no statistically significant differences in mean total food consumption for Weeks 1 through 52, or Weeks 1 through 104, compared to the mean values for the same sex controls (Group 1). Therefore, the occasional statistically significant intergroup differences in mean weekly food consumption values were spurious findings.

For Weeks 1 through 104, the average daily consumed dose (based on target dietary concentrations of Di(2-ethylhexyl)phthalate in Groups 2, 3, 4, and 5, was 5.8, 28.9, 146.6, 789.0 mg/kg/day, respectively, in males; and 7.3, 36.1, 181.7, and 938.5 mg/kg/day, respectively, in females. The recovery animals (Group 6) were administered the test material through Week 78, and males and females consumed 679.3 and 808.2 mg/kg/day, respectively.

Clinical Pathology

Mean hematology and chemistry values are presented in Tables 7A and 7B, respectively. Individual clinical pathology data are presented in

Appendices 7A (hematology), 7B (serum chemistry), and 7C (urinalysis). Findings are further discussed in the Clinical Pathology Report.

Although significant depressions were observed in several hematology parameters (erythrocyte count, hemoglobin, and hematocrit), the decreases were of low magnitude (no reticulocyte response was observed) and considered of little biologic importance; they may be related to the depressed body weight gains noted for Groups 5 and 6. There was no evidence of hematopoietic neoplasia in the peripheral blood smears examined in Groups 1, 5, and 6. No significant differences in the myeloid/erythroid ratios between control and Group 4 and 5 animals at Week 79 or control and treated groups at Week 105 were noted.

Significant, but slight, increases were observed in the mean urea nitrogen values for Group 4 males and Group 5 and 6 animals at Weeks 26, and Group 5 and 6 animals at Weeks 52 and 78. These changes are of low magnitude and are not accompanied by similar increases in creatinine (in fact, mean creatinine values were significantly decreased in Group 2 and 6 males at Week 78). However, since increases in mean urea nitrogen values occurred consistently throughout the study in the Group 5 and 6 animals, especially the males, they are likely related to treatment.

Significant changes were observed in the mean protein values, including increases in total protein in Group 5 and 6 animals at Week 26, and Group 5 and 6 males at Week 52; and in albumin in Group 4, 5, and 6 animals at Weeks 26 and 78, Group 3 males and Group 4, 5, and 6 animals at Week 52, and Group 4 and 5 males at Week 104. Significant decreases were observed in the mean globulin values in Group 4, 5, and 6 animals at Week 26; Group 4 and 5 males and Group 6 animals at Week 52; Group 4 females and Group 5 and 6 animals at Week 78; and Group 5 animals at Week 104. The aforementioned changes in albumin are attributed to the administration of the test material, but the mechanism is not apparent from the remainder of the clinical laboratory data.

There were no significant changes in the urine chemistry analytes attributable to administration of the test material. There were no significant changes in mean values for urine volume, urine creatinine, and creatinine clearance and no evidence of a compromise in renal concentrating ability due to test material administration.

Terminal Studies

Gross Pathology - Gross pathology findings are summarized in Tables 8A, 8B, and 8C for unscheduled deaths, interim sacrifice (Week 79), and terminal sacrifices (Weeks 105/106), respectively. Corresponding individual gross pathology findings are presented in Appendices 9A, 9B, and 9C.

In males and females of Groups 4, 5, and 6, that died or were sacrificed in extremis during the study (unscheduled deaths), the incidence of the following necropsy findings was increased: enlarged spleen, granular/pitted/rough and/or pale appearance of the liver, liver mass, dark kidney, dark area of the stomach, small and/or soft testis, small epididymis and/or seminal vesicle, or uterine mass.

At the Week 79 sacrifice, a liver mass was observed in the Group 5 animals (6/15 males and 3/15 females); and various gross-pathologies of the liver (enlarged and pale areas) were observed in the Group 5 males.

During necropsy at study termination, the following abnormalities were observed to have a dose-related increase in the Group 4 and 5 animals: enlarged spleen; granular/pitted/rough or pale appearance of the liver, liver mass and/or enlarged liver (seen primarily in the Group 5 animals); granular/pitted/rough and/or dark kidney (seen primarily in the males); dark area of the stomach (seen primarily in the males); thickened cervical wall; and small and/or soft testis. Group 6 animals exhibited the following increased (when compared to the control) abnormalities:

enlarged spleen; granular/pitted/rough liver (males); liver mass; small or soft testis or uterine cyst.

Other observations were incidental to treatment or were commonly seen in this age and strain of laboratory animal.

Organ Weights - Organ weight data are presented in Tables 9A (interim sacrifices - liver weight - Weeks 1, 2, and 13), 9B (Week 79 sacrifice), and 9C (terminal sacrifice). Corresponding individual organ weight data are presented in Appendices 9A, 9B, and 9C.

Absolute liver weights and liver to body weight ratios for the Week 1, 2, and 13 interim sacrifices were significantly increased in Group 5 animals when compared to the control group. Absolute liver weights were increased in the Group 4 animals at all intervals, although not always significantly; however, liver/body weight ratios in the Group 4 animals were significantly increased at all intervals. The liver to body weight ratio for the Group 3 males was significantly increased at the Week 1 sacrifice.

At the Week 79 sacrifice, kidney and liver weights (absolute, relative to body, and relative to brain) were statistically increased in Group 5 animals compared to the control group. In Group 4, the absolute liver weight was increased in males, and significantly increased in the females; and liver weights relative to body and relative to brain weight were significantly increased in both sexes. For the kidneys in Group 4, the absolute and relative to brain weight ratios for the females were statistically increased. Testis/epididymis weights (absolute, relative to body, and relative to brain) were significantly decreased in the Group 5 males. Reflecting a lower mean terminal body weight rather than an increase in absolute organ weight, the organ-to-body-weight ratio was significantly increased for brain in the Group 5 males and females; and for lung in the Group 5 females.

For the animals sacrificed after at least 104 weeks of treatment, a dose-related, significant increase in liver weights (absolute, relative

to body, and relative to brain) was apparent in males and females of Groups 4 and 5. In Group 6 (recovery animals), mean liver weights (absolute and relative) were increased compared to the controls (Group 1); but were decreased compared to Group 5. In Group 6 males and females, the mean absolute liver weight was approximately 10% greater than the mean value for the same sex controls; but was also approximately 33% lower than the mean value for the same sex in Group 5. Compared to control Group 1, the mean liver to brain weight ratio in Group 6 males and mean absolute liver and liver to body weight ratios in Group 6 females were significantly increased.

In the kidneys, absolute, relative to body, and relative to brain weights for the Groups 4, 5, and 6 males and the Group 5 females were significantly increased; comparable kidney weights in females of Group 6 were increased, but not significantly. For testis/epididymis, the absolute, relative to body, and relative to brain weights were significantly decreased in the Group 5 and 6 males.

Histopathology - Microscopic findings are summarized in Tables 10A (unscheduled deaths), 10B (Weeks 1, 2, 3, and 79 sacrifices), and 10C (terminal sacrifices). Corresponding individual histopathology findings are presented in Appendices 9A, 9B, and 9C. Additional summaries (Groups 1-6) are presented in Tables 10D (expanded histopathology - liver, kidney and pituitary) and 10E (all deaths). The findings are further discussed in the Pathology Report.

Dietary administration of Di(2-ethylhexyl)-phthalate to Fischer-344 rats for at least 104 weeks at a level of 12,500 ppm (Group 5) resulted in compound-related histomorphologic alterations in the liver and kidneys in rats of both sexes and in the pituitary, testes, and epididymides of the males. Liver changes noted in Group 5 rats sacrificed at Weeks 1, 2, and 13 for cell proliferation studies consisted of increased mitotic activity (Week 1) and increased cytoplasmic eosinophilia and diffuse hepatocellular enlargement (Weeks 2 and 13). Liver changes at

the 79-week interim sacrifice and at termination consisted of increased cytoplasmic eosinophilia, diffuse hepatocellular enlargement, pigment in Kupffer cells/hepatocytes and increased hepatocellular neoplasia. Although the incidence of hepatocellular neoplasia was also increased in rats of the high-dose recovery group (Group 6) at the terminal sacrifice, the numbers of animals with neoplasms and the occurrence of multiple neoplasms were decreased compared to Group 5.

Kidney changes in the high-dose rats after 104 weeks of test material administration consisted of increased tubule cell pigment (males and females) and increased severity of nephropathy and mineralization of the renal papilla in the males. Castration cells were noted in the pituitary of 18 of 35 Group 5 males and 17 of 33 Group 6 males at study termination. In Group 1, 4, 5, and 6 males, the total incidence of animals with increased castration cells in the pituitary was 1/60, 1/52, 30/60, and 20/48. Castration cells were not detected in the pituitary of any females, all groups. Bilateral aspermatogenesis was present in all high-dose males at the 79-week interim sacrifice and a decreased incidence of interstitial cell neoplasia was noted in testes of Group 5 (high dose) and 6 (high-dose recovery) males compared to control and lower-dose groups at termination. The presence of mononuclear leukemia as the cause of death was slightly higher in rats of Groups 4, 5, and 6, and the total incidence of leukemia was greatest in rats of these groups.

Other spontaneous disease lesions were of the expected types and severity for rats of this age and strain.

DISCUSSION AND CONCLUSION

Di(2-ethylhexyl)phthalate (DEHP) was administered in the diet to male and female F-344 rats for at least 104 weeks to assess its oncogenic potential, and to evaluate its potential to cause hepatocellular proliferation and peroxisomal proliferation. For Groups 1, 2, 3, 4, and 5, the target dietary concentration of DEHP was 0, 100, 500, 2,500, and 12,500 ppm, respectively. Rats in Group 6 were administered the 12,500 ppm DEHP diet admixture for 78 weeks, followed by a 26-week recovery period during which they were fed the basal diet only. The sole purpose of Group 7, consisting of 15 male rats, was to provide a positive control for the hepatocellular proliferation assays; and was administered WY 14,643 at a dietary concentration of 1000 ppm for up to 13 weeks.

For Groups 2, 3, 4, and 5, the average daily consumed dose (based on target dietary concentrations) during Weeks 1 through 104 was 5.8, 28.9, 146.6, and 789.0 mg/kg/day, respectively, in the males; and 7.3, 36.1, 181.7, and 938.5 mg/kg/day, respectively, in the females. For Group 6, the average daily consumed dose (based on target dietary concentrations) during Weeks 1 through 78 was 679.3 and 808.2 mg/kg/day in males and females, respectively. Therefore, in each of the DEHP dose groups, the average daily dose (mg/kg/day) consumed by females was higher (range of 19 to 26%) than males administered the same dietary concentration of DEHP.

Survival was slightly decreased (not statistically significant) at Week 104 in the Group 4, 5, and 6 males, and Group 5 and 6 females due to DEHP administration. At Week 79 (the first week of the recovery period for Group 6), the percent survival in Groups 1-6 was 96, 96, 96, 93, 96, and 98%, respectively, for the males; and 96, 98, 96, 95, 95, and 96%, respectively, for the females. However, at the end of Week 104, the percent survival in Groups 1-6 was 82, 78, 78, 70, 73, and 73%, respectively, for the males; and 80, 86, 80, 76, 70, and 67%,

respectively, for the females. Compared to Group 5, survival in Group 6 males and females was not improved by removal of DEHP exposure during the last 26 weeks of the study. For unscheduled deaths in all groups, the most frequent attributable cause of death was monocellular leukemia (a known spontaneous neoplasm in F-344 rats). For all deaths combined, the percent of rats examined histopathologically and found to have monocellular leukemia in Groups 1-6 was 23, 26, 29, 49, 42, and 47%, respectively, in males; and 22, 34, 20, 25, 26, and 33%, respectively, in females. For unscheduled deaths in Groups 1-6, the percent of rats for which monocellular leukemia was attributed to be the cause of death was 80, 46, 50, 76, 80, and 60%, respectively, in males; and 50, 38, 60, 54, 47, and 53%, respectively, in females. Therefore, there was no correlation between the increased prevalence of monocellular leukemia and the increased mortality observed in the Group 4, 5, and 6 males, and Group 5 and 6 females. A single definitive physiological cause was not apparent for the increased deaths in the Group 4, 5, and 6 males, and Group 5 and 6 females.

DEHP administration did not produce any unique or unusual clinical abnormalities. Reflecting a sustained body weight depression and/or ante-mortem condition, the incidence of the following signs collectively, were increased in the Group 4, 5, and 6 males, and Group 5 and 6 females compared to the controls: thin appearance, hunched posture, hypoactive, prostrate, pale body, few and/or no feces, and urine stains.

DEHP administration caused a sustained depression of body weight gain in the Group 4 and 5 males, and Group 5 females; and in the Group 6 animals up to the beginning of the recovery phase, during which body weight gain markedly improved. For Weeks 1 through 105, mean total body weight gain was 4 and 15% lower in the Group 4 and 5 males, respectively; and was 15% lower in the Group 5 females, compared to the mean value for the same sex controls (Group 1). Reversibility of the depression of body weight gain upon cessation of DEHP exposure is illustrated by a comparison

of Group 5 and 6 body weights at the beginning and end of the recovery phase for Group 6. Week 77 (prior to the beginning of the recovery phase at Week 79), the mean body weight for Groups 5 and 6 was 8% lower and 8% lower, respectively, in the males; and 11% lower and 9% lower, respectively, in the females, compared to the same sex in Group 1. At Week 105 (end of the 26-week recovery phase for Group 6), the mean body weight for Groups 5 and 6 was 11% lower and 4% lower, respectively, in the males; and 9% lower and 2% lower, respectively, in the females, compared to the same sex in Group 1.

DEHP administration did not affect food consumption. Throughout the study, mean weekly food consumption values for males and females exhibited sporadic intergroup differences (with occasional statistical significance) lacking any dose- or treatment-related pattern. For each sex in each DEHP dose group, there were no statistically significant differences in mean total food consumption for Weeks 1 through 52, or Weeks 1 through 104, compared to the mean values for the same sex controls (Group 1). Therefore, the occasional statistically significant intergroup differences in mean weekly food consumption values were not related to DEHP administration.

DEHP administration caused a mild decrease in erythrocyte mass (in the absence of increased reticulocytes) in the Group 5 and 6 males and females. At Weeks 26, 52, 78, and 104, mean values for erythrocyte parameters (erythrocyte count, hemoglobin, and hematocrit) were generally lower (usually significantly lower) in the Group 5 males and females compared to the controls. In Group 6, there was no definitive evidence at Week 104 of an improvement in erythrocyte mass parameters during the recovery phase.

Treatment-related effects on the kidney were indicated by slight but statistically significant increased mean values for serum urea nitrogen in the Group 4 males, and Group 5 and 6 males and females. However, there were no corresponding increases in mean serum creatinine

concentration. At Week 104, mean serum urea nitrogen concentrations remained increased in Group 5 animals, but approximated control values in Group 6 males and females, suggesting that the cause of the elevated serum urea nitrogen was reversible upon cessation of DEHP exposure.

DEHP administration caused changes in serum protein concentrations in the Group 4, 5, and 6 males and females. Mean serum albumin concentration was increased (significantly at most of the measurement intervals) in the Group 4, 5, and 6 animals, with the notable exception of Week 104 in the Group 6 males and females. Mean serum total protein was not significantly increased with the same frequency, and thus significant decreases in mean serum globulin concentration simply reflected the corresponding increased albumin concentration. A cause of the elevated albumin values was not apparent. However, at Week 104, albumin mean values in Group 6 males and females approximated control mean values, while mean values for Group 5 males and females remained elevated, suggesting the cause was reversible upon cessation of DEHP exposure.

The liver was confirmed to be a target organ of DEHP effects, including oncogenic potential. Liver weight data was collected during Week 1, 2, 13, 79, and 104. At dietary concentrations of 2,500 and 12,500 ppm, DEHP caused significantly increased liver weights, with the severity of liver enlargement increasing with dose. DEHP dietary concentrations of 2,500 and 12,500 ppm caused a dose-related increase in hepatocellular neoplasms in males, but only the 12,500 ppm concentration caused an increase in hepatocellular neoplasms in females. DEHP dietary concentrations of 2,500 and 12,500 ppm caused a sustained increase in liver peroxisome proliferation, but not hepatocellular proliferation in males and females. After 78 weeks of DEHP administration at 12,500 ppm, a 6-month cessation of DEHP exposure resulted in reversal of hepatomegaly, no detectable level of liver peroxisomal proliferation, and a decrease in the incidence of hepatocellular neoplasms in male and females.

During Week 1 of DEHP administration, a dose-related increase in mean absolute liver weight was evident in males and females of Groups 4 and 5 (2,500, and 12,500 ppm, respectively), with the increase in both sexes of Group 5 being significantly greater than the control mean value. Mean liver-to-body-weight ratio was significantly increased in males and females of Groups 3, 4, and 5, with the exception of the Group 3 females. DEHP induction of hepatocellular proliferation and of liver peroxisome proliferation was also evident in Week 1. Compared to the negative controls (Group 1), hepatocellular proliferation was significantly increased (approximately 10-fold higher) in the Group 5 males and females during Week 1; and increased numbers of mitotic figures were evident in histological liver sections. Additionally, liver peroxisome proliferation, as indicated by significantly increased palmitoyl-CoA oxidase activity, was increased (approximately 3-fold higher) in the Group 5 males and females during Week 1.

During Week 2 of DEHP administration, a dose-related increase in mean absolute liver weight and liver-to-body-weight ratio was again evident in males and females of Groups 4 and 5, with statistically significant increases occurring in Groups 4 and 5, compared to Group 1 controls. In Group 5 males and females, DEHP induction of hepatocellular proliferation was no longer evident, with the level of hepatocellular proliferation being approximately equal to Group 1 values. However, liver peroxisome proliferation was significantly increased (at least 5-fold greater) compared to Group 1. Diffuse hepatocellular enlargement (of minimal to slight severity), as well as increased cytoplasmic eosinophilia was evident in histological liver sections of Group 5 rats.

During Week 13 of DEHP administration, a dose-related increase in mean absolute liver weight and liver-to-body-weight ratio was again evident in males and females of Groups 4 and 5, with statistically significant increases occurring in Groups 4 and 5, compared to Group 1 controls. In Group 5 males and females, DEHP induction of hepatocellular

proliferation was again not evident. Liver peroxisome proliferation remained significantly increased (at least 5-fold greater) in the Group 5 males and females compared to Group 1. Diffuse hepatocellular enlargement (of slight severity), and increased cytoplasmic eosinophilia were again evident in histological liver sections of Group 5 rats.

During Week 79 of DEHP administration, a dose-related increase in mean absolute liver weight and liver-to-body-weight ratio was again evident in males and females of Groups 4 and 5, with all increases being significantly greater compared to the Group 1 controls with exception of the increased mean absolute liver weight in the Group 4 males. Liver peroxisome proliferation was not evaluated at Week 79. However, there were no treatment-related morphologic lesions in liver sections from Group 4 males or females killed at Week 79. In liver sections from Group 5 rats, diffuse hepatocellular enlargement (of moderate severity), and increased cytoplasmic eosinophilia were again evident; and pigment in Kupffer cells/hepatocytes was evident in 9/10 males and 7/10 females. At necropsy, liver masses were observed in one Group 4 male, six Group 5 males, and three Group 5 females. Microscopically, hepatocellular adenoma was detected in one Group 4 male (judged to be a spontaneous neoplasm), one Group 5 male, and one Group 5 female; and hepatocellular carcinoma was detected in four Group 5 males and two Group 5 females. Week 79 was the first week in which liver neoplasms were detected in either scheduled or unscheduled deaths.

At study termination, after 104 weeks of DEHP administration, a dose-related increase in liver weights (absolute, relative to body, and relative to brain) was evident in males and females of Groups 4 and 5, with liver weights (absolute and relative) being significantly increased in both sexes of Groups 4 and 5. In Group 6 (12,500 ppm recovery animals), mean liver weights (absolute and relative) were increased (significantly except for mean absolute and relative to body weight in the males) compared to Group 1; but were decreased compared to Group 5. In

Group 6 males and females, the mean absolute liver weight was approximately 10% greater than the mean value for the same sex controls; but was also approximately 33% lower than the mean value for the same sex in Group 5. The data indicates that liver enlargement due to DEHP administration at 12,500 ppm in the diet was reversible following cessation of DEHP exposure.

At Week 104, significant dose-related increases in liver peroxisome proliferation were detected in Group 4 and 5 males and females. In Group 3 males and females, there was no detectable liver peroxisome proliferation compared to Group 1, suggesting that 500 ppm was a no-effect level for DEHP induction of liver peroxisome proliferation. In the Group 6 males and females, liver peroxisome proliferation activity was also comparable to Group 1, indicating that the severity of peroxisome proliferation observed in Group 5 was reversible after 6 months of nonexposure to DEHP.

For treatment-related nonneoplastic liver lesions evident at study termination, the incidence of spongiosis hepatis was increased in the Group 4 and 5 males compared to Group 1; and the incidences of diffuse hepatocellular enlargement and of increased cytoplasmic eosinophilia were increased only in the Group 5 males and females compared to Group 1. In Groups 4, 5, and 6, the incidence of pigment in Kupffer cells/hepatocytes was 1/38, 33/40, and 8/40, respectively, in males; and 0/42, 15/40, and 1/38, respectively, in females. As indicated by the decreased incidence of pigment in Kupffer cells/hepatocytes in Group 6 versus Group 5, the presence of treatment-related nonneoplastic lesions was reversible upon cessation of DEHP exposure. In Group 6 males and females, there was no evidence of diffuse hepatocellular enlargement or of increased cytoplasmic eosinophilia. The incidence of spongiosis hepatis in Group 6 males was comparable to the incidence observed in the Group 1 males.

For treatment-related neoplastic liver lesions evident at study termination, the incidence was increased in Group 4, 5, and 6 males, and

Group 5 and 6 females. In Groups 1, 4, 5, and 6, the percent of rats with hepatocellular adenomas was 9, 16, 45, and 25%, respectively, in the males; and 0, 2, 8, and 13%, respectively, in the females; and the percent with hepatocellular carcinomas was 2, 3, 43, and 18%, respectively, in the males; and 0, 2, 28, and 8%, respectively, in the females. However, comparison of the Group 5 and 6 incidences of liver neoplasms illustrates the marked reduction in tumor incidence in Group 6 resulting from the cessation of DEHP exposure.

The kidney was also a target organ of DEHP effects; but there was no evidence of DEHP-induced carcinogenicity in the kidney. At Week 79, absolute and relative kidney weights were significantly increased (except for kidney-to-body-weight ratio) in the Group 4 females; and were significantly increased in Group 5 males and females. At study termination, absolute and relative kidney weights were significantly increased in the Group 4 males, the Group 5 males and females, and the Group 6 males. However, an increase in the incidence and/or severity of treatment-related morphologic lesions occurred only in the kidneys of Group 5 and 6 animals. The incidence and severity of mineralization of the renal papilla were increased in the Group 5 and 6 males compared to Group 1. Pigment in renal tubule cells occurred with increased incidence and severity in males of Groups 5 and 6, and with increased severity in females of Groups 5 and 6. Pigment in renal tubule cells of Groups 5 and 6 may have resulted from the decrease in erythrocyte mass that was evident in these groups. Although there were no intergroup differences in the total incidence of chronic progressive nephropathy (a spontaneous condition in rats associated with increased age), the severity of chronic progressive nephropathy was increased in males of Groups 5 and 6, and females of Group 6. An exacerbation of chronic progressive nephropathy in Group 5 and 6 rats may have been a secondary effect resulting from the treatment-related severe sustained depression of body weight gain and associated physiological stress. In contrast to the liver, there was no

indication that DEHP-related changes in the kidney were reversible upon cessation of DEHP exposure.

The testis was also a target organ of DEHP effects; but there was no evidence of DEHP-induced carcinogenicity in the testis. In unscheduled deaths, as well as animals killed in Week 79 and at study termination, necropsy observations of small and/or soft were most frequently noted for the testis in Group 5 and 6 males. Absolute and relative testis weights were decreased (significantly) only in the Group 5 males, but not Group 4 males, at the Week 79 necropsy; and were decreased (significantly) only in the Group 5 and 6 males killed at study termination. Histopathological findings in the testis were an increased incidence of bilateral aspermatogenesis, and a decreased incidence of interstitial cell neoplasms in the Group 5 and 6 males. In contrast to the liver, there was no indication that treatment-related changes in the testis were reversible upon cessation of DEHP exposure.

In the pituitary, DEHP exposure resulted in an increase in castration cells only in the Group 5 and 6 males, compared to Group 1. At the Week 79 necropsy, increased castration cells in the pituitary was noted in 7/10 Group 5 males compared to 0/10 in the Group 1 males. In males killed at study termination, increased castration cells in the pituitary was observed in 18/35 (51%) of Group 5 males, and 17/33 (52%) of Group 6 males compared to 0/40 Group 1 males. For all male deaths, the percent examined in Groups 1-6 that exhibited increased castration cells in the pituitary was 2, 0, 0, 2, 50, and 42%, respectively.

Although monocellular leukemia is a spontaneous neoplasm known to occur in F-344 rats, the incidence of monocellular leukemia was increased in the Group 4, 5, and 6 males compared to the control males, and therefore was considered a treatment-related effect. In Groups 1-6, the percent of all animals examined and found to have monocellular leukemia was 23, 26, 29, 49, 42, and 47%, respectively, in the males; and 22, 34, 20, 25, 26, and 33%, respectively, in the females.

In conclusion, for F-344 rats, a DEHP dietary concentration of 500 ppm (Group 3) was the no-effect-level (NOEL) and no-adverse-effect-level (NOAEL) in males and females for systemic effects, with no evidence of carcinogenic potential. The DEHP dietary concentration of 2,500 ppm (Group 4) induced gross and microscopic evidence of liver effects in males and females, with an increased incidence of liver neoplasms in males; evidence of kidney effects in males and females; and an increased incidence of monocellular leukemia in males. The DEHP dietary concentration of 12,500 ppm also induced gross and microscopic evidence of liver effects in males and females, including an increased incidence of liver neoplasms in each sex; evidence of kidney effects in each sex; an increased incidence of monocellular leukemia in males; evidence of testis effects; and an increased incidence of males exhibiting increased numbers of castration cells in the pituitary. In Group 6, administration of a dietary concentration of 12,500 ppm for 78 weeks, followed by a 26-week recovery period indicated that effects of DEHP in the liver, including the induction of neoplasms, were reversible. However, DEHP effects in the kidney, testis, and pituitary were not reversible; and the incidence of monocellular leukemia in Group 6 males was not decreased compared to Group 5 males.

Study Director:

Michael R. Moore — Sept. 27, 1996

Michael R. Moore, Ph.D., D.A.B.T.
Department of Toxicology

Date

CLINICAL PATHOLOGY REPORT

Summary

The test material, Di(2-ethylhexyl)phthalate, was administered to Fischer-344 rats at dietary levels of 0, 100, 500, 2,500, 12,500, and 12,500 ppm (Groups 1-6, respectively) for at least 104 weeks. The animals assigned to Group 6 were removed from the test diet at Week 78 and placed on a basal diet for the remainder of the study. Hematology and serum chemistry tests were performed on samples collected at Weeks 26, 52, 78, and 104. Differential leukocyte counts and cellular morphology examinations were performed for Groups 1, 5, and 6 at Weeks 26, 52, 78, and 104; myeloid/erythroid ratios were determined from bone marrow smears for Groups 1, 4, and 5 at Week 79 and for Groups 1-6 at study termination (designated as Week 105). Significant, mild, treatment-related changes were observed primarily in Groups 5 and 6 and included decreases in erythrocyte mass (erythrocyte count, hemoglobin, and hematocrit) and globulin concentration and increases in urea nitrogen, total protein, and albumin (increases also noted in albumin for Group 4 animals). There was no evidence of hematopoietic neoplasia (leukemia) in the peripheral blood smears examined.

Results and Discussion

Hematology - The significant, treatment-related decreases in erythrocyte mass are illustrated in Text Table 1.

Text Table 1
Significant Changes in Hematology Data

		ERYTHROCYTE		HEMOGLOBIN			HEMATOCRIT			
Group/Sex	Week:	26	78	26	52	78	26	52	78	104
3/F		↓					↓			
4/M										↓
5/M		↓	↓		↑	↓	↓	↓	↓	
5/F		↓	↓	↓	↓	↓	↓	↓	↓	
6/M		↓			↑	↓	↓	↓	↓	
6/F		↓	↓	↓	↓	↓	↓	↓	↓	

↓ = Significantly lower than control group, $p \leq 0.05$.

The decreases were of low magnitude (no reticulocyte response was observed) and considered of little biologic importance; they may be related to the depressed body weight gains noted for Groups 5 and 6. Corresponding changes observed in the erythrocyte indices included significant decreases in mean cell volume in Group 5 and 6 females at Weeks 26 and 52 and Group 5 and 6 animals at Week 78 and increases in mean cell hemoglobin in Group 4, 5, and 6 males at Weeks 26 and 52 and Group 3 females at Week 78 and mean cell hemoglobin concentration in Group 4, 5, and 6 females at Week 26, Group 5 and 6 males at Week 52, and Group 3, 4, 5, and 6 females at Week 78.

The mean platelet counts were significantly increased in Group 5 males at Week 26, Group 3, 5, and 6 males at Week 52, and Group 5 and 6 animals at Week 78. The elevations in platelet counts were mild and cannot be definitively attributed to the administration of the test material.

The significant changes in the remaining hematologic parameters are considered incidental to the administration of the test material due to the low magnitude of the changes and the lack of biologic importance of the changes; they are listed in this report for documentation purposes. The mean lymphocyte counts were significantly increased in Group 5 and 6

animals at Week 52 and Group 5 males at Week 78; the mean eosinophil count was significantly decreased in Group 5 males at Week 52. Cellular morphology findings were generally comparable between control and Group 5 and 6 animals at Weeks 26, 52, 78, and 104, with the exception that echinocytosis was slightly increased in Group 5 and 6 females at Weeks 26, 52, and 78. The toxicologic importance of echinocytosis is questionable. There was no evidence of hematopoietic neoplasia in the peripheral blood smears examined in Groups 1, 5, and 6. No significant differences in the myeloid/erythroid ratios between control and Group 4 and 5 animals at Week 79 or control and treated groups at Week 105 were noted.

Serum and Urine Biochemistry - Significant changes were observed in the mean protein values, including increases in total protein in Group 5 and 6 animals at Week 26 and Group 5 and 6 males at Week 52 and in albumin in Group 4, 5, and 6 animals at Weeks 26 and 78, Group 3 males and Group 4, 5, and 6 animals at Week 52, and Group 4 and 5 males at Week 104. The most common cause of an increase in albumin above the reference range is hemoconcentration due to dehydration but the mechanism in this study is not apparent from the remainder of the clinical laboratory data. The significant decreases observed in the mean globulin values in Group 4, 5, and 6 animals at Week 26, Group 4 and 5 males and Group 6 animals at Week 52, Group 4 females and Group 5 and 6 animals at Week 78, and Group 5 animals at Week 104 are considered to be compensatory to the elevated albumin values. The aforementioned changes in albumin occurred consistently throughout the study, were dose dependent, and are attributed to the administration of the test material.

Significant, but slight, increases were observed in the mean urea nitrogen values for Group 4 males and Group 5 and 6 animals at Week 26 and Group 5 and 6 animals at Weeks 52 and 78. These changes are of low magnitude and are not accompanied by similar increases in creatinine (in fact, mean creatinine values were significantly decreased in Group 2 and

6 males at Week 78); however, they occur consistently throughout the study and are likely related to treatment.

Significant decreases were observed in the mean alanine aminotransferase and aspartate aminotransferase values in Group 4 males and Group 5 and 6 animals at Week 26 and Group 5 and 6 animals at Week 52. These changes are transient and of little biologic importance; they cannot be definitively attributed to the administration of the test material.

The significant changes in the remaining serum chemistry analytes are considered incidental to the administration of the test material due to the low magnitude of the changes, the lack of biologic importance of the differences, the lack of a dose response, and/or the inconsistent occurrence of the changes over time; they are listed in this report for documentation purposes. Significant increases were observed in the mean values for glucose in Group 6 males at Weeks 52 and 78 and for inorganic phosphorus in Group 5 and 6 females at Week 52 and Group 5 and 6 males at Week 78; decreases were observed in the mean values for gamma glutamyltransferase in Group 2, 3, and 4 females at Week 26 and Group 5 males at Weeks 52, 78, and 104 and for chloride in Group 5 males at Week 52.

The significant changes in the urine chemistry analytes cannot be definitively attributed to the administration of the test material due to the fact that there were no significant changes in the mean values for urine volume, urine creatinine, and creatinine clearance and the fact that there was no evidence of a compromise in renal concentrating ability; the changes are listed in this report for documentation purposes. Significant decreases were observed in the mean values for urine calcium in Group 2, 3, 4, 5, and 6 males at Week 52 and urine chloride in Group 5 females at Week 78 and Group 5 animals at Week 104. Significant increases were observed in the mean values for urine inorganic phosphorus in Group 5 animals at Week 26, Group 5 and 6 males at Week 78, and Group 5 males at Week 104 and for urine chloride in Group 3 females at Week 52. The mean

values for urine chloride, urine sodium, and urine potassium were significantly increased in Group 5 males at Week 26 due to a concurrent significant increase in the mean urine osmolality.

It should be noted that marked increases were observed in the individual values of total bilirubin, gamma glutamyltransferase, alanine aminotransferase, and aspartate aminotransferase in Group 3 female B29080 at Week 78; these findings were not observed at Week 52. This female had mild anemia and thrombocytopenia with leukocytosis at Week 78. These findings cannot be definitively attributed to the administration of the test material.

Conclusion

The mild treatment-related changes observed primarily in Group 5 and 6 animals included significant decreases in erythrocyte mass and globulin and increases in urea nitrogen, total protein, and albumin. There was no evidence of hematopoietic neoplasia (leukemia) in the peripheral blood smears examined for Groups 1, 5, and 6.

Clinical Pathologist:

Renée C. Pearson

Renée C. Pearson, M.S., D.V.M.,
Diplomate, American College of Veterinary Pathologists
Department of Pathology

Sept. 27, 1996
Date

PATHOLOGY REPORT

Final Report

General Protocol

The purpose of this study was to evaluate the oncogenic potential of Di(2-ethylhexyl)phthalate when administered to Fischer-344 rats in the diet for at least 104 weeks and to provide information on the ability of Di(2-ethylhexyl)phthalate to cause hepatocellular proliferation and peroxisomal proliferation.

The control group (Group 1), consisting of 85 rats/sex, received the basal diet only. The low- and mid-low-dose groups (Groups 2 and 3), consisting of 70 rats/sex/group, received the test article at dose levels of 100 and 500 ppm, respectively. The mid-high- and high-dose groups (Groups 4 and 5), consisting of 85 rats/sex/group, received the test article at dose levels of 2,500 and 12,500 ppm, respectively. A recovery high-dose group of 55 rats/sex (Group 6) received 12,500 ppm Di(2-ethylhexyl)phthalate; the rats in this group were removed from the test diet after 78 weeks. A positive control group (Group 7), consisting of 15 male rats, received WY 14,643 at a dietary concentration of 1000 ppm for 13 weeks.

Five rats of each sex in Groups 1-5 and five males in Group 7 were sacrificed during Weeks 1, 2, and 13 to determine hepatocellular proliferation. Following 78 weeks of compound administration, 15 rats/sex/group were sacrificed in Groups 1, 4, and 5, with 5/sex/group used for possible hepatocellular proliferation studies. During Week 104, five rats/sex/group were sacrificed for hepatocellular proliferation studies.

Hematoxylin-and-eosin-stained sections of three liver lobes (left lateral, median, and right lateral) were evaluated microscopically from

the rats of Groups 1, 5, and 7 sacrificed at Weeks 1, 2, and 13 and from five rats/sex/group in Groups 1, 3, 4, 5, and 6 at Week 104.

At Week 79, complete sets of protocol-specified tissues from 10 rats/sex/group in the control and high-dose (Group 5) groups and the liver, testes with epididymides, uterus, spleen, kidneys, and gross lesions from 10 Group 4 rats/sex were examined microscopically.

Complete sets of protocol-specified tissues were examined microscopically from all Group 1 and Group 5 rats which were sacrificed at termination of the study (after 104 weeks) and from all rats that died or were sacrificed in extremis during the study. In addition, liver, testes with epididymides, uterus, spleen, kidneys, and gross lesions were examined from the rats in Groups 2, 3, 4, and 6 sacrificed at termination. Pituitary gland was also examined from male rats sacrificed at termination.

Results

Week 1 Sacrifice - Liver sections examined from the Group 1, 5, and 7 rats revealed increased numbers of mitotic figures in the Group 5 (high dose) males and females and Group 7 (positive control) males. Also, minimal individual cell necrosis was noted in the livers of 4/5 males in Group 7. Minimal focal necrosis was present in single male and female control rats.

Week 2 Sacrifice - Minimal to slight diffuse hepatocellular enlargement was present in liver sections from rats in Group 5, in addition to the presence of increased cytoplasmic eosinophilia. Minimal or slight focal hepatocellular necrosis was present in three Group 5 males. In the Group 7 rats, moderate diffuse hepatocellular enlargement and increased cytoplasmic eosinophilia were present and individual cell/focal necrosis was noted in all five rats.

Week 13 Sacrifice - In liver sections from Group 5 rats at Week 13, increased cytoplasmic eosinophilia and slight diffuse hepatocellular enlargement were present. Focal necrosis (minimal or slight) was present in two Group 5 males. In Group 7 rats, in addition to increased cytoplasmic eosinophilia and moderate hepatocellular enlargement, pigment and individual cell necrosis were present.

Week 79 Sacrifice - Compound-related histomorphologic alterations were noted in liver and kidney sections from the Group 5 (12,500 ppm) males and females and in the pituitary, testes, epididymides, and pancreas of the Group 5 males.

Liver changes consisted of increased cytoplasmic eosinophilia and moderate diffuse hepatocellular enlargement. Also, pigment was noted in Kupffer cells/hepatocytes of 16 rats in Group 5 (9 males, 7 females). Hepatocellular neoplasms were present in 8/20 rats (five males, three females) and consisted of two adenomas and six carcinomas. Hepatocellular neoplasms were not present in the control rats. Hepatocellular adenoma was present in a Group 4 male (No. B29106) and is considered to be a spontaneous neoplasm. There were no compound-related histomorphologic alterations in liver sections from the Group 4 (2,500 ppm) rats.

Kidney sections from male and female rats of Group 5 revealed increased tubule cell pigment, and the severity of nephropathy in the males was increased slightly compared to the control group. In the pancreas of Group 5 males, an increase in proliferative lesions of acinar cell origin consisted of focal hyperplasia in three rats and an adenoma in one rat. Proliferative lesions of acinar cell origin were not observed in the pancreas of control rats or in Group 5 females.

Pituitary sections revealed increased numbers of castration cells in seven Group 5 males. Bilateral aspermatogenesis was present in all Group 5 males and was accompanied by hypospermia in the epididymides. Unilateral aspermatogenesis was present in four control males and in three

Group 4 males with normal spermatogenic activity in the contralateral testis. A decrease in interstitial cell tumors of the testes was noted in Group 5 males (3/10) compared to the control (9/10) and Group 4 (10/10) rats.

A variety of spontaneous disease lesions and incidental findings occurred without relationship to treatment. Early mononuclear cell leukemia was present in single rats of Groups 1, 4, and 5. The most common findings were peribronchial/perivascular lymphoid infiltration in the lungs; chronic inflammation, bile duct hyperplasia, inflammation, and fibrosis in the liver; and chronic progressive nephropathy and microconcretions in the tubules of the kidneys. Heart sections revealed degenerative cardiomyopathy of minimal or slight severity in many of the control and high-dose rats. Neoplastic findings occurred primarily in the testes and are typical for rats of this age and strain.

Terminal Sacrifice

Text Table 1 presents survival data, including the numbers of rats in the various groups at termination of the study and unscheduled deaths during Weeks 1-79 and 80-106.

Text Table 1
Survival Data

Sex	Male						Female					
Group	1	2	3	4	5	6	1	2	3	4	5	6
Unscheduled Deaths												
Weeks 1-79	2	2	2	4	2	1	2	1	2	3	3	2
Weeks 80-106	8	13	10	13	13	14	8	7	8	10	12	15
Interim Sacrifice												
Week 79	15	-	-	15	15	-	15	-	-	15	15	-
Terminal Sacrifice	45	40	43	38	40	40	45	47	45	42	40	38
Total[a]	70	55	55	70	70	55	70	55	55	70	70	55

[a]Does not include five rats/sex/group in Groups 1-5 sacrificed at Weeks 1, 2, and 13 for cell proliferation studies.

Compound-related histomorphologic alterations were noted in the livers of rats in Groups 5 and 6 and in the kidneys of male rats of Groups 5 and 6 and female rats of Group 5. Liver changes in Group 5 rats consisted of increased cytoplasmic eosinophilia in 58 rats and diffuse hepatocellular enlargement in 54 rats (23/40 males, 31/40 females). Pigment was noted in Kupffer cells/hepatocytes of 33/40 males and 15/40 females in Group 5. Hepatocellular neoplasms occurred with increased frequency in Group 5 and 6 males and to a lesser degree in the females of these groups, as presented in Text Table 2.

Text Table 2
Hepatocellular Neoplasia - Terminal Sacrifice

Sex	Male						Female					
Group	1	2	3	4	5	6	1	2	3	4	5	6
Number Examined	45	35	43	38	40	40	45	42	45	42	40	38
Hepatocellular												
Adenoma	4	4	2	6	18	10	0	3	1	1	3	5
Carcinoma	1	0	1	1	17	7	0	1	0	1	11	3

In the kidneys, mineralization of the renal papilla and pigment in tubule cells occurred with increased incidence and severity in male rats of Groups 5 and 6, as presented in Text Table 3.

Text Table 3
Mineralization of Renal Papilla and Tubule Cell Pigment in Male Rats

Group	1	2	3	4	5	6
Number Examined	40	35	39	35	37	36
Mineralization of Renal Papilla						
Minimal	7	12	16	16	18	20
Slight	0	1	1	2	13	12
Total	7	13	17	18	31	32
Tubule Cell Pigment						
Minimal	38	31	31	21	0	5
Slight	2	2	6	11	32	27
Moderate	0	1	1	0	5	1
Moderately Severe	0	1	1	2	0	3
Severe	0	0	0	1	0	0
Total	40	35	39	35	37	36

Tubule cell pigment was also slightly increased in severity in female rats of Groups 5 and 6. This finding is often noted in association with mononuclear cell leukemia, but was also observed in the absence of leukemia. Chronic progressive nephropathy occurred with slightly increased severity in Group 5 and 6 males and Group 6 females.

In the testes, the incidence of interstitial cell neoplasia was greatly reduced in rats of Groups 5 and 6 (12/39 and 11/38, respectively) compared to the control group (41/44). Also, increased castration cells were noted in the pituitary gland of 18 Group 5 males and 17 Group 6 males.

A variety of spontaneous disease lesions and incidental findings occurred without relationship to treatment. The most common findings were peribronchial/perivascular lymphoid infiltration in the lungs; focal mononuclear cell infiltration, chronic inflammation, bile duct hyperplasia, inflammation, and fibrosis in the liver; and microconcretions in the tubules of the kidneys. Heart sections revealed degenerative cardiomyopathy of minimal or slight severity in many of the control and

high-dose rats. Mononuclear cell leukemia occurred in rats sacrificed at termination, as presented in Text Table 4.

Text Table 4
Mononuclear Cell Leukemia - Terminal Sacrifice

Group	1	2	3	4	5	6
Males	7/45	6/35	10/43	19/38	14/40	20/40
Females	8/45	13/42	5/45	8/42	10/40	9/38
Total	15	19	15	27	24	29

Note: Numerals represent the number of animals with finding over the number of animals observed.

Unscheduled Deaths

One hundred fifty-seven rats (84 males, 73 females) died or were killed in a moribund condition during the course of the study.

The most common cause of death was mononuclear cell leukemia in 92 rats (55 males, 37 females), and as noted in Text Table 5, mononuclear leukemia was observed slightly more frequently as the cause of death in rats of Groups 4, 5, and 6.

Text Table 5
Mononuclear Leukemia as Cause of Death

Group	1	2	3	4	5	6
Males	8	7	6	13	12	9
Females	5	3	6	7	7	9
Total	13	10	12	20	19	18

Pituitary neoplasia as the cause of death was noted in 28 rats (11 males, 17 females). In four rats, both leukemia and pituitary neoplasm were present as multiple death causes. A variety of other neoplastic or inflammatory processes resulted in death of occasional rats.

Discussion

The total incidence of hepatocellular neoplasia is presented in Text Table 6.

Text Table 6
Hepatocellular Neoplasia

Sex	Male						Female					
Group	1	2	3	4	5	6	1	2	3	4	5	6
Number Examined	80	50	55	65	80	55	80	50	55	65	80	55
Hepatocellular												
Adenoma	4	5	3	8	21	12	0	3	1	2	8	6
Carcinoma(s)	1	0	1	3	24	7	0	1	0	1	14	4
Multiple Neoplasms[a]	0	2	0	2	19	2	0	0	0	0	2	1
Total Rats with Hepatocellular Neoplasms	5	5	4	11	34	18	0	4	1	3	21	9

[a]Both adenoma and carcinoma or multiple adenomas/carcinomas.

As noted, the incidence of hepatocellular neoplasia was increased in rats of both sexes in Group 5 when compared to the control and lower-dose groups. The occurrence of hepatocellular neoplasia was increased to a lesser degree in rats of Group 6, which received the test article at the high-dose dietary level of 12,500 ppm for 78 weeks and then received the basal diet for the remainder of the study. The hepatocellular neoplasms occurred late in the study, with the earliest neoplasms noted at the 78-week interim sacrifice. In the 55 Group 5 rats with hepatocellular neoplasms, only 9 rats (4 males, 5 females) died prior to scheduled sacrifice and death was attributed to hepatocellular neoplasia in only one Group 5 male. The incidence and severity of foci of basophilic cellular alteration were decreased in rats of both sexes in Groups 4, 5, and 6.

As noted previously, mononuclear cell leukemia as the cause of death occurred with greatest frequency in rats of Groups 4, 5, and 6. The total incidence of mononuclear cell leukemia is presented in Text Table 7.

Text Table 7
Mononuclear Cell Leukemia

Group	1	2	3	4	5	6
Males	15	13	16	32	27	29
Females	14	17	11	16	17	18
Total	29	30	27	48	44	47

Although hepatocellular enlargement and increased cytoplasmic eosinophilia occurred as treatment-related changes in Group 5 rats, the presence of hepatopathy associated with leukemia often precluded the determination of these findings.

In addition to increased severity of nephropathy and mineralization of the renal papilla, increased tubule cell pigment was present in male rats of Groups 5 and 6 and females of Group 5. Primary renal neoplasms were not present in rats of Groups 4, 5, and 6.

Conclusion

In conclusion, dietary administration of Di(2-ethylhexyl)-phthalate to Fischer-344 rats for at least 104 weeks at a level of 12,500 ppm (Group 5) resulted in compound-related histomorphologic alterations in the liver and kidneys in rats of both sexes and in the pituitary, testes, and epididymides of the males. Liver changes noted in Group 5 rats sacrificed at Weeks 1, 2, and 13 for cell proliferation studies consisted of increased mitotic activity (Week 1) and increased cytoplasmic eosinophilia and diffuse hepatocellular enlargement (Weeks 2 and 13). Liver changes at the 79-week interim sacrifice and at termination consisted of increased cytoplasmic eosinophilia, diffuse hepatocellular enlargement, pigment in Kupffer cells/hepatocytes and increased hepatocellular neoplasia. Although the incidence of hepatocellular neoplasia was also increased in rats of the high-dose recovery group (Group 6) at the terminal sacrifice, the numbers of animals

with neoplasms and the occurrence of multiple neoplasms were decreased compared to Group 5.

Kidney changes in the high-dose rats after 104 weeks of test material administration consisted of increased tubule cell pigment (males and females) and increased severity of nephropathy and mineralization of the renal papilla in the males. Castration cells were noted in the pituitary of 18 of 35 Group 5 males and 17 of 33 Group 6 males at termination. Bilateral aspermatogenesis was present in all high-dose males at the 79-week interim sacrifice and a decreased incidence of interstitial cell neoplasia was noted in testes of Group 5 (high dose) and 6 (high-dose recovery) males compared to control and lower-dose groups at termination. The presence of mononuclear leukemia as the cause of death was slightly higher in rats of Groups 4, 5, and 6, and the total incidence of leukemia was greatest in rats of these groups.

Other spontaneous disease lesions were of the expected types and severity for rats of this age and strain.

Pathologist:

Richard W. Voelker 9-27-96

Richard W. Voelker, D.V.M., Ph.D., Date
Diplomate, American College of Veterinary Pathologists
Department of Pathology

ANCILLARY STUDIES REPORT
CHV PROJECT 663-134
MEASUREMENT OF CHEMICALLY-INDUCED CELL PROLIFERATION AND PEROXISOME PROLIFERATION IN LIVERS OF MALE AND FEMALE RATS IN AN ONCOGENICITY STUDY WITH DI(2-ETHYLHEXYL)PHTHALATE

I. INTRODUCTION

The cell proliferation assay described in this study is designed to measure the fraction of rat liver cells undergoing cell replication (1,2). Animals were fed Di(2-ethylhexyl)-phthalate (DEHP) daily and the livers isolated following administration of bromodeoxyuridine (BrdUrd) in vivo with ALZET® osmotic pumps implanted subcutaneously for 72 hours. The pumps were implanted at several timepoints to determine the pattern of the proliferative response. Quantitation of the fraction of proliferating cells in the tissue sections can be correlated with other endpoints such as toxicity and carcinogenicity.

It is not apparent how cell proliferation acts on the carcinogenic process, but there are numerous processes that can be affected during replication (3-6). Chemically induced cell proliferation may increase the probability of spontaneous mutations as well as increase the probability of converting DNA adducts into mutations prior to a repair process. Unscheduled cell proliferation may also play a role in the expansion of preneoplastic cells leading to the emergence of a fully transformed clone of cells. Some of these examples act by nongenotoxic mechanisms.

One nongenotoxic mechanism thought to be involved in cell proliferation is hepatocellular peroxisome proliferation. The test chemical, DEHP, comes from a family of chemicals being investigated for their ability to induce both peroxisome proliferation and cell proliferation (6). Animals exposed to some agents which are known to induce peroxisome proliferation have an increased risk for tumor formation in the liver. For this reason, the activity of palmitoyl-CoA oxidase was also determined from liver homogenates prepared from

treated and control animals. The stimulation of this enzyme is related to peroxisome proliferation. Hepatocellular DNA and protein content were also determined.

II. METHODS

A. Cell Proliferation

Details of the study design are presented elsewhere in the report. Briefly, rats were placed in Groups 1 to 7 and administered DEHP or a positive control compound (Wy 14,643) in the diet. The test compound was administered at 0, 100, 500, 2500 and 12,500 ppm; Wy 14,643 was administered at 1000 ppm to male rats only for the first 13 weeks. A high dose recovery group (Group 6) was also included in the dosing. This group received 12,500 ppm of DEHP and animals were removed from the test diet after 78 weeks. The only Group 6 timepoint for analysis of cell proliferation and biochemical analysis was week 104. At the end of weeks 1, 2, 13 and 104, five animals per sex from all designated groups were labeled with BrdUrd (20 mg/ml; 10 μl/hr) for 72 hours using ALZET® osmotic pumps, Model No. 2ML1 (ALZA Corporation, Palo Alto, CA). A single lot of osmotic pumps was used for each sacrifice. ALZET® Model No. 2ML1 has a 2000 μl capacity with a pump rate of approximately 10 μl/hr. At the time of sacrifice, samples of the liver and duodenum were fixed in 10% neutral Formalin and later embedded in paraffin. Unfixed samples of the livers were frozen for biochemical analysis. At weeks 1, 2 and 13, Groups 1 (0 ppm), 5 (12,500 ppm) and 7 (Wy 14,643) were analyzed and Groups 2 through 4 saved for possible future analysis. At the end of 104 weeks, animals from Groups 1 (0 ppm), 3 (500 ppm), 4 (2500 ppm), 5 (12,500 ppm) and 6 (high dose recovery group) were analyzed. Group 2 was saved for possible future analysis of labeling index. Biochemical analysis was inadvertently done with Group 2 rats (data not shown).

For the cell proliferation portion of the study, five micron paraffin embedded sections from the left lateral, median and right lateral lobes of the livers of each animal as well as samples from the duodenum were taken and processed for immunohistochemistry. Each slide was prepared with sections from both liver and duodenum so that the duodenum (a rapidly proliferating organ) could be used as an internal control for delivery of label and immunohistochemical staining. The slides were deparaffinized and rehydrated prior to staining. The slides were stained for determination of cell proliferation as measured by incorporation of BrdUrd into DNA using Biogenix antibodies with peroxidase-conjugated streptavidin and a 3,3-diaminobenzidine tetrahydrochloride (DAB) chromogen and hematoxylin counterstain. Samples from all groups were also processed for analysis by a pathologist.

The section of the duodenum was microscopically examined to ensure that the label was properly administered to the animal. Once label delivery was confirmed, slides from the different lobes were examined for lobular differences. In animals from weeks 1, 2 and 13, labeling was similar among the lobes, therefore cell counting was performed with sections from the left lateral lobe. At week 104, there was an occasional increase in labeling in one or two of the lobes of some animals. Because of this observation, one slide from each lobe was counted from each animal. The percentage of nuclei incorporating label in the liver was determined microscopically at approximately 400 to 600X magnification. The areas to be counted were randomly generated by computer. A 1.0 mm square indexed ocular grid divided into 10 x 10 squares was used to define the counting area. At least 2000 nuclei were examined per animal with a minimum of 3 sections and 6 fields per section.

Any nuclei that were blue were considered unlabeled and any nuclei containing any brown chromogenic hue were considered

labeled unless a clear artifact was present. Only hepatocyte nuclei were enumerated. Fields that contained areas of necrosis or hepatocellular neoplasms were not included in the evaluation. The slides were coded for (blind) evaluation as to treatment group.

S-phase nuclei labeling indices for each animal were calculated as follows:

$$\text{Labeled S-phase nuclei (LI)} = \frac{\text{no. of labeled hepatocyte nuclei}}{\text{total no. of hepatocytes counted}}$$

B. Biochemical Analyses

1. Sacrifice

Three days following implantation of the osmotic pumps at each timepoint, up to five animals/sex were sacrificed and livers were frozen for biochemical analyses. The appropriate test diet (control or containing DEHP or Wy 14,643) was administered to the respective animals up to time of sacrifice. DNA, protein and palmitoyl-CoA oxidase analyses were performed. Livers not scheduled for analysis were saved for possible future processing.

2. Liver Homogenization

Samples of livers were rinsed in cold homogenization buffer [50 mM tris(hydroxymethyl)aminomethane hydrochloride (tris·HCl), pH 8.3, 154 mM KCl], minced and homogenized using a Potter-Elvehjem-type homogenizer. Following centrifugation at 3300 x g, the supernatant was filtered through gauze pad/spun glass and stored at -70°C for determination of protein and palmitoyl-CoA oxidase activity.

Preparation of livers for determination of DNA content proceeded as described for protein and enzyme analysis up to the homogenization step. After homogenization, the samples were precipitated in the presence of cold trichloracetic acid (TCA) and centrifuged. The precipitate was washed twice with 10% cold TCA and then washed with 95% ethanol. The washed precipitate was suspended in 5% TCA and heated to 90 ± 3°C for 15 minutes. The samples were then centrifuged, washed once with cold 5% TCA and the supernatants collected. The supernatants were stored at -70°C for later use. At the first three timepoints, 0.75% TCA was used to precipitate the DNA instead of ~7.5% and 1% (instead of 10%) or 0.5% (instead of 5%) TCA was used for the remainder of the extraction due to a technical error.

3. Determination of Palmitoyl-CoA Oxidase Activity

The oxidation of palmitoyl-CoA was determined by measurement of the formation of β-adenine dinucleotide, reduced form (NADH) at A_{340} following incubation of substrate, liver homogenate, and cofactors. The reaction was performed in the presence of KCN to inhibit the reoxidation of NADH (7,8).

Liver homogenates containing 100 μg of protein in a volume of 5 μl were mixed with 45 mM Tris·HCl, 1 mM β-nicotinamide adenine dinucleotide (NAD), 0.1 mM coenzyme A (CoA), 1 mM dithiothreitol (DTT), 75 μg/ml bovine serum albumin (BSA), 0.01 mM flavin adenine dinucleotide (FAD), 0.01% Triton X-100 and 1 mM KCN. The samples were incubated at 37°C in a spectrophotometer with temperature controlled cuvette carriage until readings at A_{340} stabilized. The reaction was then started by adding 40 nM of the substrate (palmitoyl-CoA). Readings were taken at A_{340} at 1 minute intervals for at least 10 minutes. Nanomoles of NAD reduced per minute was determined by multiplying the change in absorbance of

samples minus controls per minute by the extinction coefficient (6.22).

4. Determination of Protein of Liver

Protein concentrations of liver homogenates were determined using the Lowry Reagent, Modified (Sigma Diagnostics, St. Louis, MO). This involves a colorimetric reaction between proteins and Folin and Ciocalteu's Reagent.

5. Determination of DNA Content of Liver.

The procedure for the determination of DNA was based on the finding that DNA can be separated from other tissue compounds by its preferential solubility in hot trichloroacetic acid (TCA). Lipids were removed with an alcohol wash. The isolated DNA was then quantitated by means of diphenylamine which produces a colorimetric reaction involving the pentose component of DNA.

C. Statistical Analysis

Statistical analysis of labeling index, palmitoyl-CoA oxidase activity, DNA and protein were performed using one-way analysis of variance techniques (9) for each sacrifice interval. Control versus DEHP treatment group comparisons were done with Dunnett's t-test (10,11). In the case of variance heterogeneity, rank transformation of the data was performed prior to analysis of variance and Dunnett's t-test. The control (Group 1) versus positive control group comparisons were done using Students's t-test (9). The outcome of the statistical analyses are indicated in Text Table 1.

III. RESULTS AND DISCUSSION

A. Cell Proliferation Results

1. General Observations

Cells stained with the brown DAB chromogen were observed in the duodenum from all of the animals used in the study. The presence of label in all the animals indicated proper delivery of the BrdUrd label and acceptable immunohistochemical staining. There was no apparent preferential labeling in any of the lobes at the 1 week, 2 week and 13 week timepoints. In addition, the label was random within the lobes, except where necrosis was observed. The necrotic areas were noted but not included in the count. At week 104, there was an occasional increase in labeling in some lobes of some animals. Because of this observation, one slide from each lobe was counted from each animal instead of the usual three from the left lobe. The labeling that was observed was clustered, unlike the random labeling observed at week 1. See Appendix B for further discussion on lobular labeling patterns.

Microscopic evaluation of H&E stained liver sections from rats used for evaluation of cell proliferation was performed by a pathologist.

In the animals from the terminal sacrifice, several of the rats had leukemia with or without hepatopathy. A summary of the pathology observations for the terminal sacrifice is shown in Text Table 4. Animals with leukemia and hepatopathy were not analyzed for cell proliferation since the cell proliferation labeling index could be affected by degenerative/regenerative changes. However, rats with early leukemia that had small hepatocellular neoplasms that could be avoided during cell counting, were not excluded. There

were five male rats, one in Group 3, three in Group 4 and one in Group 6 that were eliminated. One female rat in Group 3 was eliminated from evaluation. In addition, only four female rats were available for analysis from Group 6 females (technical error). Biochemistry (DNA, protein and palmatoyl CoA oxidase) was performed on all livers but the data from only the animals used for evaluation of cell proliferation is included in the evaluation (see Text Table 1). Individual values are shown in Appendix 10.

2. Summary of Labeled Cell Counts for the Liver

A summary of the labeled cell counts for each group is shown in Text Table 1. The mean labeling index (LI) for each group is presented in the third column.

At the first interim sacrifice, the background labeling index (Group 1) for male rats was 0.57% and the background labeling index for female rats was 1.59%. Significant increases were observed in the dosed group (Group 5; $p \leq 0.01$) in both male and female animals. Cell proliferation was not increased by the chemical at the other three timepoints. The lack of an increase in the LI at weeks 2, 13 and 104 was observed even though large increases in palmitoyl-CoA oxidase were observed (see Section III.B.). When slides for week 104 animals were analyzed for lobular differences, some lobes were observed that had, what appeared to be elevated labeling indices compared to other lobes from the same animals. Because of this observation, the three liver sections per animal that were counted for cell proliferation consisted of one slide from the left lateral lobe, one slide from the median lobe and one slide from the right lateral lobe instead of three slides from the left lateral lobe. The observation that some of the animals had lobular differences at week 104 did not coincide with a significant increase in the labeling index. However, since

there were lobular differences, the data was also analyzed looking at labeling indices in the individual lobes.

Labeling indices organized by group and by liver lobe are shown in Text Table 2. Labeling indices below 1% are considered similar. The differences observed among the lobes is slight and appears most pronounced in Group 6 males. To look at this closer, the individual animal counts for Groups 1, 5 and 6 were organized by lobe. These results are shown in Text Table 3.

Sporadic elevation in the labeling index was observed in some lobes, primarily in Group 6 males. However, the increases were small (except for animal number 29427) and no consistent pattern was observed. The observation that increases in labeling indices were present in some animals probably related to the pattern of labeling that was observed. It was clustered and gave the impression that it was much higher than it actually was when random counts were made (see Appendix 10). The animals were 104 weeks old and the changes in pattern and lobular labeling may have been related to the age of the animals or to underlying disease.

Large increases in the labeling index ($p \leq 0.05$) were observed in the first sacrifice in the positive control (1000 mg/kg Wy 14,643; Group 7). The positive control response was not considered significantly elevated in the second sacrifice even though the labeling index increased by close to 8-fold. The positive control in the third sacrifice was significantly elevated ($p \leq 0.05$) even though the labeling index in the positive control animals remained less than 1%. The apparent incongruity of the results appears to be related to the variability or consistency of the responses seen among the animals. This is often observed in a weak response. No positive control animals were included for the week 104 sacrifice.

These results demonstrate that DEHP induced significant increases in the LI in the liver in male and female rats only during the first week of dosing. At Weeks 2, 13 and 104, the labeling indices for both sexes were similar to the controls. Large increases in the labeling index were observed in the positive control animals at Week 1, but questionable responses were observed at Weeks 2 and 13. The labeling index of Wy 14,643 is known to decrease with time (6,12).

B. Results from Biochemical Analyses.

1. Palmitoyl-CoA Oxidase Activity

Increases in palmitoyl-CoA oxidase activity ($p \leq 0.01$) were observed in Group 5 rats (12,500 ppm) at all timepoints. At week 104, there was also an elevation in palmatoyl-CoA oxidase activity in male ($p \leq 0.05$) and female rats ($p \leq 0.01$) at 2500 ppm. Animals dosed with 2500 ppm were only evaluated at Week 104. Results are summarized in Text Table 1 (column 4) and are expressed as nanomoles of NADH generated per minute per mg of protein.

2. DNA and Protein Analyses

Levels of DNA varied randomly among the groups at weeks 1, 2 and 13 (Text Table 1, column 6). At the terminal sacrifice, female rats in Groups 4, 5 and 6 had small but statistically significant increases. Group 6 males from the terminal sacrifice were also elevated. These results do not correlate with the cell proliferation data and may reflect an increase in DNA which could be the result of an increase in ploidy or an increase in multinucleates.

As discussed in II.B.2, Liver Homogenization, different TCA concentrations were used to precipitate the DNA for the

Week 1, 2, and 13 samples versus Week 104, with no effect on data interpretation.

Protein analysis did not indicate a clear pattern in any of the groups at any of the sacrifice times.

C. Liver Weights

Liver weights were significantly elevated in Group 5 animals throughout the study in both male and female rats. Group 4 female rats from the terminal sacrifice were also significantly elevated as were the positive control animals included at 1, 2 and 13 weeks (Text Table 1, column 7).

IV. Conclusions

Significant increases in the labeling index were observed during Week 1 in the livers of male and female rats treated with the test material. The response was not observed at Weeks 2, 13 or 104. Increases in palmitoyl CoA oxidase, a monitor of the level of peroxisome proliferation were observed at all four timepoints. Therefore, there is no evidence for sustained cell proliferation associated with the peroxisome proliferation induced by di(2-ethylhexyl)phthalate. However, some evidence for an elevation in DNA per gram of liver was observed at week 104. It is possible that these increases reflect a slow accumulation in DNA as a result of increases in ploidy or increases in multinucleates not detected in the short labeling period used for cell proliferation.

Maria A. Cifone / 9-27-96

MARIA A. CIFONE, PH.D./Date
Department of Genetic and Cellular Toxicology

Figure 1. Photomicrographs of liver sections from animal # 28720, a male rat from the high dose recovery group that received 12,500 ppm of DEHP; was removed from the test diet after 78 weeks and sacrificed at week 104. A. Median lobe; L.I. = 0.14. B. Left lateral lobe; L.I. = 6.57. Magnification = 300X.



Figure 2. Photomicrographs of liver sections from week 1 sacrifice. A. Animal # 28720, a female that received 0 ppm of DEHP for 1 week. Left lateral lobe; L.I. = 0.86. B. Animal # 29339, a female rat that received 12,500 ppm of DEHP for 1 week. Left lateral lobe; L.I. = 6.57. Magnification = 300X.

Figure 3. Photomicrographs of liver sections from animal # 29421,, a male rat from the high dose recovery group that received 12,500 ppm of DEHP; was removed from the test diet after 78 weeks and sacrificed at week 104. A.& B. Right lateral lobe; L.I. = 2.29. Magnification = 300X.

V. References

(1) DeFazio, A., Leary, J.A., Hedley, D.W. and Tattersall, M.H.N. (1987). Immunohistochemical detection of proliferating cells in vivo. J. Histochem. Cytochem. 35, 571-577.

(2) Lanier, T.L., Berger, E.K., and Eacho, P.I. (1989). Comparison of 5-bromodeoxyuridine and ^{3}H-thymidine in rodent hepatocellular proliferation studies. Toxicologist 9, 64.

(3) Craddock, V.M. (1976). Cell proliferation and experimental liver cancer. In: "liver Cell Cancer", Cameron, H.M., Linsell, C.A. and Warwick, G.P., Elsevier, North Holland Biomedical Press, Amsterdam.

(4) Columbano, A., Rajalaksmi, S., and Sarma, D.S.R. (1981). Requirement of cell proliferation for the initiation of liver carcinogenesis as assayed by three different procedures. Cancer Res. 41, 2079-2083.

(5) Glinos, A.D., Butcher, N.L. R., and Aub, J.C. (1951). The effect of liver regeneration on tumor formation in rats fed 4-diaminobenzene. J. Exp. Med. 933, 313-324.

(6) Marsman, D.S., Cattley, R.C., Conway, J.G., and Popp, J.A. (1988). Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in rats. Cancer Res. 48, 6739-6744.

(7) Inestrosa, N.C., Bronfman, M. and Leighton, F. (1979). Detection of peroxisomal fatty acyl-coenzyme A oxidase activity. Biochem. J. 182, 779-788.

(8) Gray, T.J.B., Lake, B.G., Beamand, J.A., Foster, J.R., and Gangolli, S.D. (1983). Peroxisome proliferation in primary cultures of rat hepatocytes. Toxicology and Applied Pharmacology 67, 15-25.

(9) Winer, B.J. (1971). Statistical Principles in Experimental Design, McGraw-Hill, New York, 2nd Edition, pp. 149-220.

(10) Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50, 1096-1121.

(11) Dunnett, C.W. (1964). New tables for multiple comparisons with a control. Biometrics 20, 482-491.

(12) Eacho, P.I., Lanier, T.L. and Brodhecker, C.A. (1991). Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883. Carcinogenesis 12, 1557-1561.

TEXT TABLE 1
ONCOGENICITY STUDY IN RATS WITH DEHP
CELL PROLIFERATION AND BIOCHEMICAL ANALYSIS SUMMARY

Sacrifice	Group/Sex[a]	Labeling Index[b]	nm NADH/min/ mg protein[c]	mg protein/g liver	mg DNA/g liver	Liver Weight (g)
Week 1	1/M	0.57 ± 0.23	0.50 ± 0.12	137.06 ± 19.00	1.49 ± 0.23	5.68 ± 0.41
	5/M	11.06 ± 7.48** ↑	1.78 ± 0.62** ↑	212.00 ± 54.40* ↑	1.22 ± 0.37** ↑	7.69 ± 0.64** ↑
	7/M	13.21 ± 8.37** ↑				7.96 ± 0.58** ↑
	1/F	1.59 ± 1.32	0.73 ± 0.22	143.69 ± 25.31	1.84 ± 0.32	4.74 ± 0.26
	5/F	11.73 ± 8.09** ↑	1.80 ± 0.38** ↑	150.34 ± 10.29	0.71 ± 0.13** ↓	5.97 ± 0.40** ↑
Week 2	1/M	0.24 ± 0.27	0.54 ± 0.05	148.36 ± 16.06	0.69 ± 0.13	7.36 ± 0.44
	5/M	0.31 ± 0.10	3.62 ± 0.44** ↑	156.68 ± 22.55	1.15 ± 0.16** ↑	12.40 ± 1.56** ↑
	7/M	2.02 ± 1.92				13.56 ± 1.13** ↑
	1/F	0.48 ± 0.22	0.50 ± 0.08	144.87 ± 31.09	1.49 ± 0.43	4.02 ± 0.84
	5/F	0.60 ± 0.34	2.50 ± 0.60** ↑	141.29 ± 11.44	1.30 ± 0.30	7.73 ± 1.42** ↑
Week 13	1/M	0.12 ± 0.09	0.60 ± 0.10	126.44 ± 7.52	1.14 ± 0.26	9.17 ± 0.10
	5/M	0.15 ± 0.07	2.96 ± 1.38** ↑	138.46 ± 17.47	1.19 ± 0.17	15.34 ± 1.16** ↑
	7/M	1.15 ± 0.94* ↑				15.79 ± 0.73** ↑
	1/F	0.31 ± 0.35	0.55 ± 0.09	121.21 ± 8.97	1.47 ± 0.59	5.37 ± 0.51
	5/F	0.21 ± 0.14	2.43 ± 0.56** ↑	152.53 ± 12.27** ↑	1.16 ± 0.32	8.97 ± 0.53** ↑
Week 104	1/M	0.30 ± 0.17	0.63 ± 0.09	147.57 ± 21.81	2.93 ± 1.17	10.89 ± 1.08
	3/M[d]	0.42 ± 0.37	0.46 ± 0.10	181.56 ± 15.80** ↑	3.28 ± 1.12	11.58 ± 1.56
	4/M[e]	0.36 ± 0.10	1.08 ± 0.18* ↑	167.83 ± 11.73	5.13 ± 1.92	12.30 ± 0.51
	5/M	0.41 ± 0.38	2.27 ± 0.82** ↑	175.05 ± 9.48** ↑	4.42 ± 0.20	17.16 ± 0.95** ↑
	6/M[d]	1.21 ± 0.94	0.46 ± 0.27	153.99 ± 3.06	4.81 ± 0.25* ↑	11.15 ± 0.32
	1/F	1.03 ± 0.59	0.47 ± 0.11	154.62 ± 16.50	2.18 ± 0.49	7.36 ± 0.55
	3/F[d]	0.51 ± 0.16	0.40 ± 0.05	147.12 ± 12.45	2.13 ± 0.42	8.00 ± 0.37
	4/F	0.19 ± 0.11	0.90 ± 0.13** ↑	177.15 ± 10.11* ↑	3.26 ± 0.18** ↑	9.76 ± 0.64** ↑
	5/F	0.27 ± 0.17	2.39 ± 0.35** ↑	173.92 ± 11.64	3.80 ± 0.44** ↑	11.67 ± 0.86** ↑
	6/F[d]	0.38 ± 0.22	0.54 ± 0.19	153.58 ± 11.65	4.30 ± 0.31** ↑	7.79 ± 1.18

a 5 animals per group
b Number of labeled hepatocyte nuclei per total number of hepatocytes counted (at least 2000)
c Measurement of CN insensitive palmitoyl CoA oxidase; expressed as nanomoles NADH generated per minute per mg protein
d 4 animals per group
e 2 animals per group
* Significant at $p \leq 0.05$
** Significant at $p \leq 0.01$
↑ Increase in the mean;
↓ Decrease in the mean

TEXT TABLE 2 - Terminal Sacrifice
Lobular Labeling
Group Means

Group	Animal per Group	Mean Labeling Index (%)[a] Left Lateral Lobe	Media Lobe	Right Lateral Lobe
1/M	5	0.34 ± 0.33	0.23 ± 0.26	0.34 ± 0.26
3/M	4	0.29 ± 0.31	0.39 ± 0.49	0.57 ± 1.05
4/M	2	0.50 ± 0.30	0.36 ± 0.30	0.21 ± 0.30
5/M	5	0.29 ± 0.34	0.66 ± 0.74	0.29 ± 0.29
6/M	4	1.86 ± 3.16	0.61 ± 0.84	1.18 ± 1.20
1/F	5	0.74 ± 0.58	1.00 ± 0.65	1.34 ± 0.76
3/F	4	0.04 ± 0.07	0.46 ± 0.21	1.04 ± 0.62
4/F	5	0.20 ± 0.22	0.14 ± 0.17	0.23 ± 0.16
5/F	5	0.09 ± 0.13	0.17 ± 0.16	0.54 ± 0.40
6/F	4	0.14 ± 0.12	0.36 ± 0.34	0.64 ± 0.38

[a]Number of labeled hepatocyte nuclei per total number of hepatocytes counted (at least 700)

TEXT TABLE 3 - Terminal Sacrifice
Lobular Labeling in Control,
High Dose and High Dose Recovery Rats
Individual Animal Counts

Animal ID	Group	Labeling Index (%)* Left Lateral Lobe	Media Lobe	Right Lateral Lobe
28662	1/M	0.00	0.00	0.43
28663	1/M	0.00	0.00	0.57
28664	1/M	0.71	0.14	0.00
28665	1/M	0.57	0.57	0.57
28666[a]	1/M	0.43	0.43	0.14
29282[c]	5/M	0.14	0.86	0.57[c]
29283	5/M	0.71	0.29	0.00
29284	5/M	0.00	0.00	0.29
29285	5/M	0.00	0.29	0.00
29287[a]	5/M	0.57	1.86	0.57
29421[b]	6/M	0.71	1.86	2.29
29422	6/M	0.14	0.14	2.14
29426	6/M	0.00	0.29	0.14
29427	6/M	6.57	0.14	0.14
28747	1/F	0.29	1.14	2.14
28748	1/F	0.43	0.29	0.29
28749[a]	1/F	1.71	1.86	2.00
28750	1/F	0.43	0.43	1.00
28751	1/F	0.86	1.29	1.29
29370	5/F	0.00	0.00	0.43
29371	5/F	0.00	0.14	0.14
29372	5/F	0.14	0.43	0.29
29374	5/F	0.29	0.14	1.14
29375	5/F	0.00	0.14	0.71
29476	6/F	0.14	0.00	0.14
29479	6/F	0.14	0.57	0.57
29480	6/F	0.29	0.71	0.86
29482	6/F	0.00	0.14	1.00

[a]Early leukemia
[b]Very early leukemia with small hepatocellular neoplasm in median lobe
[c]Hepatocellular neoplasm in right lateral lobe
*Number of labeled hepatocyte nuclei per total number of hepatocytes counted (at least 700)

TEXT TABLE 4

SUMMARY OF HISTOPATHOLOGY EVALUATION
HEPATOCELLULAR PROLIFERATION ANIMALS
TERMINAL SACRIFICE

GROUP	ANIMAL NUMBER	OBSERVATIONS
1M	B28662	none
	B28663	none
	B28664	none
	B28665	none
	B28666	early leukemia
1F	B28747	none
	B28748	none
	B28749	early leukemia
	B28750	none
	B28751	none
3M	B28956	none
	B28957	none
	B28958	none
	B28959	none
	B28960	leukemia with hepatopathy
3F	B29026	none
	B29029	none
	B29030	none
	B29031	none
	B29032	leukemia with hepatopathy
4M	B29112	none
	B29113	leukemia with hepatopathy
	B29115	leukemia (early) with hepatopathy
	B29117	leukemia with hepatopathy and hepatocellular carcinoma in median lobe
	B29118	early leukemia
4F	B29197	none
	B29198	none
	B29200	none
	B29201	none
	B29202	none
5M	B29282	early leukemia and hepatocellular neoplasm in right lateral lobe
	B29283	none
	B29284	none
	B29285	none
	B29287	early leukemia
5F	B29370	none
	B29371	none
	B29372	none
	B29374	none
	B29375	none
6M	B29421	very early leukemia and small hepatocellular neoplasm in median lobe
	B29422	none
	B29424	leukemia with hepatopathy
	B29426	none
	B29427	none
6F	B29476	none
	B29479	none
	B29480	none
	B29482	none

Table 1
Analytical Chemistry Results
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Table 1
Analytical Chemistry Results
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including Ancillary Hepatocellular Proliferation and Biochemical Analyses
Homogeneity

		Target Concentration						Corrected Assayed Level (ppm)						Percent of Target					
Group:		1	2	3	4	5	6	1	2	3	4	5	6	1	2	3	4	5	6
Dose Level (ppm):		0	100	500	2500	12500	12500	0	100	500	2500	12500	12500	0	100	500	2500	12500	12500
Pretest								ND											
Top	A								94.20			12360	12050		94.2			98.9	96.4
	B								92.73			12210	11940		92.7			97.7	95.5
Middle	A								91.13			12050	12190		91.1			96.4	97.5
	B								93.63			12470	12110		93.6			99.8	96.9
Bottom	A								91.29			12250	12180		91.3			98.0	97.4
	B								93.61			12250	12360		93.6			98.0	98.9
													MEAN		92.8			98.1	97.1
													S.D.		1.29			1.15	1.15
													%RSD		1.39			1.17	1.18
Week 14[a,b]								ND											
Top	A								94.96			11450			95.0			91.6	
	B								97.37			11500			97.4			92.0	
Middle	A								95.67			11390			95.7			91.1	
	B								96.00			10910			96.0			87.3	
Bottom	A								97.36			11000			97.4			88.0	
	B								96.37			11140			96.4			89.1	
													MEAN		96.3			89.9	
													S.D.		± 0.956			± 1.99	
													%RSD		0.993			2.21	

[a] Samples were frozen prior to analysis.
[b] Group 2 samples were re-diluted and re-analyzed due to improper initial dilution. Group 2 samples were stored under refrigeration prior to analysis.

Note: A and B = Duplicate samples
ND = None detected
S.D. = Standard Deviation
%RSD = Percent Relative Deviation

Table 1
Analytical Chemistry Results
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate including hepatocellular proliferation and biochemical analyses
Homogeneity

		Target Concentration						Corrected Assayed Level (ppm)						Percent of Target					
Group:		1	2	3	4	5	6	1	2	3	4	5	6	1	2	3	4	5	6
Dose Level (ppm):		0	100	500	2500	12500	12500	0	100	500	2500	12500	12500	0	100	500	2500	12500	12500
Week 80[a]																			
								ND											
Top	A										2412	11885					96.5	95.1	
	B										2430	12373					97.2	99.0	
Middle	A										2453	11178					98.1	89.4	
	B										2382	12193					95.3	97.5	
Bottom	A										2337	11813					93.5	94.5	
	B										2347	12022					93.9	96.2	
																MEAN	95.7	95.3	
																SD	± 1.86	3.30	
																%RSD	1.94	3.47	

[a] Samples were frozen prior to analysis.

Note: A and B = Duplicate samples
ND = None detected.
S.D = Standard Deviation
%RSD = Percent Relative Deviation

Table 1
Analytical Chemistry Results
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate including hepatocellular proliferation and biochemical analyses
Room Temperature Stability

		Target Concentration						Corrected Assayed Level (ppm)						Percent of Target					
Group:		1	2	3	4	5	6	1	2	3	4	5	6	1	2	3	4	5	6
Dose Level (ppm):		0	100	500	2500	12500	12500	0	100	500	2500	12500	12500	0	100	500	2500	12500	12500
Stability																			
Day 0[a]	A							ND	99.22	475.4	2440	12220	11880	-	99.2	95.1	97.6	97.8	950
	B								95.61	466.8	2446	11970	11980	-	95.6	93.4	97.8	95.8	958
7[b] and 8[c] Day	A							ND	93.35	-	-	12170	-	-	93.4	-	-	97.4	-
	B								91.75	-	-	12050	-	-	91.8	-	-	96.4	-
14[b] and 15[c] Day	A							ND	94.91	-	-	12160	-	-	94.9	-	-	97.3	-
	B								93.76	-	-	11980	-	-	93.8	-	-	95.8	-

[a] Results from Groups 2 and 5 are from analyses of formulations made the day prior to analysis (Group 2) and on the day of analysis (Group 5).
[b] Group 5.
[c] Group 2.

Note: A and B = Duplicate samples.
ND = None detected.
- = Analysis not required.

Table 1
Analytical Chemistry Results
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate including hepatocellular proliferation and biochemical analyses
Concentration Analyses

		Target Concentration						Corrected Assayed Level (ppm)						Percent of Target					
Group:		1	2	3	4	5	6	1	2	3	4	5	6	1	2	3	4	5	6
Dose Level (ppm):		0	100	500	2500	12500	12500	0	100	500	2500	12500	12500	0	100	500	2500	12500	12500
Week 1	A							ND	99.22	475.4	2440	12220	11880	-	99.2	95.1	97.6	97.8	95.0
	B								95.61	466.8	2446	11970	11980	-	95.6	93.4	97.8	95.8	95.8
Week 13[a,b]	A							ND	105.3	499.8	2467	11770	11990	-	105	100	98.7	94.2	95.9
	B								111.2	495.0	2536	12180	12320	-	111	99.0	101	97.4	98.6
Week 26[a]	A							ND	92.47	465.9	2398	12295	12279	-	92.5	93.2	95.9	98.4	98.2
	B								93.65	469.8	2367	12081	12253	-	93.6	94.0	94.7	96.7	98.0
Week 52[a]	A							ND	95.61	489.8	2391	12630	11905	-	95.6	98.0	95.6	101	95.2
	B								93.10	481.3	2351	12478	12125	-	93.1	96.3	94.0	99.8	97.0
Week 78[a]	A							ND	94.05	487.1	2328	12265	11581	-	94.0	97.4	93.1	98.1	92.6
	B								93.85	485.0	2334	11831	11764	-	93.9	97.0	93.4	94.6	94.1
Week 104[a]	A							ND	97.30	486.2	2395	11936		-	97.3	97.2	95.8	95.5	-
	B								94.94	477.8	2381	11864		-	94.9	95.6	95.3	94.9	-

[a] Samples were stored in the freezer prior to analysis.
[b] Group 2 sample results are from reextracted and reanalyzed samples.

Note: A and B = Duplicate samples.
- = Analysis not required.
No test material was detected in any analysis of control samples.

Table 2
Animal Survival/Adjusted Survival Table
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Note: All males in Group 7 were sacrificed by Week 13.

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: START	1	2	3	4	5	6	7	8	9	10	11
					MALE							
1	85/85 100%	80/80 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%
2	70/70 100%	65/65 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%
3	70/70 100%	65/65 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%
4	85/85 100%	80/80 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%
5	85/85 100%	80/80 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%
6	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
7	15/15 100%	10/10 100%	5/5 100%	5/5 100%	5/5 100%	5/5 100%	5/5 100%	5/5 100%	5/5 100%	5/5 100%	5/5 100%	5/5 100%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 12	13	14	15	16	17	18	19	20	21	22	23
					MALE							
1	75/75 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
2	60/60 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
3	60/60 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
4	75/75 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
5	75/75 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
6	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
7	5/5 100%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 24	25	26	27	28	29	30	31	32	33	34	35
					MALE							
1	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
2	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
3	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
4	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
5	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
6	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
7	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 36	37	38	39	40	41	42	43	44	45	46	47
					MALE							
1	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
2	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
3	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
4	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
5	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
6	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
7	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 48	49	50	51	52	53	54	55	56	57	58	59
					MALE							
1	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
2	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
3	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
4	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
5	70/70 100%	70/70 100%	70/70 100%	70/70 100%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%
6	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
7	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 60	61	62	63	64	65	66	67	68	69	70	71
					MALE							
1	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	69/70 99%	69/70 99%
2	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	54/55 98%
3	55/55 100%	55/55 100%	55/55 100%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%
4	70/70 100%	70/70 100%	70/70 100%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	68/70 97%	68/70 97%	68/70 97%	67/70 96%	67/70 96%
5	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%
6	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
7	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 72	73	74	75	76	77	78	79	80	81	82	83
					MALE							
1	69/70 99%	69/70 99%	69/70 99%	68/70 97%	68/70 97%	68/70 97%	68/70 97%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%
2	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	52/55 95%	52/55 95%
3	54/55 98%	54/55 98%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%
4	67/70 96%	67/70 96%	67/70 96%	67/70 96%	67/70 96%	66/70 94%	66/70 94%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	51/55 93%
5	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	68/70 97%	68/70 97%	53/55 96%	52/55 95%	52/55 95%	52/55 95%	51/55 93%
6	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	53/55 96%	53/55 96%	53/55 96%
7	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 84	85	86	87	88	89	90	91	92	93	94	95
					MALE							
1	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	52/55 95%	52/55 95%	51/55 93%	51/55 93%	51/55 93%	51/55 93%
2	52/55 95%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	50/55 91%	49/55 89%	48/55 87%	48/55 87%	47/55 85%	47/55 85%	47/55 85%
3	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	51/55 93%	50/55 91%	50/55 91%	49/55 89%	48/55 87%	47/55 85%
4	49/55 89%	49/55 89%	48/55 87%	48/55 87%	48/55 87%	48/55 87%	48/55 87%	48/55 87%	47/55 85%	47/55 85%	47/55 85%	47/55 85%
5	51/55 93%	50/55 91%	48/55 87%	47/55 85%	46/55 84%	46/55 84%	46/55 84%	46/55 84%	46/55 84%	45/55 82%	44/55 80%	43/55 78%
6	53/55 96%	52/55 95%	52/55 95%	52/55 95%	52/55 95%	52/55 95%	52/55 95%	51/55 93%	50/55 91%	50/55 91%	50/55 91%	49/55 89%
7	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 96	97	98	99	100	101	102	103	104
					MALE				
1	51/55 93%	50/55 91%	49/55 89%	49/55 89%	48/55 87%	48/55 87%	48/55 87%	48/55 87%	45/55 82%
2	45/55 82%	45/55 82%	45/55 82%	44/55 80%	44/55 80%	44/55 80%	43/54 80%	43/54 80%	42/54 78%
3	46/55 84%	44/55 80%	44/55 80%	44/55 80%	44/55 80%	43/55 78%	43/55 78%	43/55 78%	43/55 78%
4	47/55 85%	46/55 84%	45/55 82%	44/55 80%	43/55 78%	41/55 75%	41/55 75%	39/55 71%	38/54 70%
5	43/55 78%	43/55 78%	43/55 78%	43/55 78%	42/55 76%	42/55 76%	41/55 75%	41/55 75%	40/55 73%
6	48/55 87%	47/55 85%	47/55 85%	47/55 85%	45/55 82%	44/55 80%	44/55 80%	42/55 76%	40/55 73%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: START	1	2	3	4	5	6	7	8	9	10	11
					FEMALE							
1	85/85 100%	80/80 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%
2	70/70 100%	65/65 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%
3	70/70 100%	65/65 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%	60/60 100%
4	85/85 100%	80/80 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%
5	85/85 100%	80/80 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%	75/75 100%
6	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 12	13	14	15	16	17	18	19	20	21	22	23
					FEMALE							
1	75/75 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
2	60/60 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
3	60/60 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
4	75/75 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
5	75/75 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	69/70 99%	69/70 99%
6	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 24	25	26	27	28	29	30	31	32	33	34	35
					FEMALE							
1	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
2	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	54/55 98%	54/55 98%	54/55 98%	54/55 98%
3	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
4	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
5	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%
6	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 36	37	38	39	40	41	42	43	44	45	46	47
					FEMALE							
1	70/70 100%	70/70 100%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%
2	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%
3	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
4	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
5	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%
6	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 48	49	50	51	52	53	54	55	56	57	58	59
					FEMALE							
1	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%
2	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%
3	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
4	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%	70/70 100%
5	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%
6	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 60	61	62	63	64	65	66	67	68	69	70	71
					FEMALE							
1	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	68/70 97%	68/70 97%
2	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%
3	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%
4	70/70 100%	70/70 100%	70/70 100%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	68/70 97%
5	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%	69/70 99%
6	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 72	73	74	75	76	77	78	79	80	81	82	83
					FEMALE							
1	68/70 97%	68/70 97%	68/70 97%	68/70 97%	68/70 97%	68/70 97%	68/70 97%	53/55 96%	53/55 96%	52/55 95%	52/55 95%	52/55 95%
2	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%	54/55 98%
3	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	55/55 100%	53/55 96%	53/55 96%	53/55 96%	52/55 95%	52/55 95%	52/55 95%
4	68/70 97%	68/70 97%	68/70 97%	68/70 97%	68/70 97%	68/70 97%	68/70 97%	52/55 95%	51/55 93%	51/55 93%	51/55 93%	51/55 93%
5	68/70 97%	68/70 97%	68/70 97%	68/70 97%	67/70 96%	67/70 96%	67/70 96%	52/55 95%	52/55 95%	52/55 95%	52/55 95%	52/55 95%
6	54/55 98%	54/55 98%	54/55 98%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	53/55 96%	52/55 95%	52/55 95%	51/55 93%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 84	85	86	87	88	89	90	91	92	93	94	95
					FEMALE							
1	52/55 95%	52/55 95%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	49/55 89%	49/55 89%	48/55 87%
2	54/55 98%	54/55 98%	53/55 96%	53/55 96%	52/55 95%	52/55 95%	52/55 95%	50/55 91%	50/55 91%	50/55 91%	50/55 91%	50/55 91%
3	52/55 95%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	51/55 93%	50/55 91%	50/55 91%
4	51/55 93%	51/55 93%	51/55 93%	50/55 91%	50/55 91%	50/55 91%	50/55 91%	50/55 91%	50/55 91%	49/55 89%	48/55 87%	48/55 87%
5	51/55 93%	50/55 91%	50/55 91%	50/55 91%	50/55 91%	50/55 91%	49/55 89%	49/55 89%	48/55 87%	45/55 82%	45/55 82%	44/55 80%
6	51/55 93%	51/55 93%	50/55 91%	50/55 91%	50/55 91%	48/55 87%	48/55 87%	48/55 87%	47/55 85%	46/55 84%	46/55 84%	45/55 82%

TABLE 2
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ANIMAL SURVIVAL/ADJUSTED SURVIVAL TABLE

DOSE GROUP	WEEK: 96	97	98	99	100	101	102	103	104
					FEMALE				
1	47/55 85%	47/55 85%	46/55 84%	46/55 84%	45/55 82%	45/55 82%	45/55 82%	45/55 82%	40/50 80%
2	50/55 91%	50/55 91%	50/55 91%	50/55 91%	50/55 91%	50/55 91%	50/55 91%	48/55 87%	42/49 86%
3	49/55 89%	48/55 87%	48/55 87%	46/55 84%	46/55 84%	46/55 84%	46/55 84%	45/55 82%	40/50 80%
4	48/55 87%	47/55 85%	46/55 84%	46/55 84%	46/55 84%	46/55 84%	45/55 82%	44/55 80%	37/49 76%
5	44/55 80%	44/55 80%	44/55 80%	42/55 76%	41/55 75%	40/55 73%	40/55 73%	40/55 73%	35/50 70%
6	45/55 82%	45/55 82%	44/55 80%	42/55 76%	41/55 75%	40/55 73%	40/55 73%	40/55 73%	34/51 67%

Table 3
Summary Incidence of Clinical Observations
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Notes: Clinical observations (during Weeks 1-13) of Group 7 males were unremarkable.

Dose levels were measured in ppm.

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

WEEKS 1-106

NUMBER OF ANIMALS AFFECTED

CATEGORY / KEYWORD / QUALIFIER						
SEX:	MALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	12500	12500
NUMBER:	85	70	70	85	85	55
*** TOP OF LIST ***						
APPEARANCE						
COLD TO TOUCH	2	0	1	4	0	3
DISTENDED ABDOMEN	0	1	2	0	0	0
HEAD TILT	0	3	0	2	2	2
HUNCHED POSTURE	2	7	6	7	9	10
LIMITED USE						
LIMB-FRONT, RIGHT	0	0	1	1	0	0
LIMB-FRONT, LEFT	0	1	0	1	0	1
LIMBS-HIND	0	0	1	1	1	1
LIMB-HIND, LEFT	0	1	0	0	0	1
FEET-HIND	0	0	0	0	1	0
MALOCCLUSION	2	1	1	1	0	0
MISSING BODY PART						
TAIL-DISTAL	0	1	0	0	0	0
PALE						
EYES-BOTH	1	2	1	0	0	4
ENTIRE BODY	5	10	11	11	10	9
PARAPHIMOSIS (FORESKIN)	1	1	1	0	2	1
SWOLLEN						
PERI-ORBITAL, RIGHT	1	0	0	0	0	0
PERI-ORBITAL, LEFT	0	0	1	0	0	0
LATERAL-ABDOMINAL, RIGHT	0	0	0	0	1	0
LATERAL-LEFT	0	0	0	1	0	0
LATERAL-THORACIC, LEFT	0	0	0	1	0	0
AXILLARY REGION - RIGHT	1	0	0	0	0	0
AXILLARY REGION - LEFT	0	0	0	0	0	1
VENTRAL-THORACIC, RIGHT	0	0	0	0	1	0
VENTRAL-ABDOMINAL	2	4	4	5	1	3
VENTRAL-ABDOMINAL, RIGHT	2	11	13	4	2	3
VENTRAL-ABDOMINAL, LEFT	7	4	5	3	0	2
DORSAL-THORACIC, RIGHT	1	0	0	0	0	0
SACRAL-LEFT	0	0	0	1	0	0
SCROTUM	2	1	0	2	0	0

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

WEEKS 1-106

NUMBER OF ANIMALS AFFECTED

CATEGORY / KEYWORD / QUALIFIER	SEX: MALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	1250	12500
NUMBER:	85	70	70	85	85	55
APPEARANCE						
SWOLLEN						
SCROTUM-RIGHT	3	0	0	0	1	0
SCROTUM-LEFT	1	1	0	1	0	0
PERINEAL AREA	5	3	4	6	0	1
LIMBS-HIND	0	0	0	1	0	0
FEET-HIND	0	0	0	1	0	0
FOOT-HIND, RIGHT	0	1	0	0	0	0
FOOT-HIND, LEFT	0	0	0	1	0	0
TAIL-MID	0	0	0	1	0	0
TAIL-PROXIMAL	1	1	0	0	0	0
HEAD-MAXILLARY, RIGHT	0	1	0	0	0	0
MOUTH	1	1	2	4	2	0
PERI-ORAL	4	2	2	1	2	1
THIN	5	7	7	5	6	5
BEHAVIOR						
ANOREXIA	2	2	2	1	1	3
ATAXIA						
<UNSPECIFIED>	0	0	2	0	0	0
HYPOACTIVE	6	9	10	12	10	14
PROSTRATE	0	2	1	1	2	4
EXCRETION						
DISCHARGE						
ANUS	0	0	0	1	0	0
DISCOLORED URINE						
RED	1	0	0	0	0	0
FEW FECES	5	9	10	10	8	10
NO FECES	2	3	8	3	3	6
SOFT FECES	16	5	15	29	23	15

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

WEEKS 1-106

NUMBER OF ANIMALS AFFECTED

CATEGORY / KEYWORD / QUALIFIER	SEX: MALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	12500	12500
NUMBER:	85	70	70	85	85	55
RESPIRATION						
ABNORMAL RESPIRATORY SOUND						
<UNSPECIFIED>	0	0	0	0	1	0
DYSPNEA	4	3	2	0	3	2
POLYPNEA	1	0	0	0	0	0
EYE						
CHROMODACRYORRHEA						
EYES-BOTH	1	3	3	6	0	0
EYE-RIGHT	12	16	15	15	12	6
EYE-LEFT	15	15	16	15	11	8
DARK						
EYE-RIGHT	0	0	1	1	0	0
EXOPHTHALMUS						
EYE-RIGHT	0	0	0	1	0	0
LACRIMATION						
EYES-BOTH	0	0	0	1	0	0
EYE-RIGHT	0	1	1	0	0	1
EYE-LEFT	0	2	1	0	0	0
MICROPHTHALMUS						
EYE-RIGHT	2	1	4	0	2	0
EYE-LEFT	1	1	0	0	0	1
NORMAL STRUCTURE NOT VISIBLE						
EYE-RIGHT	0	0	2	0	1	2
OPAQUE						
EYES-BOTH	0	1	0	1	2	2
EYE-RIGHT	4	8	7	7	6	9
EYE-LEFT	5	3	3	3	2	3
PALE						
EYES-BOTH	0	0	0	1	1	0
EYE-RIGHT	0	1	0	0	0	0
PARTIAL CLOSURE						
EYE-RIGHT	0	0	1	0	1	0

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

WEEKS 1-106	NUMBER OF ANIMALS AFFECTED					
SEX:	MALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	12500	12500
NUMBER:	85	70	70	85	85	55
CATEGORY / KEYWORD / QUALIFIER						
EYE						
ULCERATION						
EYE-RIGHT	0	0	1	0	1	3
SKIN/PELAGE						
ALOPECIA						
LATERAL-LEFT	0	1	0	0	0	0
SACRAL-LEFT	0	0	1	0	0	0
SCROTUM-LEFT	0	0	1	0	0	0
PERINEAL AREA	0	1	0	0	0	0
LIMBS-FRONT	0	1	0	0	2	0
LIMB-FRONT, LEFT	0	0	1	0	0	0
FEET-FRONT	0	0	0	0	1	0
MULTIPLE SITES	0	1	1	0	0	0
CRUST						
PERI-ORBITAL, RIGHT	1	0	1	1	0	1
PERI-ORBITAL, LEFT	0	0	0	1	1	0
VENTRAL-ABDOMINAL, RIGHT	0	1	0	0	0	1
VENTRAL-ABDOMINAL, LEFT	0	1	1	0	0	0
ROUGH HAIRCOAT	0	5	2	3	6	0
SORE(S)						
PERI-ORBITAL, RIGHT	1	0	1	0	0	0
LATERAL-ABDOMINAL, RIGHT	0	0	0	1	0	0
LATERAL-LEFT	0	0	1	0	0	0
LATERAL-THORACIC, LEFT	0	0	1	0	0	0
LATERAL-ABDOMINAL, LEFT	0	0	1	0	0	0
VENTRAL-ABDOMINAL	1	1	2	0	0	2
VENTRAL-ABDOMINAL, RIGHT	3	4	4	0	2	1
VENTRAL-ABDOMINAL, LEFT	0	2	1	3	0	1
DORSAL	0	0	0	0	0	1
SCROTUM-RIGHT	0	2	0	0	0	0
SCROTUM-LEFT	0	0	0	1	0	0
PERINEAL AREA	1	3	1	1	2	1

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

NUMBER OF ANIMALS AFFECTED

WEEKS 1-106

CATEGORY / KEYWORD / QUALIFIER	SEX: MALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	12500	12500
NUMBER:	85	70	70	85	85	55
SKIN/PELAGE						
SORE(S)						
FEET-HIND	0	0	0	0	1	0
FOOT-HIND, RIGHT	2	0	0	0	0	0
FOOT-HIND, LEFT	1	2	2	0	0	0
SHOULDER-RIGHT	0	0	1	0	0	0
SHOULDER-LEFT	0	0	0	0	0	1
TAIL	8	8	9	9	11	8
TAIL-DISTAL	2	0	1	1	1	1
TAIL-MID	2	2	4	2	3	5
TAIL-PROXIMAL	13	6	5	7	6	10
PERI-NASAL	0	1	0	0	0	0
MOUTH	3	1	2	4	2	0
PERI-ORAL	3	2	1	3	1	2
URINE STAINS	8	10	8	17	61	32
MASS(ES)						
SMALL TISSUE MASS						
LATERAL-THORACIC, RIGHT	2	0	0	0	0	0
LATERAL-ABDOMINAL, RIGHT	0	0	0	0	1	1
LATERAL-LEFT	0	0	1	0	0	0
LATERAL-THORACIC, LEFT	1	0	0	1	0	0
AXILLARY REGION - RIGHT	1	0	0	1	0	0
AXILLARY REGION - LEFT	1	0	2	0	0	0
VENTRAL-CERVICAL	0	0	1	0	0	0
VENTRAL-THORACIC, RIGHT	0	0	0	0	1	0
VENTRAL-ABDOMINAL	2	0	3	1	0	3
VENTRAL-ABDOMINAL, RIGHT	6	3	5	3	0	0
VENTRAL-ABDOMINAL, LEFT	1	3	2	1	0	0
DORSAL-THORACIC, RIGHT	1	0	0	0	0	0
SACRAL-RIGHT	0	2	0	0	0	2
PERINEAL AREA	2	1	2	1	0	0
LIMB-HIND, RIGHT	0	1	0	0	0	0

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

WEEKS 1-106	NUMBER OF ANIMALS AFFECTED					
SEX:	MALE					
CATEGORY / KEYWORD / QUALIFIER — GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	12500	12500
NUMBER:	85	70	70	85	85	55
MASS(ES)						
SMALL TISSUE MASS						
SHOULDER-RIGHT	0	0	0	0	0	1
TAIL-PROXIMAL	0	1	0	0	0	0
HEAD-MAXILLARY, RIGHT	0	1	0	0	0	0
HEAD-MAXILLARY, LEFT	0	0	0	0	0	1
MOUTH	1	0	0	0	0	0
LARGE TISSUE MASS						
LATERAL-ABDOMINAL, RIGHT	0	0	0	0	1	1
LATERAL-ABDOMINAL, LEFT	0	0	1	0	0	0
AXILLARY REGION - RIGHT	0	0	0	1	0	0
VENTRAL-CERVICAL	0	0	1	0	0	0
VENTRAL-THORACIC	0	0	0	0	1	0
VENTRAL-THORACIC, RIGHT	0	0	0	0	1	0
VENTRAL-ABDOMINAL	0	0	1	0	0	0
VENTRAL-ABDOMINAL, LEFT	1	0	0	0	0	0
SCROTUM	1	0	0	1	0	0
SHOULDER-RIGHT	0	0	0	0	0	1
HEAD-MAXILLARY, RIGHT	0	1	0	0	0	0
SMALL ULCERATED TISSUE MASS						
PERI-ORBITAL, RIGHT	1	0	0	0	0	0
LATERAL-LEFT	0	0	1	0	0	0
LATERAL-THORACIC, LEFT	0	0	1	0	0	0
VENTRAL-ABDOMINAL	0	0	1	0	0	0
VENTRAL-ABDOMINAL, RIGHT	0	0	1	0	0	0
VENTRAL-ABDOMINAL, LEFT	1	0	0	0	0	1
LUMBAR-RIGHT	0	0	0	1	0	0
PERINEAL AREA	0	1	0	0	0	0
LIMB-HIND, RIGHT	0	1	0	0	0	0
HEAD-MAXILLARY, RIGHT	0	1	0	0	0	0
LARGE ULCERATED TISSUE MASS						
LATERAL-ABDOMINAL, RIGHT	0	0	0	1	0	0
VENTRAL-ABDOMINAL	0	0	1	0	0	0

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

WEEKS 1-106	NUMBER OF ANIMALS AFFECTED					
SEX:	MALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	12500	12500
NUMBER:	85	70	70	85	85	55
CATEGORY / KEYWORD / QUALIFIER						
MASS(ES)						
LARGE ULCERATED TISSUE MASS						
VENTRAL-ABDOMINAL, RIGHT	0	0	1	0	0	0
HEAD-MAXILLARY, RIGHT	0	1	0	0	0	0
WART-LIKE GROWTH						
PERI-ORBITAL, RIGHT	1	0	0	0	0	0
VENTRAL-CERVICAL	1	0	0	0	0	0
VENTRAL-ABDOMINAL	0	1	0	0	0	0
SACRAL-LEFT	0	0	0	1	0	0
SCROTUM-RIGHT	0	1	0	0	0	0
FOOT-FRONT, RIGHT	0	0	1	0	0	0
TAIL-PROXIMAL	0	0	0	0	0	1
MOUTH	0	1	0	0	0	2
PERI-ORAL	2	1	1	2	5	4
EAR-RIGHT	0	0	0	0	0	1
EAR-LEFT	0	0	0	0	0	1

*** END OF LIST ***

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

NUMBER OF ANIMALS AFFECTED

WEEKS 1-105						
SEX:	FEMALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	12500	12500
NUMBER:	85	70	70	85	85	55
CATEGORY / KEYWORD / QUALIFIER						
*** TOP OF LIST ***						
APPEARANCE						
COLD TO TOUCH	2	2	3	2	3	3
DISTENDED ABDOMEN	0	1	0	0	0	0
HEAD TILT	0	0	1	0	2	0
HUNCHED POSTURE	5	4	4	5	8	8
LIMITED USE						
LIMB-FRONT, LEFT	0	0	1	0	0	0
LIMB-HIND, LEFT	0	0	1	0	0	0
MALOCCLUSION	2	1	0	0	0	0
PALE						
EYES-BOTH	0	1	0	3	0	0
ENTIRE BODY	5	8	7	12	10	12
APPARENT PROLAPSED VAGINA	1	0	0	2	1	0
SWOLLEN						
AXILLARY REGION - RIGHT	0	0	2	0	0	0
VENTRAL-ABDOMINAL	0	1	0	1	0	0
DORSAL-THORACIC	0	0	0	0	0	1
INGUINAL REGION-RIGHT	0	0	0	0	0	1
VAGINA	0	0	1	0	0	0
PERINEAL AREA	2	3	2	2	2	2
DIGIT	0	0	1	0	0	0
TAIL-DISTAL	0	1	0	0	0	0
HEAD	0	0	0	1	0	0
HEAD-MAXILLARY, RIGHT	0	1	0	0	0	0
MOUTH	2	2	1	0	0	0
PERI-ORAL	1	0	0	3	1	2
EAR-RIGHT	1	0	0	0	0	0
THIN	6	4	5	5	13	10
BEHAVIOR						
ANOREXIA	2	0	0	1	0	1
ATAXIA						
<UNSPECIFIED>	0	3	0	1	2	0

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

WEEKS 1-105	NUMBER OF ANIMALS AFFECTED					
SEX:	FEMALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	12500	12500
NUMBER:	85	70	70	85	85	55
CATEGORY / KEYWORD / QUALIFIER						
BEHAVIOR						
HYPOACTIVE	6	5	7	7	7	11
PROSTRATE	4	1	4	1	4	6
TREMORS	0	1	0	0	0	0
EXCRETION						
DISCHARGE						
VAGINA	0	4	5	1	0	4
RED	1	1	2	2	0	0
DISCOLORED URINE						
RED	0	0	0	0	1	0
BROWN	0	0	2	0	0	0
FEW FECES	7	6	3	8	10	12
NO FECES	3	4	3	2	1	7
SOFT FECES	12	13	6	5	6	4
RESPIRATION						
ABNORMAL RESPIRATORY SOUND						
SLIGHT	0	1	0	0	0	0
DYSPNEA	4	2	1	2	3	3
EYE						
CHROMODACRYORRHEA						
EYES-BOTH	35	25	23	24	19	15
EYE-RIGHT	41	34	37	40	31	26
EYE-LEFT	45	40	29	29	25	27
DARK						
EYE-RIGHT	0	0	0	1	0	1
EXOPHTHALMUS						
EYE-RIGHT	1	0	0	0	0	0
EYE-LEFT	0	0	1	0	0	1
LACRIMATION						
EYES-BOTH	11	12	9	5	2	1

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

NUMBER OF ANIMALS AFFECTED

WEEKS 1-105

CATEGORY / KEYWORD / QUALIFIER	SEX: FEMALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	12500	12500
NUMBER:	85	70	70	85	85	55
EYE						
LACRIMATION						
EYE-RIGHT	9	4	10	9	3	0
EYE-LEFT	7	5	2	8	3	2
MICROPHTHALMUS						
EYE-RIGHT	1	0	1	2	1	3
EYE-LEFT	2	0	2	1	0	0
NORMAL STRUCTURE NOT VISIBLE						
EYE-LEFT	1	0	0	0	0	0
OPAQUE						
EYES-BOTH	1	1	1	2	4	2
EYE-RIGHT	4	3	9	13	6	9
EYE-LEFT	8	4	6	7	5	4
PALE						
EYES-BOTH	1	0	0	0	0	0
PARTIAL CLOSURE						
EYE-LEFT	0	0	0	1	0	1
ULCERATION						
EYE-RIGHT	1	1	2	0	4	4
SKIN/PELAGE						
ALOPECIA						
PERI-ORBITAL	0	0	0	0	0	1
LIMBS-FRONT	0	0	1	0	0	0
LIMB-FRONT, LEFT	0	0	1	0	0	0
SHOULDER-LEFT	0	1	0	0	0	0
PERI-ORAL	0	0	0	0	0	1
MULTIPLE SITES	0	0	0	0	0	1
CRUST						
PERI-ORBITAL	0	0	0	1	0	1
PERI-ORBITAL, LEFT	2	1	1	0	0	0
TAIL	0	0	1	0	0	0

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

NUMBER OF ANIMALS AFFECTED

WEEKS 1-105

CATEGORY / KEYWORD / QUALIFIER						
SEX:	FEMALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	12500	12500
NUMBER:	85	70	70	85	85	55
SKIN/PELAGE						
ROUGH HAIRCOAT	2	1	0	0	1	0
SORE(S)						
PERI-ORBITAL, LEFT	0	0	0	0	0	1
VENTRAL-ABDOMINAL	0	0	1	0	0	1
VENTRAL-ABDOMINAL, LEFT	0	0	1	0	0	0
DORSAL-THORACIC	0	0	0	0	0	1
DORSAL-THORACIC, RIGHT	0	0	0	0	0	1
PERINEAL AREA	2	2	2	1	1	2
DIGIT	0	1	0	0	0	0
SHOULDER-RIGHT	0	0	0	0	0	1
HAND-RIGHT	0	0	0	1	0	0
TAIL	0	2	1	3	3	3
TAIL-DISTAL	1	0	0	0	0	0
TAIL-MID	0	0	0	1	0	0
TAIL-PROXIMAL	3	4	4	2	8	3
MOUTH	0	2	0	2	0	0
PERI-ORAL	2	0	0	0	0	2
EAR-RIGHT	1	0	0	0	0	0
URINE STAINS	37	40	34	44	71	47
MASS(ES)						
SMALL TISSUE MASS						
LATERAL-THORACIC, RIGHT	0	1	0	2	0	0
LATERAL-ABDOMINAL, RIGHT	1	0	0	0	0	0
LATERAL-THORACIC, LEFT	0	0	0	2	0	0
LATERAL-ABDOMINAL, LEFT	0	0	0	1	0	0
AXILLARY REGION - RIGHT	0	2	4	0	0	0
AXILLARY REGION - LEFT	0	0	0	1	1	1
VENTRAL-CERVICAL	0	2	0	0	0	0
VENTRAL-ABDOMINAL	0	0	0	0	1	0
VENTRAL-ABDOMINAL, LEFT	0	1	1	1	1	0
INGUINAL REGION-RIGHT	0	1	1	1	0	1

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

WEEKS 1-105

NUMBER OF ANIMALS AFFECTED

CATEGORY / KEYWORD / QUALIFIER						
SEX:	FEMALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	12500	12500
NUMBER:	85	70	70	85	85	55
MASS(ES)						
SMALL TISSUE MASS						
INGUINAL REGION-LEFT	0	0	0	0	0	1
PERINEAL AREA	3	1	1	0	1	0
FOOT-FRONT, LEFT	0	1	0	0	0	0
SHOULDER-RIGHT	0	0	1	0	0	0
SHOULDER-LEFT	0	0	0	1	0	0
PERI-ORAL	0	0	0	0	1	0
EAR-RIGHT	1	0	0	0	0	0
LARGE TISSUE MASS						
LATERAL-THORACIC, RIGHT	0	0	0	1	0	0
LATERAL-ABDOMINAL, RIGHT	1	0	0	0	0	0
LATERAL-THORACIC, LEFT	0	0	0	1	0	0
AXILLARY REGION - RIGHT	0	0	2	0	0	1
AXILLARY REGION - LEFT	0	0	0	1	0	0
VENTRAL-CERVICAL	0	1	0	0	0	0
VENTRAL-CERVICAL, RIGHT	0	0	1	0	0	0
VENTRAL-THORACIC, RIGHT	0	1	0	0	0	0
VENTRAL-ABDOMINAL	0	0	1	0	0	0
VENTRAL-ABDOMINAL, LEFT	0	1	1	1	1	0
INGUINAL REGION-RIGHT	0	0	1	0	0	1
INGUINAL REGION-LEFT	0	0	0	0	0	1
PERINEAL AREA	2	0	0	0	1	0
SHOULDER-RIGHT	0	0	1	0	0	0
SHOULDER-LEFT	0	0	0	1	0	0
SMALL ULCERATED TISSUE MASS						
PERINEAL AREA	0	1	2	1	0	0
LARGE ULCERATED TISSUE MASS						
PERINEAL AREA	0	0	1	0	0	0
WART-LIKE GROWTH						
PERI-ORBITAL, RIGHT	0	2	0	0	0	0
PERI-ORBITAL, LEFT	0	1	0	0	0	0
SACRAL-RIGHT	0	0	0	0	0	1

TABLE 3
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
SUMMARY INCIDENCE OF CLINICAL OBSERVATIONS

NUMBER OF ANIMALS AFFECTED

WEEKS 1-105

CATEGORY / KEYWORD / QUALIFIER	SEX: FEMALE					
GROUP:	1	2	3	4	5	6
DOSE:	0	100	500	2500	1250	12500
NUMBER:	85	70	70	85	85	55
MASS(ES)						
WART-LIKE GROWTH						
SCROTUM	1	0	0	0	0	0
TAIL	0	0	0	0	1	0
TAIL-PROXIMAL	0	1	0	0	0	0
MOUTH	0	0	0	2	1	1
PERI-ORAL	5	2	4	7	0	1
EAR-RIGHT	1	0	0	0	0	0

*** END OF LIST ***

Table 4A
Body Weight Means and Standard Deviations
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Notes: All males in Group 7 were sacrificed by Week 13.

Dose levels were measured in ppm.

BODY WEIGHT FOOTNOTES

Statistical transformations of data were performed if noted by the following:

R = RANK

X^2 = SQUARE

TABLE 4A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
BODY WEIGHT MEANS AND STANDARD DEVIATIONS (G)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
1	N	85	70	70	85	85	55	15
	MEAN	124	121	121	121	120*	118*	120
	S.D.	7.3	6.7	7.4	7.7	7.4	7.4	6.7
2	N	80	65	65	80	80	55	10
	MEAN	148	145	146	146	143*	142*	147
	S.D.	9.5	9.0	10.3	10.4	10.0	10.7	10.9
3	N	75	60	60	75	75	55	5
	MEAN	176	173	173	173	166*	165*	162
	S.D.	11.3	11.8	11.6	12.6	12.2	14.1	10.3
4X[2]	N	75	60	60	75	75	55	5
	MEAN	198	193	190*	192	184*	185*	174
	S.D.	11.9	13.2	13.9	13.8	14.2	17.0	7.7
5X[2]	N	75	60	60	75	75	55	5
	MEAN	213	210	209	210	199*	199*	180
	S.D.	12.5	14.7	14.3	14.4	15.7	18.5	10.4
6X[2]	N	75	60	60	75	75	55	5
	MEAN	227	225	222	223	211*	212*	183
	S.D.	13.0	15.3	15.6	15.2	17.1	19.0	7.4
7	N	75	60	60	75	75	55	5
	MEAN	242	237	236	237	222*	222*	184
	S.D.	13.0	16.2	15.8	15.6	18.1	18.6	8.7
8	N	75	60	60	75	75	55	5
	MEAN	251	248	246	247	231*	231*	184
	S.D.	13.4	17.2	16.3	15.9	18.7	18.9	10.1

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 4A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
BODY WEIGHT MEANS AND STANDARD DEVIATIONS (G)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
9	N	75	60	60	75	75	55	5
	MEAN	260	258	256	257	237*	238*	184
	S.D.	13.9	17.2	16.0	16.1	18.9	18.9	10.4
10	N	75	60	60	75	75	55	5
	MEAN	267	265	261	263	244*	245*	188
	S.D.	13.8	17.5	16.4	17.0	19.2	19.3	11.3
11X[2]	N	75	60	60	75	75	55	5
	MEAN	267	264	261	261	244*	245*	185
	S.D.	13.4	17.7	15.6	16.7	20.1	20.0	8.0
12X[2]	N	75	60	60	75	75	55	5
	MEAN	277	274	271	273	253*	255*	188
	S.D.	13.7	16.8	15.6	16.9	19.8	19.2	10.7
13	N	75	60	60	75	75	55	5
	MEAN	282	280	277	279	259*	260*	191
	S.D.	14.3	17.4	16.0	17.1	19.7	18.6	8.7
14	N	70	55	55	70	70	55	-
	MEAN	288	287	283	285	266*	265*	
	S.D.	14.9	17.8	16.5	17.4	19.8	19.3	
15	N	70	55	55	70	70	55	-
	MEAN	292	290	287	290	269*	268*	
	S.D.	15.2	17.5	17.2	17.4	19.8	20.0	
16	N	70	55	55	70	70	55	-
	MEAN	296	295	292	294	273*	272*	
	S.D.	15.6	17.1	17.4	17.5	19.7	20.8	

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 4A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
BODY WEIGHT MEANS AND STANDARD DEVIATIONS (G)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
17	N	70	55	55	70	70	55	-
	MEAN	299	298	295	299	278*	277*	
	S.D.	15.5	16.9	16.8	18.0	19.5	21.1	
21	N	70	55	55	70	70	55	-
	MEAN	311	310	307	309	286*	284*	
	S.D.	16.1	17.8	17.8	17.4	18.9	19.9	
25	N	70	55	55	70	70	55	-
	MEAN	325	324	319	323	300*	299*	
	S.D.	16.9	17.7	19.8	17.7	19.1	20.0	
29	N	70	55	55	70	70	55	-
	MEAN	336	336	330	330	305*	303*	
	S.D.	17.6	18.1	20.5	18.7	19.4	20.9	
33	N	70	55	55	70	70	55	-
	MEAN	335	335	330	333	307*	304*	
	S.D.	16.5	18.1	20.8	19.1	18.7	21.3	
37	N	70	55	55	70	70	55	-
	MEAN	346	345	341	342	314*	313*	
	S.D.	18.4	19.8	21.1	18.9	18.9	21.3	
41	N	70	55	55	70	70	55	-
	MEAN	353	352	349	350	323*	322*	
	S.D.	17.6	19.6	22.1	19.2	20.1	21.1	
45	N	70	55	55	70	70	55	-
	MEAN	357	357	353	351	325*	324*	
	S.D.	18.6	19.1	21.7	20.7	21.3	21.9	

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 4A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
BODY WEIGHT MEANS AND STANDARD DEVIATIONS (G)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
49	N	70	55	55	70	70	55	-
	MEAN	363	362	358	353*	328*	325*	
	S.D.	18.2	19.5	21.4	20.3	19.8	21.4	
53	N	70	55	55	70	69	55	-
	MEAN	366	364	357	356*	330*	327*	
	S.D.	18.2	19.5	22.6	20.4	19.8	21.9	
57	N	70	55	55	70	69	55	-
	MEAN	368	367	363	356*	332*	330*	
	S.D.	17.9	20.2	21.2	20.8	19.8	21.6	
61	N	70	55	55	70	69	55	-
	MEAN	370	368	364	361*	336*	332*	
	S.D.	17.6	20.3	23.3	22.5	19.9	22.0	
65	N	70	55	54	69	69	55	-
	MEAN	367	369	366	361	336*	335*	
	S.D.	16.8	21.0	20.2	22.7	20.2	22.0	
69	N	70	55	54	68	69	55	-
	MEAN	363	366	363	359	336*	335*	
	S.D.	16.9	21.6	20.9	25.4	20.2	21.2	
73	N	69	53	54	67	69	54	-
	MEAN	374	374	370	365	342*	340*	
	S.D.	17.8	21.5	20.9	24.7	19.5	21.6	
77	N	68	53	53	67	69	54	-
	MEAN	370	372	365	362	339*	339*	
	S.D.	17.5	20.9	21.6	25.1	21.8	22.0	

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 4A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
BODY WEIGHT MEANS AND STANDARD DEVIATIONS (G)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
81	N	53	53	53	51	52	54	-
	MEAN	366	369	363	361	337*	342*	
	S.D.	14.9	21.8	19.9	23.6	20.1	22.8	
85	N	53	52	53	49	51	53	-
	MEAN	365	366	362	358	330*	343*	
	S.D.	16.2	26.3	20.8	22.8	27.4	26.8	
89R	N	53	51	53	48	46	52	-
	MEAN	363	361	357	355	332*	348*	
	S.D.	16.3	31.9	25.1	20.6	21.2	20.5	
93R	N	51	48	50	47	46	50	-
	MEAN	364	362	353	354*	325*	347*	
	S.D.	15.6	31.4	33.8	20.4	32.9	20.1	
97	N	51	45	46	47	43	48	-
	MEAN	360	364	354	351	329*	347	
	S.D.	19.2	23.6	29.8	30.2	22.8	23.7	
101	N	48	44	43	43	42	45	-
	MEAN	357	360	352	345	323*	346	
	S.D.	24.9	24.9	26.2	32.0	28.0	24.8	
105	N	40	37	38	33	35	35	-
	MEAN	350	349	343	338	310*	336	
	S.D.	19.0	27.3	25.0	22.2	28.3	31.7	

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 4A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
BODY WEIGHT MEANS AND STANDARD DEVIATIONS (G)

	SEX:	FEMALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
1R	N	85	70	70	85	85	55
	MEAN	95	97	95	93*	95	97
	S.D.	4.6	4.7	4.6	4.6	4.9	6.2
2	N	80	65	65	80	80	55
	MEAN	109	111	109	109	108	109
	S.D.	5.1	5.3	5.5	5.1	5.5	6.8
3R	N	75	60	60	75	75	55
	MEAN	122	124	122	122	119*	122
	S.D.	5.0	5.6	5.8	4.8	5.4	7.8
4R	N	75	60	60	75	75	55
	MEAN	130	132*	130	130	127*	130
	S.D.	5.0	6.0	6.5	6.3	5.9	8.6
5R	N	75	60	60	75	75	55
	MEAN	138	142*	139	136	134*	135*
	S.D.	5.8	6.3	7.7	4.8	6.4	9.1
6R	N	75	60	60	75	75	55
	MEAN	143	146*	144	143	139*	140
	S.D.	6.2	5.7	8.4	5.2	6.8	10.0
7R	N	75	60	60	75	75	55
	MEAN	149	152*	150	149	143*	145*
	S.D.	6.7	6.3	9.0	5.6	6.6	10.5
8	N	75	60	60	75	75	55
	MEAN	153	156	154	152	145*	144*
	S.D.	6.7	6.5	8.8	7.7	7.5	10.7

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 4A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
BODY WEIGHT MEANS AND STANDARD DEVIATIONS (G)

	SEX:	FEMALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
9R	N	75	60	60	75	75	55
	MEAN	157	160*	159	157	150*	151*
	S.D.	6.9	6.4	9.2	6.3	7.7	11.1
10R	N	75	60	60	75	75	55
	MEAN	161	163	161	157*	151*	152*
	S.D.	6.7	6.6	9.4	6.4	7.5	11.0
11R	N	75	60	60	75	75	55
	MEAN	163	166	164	162	154*	155*
	S.D.	7.0	6.5	9.5	6.6	7.4	10.8
12X[2]	N	75	60	60	75	75	55
	MEAN	165	168	166	164	156*	158*
	S.D.	7.2	7.1	9.7	6.9	7.5	10.9
13R	N	75	60	60	75	75	55
	MEAN	170	172	171	164*	159*	162*
	S.D.	7.7	7.1	10.1	6.5	7.8	10.9
14R	N	70	55	55	70	70	55
	MEAN	172	174	171	167*	160*	162*
	S.D.	8.2	7.3	10.3	6.8	7.6	11.3
15	N	70	55	55	70	70	55
	MEAN	172	175	173	171	163*	164*
	S.D.	8.3	7.1	10.9	7.9	7.9	11.2
16X[2]	N	70	55	55	70	70	55
	MEAN	175	177	175	172	165*	166*
	S.D.	8.4	7.0	10.6	7.3	8.4	11.8

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 4A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
BODY WEIGHT MEANS AND STANDARD DEVIATIONS (G)

	SEX:	FEMALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
17	N	70	55	55	70	70	55
	MEAN	175	176	175	170*	162*	165*
	S.D.	8.1	7.3	11.1	7.9	8.2	11.5
21R	N	70	55	55	70	70	55
	MEAN	181	182	181	179	171*	173*
	S.D.	8.6	6.7	10.7	8.2	8.6	11.8
25	N	70	55	55	70	69	55
	MEAN	188	188	187	185	175*	176*
	S.D.	8.6	7.5	11.0	7.7	9.1	11.6
29	N	70	55	55	70	69	55
	MEAN	190	193	192	192	180*	182*
	S.D.	9.5	8.0	11.3	8.6	9.2	11.5
33	N	70	54	55	70	69	55
	MEAN	192	194	194	191	179*	180*
	S.D.	9.0	8.9	10.4	8.6	9.7	11.3
37	N	70	54	55	70	69	55
	MEAN	196	198	198	195	183*	184*
	S.D.	9.0	9.3	11.4	8.5	9.8	11.6
41	N	69	54	55	70	69	55
	MEAN	201	203	201	201	187*	186*
	S.D.	9.6	10.3	10.7	8.6	9.9	14.2
45	N	69	54	55	70	69	54
	MEAN	200	201	200	202	187*	188*
	S.D.	9.6	10.6	11.2	8.7	9.8	12.6

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 4A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
BODY WEIGHT MEANS AND STANDARD DEVIATIONS (G)

	SEX:	FEMALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
49	N	69	54	55	70	69	54
	MEAN	205	208	206	205	190*	191*
	S.D.	10.8	10.7	11.0	8.6	10.5	12.9
53	N	69	54	55	70	69	54
	MEAN	206	208	207	210	192*	194*
	S.D.	11.3	11.5	10.7	9.7	10.2	13.1
57	N	69	54	55	70	69	54
	MEAN	212	215	214	216	196*	197*
	S.D.	11.8	12.0	12.3	10.3	11.3	13.2
61	N	69	54	55	70	69	54
	MEAN	216	220	218	220	196*	197*
	S.D.	13.0	12.3	12.5	11.0	11.5	13.7
65	N	69	54	55	69	69	54
	MEAN	221	225	222	221	197*	199*
	S.D.	13.5	14.4	12.7	12.0	12.1	14.1
69	N	69	54	55	69	69	54
	MEAN	221	225	223	224	198*	201*
	S.D.	14.9	14.4	13.7	12.1	11.3	15.0
73	N	68	54	55	68	68	54
	MEAN	232	232	232	233	203*	206*
	S.D.	15.8	13.4	15.4	12.0	13.2	17.5
77	N	68	54	55	68	67	53
	MEAN	232	233	236	237	206*	211*
	S.D.	15.6	14.8	17.8	13.8	14.0	23.3

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 4A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
BODY WEIGHT MEANS AND STANDARD DEVIATIONS (G)

	SEX:	FEMALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
81	N	53	54	53	51	52	53
	MEAN	237	239	241	243	210*	221*
	S.D.	18.0	16.5	22.4	13.3	14.9	32.5
85	N	52	54	52	51	50	51
	MEAN	242	245	247	246	215*	225*
	S.D.	17.5	19.6	23.4	12.3	14.3	20.4
89	N	51	52	51	50	50	49
	MEAN	242	248	247	248	213*	227*
	S.D.	18.2	15.9	14.1	11.7	15.5	17.9
93R	N	51	50	51	50	46	46
	MEAN	242	250	246	248	214*	233*
	S.D.	22.4	13.3	16.5	12.9	13.7	30.5
97	N	47	50	49	48	44	45
	MEAN	245	254*	250	252	217*	234*
	S.D.	22.0	14.3	17.0	17.9	18.5	19.2
101	N	45	50	46	46	41	41
	MEAN	248	251	253	253	220*	235*
	S.D.	31.7	14.7	16.8	17.7	13.6	18.7
105	N	40	42	40	37	35	34
	MEAN	243	251	255*	245	221*	238
	S.D.	23.7	18.4	16.4	22.7	14.6	21.0

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

Table 4B
Body Weight Change Means and Standard Deviations
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Notes: All males in Group 7 were sacrificed by Week 13.

Dose levels were measured in ppm.

TABLE 4B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
BODY WEIGHT CHANGE MEANS AND STANDARD DEVIATIONS (G)

	SEX:	MALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
1-52	N	70	55	55	70	69	55
	MEAN	242	244	236	235	210*	208*
	S.D.	15.9	18.0	21.4	18.0	17.8	20.9
1-105	N	40	37	38	33	35	35
	MEAN	226	229	223	216	192*	217
	S.D.	19.9	26.8	24.3	18.9	28.1	34.3

	SEX:	FEMALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
1-52	N	69	54	55	70	69	54
	MEAN	111	112	112	117*	97*	97*
	S.D.	10.0	11.5	8.9	9.1	9.4	10.2
1-105	N	40	42	40	37	35	34
	MEAN	149	155	161*	153	126*	141
	S.D.	22.3	17.5	15.4	23.7	15.3	19.4

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

Table 5A
Food Consumption Means and Standard Deviations
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Notes: All males in Group 7 were sacrificed by Week 13.

Dose levels were measured in ppm.

FOOD CONSUMPTION FOOTNOTES

Statistical transformations of data were performed if noted by the following:

R = RANK

X^2 = SQUARE

LG10 = LOG10

TABLE 5A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
FOOD CONSUMPTION MEANS AND STANDARD DEVIATIONS (G)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
1	N	80	65	65	80	79	55	10
	MEAN	108	111*	113*	112*	107	106	109
	S.D.	7.1	7.1	6.9	7.5	7.0	7.1	7.8
2	N	75	60	60	75	75	55	5
	MEAN	111	109	109	107*	105*	111	113
	S.D.	7.2	7.9	7.6	9.2	8.1	8.7	7.0
3R	N	75	60	47	75	75	55	5
	MEAN	118	115	115	114*	113*	116	124
	S.D.	7.0	8.6	8.6	9.7	9.0	12.3	6.0
4R	N	75	60	60	75	75	54	5
	MEAN	121	117	116*	117*	118	121	133
	S.D.	7.0	9.1	8.2	8.6	10.4	13.4	6.8
5R	N	75	60	60	75	75	55	5
	MEAN	115	116	114	115	117	119	128
	S.D.	7.7	9.1	9.5	8.5	11.6	12.6	5.5
6R	N	75	60	60	75	75	55	5
	MEAN	115	116	113	114	117	119	123
	S.D.	7.1	9.0	9.8	9.6	10.8	11.9	4.0
7R	N	75	60	60	74	73	55	5
	MEAN	114	114	114	117*	118*	118	120
	S.D.	7.1	9.2	9.5	8.9	10.3	11.2	6.3
8	N	75	59	60	74	74	54	5
	MEAN	111	111	113	116*	114	116*	117
	S.D.	7.7	8.5	8.5	8.1	10.2	10.3	7.0

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 5A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
FOOD CONSUMPTION MEANS AND STANDARD DEVIATIONS (G)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
9R	N	75	60	60	75	75	55	5
	MEAN	108	111	109	112*	111	114*	117
	S.D.	7.5	9.2	9.0	8.8	10.7	10.9	8.5
10	N	75	59	60	75	75	55	5
LG10	MEAN	105	106	109	110*	110*	110	113
	S.D.	9.0	9.6	8.9	9.8	11.7	13.3	5.4
11	N	75	60	60	75	75	55	5
LG10	MEAN	113	116	119	117	116	116	119
	S.D.	8.3	10.3	23.8	9.7	13.0	11.0	7.0
12	N	75	60	60	75	73	55	5
	MEAN	109	112	111	114*	116*	114*	112
	S.D.	7.6	9.7	9.9	9.1	10.4	10.2	5.8
13	N	69	52	55	70	70	55	-
	MEAN	109	109	106	109	110	112	
	S.D.	7.4	8.3	9.1	9.0	9.6	10.6	
14	N	70	55	55	70	70	54	-
	MEAN	112	110	107*	110	111	111	
	S.D.	8.5	9.0	8.5	7.7	9.3	10.4	
15	N	70	55	55	70	70	55	-
	MEAN	112	112	110	114	115	114	
	S.D.	8.6	9.3	8.2	9.1	10.3	11.5	
16	N	70	55	55	70	70	55	-
	MEAN	119	118	116	119	121	120	
	S.D.	8.4	9.5	8.5	8.4	9.3	10.0	

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 5A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
FOOD CONSUMPTION MEANS AND STANDARD DEVIATIONS (G)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
20	N	70	55	55	70	70	55	-
	MEAN	116	115	118	119	116	116	
	S.D.	10.1	10.4	8.9	7.6	8.0	8.8	
24	N	70	55	55	70	70	55	-
	MEAN	106	106	102*	108	112*	113*	
	S.D.	7.2	8.7	7.9	8.1	9.8	9.2	
28	N	70	55	55	70	70	55	-
	MEAN	106	109	109	109	113*	115*	
	S.D.	7.6	8.2	8.0	7.5	9.6	9.7	
32	N	70	54	54	70	70	55	-
LG10	MEAN	108	107	109	111	115*	112*	
	S.D.	6.0	7.3	7.9	7.6	8.9	8.8	
36	N	69	55	55	70	70	55	-
	MEAN	115	120*	112	113	117	117	
	S.D.	9.9	12.9	9.6	6.7	8.4	8.8	
40	N	70	55	55	70	70	55	-
	MEAN	120	119	115	119	120	119	
	S.D.	8.4	11.6	9.3	7.1	9.6	9.1	
44	N	70	55	55	70	70	55	-
	MEAN	116	116	115	113	117	119	
	S.D.	8.5	11.5	9.8	8.3	11.4	10.0	
48	N	70	55	55	70	70	55	-
LG10	MEAN	123	123	119*	119	124	124	
	S.D.	8.0	10.4	7.5	8.0	10.9	9.7	

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 5A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
FOOD CONSUMPTION MEANS AND STANDARD DEVIATIONS (G)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
52	N	70	55	55	70	67	54	-
	MEAN	113	122*	120*	118*	125*	126*	
	S.D.	10.0	11.4	9.6	8.8	10.5	9.5	
56	N	70	55	55	70	69	55	-
	MEAN	121	121	121	123	124	127*	
	S.D.	7.4	10.5	10.3	9.4	10.6	10.3	
60	N	70	55	55	70	69	55	-
LG10	MEAN	121	127*	125	122	127*	124	
	S.D.	7.9	11.4	13.4	12.4	11.0	10.0	
64	N	70	55	54	69	69	55	-
	MEAN	124	124	125	123	126	122	
	S.D.	10.2	12.6	13.6	10.0	10.8	9.5	
68	N	70	55	54	68	69	55	-
	MEAN	124	125	124	121	122	124	
	S.D.	12.1	14.0	12.9	10.8	10.4	9.0	
72	N	69	52	54	67	69	54	-
	MEAN	119	115	113*	111*	118	119	
	S.D.	9.5	9.5	11.3	9.6	10.5	8.2	
76R	N	68	53	53	67	69	54	-
	MEAN	112	116*	113	113	118*	121*	
	S.D.	7.7	10.5	11.1	11.2	14.9	10.0	
80	N	53	53	53	51	52	54	-
	MEAN	114	115	117	116	117	121*	
	S.D.	9.0	12.1	10.2	10.8	12.9	10.4	

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 5A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
FOOD CONSUMPTION MEANS AND STANDARD DEVIATIONS (G)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
84	N	53	50	52	49	51	53	-
	MEAN	118	116	115	116	113	111	
	S.D.	10.3	12.5	13.8	10.8	18.0	15.2	
88	N	53	51	53	48	46	52	-
	MEAN	113	110	109	112	116	111	
	S.D.	9.0	19.4	13.7	9.5	13.0	8.7	
92X[2]	N	51	48	50	47	46	50	-
	MEAN	119	113	111	116	114	112	
	S.D.	10.1	20.0	25.2	10.7	21.7	9.5	
96	N	51	45	44	47	43	48	-
	MEAN	115	114	110	110	114	111	
	S.D.	12.3	10.6	15.2	19.9	14.3	15.8	
100	N	48	44	42	43	42	45	-
	MEAN	114	115	116	112	117	115	
	S.D.	16.3	12.6	10.9	13.7	16.9	13.3	
104X[2]	N	40	37	38	33	35	35	-
	MEAN	110	114	116	115	110	111	
	S.D.	11.0	13.8	14.6	15.1	21.5	21.8	

TABLE 5A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
FOOD CONSUMPTION MEANS AND STANDARD DEVIATIONS (G)

	SEX:	FEMALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
1	N	80	65	65	80	80	55
	MEAN	93	94	93	91	84*	86*
	S.D.	6.8	6.9	5.3	4.8	4.9	5.6
2	N	70	59	60	74	74	55
	MEAN	93	94	93	91	86*	93
	S.D.	7.7	8.6	5.7	5.0	5.5	5.8
3	N	72	58	57	70	74	54
	MEAN	95	96	94	94	90*	92*
	S.D.	7.4	6.4	5.6	6.6	6.0	6.3
4	N	71	58	59	71	74	51
	MEAN	96	100*	95	96	92*	93
	S.D.	7.0	8.1	7.0	7.4	5.5	9.0
5	N	74	59	59	75	72	54
	MEAN	92	95	93	91	87*	90
	S.D.	8.5	7.5	7.7	7.3	5.8	8.5
6	N	69	57	58	71	70	53
	MEAN	93	95	92	90	85*	90
	S.D.	9.4	6.9	7.9	8.0	6.6	9.8
7	N	71	58	60	72	72	55
	MEAN	87	90	89	91*	88	91*
	S.D.	6.5	6.2	6.7	7.3	6.5	8.4
8	N	73	59	59	70	73	53
	MEAN	86	91*	89	87	83	85
	S.D.	7.3	5.9	6.8	10.1	7.4	8.3

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 5A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
FOOD CONSUMPTION MEANS AND STANDARD DEVIATIONS (G)

	SEX:	FEMALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
9	N	75	60	60	74	72	53
	MEAN	86	85	83	84	81*	85
	S.D.	7.3	6.4	7.3	7.6	6.7	8.7
10R	N	72	58	59	66	68	46
	MEAN	84	86	86	87	83	85
	S.D.	6.8	6.8	8.6	9.3	8.2	10.5
11	N	73	55	55	56	67	41
	MEAN	89	90	89	89	87	89
	S.D.	8.9	8.3	8.3	8.5	9.3	11.2
12	N	73	52	56	67	65	47
	MEAN	89	88	86	82*	86	91
	S.D.	11.1	10.1	8.7	9.8	10.2	11.1
13	N	70	54	55	69	67	50
	MEAN	83	85	84	82	83	83
	S.D.	9.1	8.5	9.7	8.2	10.1	10.7
14	N	68	55	55	70	64	53
	MEAN	81	85	84	83	82	83
	S.D.	8.4	8.4	8.2	7.7	8.3	8.1
15	N	68	55	55	70	70	53
	MEAN	83	87	86	86	86	86
	S.D.	8.4	7.3	8.1	7.4	9.0	9.3
16	N	68	52	54	69	68	54
	MEAN	87	87	89	88	88	87
	S.D.	8.4	6.8	8.3	6.7	8.3	7.8

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 5A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
FOOD CONSUMPTION MEANS AND STANDARD DEVIATIONS (G)

	SEX:	FEMALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
20	N	69	55	55	70	70	54
	MEAN	87	88	90	91*	87	87
	S.D.	7.2	5.6	7.1	7.1	7.4	7.5
24	N	70	55	55	70	69	55
	MEAN	83	85	84	83	79*	78*
	S.D.	9.1	7.7	7.1	7.6	8.6	7.6
28	N	70	55	55	69	69	54
	MEAN	87	88	84	85	81*	80*
	S.D.	7.6	6.4	8.4	7.2	7.0	7.0
32	N	70	54	55	70	69	55
	MEAN	80	82	81	80	81	80
	S.D.	5.8	6.2	5.6	5.6	6.2	8.6
36	N	70	54	55	70	68	55
	MEAN	87	88	86	86	84*	83*
	S.D.	6.3	6.7	6.2	5.5	6.7	6.7
40X[2]	N	69	54	55	70	69	55
	MEAN	87	89	89	92*	90	89
	S.D.	7.9	7.0	6.7	7.6	7.7	13.8
44	N	69	53	55	70	69	54
	MEAN	88	88	89	91	86	86
	S.D.	7.2	6.8	6.1	6.6	7.1	7.4
48	N	69	54	54	70	69	54
	MEAN	92	98*	97*	96*	91	91
	S.D.	6.1	6.4	7.0	6.9	6.5	7.9

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 5A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
FOOD CONSUMPTION MEANS AND STANDARD DEVIATIONS (G)

	SEX:	FEMALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
52	N	69	54	55	70	69	54
	MEAN	96	99	96	95	91*	89*
	S.D.	7.7	9.0	7.3	7.4	7.0	7.5
56	N	69	54	55	70	69	54
LG10	MEAN	96	96	94	93*	88*	88*
	S.D.	6.8	8.8	6.9	5.4	5.2	7.6
60	N	69	54	55	70	69	54
	MEAN	93	95	94	93	89*	89*
	S.D.	7.2	8.1	8.0	5.8	7.1	6.7
64	N	69	54	55	69	69	54
	MEAN	92	97*	93	94	93	93
	S.D.	7.3	8.6	8.5	7.0	7.9	8.0
68	N	69	54	55	69	69	54
	MEAN	93	98*	97*	98*	96	96
	S.D.	8.7	6.6	6.9	6.1	7.0	7.1
72	N	68	54	55	68	68	54
	MEAN	94	94	94	94	88*	90*
	S.D.	7.9	6.3	6.2	7.8	7.6	7.5
76	N	68	54	55	68	66	53
	MEAN	95	94	95	92	89*	89*
	S.D.	7.8	12.1	13.0	8.2	7.4	7.4
80	N	53	54	53	51	52	53
	MEAN	91	94	93	92	90	99*
	S.D.	12.7	8.4	13.3	6.5	7.6	11.1

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 5A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
FOOD CONSUMPTION MEANS AND STANDARD DEVIATIONS (G)

	SEX:	FEMALE					
	GROUP:	1	2	3	4	5	6
WEEK	DOSE:	0	100	500	2500	12500	12500
84	N	52	53	52	51	50	51
	MEAN	91	93	91	90	89	92
	S.D.	7.6	8.3	6.0	5.7	7.5	10.0
88	N	51	52	51	50	50	49
	MEAN	90	91	93	92	91	95
	S.D.	9.1	11.4	6.3	5.8	11.3	9.2
92	N	51	50	51	50	45	46
	MEAN	92	96	99*	98*	94	97
	S.D.	14.7	7.3	11.9	7.4	10.9	8.6
96	N	47	50	49	48	44	45
	MEAN	94	98	95	91	87*	92
	S.D.	8.3	8.2	9.0	13.5	12.7	8.4
100	N	45	50	46	46	41	41
	MEAN	94	99	96	95	93	92
	S.D.	9.5	25.1	9.7	11.5	7.4	11.9
104X[2]	N	40	42	40	37	35	34
	MEAN	89	93	95	88	86	90
	S.D.	12.7	10.2	8.8	18.9	9.4	9.4

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

Table 5B
Mean Total Food Consumption and Standard Deviations
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Notes: All males in Group 7 were sacrificed by Week 13.

Dose levels were measured in ppm.

TABLE 5B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MEAN TOTAL FOOD CONSUMPTION AND STANDARD DEVIATIONS (G)

WEEK	GROUP: / DOSE:	1 / 0	2 / 100	3 / 500	4 / 2500	5 / 12500	6 / 12500
MALES							
1-52	N	68	50	40	68	63	53
	MEAN	2816	2819	2796	2835	2851	2883
	S.D.	145.0	151.2	171.8	161.0	196.9	215.7
1-104	N	40	35	29	33	32	34
	MEAN	4324	4334	4286	4361	4368	4365
	S.D.	217.8	219.9	288.0	275.9	323.8	302.3
FEMALES							
1-52	N	51	37	43	43	48	28
	MEAN	2170	2224	2212	2183	2127	2139
	S.D.	110.9	104.4	132.9	136.3	141.7	145.5
1-104	N	27	28	32	24	21	16
	MEAN	3380	3446	3411	3354	3300	3321
	S.D.	185.3	140.7	149.4	189.6	180.3	166.0

Table 6
Compound Consumption Means and Standard Deviations
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Notes: All males in Group 7 were sacrificed by Week 13.

Group 6 animals were removed from the test material after 78 weeks of treatment.

Dose levels were measured in ppm.

TABLE 6
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
COMPOUND CONSUMPTION MEANS AND STANDARD DEVIATIONS (MG/KG/DAY)

COMPOUND CONSUMPTION (ACHIEVED DOSAGE)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
1	N	80	65	65	80	79	55	10
	MEAN	0.0	11.9	60.5	298.6	1452.8	1464.7	115.6
	S.D.	0.0	0.5	2.5	13.4	67.7	66.8	4.7
2	N	75	60	60	75	75	55	5
	MEAN	0.0	9.7	48.5	239.8	1217.0	1293.2	105.9
	S.D.	0.0	0.3	1.9	11.0	50.8	50.0	3.9
3	N	75	60	47	75	75	55	5
	MEAN	0.0	9.0	45.3	222.7	1150.4	1181.6	105.7
	S.D.	0.0	0.3	2.0	12.3	50.7	51.8	5.2
4	N	75	60	60	75	75	54	5
	MEAN	0.0	8.3	41.4	208.0	1104.1	1129.9	107.3
	S.D.	0.0	0.3	1.4	7.4	47.0	54.6	2.6
5	N	75	60	60	75	75	55	5
	MEAN	0.0	7.6	37.8	189.1	1022.6	1032.6	100.6
	S.D.	0.0	0.3	1.7	6.7	49.8	47.2	3.1
6	N	75	60	60	75	75	55	5
	MEAN	0.0	7.2	35.3	176.6	962.1	976.4	95.8
	S.D.	0.0	0.3	1.8	8.7	38.8	42.2	1.7
7	N	75	60	60	74	73	55	5
	MEAN	0.0	6.7	33.8	173.3	935.1	926.3	93.0
	S.D.	0.0	0.3	1.3	8.1	45.0	41.1	3.3
8	N	75	59	60	74	74	54	5
	MEAN	0.0	6.3	32.2	164.6	870.0	883.8	90.5
	S.D.	0.0	0.3	1.3	6.9	43.6	36.4	2.8

TABLE 6
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
COMPOUND CONSUMPTION MEANS AND STANDARD DEVIATIONS (MG/KG/DAY)

COMPOUND CONSUMPTION (ACHIEVED DOSAGE)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
9	N	75	60	60	75	75	55	5
	MEAN	0.0	6.1	30.1	154.4	826.2	841.8	89.8
	S.D.	0.0	0.3	1.6	6.3	47.5	40.3	2.7
10	N	75	59	60	75	75	55	5
	MEAN	0.0	5.7	29.9	149.4	807.9	803.1	86.6
	S.D.	0.0	0.3	1.7	9.4	53.1	53.7	6.5
11	N	75	60	60	75	75	55	5
	MEAN	0.0	6.2	32.1	157.0	834.5	827.1	91.0
	S.D.	0.0	0.3	6.1	8.9	56.7	41.3	1.1
12	N	75	60	60	75	73	55	5
	MEAN	0.0	5.8	28.8	147.2	809.6	793.2	84.4
	S.D.	0.0	0.3	1.6	8.0	41.7	41.5	3.2
13	N	69	52	55	70	70	55	-
	MEAN	0.0	5.5	27.2	138.3	750.5	759.9	
	S.D.	0.0	0.3	1.4	6.2	41.8	37.2	
14	N	70	55	55	70	70	54	-
	MEAN	0.0	5.4	26.7	137.1	743.3	746.1	
	S.D.	0.0	0.3	1.1	5.5	36.1	32.2	
15	N	70	55	55	70	70	55	-
	MEAN	0.0	5.5	27.2	139.1	756.2	755.2	
	S.D.	0.0	0.3	1.0	7.2	40.0	42.4	
16	N	70	55	55	70	70	55	-
	MEAN	0.0	5.7	28.2	143.4	786.5	779.6	
	S.D.	0.0	0.3	1.1	6.3	28.8	32.1	

TABLE 6
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
COMPOUND CONSUMPTION MEANS AND STANDARD DEVIATIONS (MG/KG/DAY)

COMPOUND CONSUMPTION (ACHIEVED DOSAGE)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
20	N	70	55	55	70	70	55	-
	MEAN	0.0	5.3	27.6	138.0	724.2	731.2	
	S.D.	0.0	0.3	1.6	7.3	34.9	27.7	
24	N	70	55	55	70	70	55	-
	MEAN	0.0	4.7	22.9	120.2	670.4	680.4	
	S.D.	0.0	0.3	1.1	6.1	38.3	29.3	
28	N	70	55	55	70	70	55	-
	MEAN	0.0	4.6	23.6	118.1	660.6	680.5	
	S.D.	0.0	0.2	1.1	4.9	32.6	32.8	
32	N	70	54	54	70	70	55	-
	MEAN	0.0	4.6	23.7	119.3	668.2	657.2	
	S.D.	0.0	0.2	1.1	5.9	35.7	27.7	
36	N	69	55	55	70	70	55	-
	MEAN	0.0	5.0	23.6	118.7	665.7	671.2	
	S.D.	0.0	0.5	1.5	5.8	34.9	29.8	
40	N	70	55	55	70	70	55	-
	MEAN	0.0	4.9	23.7	121.8	666.6	661.4	
	S.D.	0.0	0.4	1.2	5.4	35.8	33.3	
44	N	70	55	55	70	70	55	-
	MEAN	0.0	4.7	23.3	115.6	644.6	653.7	
	S.D.	0.0	0.4	1.4	6.1	44.3	35.0	
48	N	70	55	55	70	70	55	-
	MEAN	0.0	4.9	23.7	120.8	673.7	678.2	
	S.D.	0.0	0.3	1.0	5.8	43.3	33.0	

TABLE 6
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
COMPOUND CONSUMPTION MEANS AND STANDARD DEVIATIONS (MG/KG/DAY)

COMPOUND CONSUMPTION (ACHIEVED DOSAGE)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
52	N	70	55	55	70	67	54	-
	MEAN	0.0	4.8	24.0	118.2	680.0	688.4	
	S.D.	0.0	0.4	1.3	7.0	40.8	33.4	
56	N	70	55	55	70	69	55	-
	MEAN	0.0	4.7	23.9	122.9	669.7	687.4	
	S.D.	0.0	0.4	1.6	7.5	42.1	39.6	
60	N	70	55	55	70	69	55	-
	MEAN	0.0	4.9	24.7	121.4	673.8	669.5	
	S.D.	0.0	0.4	2.2	10.2	47.4	41.0	
64	N	70	55	54	69	69	55	-
	MEAN	0.0	4.8	24.4	121.5	667.8	652.8	
	S.D.	0.0	0.5	2.1	8.6	44.2	33.5	
68	N	70	55	54	68	69	55	-
	MEAN	0.0	4.9	24.3	120.5	649.9	659.6	
	S.D.	0.0	0.5	2.0	7.6	42.0	32.7	
72	N	69	52	54	67	69	54	-
	MEAN	0.0	4.4	21.9	108.6	616.5	626.5	
	S.D.	0.0	0.3	1.6	7.6	45.0	30.7	
76	N	68	53	53	67	69	54	-
	MEAN	0.0	4.5	22.0	111.1	622.1	637.8	
	S.D.	0.0	0.4	1.7	8.6	63.1	42.8	
80	N	53	53	53	51	52	54	-
	MEAN	0.0	4.5	23.0	115.2	617.7	0.0	
	S.D.	0.0	0.4	1.7	10.2	55.2	0.0	

TABLE 6
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(MALES)
COMPOUND CONSUMPTION MEANS AND STANDARD DEVIATIONS (MG/KG/DAY)

COMPOUND CONSUMPTION (ACHIEVED DOSAGE)

	SEX:	MALE						
	GROUP:	1	2	3	4	5	6	7
WEEK	DOSE:	0	100	500	2500	12500	12500	1000
84	N	53	50	52	49	51	53	-
	MEAN	0.0	4.6	22.7	115.4	610.0	0.0	
	S.D.	0.0	0.5	2.2	9.3	78.8	0.0	
88	N	53	51	53	48	46	52	-
	MEAN	0.0	4.3	21.7	113.0	621.5	0.0	
	S.D.	0.0	0.7	2.2	8.8	55.1	0.0	
92	N	51	48	50	47	46	50	-
	MEAN	0.0	4.4	22.3	117.3	618.5	0.0	
	S.D.	0.0	0.7	5.1	9.0	94.2	0.0	
96	N	51	45	44	47	43	48	-
	MEAN	0.0	4.5	21.9	110.6	619.9	0.0	
	S.D.	0.0	0.4	2.3	17.4	64.1	0.0	
100	N	48	44	42	43	42	45	-
	MEAN	0.0	4.6	23.4	115.7	641.6	0.0	
	S.D.	0.0	0.4	2.0	9.0	69.5	0.0	
104	N	40	37	38	33	35	35	-
	MEAN	0.0	4.6	24.2	121.3	625.8	0.0	
	S.D.	0.0	0.4	4.6	14.1	107.8	0.0	
1-104	MEAN	0.0	5.8	28.9	146.6	789.0	679.3	98.6

TABLE 6
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
COMPOUND CONSUMPTION MEANS AND STANDARD DEVIATIONS (MG/KG/DAY)

COMPOUND CONSUMPTION (ACHIEVED DOSAGE)

	SEX:	FEMALE				
	GROUP:	2	3	4	5	6
WEEK	DOSE:	100	500	2500	12500	12500
1	N	65	65	80	80	55
	MEAN	12.9	65.4	321.8	1474.2	1500.6
	S.D.	0.9	3.8	16.5	92.4	96.9
2	N	59	60	74	74	55
	MEAN	11.5	57.6	281.0	1344.2	1434.4
	S.D.	1.0	3.0	13.5	77.7	62.4
3	N	58	57	70	74	54
	MEAN	10.7	53.3	267.1	1305.9	1307.2
	S.D.	0.5	1.9	15.1	71.9	54.7
4	N	58	59	71	74	51
	MEAN	10.4	50.4	257.4	1259.3	1256.5
	S.D.	0.8	2.3	18.0	52.8	121.1
5	N	59	59	75	72	54
	MEAN	9.4	46.9	233.5	1142.5	1169.3
	S.D.	0.8	2.4	14.5	54.9	86.2
6	N	57	58	71	70	53
	MEAN	9.1	44.4	220.5	1082.0	1129.1
	S.D.	0.6	2.6	15.8	66.8	100.8
7	N	58	60	72	72	55
	MEAN	8.3	41.9	215.9	1095.5	1125.0
	S.D.	0.5	2.1	15.9	65.6	89.6
8	N	59	59	70	73	53
	MEAN	8.2	40.6	200.5	1007.2	1033.0
	S.D.	0.5	2.3	21.0	73.4	73.9

TABLE 6
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
COMPOUND CONSUMPTION MEANS AND STANDARD DEVIATIONS (MG/KG/DAY)

COMPOUND CONSUMPTION (ACHIEVED DOSAGE)

	SEX:	FEMALE				
	GROUP:	2	3	4	5	6
WEEK	DOSE:	100	500	2500	12500	12500
9	N	60	60	74	72	53
	MEAN	7.5	37.2	190.1	959.8	996.7
	S.D.	0.5	2.3	13.1	67.5	79.6
10	N	58	59	66	68	46
	MEAN	7.5	37.9	195.3	971.6	986.4
	S.D.	0.5	2.7	17.0	84.1	117.8
11	N	55	55	56	67	41
	MEAN	7.7	38.3	195.3	998.2	1021.2
	S.D.	0.6	2.7	15.6	90.5	109.1
12	N	52	56	67	65	47
	MEAN	7.3	36.6	177.5	976.5	1011.3
	S.D.	0.8	2.9	18.8	98.0	93.0
13	N	54	55	69	67	50
	MEAN	7.0	35.2	177.3	931.7	915.0
	S.D.	0.6	3.5	15.0	93.9	102.0
14	N	55	55	70	64	53
	MEAN	7.0	34.8	174.6	903.3	904.8
	S.D.	0.6	2.4	12.1	78.6	71.5
15	N	55	55	70	70	53
	MEAN	7.0	35.1	177.8	940.1	929.4
	S.D.	0.5	2.3	12.4	72.7	68.3
16	N	52	54	69	68	54
	MEAN	7.0	36.5	184.0	959.2	942.4
	S.D.	0.5	2.5	9.7	64.6	62.1

TABLE 6
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
COMPOUND CONSUMPTION MEANS AND STANDARD DEVIATIONS (MG/KG/DAY)

COMPOUND CONSUMPTION (ACHIEVED DOSAGE)

	SEX:	FEMALE				
	GROUP:	2	3	4	5	6
WEEK	DOSE:	100	500	2500	12500	12500
20	N	55	55	70	70	54
	MEAN	6.9	35.7	183.0	912.7	902.7
	S.D.	0.4	2.2	10.8	54.0	50.5
24	N	55	55	70	69	55
	MEAN	6.5	32.1	160.2	808.8	796.4
	S.D.	0.6	2.1	11.4	72.0	58.7
28	N	55	55	69	69	54
	MEAN	6.5	31.5	159.3	808.8	794.6
	S.D.	0.4	2.6	11.3	46.1	53.1
32	N	54	55	70	69	55
	MEAN	6.1	29.9	149.2	810.0	799.2
	S.D.	0.4	1.6	7.7	48.9	79.4
36	N	54	55	70	68	55
	MEAN	6.4	31.1	157.8	825.0	806.6
	S.D.	0.4	2.1	8.8	48.2	58.6
40	N	54	55	70	69	55
	MEAN	6.3	31.7	163.5	860.3	853.3
	S.D.	0.5	2.2	11.2	55.8	112.9
44	N	53	55	70	69	54
	MEAN	6.3	31.8	161.0	826.3	820.8
	S.D.	0.5	1.9	10.4	51.6	55.0
48	N	54	54	70	69	54
	MEAN	6.8	33.9	167.0	854.0	848.7
	S.D.	0.5	2.4	10.2	49.6	57.8

TABLE 6
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
COMPOUND CONSUMPTION MEANS AND STANDARD DEVIATIONS (MG/KG/DAY)

COMPOUND CONSUMPTION (ACHIEVED DOSAGE)

	SEX:	FEMALE				
	GROUP:	2	3	4	5	6
WEEK	DOSE:	100	500	2500	12500	12500
52	N	54	55	70	69	54
	MEAN	6.8	33.3	162.5	848.2	825.0
	S.D.	0.6	2.4	10.0	57.2	55.8
56	N	54	55	70	69	54
	MEAN	6.4	31.5	154.2	804.8	803.1
	S.D.	0.6	2.1	7.3	35.2	59.4
60	N	54	55	70	69	54
	MEAN	6.2	30.8	151.8	810.2	808.1
	S.D.	0.5	2.5	7.0	55.4	56.0
64	N	54	55	69	69	54
	MEAN	6.2	30.2	151.7	840.2	833.5
	S.D.	0.5	2.6	9.2	61.5	63.8
68	N	54	55	69	69	54
	MEAN	6.2	31.2	157.8	861.4	853.4
	S.D.	0.5	2.3	8.8	53.9	57.3
72	N	54	55	68	68	54
	MEAN	5.8	29.1	144.5	780.2	787.1
	S.D.	0.4	1.8	11.1	50.7	54.4
76	N	54	55	68	66	53
	MEAN	5.8	28.8	138.4	772.9	756.8
	S.D.	0.7	3.5	9.7	55.8	50.6
80	N	54	53	51	52	53
	MEAN	5.6	27.6	135.9	766.5	0.0
	S.D.	0.4	3.2	9.3	55.8	0.0

TABLE 6
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(FEMALES)
COMPOUND CONSUMPTION MEANS AND STANDARD DEVIATIONS (MG/KG/DAY)

COMPOUND CONSUMPTION (ACHIEVED DOSAGE)

	SEX:	FEMALE				
	GROUP:	2	3	4	5	6
WEEK	DOSE:	100	500	2500	12500	12500
84	N	53	52	51	50	51
	MEAN	5.4	26.3	130.8	739.7	0.0
	S.D.	0.4	2.1	7.6	53.1	0.0
88	N	52	51	50	50	49
	MEAN	5.3	26.9	133.3	761.5	0.0
	S.D.	0.7	1.7	7.6	78.2	0.0
92	N	50	51	50	45	46
	MEAN	5.5	28.5	141.9	786.4	0.0
	S.D.	0.4	3.1	9.3	76.3	0.0
96	N	50	49	48	44	45
	MEAN	5.5	27.3	128.4	715.6	0.0
	S.D.	0.4	2.6	15.5	72.3	0.0
100	N	50	46	46	41	41
	MEAN	5.6	27.2	133.8	757.4	0.0
	S.D.	1.4	2.4	12.2	46.1	0.0
104	N	42	40	37	35	34
	MEAN	5.3	26.5	126.0	690.7	0.0
	S.D.	0.4	2.1	23.0	55.2	0.0
1-104	MEAN	7.3	36.1	181.7	938.5	808.2

Table 7A
Summary of Clinical Hematology Data
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Note: Dose levels were measured in ppm.

Key to Summary of Clinical Hematology Data

Parameters

RBC	Erythrocyte count
RETIC	Reticulocyte count
A RETIC	Absolute reticulocyte count
HGB	Hemoglobin
HCT	Hematocrit
MCV	Mean cell volume
MCH	Mean cell hemoglobin
MCHC	Mean cell hemoglobin concentration
PLATELET	Platelet
M/E	Myeloid/Erythroid ratio
WBC	Leukocyte count
COR WBC	Corrected leukocyte count

Leukocyte Differentials

BLAST	Blast cells
PRO/MYEL	Promyelocytes/Myelocytes
META	Metamyelocytes
BAND	Band neutrophils
SEG	Segmented neutrophils
LYMPH	Lymphocytes
MONO	Monocytes
EOSIN	Eosinophils
BASO	Basophils

Units

MI/µL	millions/microliter
TH/µL	thousands/microliter
mg/dL	milligrams/deciliter
g/dL	grams/deciliter
%	percent
pg	picograms
fl	femtoliters

CLINICAL HEMATOLOGY FOOTNOTES

Statistical transformations of data were performed if noted by the following:

R = RANK

1/X = RECIPROCAL

SQ = SQUARE

LG10 = LOG10

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	RBC - MI/UL WEEK 26	52	78	104	RETIC - % RBC WEEK 26	52	78 1/X	104 LG10	A RETIC - MI/UL WEEK 26	52	78 1/X	104 LG10
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	8.89	8.48	8.83	8.91	2.5	.4	.3	.7	.22	.03	.02	.06
S.D.	.466	.745	.719	1.074	1.82	.19	.21	.47	.134	.016	.019	.041
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	9.08	8.67	8.76	8.38	2.0	.4	.1	.7	.18	.04	.01	.06
S.D.	.276	.299	.255	1.155	.59	.19	.12	.40	.054	.016	.012	.032
3 (500 PPM)												
N	10	10	9	9	10	10	9	9	10	10	9	9
MEAN	8.91	8.72	8.96	8.22	1.9	.3	.2	1.0	.17	.03	.02	.08
S.D.	.225	.270	.366	1.320	.38	.19	.17	.95	.036	.016	.015	.069
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	8.69	8.46	8.60	7.49	2.1	.5	.7	3.2	.18	.04	.05	.20
S.D.	.187	.312	.641	.965	.54	.23	1.30	5.96	.048	.018	.087	.304
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	8.39*	8.17	8.17*	8.01	2.6	.5	.2	.6	.22	.04	.02	.05
S.D.	.228	.248	.180	.436	.55	.42	.17	.33	.051	.033	.013	.028
6 (12500 PPM)												
N	10	10	9	10	10	10	9	10	10	10	9	10
MEAN	8.42*	8.23	8.31	7.74	2.6	.4	.2	5.6	.22	.04	.02	.09
S.D.	.264	.244	.397	2.524	.85	.21	.24	15.72	.068	.018	.017	.151

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	RBC - MI/UL				RETIC - % RBC				A RETIC - MI/UL			
	WEEK				WEEK				WEEK			
	26	52	78	104 SQ	26	52	78	104 R	26	52	78	104 R
1 (0 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	8.69	8.12	8.33	8.46	2.4	.3	1.3	.5	.21	.03	.10	.04
S.D.	.291	.255	.260	.385	.63	.24	.53	.21	.057	.020	.044	.018
2 (100 PPM)												
N	10	10	9	10	10	10	9	10	10	10	9	10
MEAN	8.66	7.87	8.43	7.77	1.9	.5	1.2	4.2	.16	.04	.10	.10
S.D.	.209	.919	.204	2.261	.74	.29	.44	11.38	.064	.023	.037	.150
3 (500 PPM)												
N	10	10	10	9	10	10	10	9	10	10	10	9
MEAN	8.24*	7.99	7.89	7.96	2.9	.5	1.4	.6	.22	.04	.11	.05
S.D.	.731	.261	.942	.744	2.59	.25	.74	.28	.152	.020	.057	.022
4 (2500 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	8.52	8.04	8.22	7.31	2.3	.4	1.7	3.9	.20	.03	.14	.19
S.D.	.219	.263	.374	1.785	.73	.32	.77	6.67	.062	.026	.063	.248
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	8.11*	7.73	7.66*	7.79	2.3	.4	1.7	.6	.19	.03	.13	.04
S.D.	.233	.126	.235	.306	.49	.28	.49	.34	.043	.022	.039	.024
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	8.19*	7.71	7.56*	8.54	2.1	.3	1.5	.7	.17	.02	.11	.06
S.D.	.220	.304	.398	.813	.76	.17	.68	.43	.062	.014	.047	.035

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	HGB - G/DL WEEK 26	52	78	104	HCT - % WEEK 26	52	78	104	MCV - FL WEEK 26	52	78	104
		SQ										LG10
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	15.9	14.6	16.0	16.1	43.7	41.1	44.7	45.8	49.2	48.5	50.7	51.4
S.D.	.74	2.72	1.14	1.72	1.56	3.73	3.10	4.88	1.18	.52	1.27	1.83
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	16.3	15.4	15.6	15.3	44.2	41.8	43.5	44.0	48.7	48.2	49.7	53.1
S.D.	.42	.48	.43	1.20	1.25	1.40	.90	3.17	.31	.32	1.01	5.35
3 (500 PPM)												
N	10	10	9	9	10	10	9	9	10	10	9	9
MEAN	16.2	15.6	15.8	15.1	43.7	42.3	44.3	42.5	49.1	48.5	49.5	52.3
S.D.	.40	.56	.41	1.49	1.10	1.27	1.16	4.46	.53	.36	1.29	4.49
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	15.9	15.3	15.0	13.7	42.8	41.3	42.3	38.7*	49.2	48.8	49.1	52.3
S.D.	.35	.45	1.81	.80	.95	1.50	4.59	2.30	.35	.70	2.54	6.30
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	15.3	14.8*	14.3*	14.2	41.1*	39.4*	39.9*	39.6	49.0	48.3	48.9*	49.5
S.D.	.44	.52	.36	.51	1.22	1.32	.79	1.32	.46	.36	.33	1.26
6 (12500 PPM)												
N	10	10	9	10	10	10	9	10	10	10	9	10
MEAN	15.3	14.9*	14.5*	14.5	41.3*	39.7*	40.5*	40.7	49.1	48.3	48.8*	58.9
S.D.	.57	.44	.70	3.74	1.48	1.23	1.66	10.81	.38	.36	1.07	23.08

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	HGB - G/DL WEEK 26	52	78	104	HCT - % WEEK 26	52 SQ	78	104	MCV - FL WEEK 26 LG10	52	78 R	104 R
1 (0 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	16.3	15.9	15.8	15.9	45.5	42.6	44.1	45.2	52.3	52.4	53.0	53.5
S.D.	.57	.47	.33	.73	1.52	1.20	1.42	1.88	.32	.48	.30	.64
2 (100 PPM)												
N	10	10	9	10	10	10	9	10	10	10	9	10
MEAN	16.3	15.7	16.1	14.7	45.2	41.5	44.5	42.0	52.2	52.8	52.8	58.3
S.D.	.35	1.22	.32	3.79	1.15	4.95	1.13	9.78	.28	.62	.42	16.38
3 (500 PPM)												
N	10	10	10	9	10	10	10	9	10	10	10	9
MEAN	15.7	15.7	15.4	15.2	43.2*	42.1	42.0	43.2	52.5	52.7	53.3	54.6
S.D.	1.22	.49	1.45	1.12	2.86	1.34	4.61	2.63	1.74	.28	.90	3.25
4 (2500 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	16.0	15.8	15.8	14.5	44.0	42.5	43.3	41.2	51.6	52.9	52.6	58.6
S.D.	.49	.65	.67	2.40	1.39	1.66	1.87	5.75	.39	.46	.61	11.93
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	15.1*	14.8*	14.4*	14.4	40.8*	39.9*	39.1*	40.4	50.3*	51.6*	51.0*	51.9
S.D.	.42	.25	.39	.70	1.17	.58	1.32	1.59	.32	.66	.81	1.70
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	15.3*	14.7*	14.2*	16.0	41.3*	39.8*	38.6*	45.0	50.5*	51.7*	51.1*	52.8
S.D.	.40	.42	.51	1.14	1.01	1.44	1.45	3.53	.30	.58	1.20	1.10

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	MCH - PG				MCHC - G/DL				PLATELET - TH/UL			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78	104	26	52	78	104
	R	R		R	R	R						
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	17.9	17.1	18.1	18.1	36.4	35.2	35.8	35.2	734	677	692	634
S.D.	.38	2.23	.47	.52	1.07	4.48	.49	.58	86.1	61.7	50.0	133.4
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	17.9	17.8	17.8	18.5	36.8	37.0	35.8	34.8	731	697	678	628
S.D.	.17	.36	.55	1.43	.39	.66	.55	1.15	46.2	41.6	40.1	187.9
3 (500 PPM)												
N	10	10	9	9	10	10	9	9	10	10	9	9
MEAN	18.1	17.9	17.6	18.6	37.0	37.0	35.6	35.6	724	743*	736	767
S.D.	.18	.31	.63	1.93	.48	.48	.53	.69	72.3	54.3	71.9	235.5
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	18.3*	18.1*	17.4	18.5	37.3	37.2	35.4	35.4	742	680	748	648
S.D.	.14	.28	1.12	2.24	.32	.58	.70	.66	49.8	37.5	115.0	173.7
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	18.3*	18.1*	17.5	17.7	37.3	37.6*	35.8	35.8	825*	765*	801*	769
S.D.	.25	.14	.25	.46	.48	.26	.45	.42	37.7	32.8	58.6	136.2
6 (12500 PPM)												
N	10	10	9	10	10	10	9	10	10	10	9	10
MEAN	18.2*	18.1*	17.4	21.3	37.1	37.5*	35.7	35.9	802	784*	794*	665
S.D.	.19	.20	.35	8.92	.40	.51	.55	.80	64.2	62.4	60.4	193.0

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	MCH - PG				MCHC - G/DL				PLATELET - TH/UL			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78	104	26	52	78	104
	---R----	--------	--------	--LG10--	--------	--------	---R----	--------	--------	--------	--------	--------
1 (0 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	18.7	19.6	19.0	18.8	35.8	37.3	35.8	35.2	720	690	584	563
S.D.	.35	.39	.27	.21	.59	.55	.64	.36	80.5	32.3	49.5	49.6
2 (100 PPM)												
N	10	10	9	10	10	10	9	10	9	10	9	10
MEAN	18.8	20.0	19.1	19.7	36.0	38.0	36.2	34.4	742	643	608	496
S.D.	.18	1.10	.27	3.07	.46	2.23	.57	2.65	47.1	101.7	55.9	189.3
3 (500 PPM)												
N	10	10	10	9	10	10	10	9	10	10	10	9
MEAN	19.0	19.7	19.6*	19.2	36.2	37.4	36.7*	35.2	740	665	554	536
S.D.	.30	.23	.78	.87	.69	.53	1.08	.59	124.1	53.2	98.3	67.7
4 (2500 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	18.8	19.6	19.2	20.4	36.5*	37.1	36.5*	35.1	701	705	638	592
S.D.	.12	.27	.25	3.29	.29	.64	.50	1.44	134.9	41.1	65.8	297.8
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	18.6	19.1	18.8	18.4	36.9*	37.1	36.9*	35.6	791	727	666*	614
S.D.	.17	.30	.25	.63	.20	.52	.38	.51	31.1	24.1	71.0	106.0
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	9	10	10	10
MEAN	18.7	19.1	18.8	18.8	37.0*	36.9	36.8*	35.5	779	724	676*	586
S.D.	.11	.41	.50	.59	.36	.69	.18	.51	42.3	62.8	58.9	204.4

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	WBC - TH/UL				COR WBC - TH/UL			
	WEEK				WEEK			
	26	52	78	104 R	26	52	78	104
1 (0 PPM)								
N	10	10	10	10	10	10	10	10
MEAN	9.3	7.8	8.2	12.2	9.3	7.8	8.1	11.9
S.D.	1.62	1.89	2.31	12.06	1.60	1.89	2.32	11.52
2 (100 PPM)								
N	10	10	10	9	0	0	0	0
MEAN	9.0	8.2	9.8	9.7	.0	.0	.0	.0
S.D.	1.38	1.33	1.98	2.23	.00	.00	.00	.00
3 (500 PPM)								
N	10	10	9	9	0	0	0	0
MEAN	9.5	8.2	9.8	9.5	.0	.0	.0	.0
S.D.	1.03	.84	3.25	1.79	.00	.00	.00	.00
4 (2500 PPM)								
N	10	10	10	10	0	0	0	0
MEAN	10.4	8.4	10.1	18.1	.0	.0	.0	.0
S.D.	1.09	.87	3.40	12.97	.00	.00	.00	.00
5 (12500 PPM)								
N	10	10	10	10	10	10	10	10
MEAN	10.1	9.1	9.0	10.7	10.1	9.1	9.0	10.7
S.D.	1.51	1.16	1.06	5.06	1.51	1.16	1.07	5.02
6 (12500 PPM)								
N	10	10	9	10	10	10	9	10
MEAN	9.9	8.9	9.8	17.1	9.9	8.9	9.8	15.7
S.D.	1.02	1.29	3.24	17.36	1.04	1.29	3.24	13.79

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	WBC - TH/UL				COR WBC - TH/UL			
	WEEK				WEEK			
	26	52	78 --LG10--	104 --LG10--	26	52	78	104
1 (0 PPM)								
N	10	9	10	10	10	9	10	10
MEAN	8.5	6.9	5.7	6.3	8.5	6.9	5.7	6.2
S.D.	1.18	1.09	1.00	1.25	1.19	1.08	1.00	1.22
2 (100 PPM)								
N	10	10	9	10	0	0	0	0
MEAN	8.9	7.2	6.2	10.7	.0	.0	.0	.0
S.D.	1.48	1.06	.97	10.80	.00	.00	.00	.00
3 (500 PPM)								
N	10	10	10	9	0	0	0	0
MEAN	8.2	6.9	11.1	6.2	.0	.0	.0	.0
S.D.	1.44	.93	17.47	.76	.00	.00	.00	.00
4 (2500 PPM)								
N	10	9	10	10	0	0	0	0
MEAN	8.0	7.1	5.8	15.9	.0	.0	.0	.0
S.D.	1.14	.82	.87	24.47	.00	.00	.00	.00
5 (12500 PPM)								
N	10	10	10	10	10	10	10	10
MEAN	7.9	7.4	6.7	9.0	7.9	7.3	6.7	8.9
S.D.	1.43	.81	1.56	3.70	1.46	.81	1.58	3.66
6 (12500 PPM)								
N	10	10	10	10	10	10	10	10
MEAN	8.6	7.5	6.1	11.9	8.6	7.4	6.1	11.8
S.D.	1.35	.61	1.73	15.06	1.34	.60	1.71	15.08

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	BLAST - TH/UL WEEK 26	52	78	104	PRO/MYEL - TH/UL WEEK 26	52	78	104	META - TH/UL WEEK 26	52	78	104
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
2 (100 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
3 (500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
4 (2500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
6 (12500 PPM)												
N	10	10	9	10	10	10	9	10	10	10	9	10
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	BLAST - TH/UL WEEK 26	52	78	104	PRO/MYEL - TH/UL WEEK 26	52	78	104	META - TH/UL WEEK 26	52	78	104
1 (0 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
2 (100 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
3 (500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
4 (2500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	BAND - TH/UL WEEK 26	52	78	104 -R-	SEG - TH/UL WEEK 26	52	78	104	LYMPH - TH/UL WEEK 26	52	78	104 -R-
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.0	.0	.0	.0	1.4	2.4	2.9	7.3	7.7	5.2	5.1	4.4
S.D.	.00	.00	.00	.00	.68	.97	1.73	12.20	1.21	1.17	.65	1.02
2 (100 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
3 (500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
4 (2500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.0	.0	.0	.0	1.5	1.9	2.2	4.2	8.5	7.2*	6.6*	6.2
S.D.	.00	.00	.00	.00	.38	.41	.64	3.12	1.36	1.15	.79	3.82
6 (12500 PPM)												
N	10	10	9	10	10	10	9	10	10	10	9	10
MEAN	.0	.0	.0	.1	1.2	2.1	3.5	3.6	8.6	6.7*	6.2	11.7
S.D.	.00	.00	.00	.32	.42	.78	2.04	1.50	1.11	1.25	1.36	13.96

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	BAND - TH/UL WEEK 26	52	78 R	104	SEG - TH/UL WEEK 26	52	78	104	LYMPH - TH/UL WEEK 26	52	78	104
1 (0 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	.0	.0	.0	.0	1.4	1.8	1.5	2.6	7.1	5.0	4.1	3.4
S.D.	.00	.00	.00	.00	.63	.65	.42	.79	1.00	.95	.96	1.15
2 (100 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
3 (500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
4 (2500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.0	.0	.0	.0	.9	1.3	1.7	1.9	7.0	5.9*	5.0	6.9
S.D.	.00	.03	.00	.00	.56	.56	.61	.73	1.37	.49	1.58	3.63
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.0	.0	.0	.0	1.0	1.4	1.4	2.0	7.6	5.9*	4.7	9.7
S.D.	.00	.03	.03	.00	.48	.58	.41	.90	1.24	.76	1.73	15.37

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	MONO - TH/UL WEEK 26 --1/X---	52 --------	78 --1/X---	104 --------	EOSIN - TH/UL WEEK 26 --------	52 ---LG10-	78 --------	104 ---R----	BASO - TH/UL WEEK 26 --------	52 ---R----	78 --------	104 --------
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.0	.0	.2	.1	.1	.1	.0	.0	.0	.0	.0
S.D.	.14	.05	.04	.25	.08	.07	.09	.04	.00	.05	.00	.00
2 (100 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
3 (500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
4 (2500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.0	.0	.0	.2	.0	.0*	.1	.0	.0	.0	.0	.0
S.D.	.05	.05	.04	.13	.07	.03	.06	.07	.00	.04	.03	.00
6 (12500 PPM)												
N	10	10	9	10	10	10	9	10	10	10	9	10
MEAN	.0	.1	.1	.2	.0	.1	.1	.0	.0	.0	.0	.0
S.D.	.04	.07	.07	.19	.05	.10	.12	.03	.00	.00	.03	.00

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	MONO - TH/UL				EOSIN - TH/UL				BASO - TH/UL			
	WEEK				WEEK				WEEK			
	26	52 R	78	104	26 R	52	78	104	26	52 R	78 R	104
1 (0 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	.0	.0	.0	.1	.0	.1	.1	.0	.0	.0	.0	.0
S.D.	.04	.00	.04	.10	.10	.07	.05	.05	.00	.05	.00	.00
2 (100 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
3 (500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
4 (2500 PPM)												
N	0	0	0	0	0	0	0	0	0	0	0	0
MEAN	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.0	.0	.0	.1	.0	.1	.1	.0	.0	.0	.0	.0
S.D.	.03	.03	.03	.12	.03	.07	.07	.07	.00	.03	.03	.00
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.0	.0	.0	.1	.0	.0	.0	.0	.0	.0	.0	.0
S.D.	.03	.05	.03	.09	.03	.07	.05	.05	.00	.03	.00	.00

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	M/E - RATIO WEEK 79 SQ	M/E - RATIO WEEK 105
1 (0 PPM)		
N	10	40
MEAN	1.01	1.17
S.D.	.131	.292
2 (100 PPM)		
N		34
MEAN		1.18
S.D.		.329
3 (500 PPM)		
N		38
MEAN		1.08
S.D.		.254
4 (2500 PPM)		
N	10	32
MEAN	.90	1.12
S.D.	.145	.456
5 (12500 PPM)		
N	10	34
MEAN	.94	1.19
S.D.	.206	.249
6 (12500 PPM)		
N		35
MEAN		1.13
S.D.		.304

TABLE 7A
SUMMARY OF CLINICAL HEMATOLOGY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	M/E - RATIO WEEK 79	M/E - RATIO WEEK 105 R
1 (0 PPM)		
N	9	33
MEAN	.76	1.15
S.D.	.170	.279
2 (100 PPM)		
N		33
MEAN		1.22
S.D.		.398
3 (500 PPM)		
N		29
MEAN		1.31
S.D.		.573
4 (2500 PPM)		
N	10	24
MEAN	.88	1.15
S.D.	.252	.378
5 (12500 PPM)		
N	10	24
MEAN	.85	1.09
S.D.	.150	.267
6 (12500 PPM)		
N		23
MEAN		1.27
S.D.		.582

Table 7B
Summary of Clinical Chemistry Data
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Note: Dose levels were measured in ppm.

Key to Summary of Clinical Chemistry Data

Parameters	
GLUCOSE	Glucose
UREA N	Urea nitrogen
CREAT	Creatinine
AST	Aspartate aminotransferase
ALT	Alanine aminotransferase
T PROT	Total protein
ALBUMIN	Albumin
GLOBULIN	Globulin
CALCIUM	Calcium
T BILI	Total bilirubin
IN PHOS	Inorganic phosphorus
GGT	Gamma glutamyltransferase
SODIUM	Sodium
POTAS	Potassium
CHLORIDE	Chloride
U CALCIUM	Urine calcium
U CHLOR	Urine chloride
U CREAT	Urine creatinine
U OSMOL	Urine osmolality
U PHOS	Urine phosphorus
U POTAS	Urine potassium
U SODIUM	Urine sodium
U VOL	Urine volume
CRECLEAR	Urine creatinine clearance

Units	
g/dL	grams/deciliter
U/L	units/liter
mg/dL	milligrams/deciliter
mEq/L	milliequivalents/liter
mOs/kg	milliosmoles/kilogram
mL	milliliter
mL/mn/kg	milliliters/minute/kilogram

CLINICAL CHEMISTRY FOOTNOTES

Statistical transformations of data were performed if noted by the following:

R = RANK

1/X = RECIPROCAL

SQ = SQUARE

LG10 = LOG10

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	GLUCOSE - MG/DL				UREA N - MG/DL				CREAT - MG/DL			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78	104	26	52	78	104
	--LG10--		---R----					---R----	---R----	---R----	---R----	
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	98	96	96	84	15	16	16	23	.6	.6	.6	.4
S.D.	11.9	18.1	10.1	19.2	1.3	1.8	1.4	24.5	.05	.05	.05	.07
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	104	92	96	92	16	16	15	17	.6	.6	.6*	.4
S.D.	28.1	9.1	3.6	18.6	1.5	1.6	1.6	3.0	.03	.05	.00	.07
3 (500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	89	87	91	101	16	15	14	15	.6	.5	.6	.4
S.D.	7.8	5.9	5.3	16.1	1.1	1.3	.9	1.1	.03	.05	.03	.07
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	91	85	89	89	18*	17	15	16	.6	.6	.6	.4
S.D.	13.4	9.3	5.9	6.9	1.4	1.7	1.9	1.9	.00	.03	.03	.08
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	103	102	106	94	24*	21*	20*	19*	.6	.5	.6	.4
S.D.	5.4	6.5	10.9	40.5	1.7	1.2	1.9	2.4	.00	.04	.03	.08
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	111	109*	106*	97	22*	21*	20*	17	.6	.5	.6*	.4
S.D.	33.1	11.9	4.6	15.9	1.7	1.1	1.9	3.5	.06	.05	.05	.09

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	GLUCOSE - MG/DL WEEK 26 ---R----	52 ---LG10-	78 ---SQ---	104 --------	UREA N - MG/DL WEEK 26 --------	52 --------	78 ---LG10-	104 --------	CREAT - MG/DL WEEK 26 --------	52 ---R----	78 --------	104 --LG10--
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	98	85	100	94	18	17	15	16	.7	.6	.6	.3
S.D.	12.4	8.8	8.1	24.7	2.3	1.7	1.1	2.3	.07	.00	.06	.05
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	93	86	105	101	17	16	16	18	.6	.6	.6	.3
S.D.	9.8	13.4	8.4	13.0	1.3	1.7	.8	9.0	.05	.04	.04	.12
3 (500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	91	84	111	101	16	17	17	17	.7	.6	.6	.4
S.D.	14.4	11.5	24.1	18.9	1.3	1.2	7.1	4.5	.05	.06	.04	.29
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	111	86	106	98	18	17	16	18	.6	.6	.6	.3
S.D.	41.8	27.7	28.3	21.8	2.5	1.9	1.2	3.3	.05	.03	.04	.08
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	111	100	113	94	20*	21*	19*	20	.6	.6	.6	.3
S.D.	22.3	23.1	19.2	22.3	1.2	1.2	1.8	3.1	.05	.05	.05	.06
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	111	90	112	112	21*	21*	20*	15	.7	.6	.6	.3
S.D.	26.2	6.4	18.0	32.7	2.3	2.3	1.4	1.7	.07	.00	.03	.06

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	AST - U/L WEEK 26	52 ---R----	78	104 ---R----	ALT - U/L WEEK 26 ---R----	52 --LG10--	78	104 ---R----	T PROT - G/DL WEEK 26	52	78	104
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	91	111	80	102	65	81	56	66	7.0	6.7	7.0	6.9
S.D.	9.5	22.3	11.0	47.0	10.0	11.0	10.2	38.0	.18	.23	.27	.68
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	91	106	81	157	62	86	61	75	6.9	6.8	7.0	7.0
S.D.	8.4	15.5	10.7	173.6	11.3	20.2	7.7	62.2	.24	.19	.20	.38
3 (500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	85	119	83	82	58	95	61	52	6.9	6.8	6.8	7.0
S.D.	6.0	30.4	28.3	9.7	6.3	30.2	18.8	8.5	.23	.20	.98	.33
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	81*	96	94	161	55*	82	76	109	7.1	6.7	7.0	7.4
S.D.	5.6	17.2	37.1	104.3	3.9	19.9	42.7	66.4	.24	.16	.39	.33
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	67*	61*	69	243	44*	45*	56	136	7.4*	7.1*	7.1	7.1
S.D.	10.6	7.8	21.3	410.8	3.4	7.5	38.3	124.9	.22	.20	.23	.44
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	66*	67*	69	101	46*	51*	48	56	7.3*	7.0*	7.1	6.8
S.D.	4.9	5.3	20.4	71.0	4.9	8.0	10.1	22.6	.22	.21	.56	.45

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	AST - U/L WEEK 26	52	78 -R-	104 -R-	ALT - U/L WEEK 26 -LG10-	52	78	104	T PROT - G/DL WEEK 26	52	78	104
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	101	112	85	85	65	80	58	56	7.0	7.9	7.3	7.4
S.D.	9.9	15.7	18.5	16.4	15.4	13.3	10.7	7.5	.23	.47	.51	.43
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	92	110	81	168	56	76	56	78	7.1	8.0	7.5	7.1
S.D.	12.7	23.8	5.6	238.1	6.1	24.9	7.3	79.7	.24	.40	.42	.88
3 (500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	92	98	282	77	53	64	78	50	7.1	8.0	7.3	7.2
S.D.	14.0	18.5	614.6	11.3	5.2	11.7	74.7	8.9	.38	.35	.40	.68
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	92	116	92	217	55	74	67	79	7.2	8.1	7.6	7.2
S.D.	30.0	49.7	26.1	419.9	25.6	31.3	39.5	89.3	.27	.59	.31	.69
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	77*	79*	85	93	48*	48*	47	66	7.8*	8.3	7.5	7.3
S.D.	5.2	12.7	32.4	40.2	4.1	7.9	13.7	40.9	.29	.41	.35	.63
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	81*	81*	79	98	49*	52*	60	74	7.7*	8.4	7.6	7.5
S.D.	14.9	15.6	33.2	47.1	5.0	20.1	45.6	49.7	.19	.25	.15	.57

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	ALBUMIN - G/DL				GLOBULIN - G/DL				CALCIUM - MG/DL			
	WEEK				WEEK				WEEK			
	26	52	78 R	104	26	52	78	104	26	52	78	104
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	4.8	4.5	4.5	4.1	2.1	2.2	2.4	2.8	11.3	11.4	11.3	11.4
S.D.	.10	.16	.12	.45	.14	.22	.24	.47	.37	.14	.32	.30
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	4.8	4.5	4.5	4.1	2.1	2.3	2.5	2.8	11.5	11.5	11.4	11.5
S.D.	.18	.13	.13	.32	.09	.15	.19	.28	.60	.37	.23	.45
3 (500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	4.9	4.6*	4.4	4.3	2.1	2.2	2.3	2.7	11.3	11.5	11.3	11.6
S.D.	.13	.16	.66	.25	.16	.13	.38	.18	.41	.23	.35	.17
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	5.2*	4.9*	4.8*	4.6*	1.8*	1.8*	2.3	2.7	11.4	11.4	11.3	11.5
S.D.	.15	.12	.20	.35	.10	.12	.29	.37	.23	.19	.29	.29
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	6.0*	5.6*	5.5*	4.8*	1.5*	1.5*	1.7*	2.3*	11.4	11.5	11.2	11.3
S.D.	.19	.15	.11	.40	.07	.15	.19	.31	.30	.24	.24	.37
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	5.9*	5.4*	5.3*	4.1	1.5*	1.5*	1.7*	2.7	11.5	11.4	11.1	11.6
S.D.	.15	.16	.46	.25	.10	.09	.16	.33	.63	.19	.44	.44

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	ALBUMIN - G/DL				GLOBULIN - G/DL				CALCIUM - MG/DL			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78	104	26	52	78	104
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	5.0	4.8	5.2	4.9	2.0	3.1	2.1	2.5	11.9	11.2	11.9	11.7
S.D.	.20	.18	.41	.18	.10	.41	.16	.47	.53	.34	.51	.49
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	5.1	4.8	5.3	4.6	2.1	3.2	2.2	2.4	11.9	11.1	12.0	11.3
S.D.	.20	.29	.31	.62	.13	.34	.22	.46	.27	.38	.31	.75
3 (500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	5.1	5.0	5.2	4.9	1.9	3.0	2.1	2.2	11.7	11.4	11.8	11.3
S.D.	.32	.20	.44	.56	.10	.22	.17	.16	.88	.20	.57	.67
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	5.5*	5.3*	5.7*	5.0	1.8*	2.8	1.9*	2.1	11.9	11.2	11.9	11.3
S.D.	.15	.29	.31	.58	.16	.33	.10	.20	.87	.26	.26	.40
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	6.1*	5.4*	5.7*	5.3	1.6*	2.9	1.8*	2.0*	12.2	11.2	11.7	11.0
S.D.	.21	.25	.29	.43	.12	.26	.27	.24	.90	.41	.43	.62
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	6.1*	5.7*	5.8*	4.8	1.6*	2.7*	1.7*	2.7	12.2	11.1	11.8	11.6
S.D.	.13	.13	.14	.38	.18	.21	.13	.47	.59	.41	.38	.61

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	T BILI - MG/DL WEEK 26	52 R	78 R	104 R	IN PHOS - MG/DL WEEK 26	52	78	104	GGT - U/L WEEK 26 R	52 R	78	104 R
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.1	.1	8.4	7.5	7.1	7.3	0	1	1	3
S.D.	.00	.06	.05	.04	.85	.65	.58	.87	.4	.5	.8	3.5
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.1	.2	8.7	7.3	7.2	7.3	0	1	1	3
S.D.	.00	.00	.03	.21	1.29	.33	.59	.55	.3	.5	.6	2.5
3 (500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.1	.1	8.8	7.2	7.3	7.6	0	0	1	1
S.D.	.00	.04	.04	.04	.75	.67	.78	.66	.3	.5	.4	1.4
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.1	.3	8.6	7.3	7.5	6.9	0	0	1	3
S.D.	.00	.04	.00	.51	.87	.44	.39	.45	.4	.5	.3	3.6
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.1	.1	9.2	7.8	8.0*	7.8	0	0*	0*	0*
S.D.	.00	.05	.00	.00	.75	.66	.74	1.40	.4	.0	.5	.4
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.1	.3	9.0	7.6	7.8*	7.4	0	0	1	1
S.D.	.00	.00	.03	.50	1.57	.39	.41	.72	.0	.3	.5	.9

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	T BILI - MG/DL				IN PHOS - MG/DL				GGT - U/L			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78	104	26	52	78	104
	---R----	--------	---R----	---R----	---R----	---R----	--------	--------	---R----	--------	---LG10-	--------
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.1	.1	9.2	7.6	7.0	7.7	1	3	1	0
S.D.	.00	.00	.03	.03	1.22	.33	.53	.32	.5	.9	.4	.3
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.1	.4	8.8	7.9	7.5	8.3	0*	2	1	1
S.D.	.03	.00	.03	.68	.80	.69	.87	.74	.5	.9	.5	2.1
3 (500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.3	.1	9.7	7.7	7.2	7.8	0*	1	3	1
S.D.	.00	.00	.76	.00	1.46	.42	.61	.80	.3	.5	7.8	1.9
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.1	.7	10.0	8.3	7.8	8.3	0*	1	1	2
S.D.	.03	.00	.00	1.93	3.18	1.00	.74	.83	.5	.8	.6	5.5
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.1	.1	9.9	8.7*	7.8	8.2	1	2	1	1
S.D.	.00	.00	.03	.03	1.68	.96	1.10	.94	.6	1.0	.9	1.8
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	.1	.1	.1	.2	10.4	8.2*	7.7	8.3	1	3	2	1
S.D.	.03	.00	.03	.05	2.07	.49	.83	.84	.0	2.6	1.3	.7

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 78
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	SODIUM - MEQ/L				POTAS - MEQ/L				CHLORIDE - MEQ/L			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78	104	26	52	78	104
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	148	147	149	147	5.6	5.5	5.8	5.7	96	99	100	98
S.D.	1.1	1.2	1.6	2.5	.27	.18	.28	.49	1.2	.8	1.3	2.8
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	148	148	149	148	5.3	5.5	5.8	5.6	96	99	99	99
S.D.	.8	1.0	1.4	1.6	.50	.16	.31	.59	1.2	.8	1.3	3.0
3 (500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	148	148	149	147	5.6	5.5	5.8	6.0	96	98	99	98
S.D.	1.4	.8	.9	1.2	.43	.25	.25	.39	1.4	1.3	1.4	1.2
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	148	148	149	146	5.4	5.5	5.9	5.8	96	99	99	98
S.D.	1.0	.7	1.1	1.0	.50	.18	.19	.22	1.4	.8	1.8	1.5
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	147	146	148	146	5.7	5.7	5.8	5.6	95	97*	99	97
S.D.	1.8	1.0	1.1	1.4	.16	.17	.35	.35	1.2	1.1	1.5	2.2
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	147	146	148	147	5.8	5.7	5.7	5.5	95	99	99	99
S.D.	1.2	1.2	1.1	1.4	.28	.24	.23	.34	.7	1.8	2.4	2.7

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	SODIUM - MEQ/L				POTAS - MEQ/L				CHLORIDE - MEQ/L			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78 R	104	26	52 R	78	104
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	152	152	148	148	5.8	5.4	5.4	5.4	103	100	100	99
S.D.	5.0	1.9	1.4	2.6	.40	.23	.28	.41	3.2	1.5	2.4	3.2
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	152	153	148	148	5.8	5.7	5.6	5.9	103	100	101	100
S.D.	4.0	.8	1.3	3.7	.28	.37	.08	.61	4.2	1.4	1.8	5.1
3 (500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	152	152	148	147	5.8	5.6	5.6	5.8	104	101	101	100
S.D.	7.1	1.2	1.8	1.6	.42	.55	.34	.52	5.5	2.0	2.8	4.6
4 (2500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	151	153	148	147	5.9	5.4	5.4	5.8	104	101	101	99
S.D.	5.7	1.2	1.3	2.4	.81	.28	.39	.63	4.5	3.4	1.4	2.7
5 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	152	152	147	147	5.9	5.5	5.4	5.3	102	100	100	99
S.D.	3.7	1.4	2.1	1.6	.59	.51	.29	.33	3.5	2.3	1.7	3.3
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	151	152	148	147	6.1	5.3	5.3	5.8	103	99	101	97
S.D.	2.7	1.5	.8	2.1	.64	.44	.16	.41	2.8	1.3	1.1	3.0

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	U VOL - ML				UCALCIUM - MG/DL				U PHOS - MG/DL			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78	104	26	52	78	104
	LG10		R		LG10		R	LG10				
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	7.0	7.0	10.3	9.8	11.0	15.1	13.8	8.8	134.4	134.3	79.6	57.1
S.D.	3.46	2.12	7.04	3.85	7.86	4.16	5.65	4.75	89.18	47.31	31.02	31.66
2 (100 PPM)												
N	10	10	10	10	10	8	10	10	10	9	10	10
MEAN	7.0	7.2	6.6	9.3	11.2	10.9*	12.3	10.1	125.6	137.9	93.8	54.6
S.D.	3.50	3.03	2.37	3.50	2.86	3.74	4.13	6.88	61.93	75.14	35.97	46.05
3 (500 PPM)												
N	10	10	10	10	10	10	9	10	10	10	9	10
MEAN	10.0	6.9	6.1	9.8	7.0	9.4*	13.7	8.2	91.6	151.0	98.8	69.8
S.D.	5.92	3.21	3.71	5.07	3.47	2.90	6.25	3.68	48.55	61.87	53.57	29.39
4 (2500 PPM)												
N	10	10	10	10	10	10	10	9	10	10	10	10
MEAN	4.8	7.3	7.7	10.0	10.8	7.7*	16.5	6.2	163.5	146.0	100.2	85.0
S.D.	1.89	3.87	2.69	4.01	4.00	3.90	11.67	3.36	74.08	84.60	62.23	34.60
5 (12500 PPM)												
N	10	10	10	10	10	7	10	10	10	7	10	10
MEAN	4.7	5.4	7.3	12.6	9.1	9.1*	11.1	4.6	256.3*	196.3	172.6*	106.8*
S.D.	1.67	2.27	2.15	4.10	3.63	1.96	2.81	1.71	77.94	24.86	50.49	38.11
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	6.0	10.4	6.2	12.8	7.4	8.1*	9.0	7.6	185.2	184.2	175.6*	51.8
S.D.	1.87	12.60	.63	5.13	1.85	2.59	1.77	3.57	80.20	69.87	42.39	16.09

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	U VOL - ML				UCALCIUM - MG/DL				U PHOS - MG/DL			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78	104	26	52	78	104
									--LG10--			
1 (0 PPM)												
N	10	10	10	10	10	8	10	10	10	9	10	10
MEAN	7.1	5.4	7.4	6.5	12.4	16.4	20.0	17.4	70.5	95.7	79.6	92.7
S.D.	2.99	3.57	4.59	2.36	8.94	14.44	13.93	11.04	40.25	52.93	29.01	71.27
2 (100 PPM)												
N	10	10	10	10	10	6	10	10	10	6	10	10
MEAN	10.0	10.5	6.3	7.5	8.1	9.3	26.2	19.2	61.3	46.3	82.8	64.1
S.D.	4.99	12.97	2.43	3.30	6.51	8.41	9.83	10.82	26.86	52.80	45.71	33.46
3 (500 PPM)												
N	10	10	10	10	10	8	9	10	10	8	10	10
MEAN	10.2	7.3	9.1	10.2	6.8	16.1	20.9	15.5	60.3	81.5	93.6	59.1
S.D.	5.15	5.54	6.57	5.79	9.44	7.24	11.31	11.32	42.21	59.89	60.51	49.72
4 (2500 PPM)												
N	10	10	10	10	10	8	10	9	10	8	10	9
MEAN	8.3	8.0	7.5	7.8	7.5	14.5	16.3	19.1	72.4	88.3	88.6	85.0
S.D.	5.40	5.19	3.46	2.89	7.62	10.24	7.78	18.72	35.57	69.28	28.13	46.65
5 (12500 PPM)												
N	10	10	10	10	10	6	10	10	10	7	10	10
MEAN	7.0	5.5	11.6	8.9	10.3	12.2	11.1	12.3	151.9*	158.1	126.0	103.3
S.D.	5.60	2.91	12.56	3.22	6.65	8.78	5.32	5.75	86.54	74.46	53.54	46.94
6 (12500 PPM)												
N	10	10	10	10	10	9	10	10	10	9	10	10
MEAN	9.3	10.6	7.4	8.0	9.1	7.4	10.1	17.8	87.6	82.9	119.5	84.5
S.D.	5.92	8.40	3.51	2.87	6.46	6.48	4.46	14.84	50.29	40.73	36.03	37.59

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	U SODIUM - MEQ/L				U POTAS - MEQ/L				U CHLOR - MEQ/L			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78	104	26	52	78	104
					---LG10-		---LG10-					
1 (0 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	50.6	22.8	48.9	36.9	132.91	148.00	119.33	126.97	56.5	51.6	52.8	66.3
S.D.	19.65	11.57	15.61	13.77	68.547	25.602	35.018	33.505	24.86	14.63	17.80	23.20
2 (100 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	55.4	30.5	54.8	25.7	137.84	177.46	137.05	124.00	63.7	66.1	61.9	51.8
S.D.	17.35	10.63	14.12	6.06	39.251	66.102	23.993	27.565	21.13	25.92	14.49	13.01
3 (500 PPM)												
N	10	10	9	10	10	10	9	10	10	10	9	10
MEAN	48.3	27.7	54.4	40.0	105.72	163.38	136.64	140.25	51.9	60.0	61.6	65.0
S.D.	22.21	8.96	19.09	14.16	45.052	52.008	38.905	37.371	20.72	17.75	20.78	17.55
4 (2500 PPM)												
N	9	10	10	10	8	10	10	10	9	10	10	10
MEAN	63.6	26.2	54.3	45.8	150.91	144.83	131.92	146.70	72.9	49.9	57.1	64.9
S.D.	22.43	14.92	16.95	15.53	49.336	53.412	35.690	36.762	22.84	22.65	20.38	16.87
5 (12500 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	88.1*	34.2	60.6	33.4	226.05*	195.81	148.63	117.43	89.3*	59.5	50.1	45.4*
S.D.	23.63	14.43	9.19	11.45	79.916	55.639	10.010	28.696	32.05	19.28	8.67	12.84
6 (12500 PPM)												
N	10	10	10	10	10	10	10	10	10	10	10	10
MEAN	63.5	26.4	64.6	38.2	157.89	153.23	157.26	106.60	62.7	43.2	53.8	63.0
S.D.	19.87	11.58	16.58	13.55	62.347	55.765	18.403	25.183	21.85	18.81	18.49	16.90

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	U SODIUM - MEQ/L				U POTAS - MEQ/L				U CHLOR - MEQ/L			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78	104	26	52	78	104
	--LG10--											
1 (0 PPM)												
N	10	6	10	10	10	6	10	10	10	6	10	10
MEAN	52.3	15.0	41.7	46.9	86.93	63.52	77.54	142.22	50.0	23.7	39.9	75.0
S.D.	13.06	11.47	12.85	15.09	28.631	31.916	23.698	31.352	18.52	20.63	13.81	21.15
2 (100 PPM)												
N	10	6	10	10	10	6	10	10	10	6	10	10
MEAN	47.3	10.6	44.5	38.8	73.16	45.36	83.34	118.26	45.7	19.0	42.6	59.1
S.D.	11.41	5.31	14.65	10.48	19.988	32.721	21.901	25.427	15.04	11.72	16.01	10.89
3 (500 PPM)												
N	10	8	9	10	10	8	9	10	10	8	9	10
MEAN	46.2	30.0	39.9	46.3	72.54	104.48	73.25	117.97	41.5	52.6*	36.4	64.8
S.D.	8.44	13.96	10.50	19.13	17.605	36.399	23.878	46.169	11.19	22.47	10.80	26.64
4 (2500 PPM)												
N	10	7	10	10	10	7	10	10	10	7	10	10
MEAN	42.5	20.6	46.1	53.0	71.51	83.88	86.90	131.24	37.5	36.0	42.4	66.9
S.D.	14.74	10.89	12.91	19.50	24.529	31.786	24.108	26.225	19.84	9.41	13.46	23.92
5 (12500 PPM)												
N	10	6	10	10	10	6	10	10	10	6	10	10
MEAN	56.6	24.1	33.4	40.0	103.39	106.89	79.05	128.29	41.8	32.3	23.4*	51.5*
S.D.	29.11	14.18	10.91	11.89	43.830	41.612	32.537	37.867	30.33	22.08	9.81	16.28
6 (12500 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	57.5	22.6	42.0	58.9	99.48	85.21	87.92	134.98	49.4	33.1	28.8	83.2
S.D.	25.59	11.32	10.62	13.32	44.012	33.260	19.015	32.832	26.58	16.70	7.95	17.41

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
MALES

GROUP	U CREAT - MG/DL WEEK 26	52	78 R	104	U OSMOL - MOS/KG WEEK 26	52	78 SQ	104	CRECLEAR - MLMNKG WEEK 26	52	78	104 R
1 (0 PPM)												
N	10	9	10	10	10	10	10	10	10	9	10	9
MEAN	124.1	136.5	113.0	124.5	1236	1309	1025	1271	2.59	3.29	2.68	5.60
S.D.	48.48	20.41	41.24	47.09	424.5	260.7	333.7	347.2	.524	.517	.439	.998
2 (100 PPM)												
N	10	8	10	10	10	10	10	10	10	8	10	9
MEAN	133.8	139.9	142.8	125.2	1255	1401	1208	1204	2.90	3.40	2.69	5.60
S.D.	40.26	37.63	32.26	37.96	258.1	468.6	237.0	296.4	.653	.604	.467	.795
3 (500 PPM)												
N	10	9	9	10	10	10	9	10	10	9	9	10
MEAN	93.5	145.1	142.1	142.0	1041	1400	1246	1337	2.80	3.47	2.43	6.70
S.D.	38.49	41.44	56.15	49.54	328.4	389.9	398.3	411.3	.632	.492	.459	1.429
4 (2500 PPM)												
N	10	7	10	10	10	10	10	10	10	7	10	9
MEAN	151.6	126.9	125.8	124.1	1585	1371	1188	1331	2.22	2.74	2.91	6.25
S.D.	39.79	47.96	32.13	41.79	442.9	475.6	323.3	368.2	.711	1.155	.577	.596
5 (12500 PPM)												
N	10	9	10	10	10	9	10	10	10	9	10	10
MEAN	140.1	137.0	109.6	97.0	1898*	1680	1322	1124	2.36	3.03	2.69	6.30
S.D.	27.24	33.73	15.17	36.59	396.1	366.8	125.1	333.5	.428	.497	.513	1.362
6 (12500 PPM)												
N	10	9	10	10	10	10	10	10	10	9	10	10
MEAN	119.3	118.5	116.8	97.0	1537	1415	1386	1008	2.75	3.25	2.57	6.05
S.D.	30.94	44.96	16.42	35.79	362.4	514.8	167.1	261.7	.666	.528	.404	2.639

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 7B
SUMMARY OF CLINICAL CHEMISTRY DATA
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
FEMALES

GROUP	U CREAT - MG/DL				U OSMOL - MOS/KG				CRECLEAR - MLMNKG			
	WEEK				WEEK				WEEK			
	26	52	78	104	26	52	78	104	26	52	78	104
1 (0 PPM)												
N	10	8	10	10	10	6	10	10	10	8	10	10
MEAN	65.1	79.8	60.3	111.5	851	883	734	1308	2.38	1.95	1.95	6.26
S.D.	19.45	25.20	18.50	47.95	202.9	201.2	220.6	436.9	.694	.604	.686	1.679
2 (100 PPM)												
N	10	7	9	10	10	6	10	10	10	7	9	8
MEAN	53.3	78.3	68.4	96.2	755	652	828	1194	2.69	1.87	1.98	6.85
S.D.	18.53	82.64	19.14	36.00	203.7	330.3	178.3	274.4	.650	.511	.469	1.705
3 (500 PPM)												
N	10	8	10	10	10	7	9	10	10	8	10	10
MEAN	50.8	78.5	63.8	82.9	733	1006	712	1122	2.47	2.18	2.15	6.15
S.D.	17.68	29.61	23.07	33.06	195.5	340.1	217.3	428.3	.575	.509	.532	2.524
4 (2500 PPM)												
N	10	8	10	10	10	7	10	9	10	8	10	9
MEAN	57.3	74.8	68.0	93.4	788	956	874	1219	2.29	2.03	2.20	5.80
S.D.	21.16	27.40	17.58	24.91	252.4	349.3	225.2	262.6	.573	.588	.385	1.955
5 (12500 PPM)												
N	10	6	10	10	10	6	10	10	10	6	10	10
MEAN	70.6	67.9	58.8	81.9	1101	1138	826	1187	2.32	2.16	2.68	7.20
S.D.	26.53	25.15	23.66	27.09	416.2	370.8	300.9	318.1	.658	.443	1.002	.870
6 (12500 PPM)												
N	10	9	9	10	10	9	10	10	10	9	9	10
MEAN	56.1	54.1	59.3	88.0	932	925	899	1192	2.52	2.31	2.41	6.69
S.D.	22.16	21.02	11.87	23.46	368.0	360.9	183.2	269.1	.799	.346	.716	2.225

Table 8A
Gross Pathology Incidence Summary - Unscheduled Deaths
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Note: Dose levels were measured in ppm.

Key to Gross Pathology Incidence Summary

Locations of Tissue Masses Observed Grossly

VHR = Ventral-Hind-Right
VFR = Ventral-Front-Right
VFM = Ventral-Front-Mid
VHM = Ventral-Hind-Mid
VHF = Ventral-Hind-Left

Other Symbols and Notations

H- = Finding noted during processing of tissues in histology (precedes keyword).

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
** TOP OF LIST **		-=-	-=-	-=-	-=-	-=-	-=-	-=-
BRAIN W/STEM (BR)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	7	11	10	11	11	12	0
MENINGES, DARK		0	0	0	1	0	0	0
DARK AREA		2	0	0	2	2	0	0
VENTRAL SURFACE, INDENTED		1	4	2	4	0	3	0
DORSAL SURFACE, INDENTED		0	0	0	0	1	0	0
H-DARK AREA		0	0	0	0	1	0	0
CORD, CERVICAL (CS)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
PITUITARY (PI)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	7	9	7	9	12	11	0
ENLARGED		1	5	4	5	0	3	0
DARK		1	4	1	5	0	2	0
MOTTLED		0	2	3	0	0	1	0
DARK AREA		1	0	1	2	1	0	0
CYST		0	0	0	1	0	0	0
RAISED AREA		0	0	0	0	1	0	0
IRREGULARLY SHAPED		0	0	0	1	1	0	0
H-DARK AREA		1	0	0	0	0	0	0
H-CYST		0	0	0	0	0	1	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	10	17	13	15	0
SPECKLED		0	0	1	0	1	0	0
UNEQUALLY SIZED		0	0	0	0	1	0	0
DARK		0	0	1	0	0	0	0
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
THYROID (TY)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	14	12	17	15	15	0
MASS		0	1	0	0	0	0	0
PARATHYROID (PT)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
TRACHEA (TR)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
LUNG (LU)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	8	14	11	15	12	12	0
DARK AREA		0	0	0	2	1	0	0
MASS		1	0	0	0	1	0	0

** CONTINUED ON NEXT PAGE **

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	MALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **								
LUNG (LU)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	8	14	11	15	12	12	0
DARK		1	0	0	0	0	2	0
MOTTLED		1	1	1	0	1	1	0
HEART (HT)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	14	12	17	15	15	0
ATRIUM, MOTTLED		0	1	0	0	0	0	0
ATRIUM, FIRM		0	1	0	0	0	0	0
SPLEEN (SP)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	3	6	6	4	4	5	0
SMALL		0	0	0	0	0	2	0
ENLARGED		7	9	6	13	10	8	0
DARK AREA		0	1	0	0	0	0	0
CONSTRICTED		0	0	0	0	1	0	0
RAISED AREA		1	0	0	1	1	1	0
GRANULAR/PITTED/ROUGH		0	0	0	1	0	0	0
MASS		0	0	0	0	0	1	0
PALE AREA		0	1	0	0	0	0	0
H-ENLARGED		0	0	0	0	1	0	0
LIVER (LI)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	3	10	7	7	4	6	0
ENLARGED		3	0	2	0	2	2	0
PALE AREA		0	1	0	0	1	0	0
PROMINENT RETICULAR PATTERN		0	0	0	1	1	0	0
DARK AREA		0	1	1	1	0	1	0
PALE		2	4	0	2	1	2	0

** CONTINUED ON NEXT PAGE **

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
SEX:		MALE						
GROUP:		-1-	-2-	-3-	-4-	-5-	-6-	-7-
NUMBER:		10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **								
LIVER (LI)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	3	10	7	7	4	6	0
GRANULAR/PITTED/ROUGH		4	0	3	4	5	4	0
MASS		0	1	0	2	5	2	0
RAISED AREA		0	0	1	0	0	0	0
SMALL		0	0	1	0	0	2	0
MOTTLED		2	0	1	2	1	1	0
LOBE, THICKENED		1	0	1	1	0	0	0
FRIABLE		1	2	0	1	1	0	0
IRREGULARLY SHAPED		0	0	0	1	0	1	0
BILE DUCT, DISTENDED		1	0	0	0	0	0	0
H-RAISED AREA		1	0	0	0	0	0	0
H-MASS		0	0	0	1	0	0	0
KIDNEY (KD)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	7	12	9	14	8	10	0
PELVIS, DILATED		0	0	0	0	1	0	0
PELVIS, FLUID		0	0	0	0	1	0	0
DARK		1	1	1	2	6	3	0
DARK AREA		0	0	0	1	0	0	0
MOTTLED		0	0	1	0	0	0	0
GRANULAR/PITTED/ROUGH		0	0	1	0	0	1	0
PALE		1	0	0	0	0	0	0
RAISED AREA		0	0	1	0	0	0	0
MASS		1	1	0	0	0	1	0
PALE AREA		0	1	0	0	0	0	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	14	11	16	14	12	0
MUCOSA, PITTED		0	1	1	1	1	1	0

** CONTINUED ON NEXT PAGE **

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **								
STOMACH, NONGL (SU)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	14	11	16	14	12	0
MUCOSA, THICKENED		0	0	1	0	0	2	0
DARK AREA		0	0	0	0	0	1	0
STOMACH, GL (ST)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	3	8	4	6	8	3	0
DARK AREA		7	7	6	11	7	12	0
MUCOSA, THICKENED		0	0	1	0	0	2	0
H-DARK AREA		0	0	1	0	0	0	0
DUODENUM (DU)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	14	0
LUMEN, GAS		0	0	0	0	0	1	0
JEJUNUM (JE)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	14	12	16	15	14	0
MASS		0	1	0	1	0	0	0
LUMEN, GAS		0	0	0	0	0	1	0
ILEUM (IL)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	15	11	17	15	14	0
DISTENDED		0	0	1	0	0	0	0
INTUSSUSCEPTED		0	0	1	0	0	0	0
RAISED AREA		1	0	0	0	0	0	0
LUMEN, GAS		0	0	0	0	0	1	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
PANCREAS (PA)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	8	15	12	16	15	14	0
MASS		1	0	0	0	0	1	0
PALE		0	0	0	1	0	0	0
H-THICKENED		1	0	0	0	0	0	0
CECUM (CE)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	15	12	16	15	14	0
RAISED AREA		1	0	0	1	0	0	0
MASS		0	0	0	0	0	1	0
COLON (CO)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
RECTUM (RE)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	8	15	10	16	14	12	0
ENLARGED		2	0	1	1	1	3	0
DARK		1	0	0	0	0	0	0
MOTTLED		0	0	0	0	1	0	0
FIRM		0	0	0	1	0	0	0
H-ENLARGED		0	0	1	0	0	0	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
TESTIS (TE)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	2	6	1	4	0	0	0
SMALL		2	6	8	7	11	12	0
SOFT		3	5	9	7	10	11	0
UNEQUALLY SIZED		6	3	2	3	4	2	0
DARK/PALE MATERIAL		7	2	4	9	5	5	0
TRANSLUCENT		0	0	0	1	1	0	0
DARK		1	0	0	0	0	0	0
EPIDIDYMIS (EP)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	11	11	16	7	7	0
SMALL		1	4	0	1	7	8	0
UNEQUALLY SIZED		0	0	1	0	1	0	0
PROSTATE (PR)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	8	14	9	15	15	12	0
SMALL		2	1	3	2	0	3	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	3	4	5	5	6	1	0
SMALL		7	11	7	12	8	13	0
FIRM		0	0	0	0	1	1	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	13	15	0
SEROSA, DARK		0	0	0	0	1	0	0
MUCOSA, DARK		0	0	0	0	1	0	0
DISTENDED		0	0	0	0	1	0	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	14	0
SMALL		0	0	0	0	0	1	0
THYMUS (TH)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	16	15	14	0
ENLARGED		0	0	0	0	0	1	0
H-ENLARGED		0	0	0	1	0	0	0
AORTA, THORACIC (AO)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	15	12	17	15	15	0
WALL, THICKENED		1	0	0	0	0	0	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	MALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
EYE (EY)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	14	10	14	15	10	0
INTERNAL, OPAQUE		1	1	2	3	0	2	0
SMALL		0	0	1	0	0	1	0
GLOBE RUPTURED ANTE MORTEM		0	0	0	0	0	2	0
UNEQUALLY SIZED		0	0	0	0	0	1	0
EXOPHTHALMUS		0	0	0	1	0	0	0
NERVE, OPTIC (ON)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
LACRIMAL GL, EX (EO)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
MUSCLE, SKELETAL (SM)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	15	11	15	14	15	0
MASS-VHR		0	0	0	0	1	0	0
MASS-VFM		0	0	1	0	0	0	0
MASS-VFR		1	0	0	1	0	0	0
THICKENED		0	0	0	1	0	0	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	MALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
MARROW, FEMUR (FM)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
BONE, FEMUR (FE)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
BONE, OTHER (OB)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	14	12	17	14	15	0
FRACTURED		0	1	0	0	0	0	0
SKULL CAP, MASS		0	0	0	0	1	0	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	14	11	16	14	15	0
FLUID		1	0	0	0	0	0	0
MESENTERY, MASS		0	0	1	0	0	0	0
MASS		0	1	0	0	0	0	0
ADIPOSE TISSUE, MASS		0	0	0	0	1	0	0
ADHESION		0	0	1	0	0	0	0
MESENTERY, THICKENED		0	0	0	1	0	0	0
SCROTUM (SC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	16	15	15	0
MASS		0	0	0	1	0	0	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	11	16	15	15	0
MASS-VHL		0	0	1	0	0	0	0
MASS-VHR		0	0	0	1	0	0	0
PENIS (PE)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	14	12	17	14	14	0
SWOLLEN		1	0	0	0	0	0	0
PARAPHIMOSIS		0	1	0	0	1	1	0
LN, OTHER (LN)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	14	12	17	14	13	0
ENLARGED		0	1	0	0	1	1	0
MULTIPLE, ENLARGED		0	0	0	0	0	1	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	6	14	12	15	14	15	0
TAIL, NECROTIC		1	0	0	1	0	0	0
TAIL, SORE		4	0	0	2	1	0	0
FOOT/PAW, SORE		1	1	0	0	0	0	0
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	14	12	17	15	15	0
FLUID		1	1	0	0	0	0	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	MALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	14	12	16	15	14	0
MASS		0	1	0	1	0	1	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	11	17	15	15	0
ENLARGED		0	0	1	0	0	0	0
CAVITY, CRANIAL (CC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
CLITORAL GLAND (CL)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0

** END OF LIST **

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	8	10	13	15	17	0
** TOP OF LIST **								
BRAIN W/STEM (BR)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	5	4	10	10	13	13	0
MENINGES, DARK		1	0	0	0	0	0	0
DARK AREA		1	0	0	0	0	1	0
VENTRAL SURFACE, INDENTED		4	4	0	3	2	3	0
CORD, CERVICAL (CS)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
PITUITARY (PI)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	4	4	6	8	8	9	0
ENLARGED		5	4	1	3	3	3	0
DARK		4	3	0	1	2	2	0
MOTTLED		0	1	0	1	0	1	0
DARK AREA		1	0	3	2	4	5	0
IRREGULARLY SHAPED		0	0	0	1	1	0	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	14	15	0
SPECKLED		0	0	0	0	0	1	0
DARK		0	0	0	0	1	0	0

** CONTINUED ON NEXT PAGE **

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	8	10	13	15	17	0
** FROM PREVIOUS PAGE **								
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	14	15	0
MASS		0	0	0	0	0	1	0
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
THYROID (TY)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
PARATHYROID (PT)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
TRACHEA (TR)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
LUNG (LU)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	8	5	10	13	14	16	0
RAISED AREA		0	1	0	0	0	0	0
MASS		0	1	0	0	0	0	0
DARK		1	0	0	0	0	0	0
MOTTLED		1	2	0	0	1	1	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	8	10	13	15	17	0
HEART (HT)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	9	8	10	13	15	16	0
ATRIUM, MOTTLED		1	0	0	0	0	1	0
SPLEEN (SP)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	5	4	6	6	11	7	0
SMALL		1	1	0	0	0	0	0
ENLARGED		4	3	4	7	4	9	0
CONSTRICTED		2	0	0	0	0	0	0
RAISED AREA		0	0	0	0	0	1	0
MOTTLED		0	0	0	0	0	1	0
LIVER (LI)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	4	5	6	3	9	9	0
ENLARGED		1	0	0	0	0	0	0
PALE AREA		0	0	0	0	1	0	0
PROMINENT RETICULAR PATTERN		1	1	0	0	1	0	0
DARK AREA		0	0	0	1	0	2	0
PALE		2	1	3	5	0	4	0
GRANULAR/PITTED/ROUGH		2	1	1	4	2	5	0
MASS		0	0	0	1	2	0	0
RAISED AREA		0	0	0	0	0	1	0
SMALL		1	1	0	1	0	0	0
MOTTLED		1	1	1	0	0	1	0
LOBE, THICKENED		0	0	0	1	0	0	0
FRIABLE		0	1	2	1	1	1	0
IRREGULARLY SHAPED		0	0	0	0	0	1	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	8	10	13	15	17	0
KIDNEY (KD)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	8	5	7	10	9	12	0
ONE COLLECTED		0	1	0	0	0	0	0
PELVIS, DILATED		0	0	1	0	1	0	0
PELVIS, FLUID		0	0	1	0	0	0	0
DARK		2	2	2	3	4	4	0
PALE		0	0	0	0	1	1	0
SMALL		0	1	0	0	0	0	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	9	7	9	11	15	14	0
MUCOSA, PITTED		0	1	0	1	0	0	0
MUCOSA, THICKENED		0	0	0	0	0	1	0
DARK AREA		0	0	1	0	0	3	0
MUCOSA, ROUGH		1	0	0	0	0	0	0
RAISED AREA		0	0	0	1	0	0	0
STOMACH, GL (ST)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	6	4	5	7	6	6	0
DARK AREA		4	4	5	6	8	11	0
RAISED AREA		0	0	0	0	1	0	0
DUODENUM (DU)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
JEJUNUM (JE)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	8	10	13	15	17	0
ILEUM (IL)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
PANCREAS (PA)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	9	12	14	17	0
MASS		0	0	1	1	1	0	0
PALE		0	0	1	0	0	0	0
CECUM (CE)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
COLON (CO)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
RECTUM (RE)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	9	8	9	12	15	15	0
ENLARGED		1	0	1	1	0	2	0
DARK		1	0	0	1	0	2	0
TESTIS (TE)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	8	10	13	15	17	0
EPIDIDYMIS (EP)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
PROSTATE (PR)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	9	12	14	17	0
WALL, THICKENED		0	0	0	0	1	0	0
DISTENDED		0	0	0	1	0	0	0
MASS		0	0	1	0	0	0	0
OVARY (OV)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	12	13	17	0
CYST		0	0	0	0	1	0	0
MASS		0	0	0	1	1	0	0
UTERUS (UT)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	9	8	6	10	7	13	0
UNEQUALLY SIZED		0	0	0	0	1	0	0
MASS		0	0	4	2	3	3	0
DISTENDED		0	0	0	1	2	0	0
CYST		0	0	0	0	1	0	0
LUMEN, FLUID		0	0	0	1	1	0	0

** CONTINUED ON NEXT PAGE **

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE	SEX:	FEMALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	8	10	13	15	17	0
** FROM PREVIOUS PAGE **								
UTERUS (UT)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	9	8	6	10	7	13	0
WALL, THICKENED		1	0	0	1	2	1	0
PALE		1	0	0	0	0	0	0
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	11	13	17	0
MASS		0	0	0	1	2	0	0
WALL, THICKENED		0	0	0	1	0	0	0
VAGINA (VA)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	11	14	17	0
PROLAPSED		0	0	0	1	1	0	0
LUMEN, FLUID		0	0	0	1	0	0	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
THYMUS (TH)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	14	16	0
DARK		0	0	0	0	1	1	0
AORTA, THORACIC (AO)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND KEYWORD(S) OR PHRASE	NUMBER:	10	8	10	13	15	17	0
EYE (EY)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	9	7	9	12	15	13	0
INTERNAL, OPAQUE		0	1	1	1	0	3	0
EXTERNAL, OPAQUE		1	0	0	0	0	1	0
UNEQUALLY SIZED		0	0	0	0	0	1	0
NERVE, OPTIC (ON)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
LACRIMAL GL, EX (EO)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
MUSCLE, SKELETAL (SM)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	9	8	7	11	14	15	0
MASS-VHM		0	0	1	0	1	1	0
MASS-VFR		0	0	3	1	0	1	0
THICKENED		1	0	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE	SEX:	--- NUMBER-OF-ANIMALS-AFFECTED --- FEMALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	8	10	13	15	17	0
** FROM PREVIOUS PAGE **								
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	9	8	7	11	14	15	0
MASS-VHR		0	0	1	1	0	0	0
MARROW, FEMUR (FM)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
BONE, FEMUR (FE)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
BONE, OTHER (OB)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	14	17	0
FRACTURED		0	0	0	0	1	0	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	7	7	10	12	14	16	0
FLUID		1	1	0	0	1	0	0
MESENTERY, MASS		0	1	0	0	0	0	0
MASS		0	1	0	0	0	0	0
ADIPOSE TISSUE, REDUCED		0	1	0	0	0	0	0
ADIPOSE TISSUE, MASS		0	0	0	1	1	0	0
ADHESION		2	0	0	0	0	0	0
ADIPOSE TISSUE, DARK		0	0	0	0	0	1	0
SCROTUM (SC)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE	SEX:	--- NUMBER-OF-ANIMALS-AFFECTED ---						
		----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	8	10	13	15	17	0
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
PENIS (PE)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
LN, OTHER (LN)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	9	13	12	17	0
ENLARGED		0	0	1	0	2	0	0
MULTIPLE, ENLARGED		0	0	0	0	1	0	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	9	7	10	12	13	17	0
TAIL, NECROTIC		0	1	0	1	2	0	0
TAIL, SORE		0	0	0	1	0	0	0
EAR, SORE		1	0	0	0	0	0	0
THICKENED		1	0	0	0	0	0	0
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	12	14	15	0
FLUID		0	0	0	1	1	2	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0

TABLE 8A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;SUBSET=T

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND KEYWORD(S) OR PHRASE	NUMBER:	10	8	10	13	15	17	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
CAVITY, CRANIAL (CC)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	12	15	17	0
ADHESION		0	0	0	1	0	0	0
CLITORAL GLAND (CL)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	10	8	10	13	15	17	0
	NOT REMARKABLE:	10	8	10	13	15	17	0

** END OF LIST **

Table 8B
Gross Pathology Incidence Summary - Interim Sacrifice - Week 79
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Note: DEATH = 4 = WEEK 79 SACRIFICE

Dose levels were measured in ppm.

Key to Gross Pathology Incidence Summary

Locations of Tissue Masses Observed Grossly

VHM = Ventral-Hind-Mid

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
** TOP OF LIST **		-=-	-=-	-=-	-=-	-=-	-=-	-=-
BRAIN W/STEM (BR)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CORD, CERVICAL (CS)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
PITUITARY (PI)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	13	0	0	15	15	0	0
DARK AREA		2	0	0	0	0	0	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
THYROID (TY)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
PARATHYROID (PT)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
TRACHEA (TR)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
LUNG (LU)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	14	0	0
MASS		0	0	0	0	1	0	0
HEART (HT)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
SPLEEN (SP)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	14	0	0
ENLARGED		0	0	0	0	1	0	0
LIVER (LI)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	12	0	0	14	5	0	0
ENLARGED		0	0	0	0	3	0	0
PALE AREA		1	0	0	0	3	0	0
PROMINENT RETICULAR PATTERN		0	0	0	0	1	0	0
MASS		0	0	0	1	6	0	0

** CONTINUED ON NEXT PAGE **

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
** FROM PREVIOUS PAGE **		-=-	-=-	-=-	-=-	-=-	-=-	-=-
LIVER (LI)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	12	0	0	14	5	0	0
RAISED AREA		2	0	0	0	0	0	0
KIDNEY (KD)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	14	0	0	15	14	0	0
DARK		0	0	0	0	1	0	0
CYST		1	0	0	0	0	0	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
STOMACH, GL (ST)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
DUODENUM (DU)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
JEJUNUM (JE)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
ILEUM (IL)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND KEYWORD(S) OR PHRASE	NUMBER:	15	0	0	15	15	0	0
PANCREAS (PA)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CECUM (CE)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
COLON (CO)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
RECTUM (RE)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
TESTIS (TE)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	11	0	0	6	0	0	0
SMALL		0	0	0	0	10	0	0
SOFT		0	0	0	0	8	0	0
UNEQUALLY SIZED		1	0	0	4	5	0	0
DARK/PALE MATERIAL		4	0	0	8	5	0	0
TRANSLUCENT		1	0	0	1	1	0	0
EPIDIDYMIS (EP)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	MALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
PROSTATE (PR)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	14	14	0	0
SMALL		0	0	0	1	1	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
THYMUS (TH)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
AORTA, THORACIC (AO)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
EYE (EY)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	14	0	0
INTERNAL, OPAQUE		0	0	0	0	1	0	0
NERVE, OPTIC (ON)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
LACRIMAL GL, EX (EO)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
MUSCLE, SKELETAL (SM)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
MARROW, FEMUR (FM)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
BONE, FEMUR (FE)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
BONE, OTHER (OB)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
SCROTUM (SC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
PENIS (PE)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	MALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
LN, OTHER (LN)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	12	0	0	15	13	0	0
TAIL, SORE		2	0	0	0	2	0	0
SORE		1	0	0	0	0	0	0
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CAVITY, CRANIAL (CC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CLITORAL GLAND (CL)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0

** END OF LIST **

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
** TOP OF LIST **		-=-	-=-	-=-	-=-	-=-	-=-	-=-
BRAIN W/STEM (BR)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CORD, CERVICAL (CS)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
PITUITARY (PI)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	11	0	0	13	15	0	0
ENLARGED		0	0	0	1	0	0	0
DARK		0	0	0	1	0	0	0
DARK AREA		2	0	0	0	0	0	0
CYST		2	0	0	1	0	0	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
THYROID (TY)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
PARATHYROID (PT)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
TRACHEA (TR)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
LUNG (LU)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
HEART (HT)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
SPLEEN (SP)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	14	15	0	0
ENLARGED		0	0	0	1	0	0	0
CONSTRICTED		0	0	0	1	0	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
LIVER (LI)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	14	11	0	0
DARK AREA		0	0	0	1	1	0	0
MASS		0	0	0	0	3	0	0
KIDNEY (KD)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
STOMACH, GL (ST)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	13	0	0
DARK AREA		0	0	0	0	2	0	0
DUODENUM (DU)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
JEJUNUM (JE)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
ILEUM (IL)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
PANCREAS (PA)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CECUM (CE)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
COLON (CO)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
RECTUM (RE)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
TESTIS (TE)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
EPIDIDYMIS (EP)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
PROSTATE (PR)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
		-=-	-=-	-=-	-=-	-=-	-=-	-=-
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
OVARY (OV)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	14	14	0	0
CYST		0	0	0	1	1	0	0
UTERUS (UT)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	11	0	0	11	9	0	0
MASS		1	0	0	2	1	0	0
DISTENDED		3	0	0	2	6	0	0
CYST		0	0	0	0	1	0	0
LUMEN, FLUID		1	0	0	0	0	0	0
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
VAGINA (VA)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
THYMUS (TH)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
AORTA, THORACIC (AO)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
EYE (EY)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	14	0	0	11	13	0	0
INTERNAL, OPAQUE		1	0	0	4	2	0	0
NERVE, OPTIC (ON)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
LACRIMAL GL, EX (EO)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
MUSCLE, SKELETAL (SM)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	14	0	0	15	15	0	0
MASS-VHM		1	0	0	0	0	0	0
MARROW, FEMUR (FM)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
BONE, FEMUR (FE)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
BONE, OTHER (OB)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
SCROTUM (SC)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
PENIS (PE)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0

TABLE 8B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	FEMALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	15	0	0	15	15	0	0
LN, OTHER (LN)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	14	0	0	15	13	0	0
TAIL, SORE		1	0	0	0	2	0	0
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CAVITY, CRANIAL (CC)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
CLITORAL GLAND (CL)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	15	0	0	15	15	0	0
	NOT REMARKABLE:	15	0	0	15	15	0	0

** END OF LIST **

Table 8C
Gross Pathology Incidence Summary - Terminal Sacrifice
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Note: Dose levels were measured in ppm.

Key to Gross Pathology Incidence Summary

Locations of Tissue Masses Observed Grossly

DFR = Dorsal-Front-Right
DHR = Dorsal-Hind-Right
DHL = Dorsal-Hind-Left
VFL = Ventral-Front-Left
VFR = Ventral-Front-Right
VHL = Ventral-Hind-Left
VHR = Ventral-Hind-Right
VFM = Ventral-Front-Mid
VHM = Ventral-Hind-Mid

Other Symbols and Notations

H- = Finding noted during processing of tissues in histology (precedes keyword).

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	40	43	38	40	40	0
** TOP OF LIST **								
BRAIN W/STEM (BR)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	42	38	41	36	39	39	0
VENTRAL SURFACE, INDENTED		3	2	2	2	1	1	0
CORD, CERVICAL (CS)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
PITUITARY (PI)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	32	32	35	30	24	33	0
ENLARGED		3	2	3	3	2	2	0
DARK		2	1	3	1	1	1	0
MOTTLED		0	0	0	2	2	0	0
DARK AREA		3	4	4	1	5	4	0
RAISED AREA		4	2	1	0	5	0	0
IRREGULARLY SHAPED		1	0	0	0	0	0	0
MASS		0	0	0	0	1	0	0
H-DARK AREA		2	0	0	2	1	1	0
H-ENLARGED		1	0	0	0	0	0	0
H-DARK		1	0	0	0	0	0	0
H-CYST		0	0	0	0	1	1	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE	SEX:	MALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	40	43	38	40	40	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	43	39	40	37	37	40	0
SPECKLED		0	0	1	0	0	0	0
UNEQUALLY SIZED		2	0	1	0	0	0	0
DARK		1	0	0	0	0	0	0
CYST		0	0	0	0	2	0	0
ENLARGED		0	1	1	1	0	0	0
DARK AREA		0	0	0	0	1	0	0
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
THYROID (TY)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	44	40	43	38	39	39	0
DARK		0	0	0	0	1	0	0
ENLARGED		0	0	0	0	1	0	0
UNEQUALLY SIZED		1	0	0	0	0	0	0
MASS		0	0	0	0	0	1	0
PARATHYROID (PT)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
TRACHEA (TR)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE	--- NUMBER-OF-ANIMALS-AFFECTED ---						
SEX:	MALE						
GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
NUMBER:	45	40	43	38	40	40	0
LUNG (LU) NUMBER EXAMINED:	45	40	43	38	40	40	0
NOT REMARKABLE:	42	40	42	35	38	34	0
DARK AREA	0	0	1	3	0	2	0
RAISED AREA	0	0	0	0	1	0	0
MASS	2	0	0	0	0	0	0
MOTTLED	0	0	0	0	0	1	0
PALE AREA	0	0	0	0	0	1	0
PALE	0	0	0	0	1	2	0
H-RAISED AREA	1	0	0	0	0	0	0
HEART (HT) NUMBER EXAMINED:	45	40	43	38	40	40	0
NOT REMARKABLE:	45	40	43	38	40	39	0
ATRIUM, ENLARGED	0	0	0	0	0	1	0
VENTRICLE, PALE	0	0	0	0	0	1	0
SPLEEN (SP) NUMBER EXAMINED:	45	40	43	38	40	40	0
NOT REMARKABLE:	43	36	34	26	30	26	0
ENLARGED	2	4	8	11	10	14	0
CONSTRICTED	0	0	0	1	0	0	0
RAISED AREA	0	0	0	1	0	0	0
MOTTLED	0	0	0	1	0	0	0
MASS	0	0	0	1	0	0	0
PALE AREA	0	0	0	2	1	0	0
IRREGULARLY SHAPED	0	0	1	1	0	0	0
DEPRESSED AREA	0	0	0	1	0	0	0
LIVER (LI) NUMBER EXAMINED:	45	40	43	38	40	40	0
NOT REMARKABLE:	35	30	34	18	8	15	0
ENLARGED	0	0	0	3	5	2	0

** CONTINUED ON NEXT PAGE **

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND KEYWORD(S) OR PHRASE	NUMBER:	45	40	43	38	40	40	0
** FROM PREVIOUS PAGE **								
LIVER (LI)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	35	30	34	18	8	15	0
PALE AREA		0	1	2	1	2	7	0
PROMINENT RETICULAR PATTERN		0	1	1	0	0	0	0
DARK AREA		1	2	1	1	2	1	0
PALE		0	0	2	1	1	1	0
GRANULAR/PITTED/ROUGH		1	2	2	7	5	4	0
MASS		2	3	2	4	18	8	0
RAISED AREA		4	2	3	7	9	3	0
SMALL		0	0	1	0	0	0	0
MOTTLED		1	0	0	0	1	2	0
LOBE, THICKENED		0	0	1	0	1	1	0
IRREGULARLY SHAPED		0	1	0	1	0	4	0
PROTRUSION INTO DIAPHRAGM		0	0	0	0	0	1	0
INTERLOBAR ADHESION		0	0	1	0	0	0	0
MARGIN, ROUNDED		0	0	0	0	1	1	0
H-RAISED AREA		1	0	0	1	0	0	0
KIDNEY (KD)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	43	39	39	34	32	31	0
PELVIS, DILATED		0	0	0	1	0	0	0
DARK		0	0	1	2	3	2	0
MOTTLED		0	0	0	1	0	1	0
GRANULAR/PITTED/ROUGH		1	0	2	2	6	6	0
PALE		0	0	1	0	0	2	0
CYST		0	1	1	0	0	0	0
MASS		1	0	0	0	0	0	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND KEYWORD(S) OR PHRASE	NUMBER:	45	40	43	38	40	40	0
STOMACH, GL (ST)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	39	41	38	33	39	0
DARK AREA		0	0	0	0	6	1	0
MUCOSA, THICKENED		0	0	1	0	0	0	0
PALE AREA		0	1	0	0	1	0	0
LUMEN, GAS		0	0	1	0	0	0	0
DUODENUM (DU)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	41	38	40	40	0
LUMEN, GAS		0	0	1	0	0	0	0
WALL, THICKENED		0	0	1	0	0	0	0
JEJUNUM (JE)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	42	37	40	40	0
MASS		0	0	0	1	0	0	0
LUMEN, GAS		0	0	1	0	0	0	0
ILEUM (IL)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	42	37	40	40	0
LUMEN, GAS		0	0	1	0	0	0	0
MASS		0	0	0	1	0	0	0
PANCREAS (PA)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	38	42	37	40	40	0
MASS		0	0	1	1	0	0	0
THICKENED		0	2	0	0	0	0	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	MALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	40	43	38	40	40	0
CECUM (CE)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	42	38	39	40	0
LUMEN, GAS		0	0	1	0	0	0	0
H-RAISED AREA		0	0	0	0	1	0	0
COLON (CO)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	42	38	40	40	0
LUMEN, GAS		0	0	1	0	0	0	0
RECTUM (RE)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	37	39	40	0
DARK AREA		0	0	0	1	0	0	0
MASS		0	0	0	0	1	0	0
TESTIS (TE)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	7	3	0	2	2	3	0
SMALL		0	3	1	2	28	28	0
SOFT		3	1	2	0	18	16	0
UNEQUALLY SIZED		21	15	20	18	9	4	0
DARK/PALE MATERIAL		34	33	40	34	11	11	0
TRANSLUCENT		0	0	1	0	0	0	0
DARK		2	1	0	1	0	0	0
ENLARGED		7	7	13	8	0	2	0
MASS		0	0	1	1	0	2	0
MOTTLED		0	1	0	0	0	0	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	MALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	40	43	38	40	40	0
EPIDIDYMIS (EP)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	37	38	0
SMALL		0	0	0	0	3	2	0
PROSTATE (PR)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	13	13	13	14	25	30	0
SMALL		28	25	30	24	12	9	0
FIRM		1	0	0	0	0	0	0
TRANSLUCENT		2	1	0	1	2	0	0
ENLARGED		1	1	0	0	1	0	0
UNEQUALLY SIZED		0	0	0	0	0	1	0
MASS		0	0	0	0	0	1	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND KEYWORD(S) OR PHRASE	NUMBER:	45	40	43	38	40	40	0
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
THYMUS (TH)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	39	39	0
ENLARGED		0	0	0	0	1	1	0
AORTA, THORACIC (AO)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
EYE (EY)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	40	32	35	33	33	32	0
INTERNAL, OPAQUE		5	8	6	5	6	7	0
GLOBE RUPTURED ANTE MORTEM		0	0	2	0	1	0	0
EXTERNAL, OPAQUE		0	0	0	0	0	1	0
UNEQUALLY SIZED		2	2	2	0	1	0	0
NERVE, OPTIC (ON)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	40	43	38	40	40	0
LACRIMAL GL, EX (EO)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
MUSCLE, SKELETAL (SM)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	40	39	42	37	38	38	0
MASS-VHR		1	0	0	0	0	1	0
MASS-VFR		1	0	0	0	1	0	0
THICKENED		1	1	0	1	0	0	0
MASS-VHM		0	0	1	0	1	0	0
MASS-DHR		0	0	0	0	0	1	0
MASS-VHL		1	0	0	0	0	0	0
MASS-VFL		1	0	0	0	0	0	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
MARROW, FEMUR (FM)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	40	43	38	40	40	0
BONE, FEMUR (FE)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
BONE, OTHER (OB)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	44	38	42	37	39	40	0
FLUID		0	2	1	1	0	0	0
MESENTERY, MASS		0	2	0	0	0	0	0
MASS		1	0	1	1	1	0	0
ADIPOSE TISSUE, MASS		0	2	0	0	0	0	0
SCROTUM (SC)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	39	43	37	39	40	0
MASS		0	1	0	1	1	0	0
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	39	42	38	40	39	0
MASS-DHR		0	1	0	0	0	0	0
MASS-VFL		0	0	1	0	0	0	0
MASS-DFR		0	0	0	0	0	1	0
PENIS (PE)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	42	38	39	40	0
PARAPHIMOSIS		0	0	1	0	1	0	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	MALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	40	43	38	40	40	0
LN, OTHER (LN)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	34	27	30	26	31	27	0
TAIL, NECROTIC		0	0	0	0	0	1	0
TAIL, SORE		8	9	9	10	9	8	0
TAIL, MASS		0	1	0	1	0	0	0
SORE		0	2	1	1	0	3	0
EAR, SORE		0	0	0	0	0	1	0
FOOT/PAW, SORE		2	0	2	0	0	0	0
TAIL, MISSING		0	0	0	0	0	1	0
MASS-VFL		0	0	1	0	0	0	0
ALOPECIA		0	1	0	0	0	0	0
MASS-DFR		1	0	0	0	0	1	0
MASS-VFM		1	0	0	0	0	0	0
MASS-VHL		1	0	0	0	0	0	0
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	39	0
FLUID		0	0	0	0	0	1	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	40	43	38	40	40	0
CAVITY, CRANIAL (CC)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0
CLITORAL GLAND (CL)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	45	40	43	38	40	40	0
	NOT REMARKABLE:	45	40	43	38	40	40	0

** END OF LIST **

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	47	45	42	40	38	0
** TOP OF LIST **								
BRAIN W/STEM (BR)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	42	43	41	41	35	34	0
VENTRAL SURFACE, INDENTED		3	4	4	1	5	4	0
CORD, CERVICAL (CS)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
PITUITARY (PI)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	31	26	28	25	29	24	0
ENLARGED		6	7	7	7	8	4	0
DARK		4	5	3	6	6	3	0
MOTTLED		1	1	4	2	2	1	0
DARK AREA		8	10	8	9	1	7	0
CYST		0	1	0	0	0	0	0
RAISED AREA		1	4	2	0	2	2	0
IRREGULARLY SHAPED		0	0	1	0	0	0	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	43	46	43	41	40	38	0
SPECKLED		0	0	1	0	0	0	0
UNEQUALLY SIZED		0	1	0	1	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	47	45	42	40	38	0
		-=-	-=-	-=-	-=-	-=-	-=-	-=-
** FROM PREVIOUS PAGE **								
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	43	46	43	41	40	38	0
ENLARGED		1	0	1	0	0	0	0
DARK AREA		1	0	0	0	0	0	0
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
THYROID (TY)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	44	46	45	42	40	36	0
ENLARGED		0	0	0	0	0	1	0
UNEQUALLY SIZED		1	0	0	0	0	1	0
MASS		0	1	0	0	0	0	0
PARATHYROID (PT)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
TRACHEA (TR)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
LUNG (LU)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	44	47	45	40	40	38	0
DARK AREA		0	0	0	1	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	47	45	42	40	38	0
		-=-	-=-	-=-	-=-	-=-	-=-	-=-
** FROM PREVIOUS PAGE **								
LUNG (LU)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	44	47	45	40	40	38	0
PALE AREA		1	0	0	1	0	0	0
HEART (HT)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
SPLEEN (SP)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	41	42	42	38	34	31	0
SMALL		0	0	1	0	0	0	0
ENLARGED		3	5	2	4	6	7	0
CONSTRICTED		0	0	0	0	0	1	0
PALE AREA		0	0	0	0	1	0	0
IRREGULARLY SHAPED		1	0	0	0	0	0	0
PLAQUE		0	0	0	1	0	0	0
H-PALE AREA		1	0	0	0	0	0	0
LIVER (LI)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	34	32	39	30	19	24	0
ENLARGED		0	0	0	1	5	0	0
PALE AREA		5	2	1	1	1	5	0
PROMINENT RETICULAR PATTERN		0	1	0	0	0	0	0
DARK AREA		3	4	1	3	3	3	0
PALE		0	0	0	1	0	0	0
GRANULAR/PITTED/ROUGH		1	3	1	2	5	1	0
MASS		1	2	0	2	11	4	0
RAISED AREA		1	3	2	2	2	1	0
MOTTLED		0	2	0	1	0	0	0
IRREGULARLY SHAPED		2	2	0	0	3	0	0

** CONTINUED ON NEXT PAGE **

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	47	45	42	40	38	0
		-=-	-=-	-=-	-=-	-=-	-=-	-=-
** FROM PREVIOUS PAGE **								
LIVER (LI)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	34	32	39	30	19	24	0
CYST		0	0	0	0	0	1	0
PROTRUSION INTO DIAPHRAGM		0	1	0	1	0	0	0
H-RAISED AREA		0	1	0	0	0	0	0
H-MOTTLED		0	0	0	1	0	0	0
H-PALE AREA		0	0	1	0	0	0	0
KIDNEY (KD)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	43	44	43	40	38	36	0
DARK		1	1	0	2	2	0	0
GRANULAR/PITTED/ROUGH		1	3	0	0	0	1	0
CYST		0	0	2	0	0	2	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	41	40	38	0
MUCOSA, ROUGH		0	0	0	1	0	0	0
STOMACH, GL (ST)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	44	45	45	38	38	38	0
DARK AREA		1	1	0	2	2	0	0
RAISED AREA		0	1	0	0	0	0	0
MUCOSA, ROUGH		0	0	0	1	0	0	0
MUCOSA, PITTED		0	0	0	1	0	0	0
H-DARK AREA		0	0	0	1	0	0	0
DUODENUM (DU)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND KEYWORD(S) OR PHRASE	NUMBER:	45	47	45	42	40	38	0
JEJUNUM (JE)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
ILEUM (IL)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
PANCREAS (PA)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	41	40	38	0
PALE		0	0	0	1	0	0	0
CECUM (CE)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
COLON (CO)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
RECTUM (RE)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	44	47	45	40	40	38	0
ENLARGED		0	0	0	1	0	0	0
DARK		1	0	0	1	0	0	0
MASS		0	0	0	1	0	0	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	47	45	42	40	38	0
TESTIS (TE)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
EPIDIDYMIS (EP)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
PROSTATE (PR)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
OVARY (OV)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	40	43	42	36	36	32	0
CYST		5	3	3	5	4	5	0
MASS		0	2	0	0	0	1	0
ENLARGED		0	0	0	1	0	0	0
UTERUS (UT)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	35	27	30	30	24	21	0
MASS		5	11	7	6	7	7	0
DISTENDED		4	3	1	2	3	4	0
CYST		0	3	3	3	2	8	0

** CONTINUED ON NEXT PAGE **

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	47	45	42	40	38	0
** FROM PREVIOUS PAGE **								
UTERUS (UT)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	35	27	30	30	24	21	0
LUMEN, FLUID		5	1	2	1	2	4	0
WALL, THICKENED		1	5	3	0	5	3	0
PALE		1	0	0	1	0	0	0
DARK AREA		1	0	0	0	0	0	0
H-MASS		0	0	0	1	0	0	0
H-WALL, THICKENED		0	0	0	1	0	0	0
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	40	41	41	38	32	35	0
MASS		0	1	0	0	0	0	0
WALL, THICKENED		5	5	4	4	8	3	0
VAGINA (VA)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	46	43	42	40	38	0
LUMEN, FLUID		0	0	1	0	0	0	0
MASS		0	1	1	0	0	0	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
THYMUS (TH)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	40	40	38	0
ENLARGED		0	0	0	2	0	0	0
FIRM		0	0	0	1	0	0	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	47	45	42	40	38	0
AORTA, THORACIC (AO)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
EYE (EY)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	41	41	35	36	36	31	0
INTERNAL, OPAQUE		4	4	9	5	1	5	0
GLOBE RUPTURED ANTE MORTEM		0	0	1	0	2	1	0
EXTERNAL, OPAQUE		0	1	0	0	0	1	0
UNEQUALLY SIZED		0	1	2	2	0	2	0
EXOPHTHALMUS		0	0	0	1	0	0	0
EXTERNAL, DARK MATERIAL		0	0	0	0	1	0	0
NERVE, OPTIC (ON)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
LACRIMAL GL, EX (EO)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
MUSCLE, SKELETAL (SM)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	FEMALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	47	45	42	40	38	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	40	36	38	34	38	35	0
MASS-VFM		0	1	0	0	0	0	0
MASS-VHM		1	0	1	0	1	0	0
MASS-VFR		0	2	2	0	0	0	0
THICKENED		4	6	4	0	1	2	0
MASS-VHR		0	1	0	1	0	1	0
MASS-VFL		0	0	0	4	0	0	0
MASS-VHL		0	1	0	3	0	0	0
MASS-DHR		1	0	0	0	0	0	0
MARROW, FEMUR (FM)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
BONE, FEMUR (FE)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
BONE, OTHER (OB)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	46	45	42	40	37	0
SKULL CAP, THICKENED		0	1	0	0	0	1	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	41	40	38	0
ADIPOSE TISSUE, DARK		0	0	0	1	0	0	0
SCROTUM (SC)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	47	45	42	40	38	0
		-=-	-=-	-=-	-=-	-=-	-=-	-=-
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	44	47	45	40	39	38	0
MASS-DHL		1	0	0	0	0	0	0
GELATINOUS		0	0	0	2	0	0	0
MASS-VFM		0	0	0	0	1	0	0
PENIS (PE)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
LN, OTHER (LN)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	41	40	38	0
MULTIPLE, ENLARGED		0	0	0	1	0	0	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	44	42	41	36	32	0
TAIL, SORE		0	0	1	0	4	4	0
SORE		0	1	1	1	0	2	0
ALOPECIA		0	0	1	0	0	1	0
FOOT/PAW, MASS		0	1	0	0	0	0	0
MASS-VFM		0	1	0	0	0	0	0
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	41	40	38	0
FLUID		0	0	0	1	0	0	0

TABLE 8C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
GROSS PATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=T

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------FEMALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	45	47	45	42	40	38	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	44	45	42	40	38	0
MASS		0	3	0	0	0	0	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	41	40	38	0
ENLARGED		0	0	0	1	0	0	0
DARK		0	0	0	1	0	0	0
CAVITY, CRANIAL (CC)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	45	42	40	38	0
CLITORAL GLAND (CL)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	43	47	44	42	40	38	0
SORE		0	0	1	0	0	0	0
PALE MATERIAL		1	0	0	0	0	0	0
MASS		1	0	0	0	0	0	0
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	45	47	45	42	40	38	0
	NOT REMARKABLE:	45	47	44	42	40	38	0
UNEQUALLY SIZED		0	0	1	0	0	0	0

** END OF LIST **

Table 9A
Complete Organ Weight Data - Liver Weights (Absolute and Relative-to-Body)
Interim Sacrifices - Weeks 1, 2, and 13
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Notes: DEATH = 1 = WEEK 1 SACRIFICE
DEATH = 2 = WEEK 2 SACRIFICE
DEATH = 3 = WEEK 13 SACRIFICE

Dose levels were measured in ppm.

ORGAN WEIGHT FOOTNOTES

At Week 13 the Group 5 male body weights (at sacrifice) were significantly decreased compared to the control.

Statistical transformations of data were performed if noted by the following:

R = RANK

LOG10 = LOG10

TABLE 9A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=1;SUBSET=ALL

LIVER

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
		LOG10	R
M 1			
NUMBER IN GROUP:	5	5	5
MEAN:	125.9	5.68	4.513
STANDARD DEV:	8.1	0.41	0.055
M 2			
NUMBER IN GROUP:	5	5	5
MEAN:	130.4	6.21	4.760
STANDARD DEV:	9.9	0.52	0.117
M 3			
NUMBER IN GROUP:	5	5	5
MEAN:	128.5	6.18	4.809*
STANDARD DEV:	7.4	0.39	0.114
M 4			
NUMBER IN GROUP:	5	5	5
MEAN:	121.1	6.52	5.319*
STANDARD DEV:	14.8	1.59	0.822

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
F 1			
NUMBER IN GROUP:	5	5	5
MEAN:	105.8	4.74	4.479
STANDARD DEV:	4.0	0.26	0.227
F 2			
NUMBER IN GROUP:	5	5	5
MEAN:	103.0	4.66	4.527
STANDARD DEV:	5.3	0.32	0.186
F 3			
NUMBER IN GROUP:	5	5	5
MEAN:	105.7	4.92	4.655
STANDARD DEV:	3.4	0.29	0.220
F 4			
NUMBER IN GROUP:	5	5	5
MEAN:	98.1	4.92	5.017*
STANDARD DEV:	5.8	0.32	0.271

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=1;SUBSET=ALL

LIVER

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
		LOG10	R
M 5			
NUMBER IN GROUP:	5	5	5
MEAN:	125.2	7.69*	6.139*
STANDARD DEV:	8.8	0.64	0.211

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
F 5			
NUMBER IN GROUP:	5	5	5
MEAN:	100.2	5.97*	5.961*
STANDARD DEV:	7.8	0.40	0.233

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=2;SUBSET=ALL

LIVER

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
M 1			
NUMBER IN GROUP:	5	5	5
MEAN:	169.5	7.36	4.344
STANDARD DEV:	8.4	0.44	0.130
M 2			
NUMBER IN GROUP:	5	5	5
MEAN:	158.0	6.65	4.197
STANDARD DEV:	14.1	0.91	0.276
M 3			
NUMBER IN GROUP:	5	5	5
MEAN:	165.4	7.75	4.669
STANDARD DEV:	20.8	1.26	0.201
M 4			
NUMBER IN GROUP:	5	5	5
MEAN:	166.2	8.78	5.264*
STANDARD DEV:	11.5	1.26	0.405

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
F 1			
NUMBER IN GROUP:	5	5	5
MEAN:	104.9	4.02	3.801
STANDARD DEV:	14.0	0.84	0.371
F 2			
NUMBER IN GROUP:	5	5	5
MEAN:	109.7	4.35	3.955
STANDARD DEV:	10.0	0.65	0.260
F 3			
NUMBER IN GROUP:	5	4	4
MEAN:	110.9	5.13	4.437
STANDARD DEV:	12.7	0.76	0.356
F 4			
NUMBER IN GROUP:	5	5	5
MEAN:	112.0	5.86*	5.204*
STANDARD DEV:	8.9	1.06	0.597

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=2;SUBSET=ALL

LIVER

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
M	5			
NUMBER IN GROUP:		5	5	5
MEAN:		164.2	12.40*	7.535*
STANDARD DEV:		13.5	1.56	0.384

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
F	5			
NUMBER IN GROUP:		5	5	5
MEAN:		114.0	7.73*	6.751*
STANDARD DEV:		13.0	1.42	0.773

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=3;SUBSET=ALL

LIVER

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
M 1			
NUMBER IN GROUP:	5	5	5
MEAN:	284.5	9.17	3.225
STANDARD DEV:	6.2	0.10	0.090
M 2			
NUMBER IN GROUP:	5	5	5
MEAN:	286.0	9.44	3.294
STANDARD DEV:	16.7	1.10	0.218
M 3			
NUMBER IN GROUP:	5	5	5
MEAN:	295.6	10.03	3.391
STANDARD DEV:	17.4	0.77	0.149
M 4			
NUMBER IN GROUP:	5	5	5
MEAN:	282.3	11.44*	4.052*
STANDARD DEV:	17.5	0.74	0.065

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
F 1			
NUMBER IN GROUP:	5	5	5
MEAN:	170.6	5.37	3.148
STANDARD DEV:	7.8	0.51	0.238
F 2			
NUMBER IN GROUP:	5	5	5
MEAN:	177.5	5.58	3.144
STANDARD DEV:	4.8	0.22	0.069
F 3			
NUMBER IN GROUP:	5	5	5
MEAN:	171.3	5.57	3.247
STANDARD DEV:	6.8	0.37	0.108
F 4			
NUMBER IN GROUP:	5	5	5
MEAN:	168.8	7.04*	4.170*
STANDARD DEV:	3.0	0.23	0.143

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=3;SUBSET=ALL

LIVER

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
M	5			
NUMBER IN GROUP:		5	5	5
MEAN:		249.7	15.34*	6.149*
STANDARD DEV:		22.4	1.16	0.145

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)
F	5			
NUMBER IN GROUP:		5	5	5
MEAN:		161.4	8.97*	5.560*
STANDARD DEV:		8.6	0.53	0.255

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

Table 9B
Complete Organ Weight Data - Interim Sacrifice - Week 79
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Notes: DEATH = 4 = WEEK 79 SACRIFICE

Dose levels were measured in ppm.

ORGAN WEIGHT FOOTNOTES

The Group 5 mean terminal body weights (at sacrifice) for males and females were significantly decreased when compared to the control.

Statistical transformations of data were performed if noted by the following:

R = RANK

LOG10 = LOG10

TABLE 9B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=ALL

LUNG

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 1				
NUMBER IN GROUP:	15	9	9	9
MEAN:	353.1	1.51	0.429	0.757
STANDARD DEV:	31.3	0.12	0.048	0.062
M 4				
NUMBER IN GROUP:	15	10	10	10
MEAN:	343.4	1.43	0.422	0.710
STANDARD DEV:	19.1	0.12	0.024	0.045
M 5				
NUMBER IN GROUP:	15	10	10	10
MEAN:	319.8	1.40	0.441	0.704
STANDARD DEV:	18.8	0.06	0.040	0.036

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 1				
NUMBER IN GROUP:	15	10	10	10
MEAN:	223.7	1.03	0.481	0.566
STANDARD DEV:	18.6	0.05	0.041	0.033
F 4				
NUMBER IN GROUP:	15	10	10	10
MEAN:	233.6	1.05	0.466	0.577
STANDARD DEV:	15.6	0.09	0.042	0.059
F 5				
NUMBER IN GROUP:	15	10	10	10
MEAN:	196.6	1.04	0.539*	0.564
STANDARD DEV:	15.4	0.09	0.041	0.039

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=ALL

UTERUS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
	NUMBER IN GROUP:	15			
	MEAN:	353.1			
	STANDARD DEV:	31.3			
M	4				
	NUMBER IN GROUP:	15			
	MEAN:	343.4			
	STANDARD DEV:	19.1			
M	5				
	NUMBER IN GROUP:	15			
	MEAN:	319.8			
	STANDARD DEV:	18.8			
F	1				
	NUMBER IN GROUP:	15	10	10	10
	MEAN:	223.7	1.08	0.513	0.592
	STANDARD DEV:	18.6	0.53	0.279	0.274
F	4				
	NUMBER IN GROUP:	15	10	10	10
	MEAN:	233.6	0.81	0.359	0.442
	STANDARD DEV:	15.6	0.16	0.074	0.081
F	5				
	NUMBER IN GROUP:	15	10	10	10
	MEAN:	196.6	1.52	0.777	0.826
	STANDARD DEV:	15.4	1.82	0.904	0.987

TABLE 9B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=ALL

BRAIN W/STEM

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
			LOG10	
M 1				
NUMBER IN GROUP:	15	10	10	10
MEAN:	353.1	2.00	0.567	1.000
STANDARD DEV:	31.3	0.09	0.036	0.000
M 4				
NUMBER IN GROUP:	15	10	10	10
MEAN:	343.4	2.02	0.595	1.000
STANDARD DEV:	19.1	0.09	0.017	0.000
M 5				
NUMBER IN GROUP:	15	10	10	10
MEAN:	319.8	2.00	0.627*	1.000
STANDARD DEV:	18.8	0.06	0.049	0.000

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 1				
NUMBER IN GROUP:	15	10	10	10
MEAN:	223.7	1.82	0.849	1.000
STANDARD DEV:	18.6	0.08	0.060	0.000
F 4				
NUMBER IN GROUP:	15	10	10	10
MEAN:	233.6	1.83	0.811	1.000
STANDARD DEV:	15.6	0.08	0.065	0.000
F 5				
NUMBER IN GROUP:	15	10	10	10
MEAN:	196.6	1.84	0.960*	1.000
STANDARD DEV:	15.4	0.07	0.088	0.000

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=ALL

SPLEEN

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 1				
NUMBER IN GROUP:	15	10	10	10
MEAN:	353.1	0.77	0.218	0.387
STANDARD DEV:	31.3	0.11	0.025	0.055
M 4				
NUMBER IN GROUP:	15	10	10	10
MEAN:	343.4	0.69	0.202	0.340
STANDARD DEV:	19.1	0.09	0.025	0.046
M 5				
NUMBER IN GROUP:	15	10	10	10
MEAN:	319.8	0.89	0.278	0.448
STANDARD DEV:	18.8	0.31	0.087	0.156

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 1				
NUMBER IN GROUP:	15	10	10	10
MEAN:	223.7	0.54	0.251	0.297
STANDARD DEV:	18.6	0.15	0.068	0.088
F 4				
NUMBER IN GROUP:	15	10	10	10
MEAN:	233.6	0.59	0.260	0.325
STANDARD DEV:	15.6	0.33	0.143	0.193
F 5				
NUMBER IN GROUP:	15	10	10	10
MEAN:	196.6	0.53	0.271	0.286
STANDARD DEV:	15.4	0.10	0.042	0.054

TABLE 9B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=ALL

KIDNEY

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 1				
NUMBER IN GROUP:	15	10	10	10
MEAN:	353.1	2.42	0.683	1.209
STANDARD DEV:	31.3	0.21	0.046	0.091
M 4				
NUMBER IN GROUP:	15	10	10	10
MEAN:	343.4	2.44	0.718	1.207
STANDARD DEV:	19.1	0.14	0.027	0.046
M 5				
NUMBER IN GROUP:	15	10	10	10
MEAN:	319.8	2.75*	0.860*	1.376*
STANDARD DEV:	18.8	0.18	0.053	0.098

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 1				
NUMBER IN GROUP:	15	10	10	10
MEAN:	223.7	1.59	0.742	0.876
STANDARD DEV:	18.6	0.08	0.043	0.048
F 4				
NUMBER IN GROUP:	15	10	10	10
MEAN:	233.6	1.74*	0.769	0.953*
STANDARD DEV:	15.6	0.13	0.035	0.075
F 5				
NUMBER IN GROUP:	15	10	10	10
MEAN:	196.6	1.82*	0.946*	0.988*
STANDARD DEV:	15.4	0.13	0.070	0.050

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=ALL

LIVER

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 1				
NUMBER IN GROUP:	15	15	15	10
MEAN:	353.1	9.27	2.640	4.295
STANDARD DEV:	31.3	1.32	0.436	0.310
M 4				
NUMBER IN GROUP:	15	15	15	10
MEAN:	343.4	10.32	3.001*	4.758*
STANDARD DEV:	19.1	1.30	0.276	0.170
M 5				
NUMBER IN GROUP:	15	15	15	10
MEAN:	319.8	15.98*	4.999*	7.939*
STANDARD DEV:	18.8	1.58	0.421	0.956

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 1				
NUMBER IN GROUP:	15	15	15	10
MEAN:	223.7	6.59	2.932	3.317
STANDARD DEV:	18.6	1.20	0.294	0.249
F 4				
NUMBER IN GROUP:	15	15	15	10
MEAN:	233.6	8.05*	3.431*	4.114*
STANDARD DEV:	15.6	1.16	0.307	0.492
F 5				
NUMBER IN GROUP:	15	15	15	10
MEAN:	196.6	11.00*	5.593*	5.716*
STANDARD DEV:	15.4	1.08	0.296	0.471

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=4;SUBSET=ALL

TESTIS/EPIDID

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 1				
NUMBER IN GROUP:	15	10	10	10
MEAN:	353.1	4.49	1.267	2.242
STANDARD DEV:	31.3	0.74	0.197	0.352
M 4				
NUMBER IN GROUP:	15	10	10	10
MEAN:	343.4	5.11	1.517	2.551
STANDARD DEV:	19.1	1.03	0.357	0.604
M 5				
NUMBER IN GROUP:	15	10	10	10
MEAN:	319.8	2.54*	0.801*	1.274*
STANDARD DEV:	18.8	1.43	0.455	0.734

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 1				
NUMBER IN GROUP:	15			
MEAN:	223.7			
STANDARD DEV:	18.6			
F 4				
NUMBER IN GROUP:	15			
MEAN:	233.6			
STANDARD DEV:	15.6			
F 5				
NUMBER IN GROUP:	15			
MEAN:	196.6			
STANDARD DEV:	15.4			

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

Table 9C
Complete Organ Weight Data - Terminal Sacrifice
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Note: Dose levels were measured in ppm.

TERMINAL ORGAN WEIGHT FOOTNOTES

Female terminal body weights were significantly different from the control group in Group 3 (increased) and Group 5 (decreased).

Male terminal body weights for Group 5 were significantly decreased from the control group.

Statistical transformations of data were performed if noted by the following:

R = RANK

LOG10 = LOG10

1/X = RECIPROCAL

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LUNG

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g) R	ORGAN-TO-BODY WT (%) R	ORGAN-TO-BRAIN WT RATIO R
M 1				
NUMBER IN GROUP:	45	39	39	39
MEAN:	331.4	1.56	0.475	0.758
STANDARD DEV:	26.0	0.17	0.053	0.090
M 2				
NUMBER IN GROUP:	40	34	34	34
MEAN:	333.6	1.56	0.471	0.764
STANDARD DEV:	24.1	0.17	0.054	0.076
M 3				
NUMBER IN GROUP:	43	38	38	38
MEAN:	325.9	1.67	0.523	0.823*
STANDARD DEV:	28.7	0.40	0.141	0.193
M 4				
NUMBER IN GROUP:	38	32	32	32
MEAN:	321.2	1.77	0.561*	0.861
STANDARD DEV:	23.5	0.47	0.163	0.238

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g) R	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO R
F 1				
NUMBER IN GROUP:	45	39	39	39
MEAN:	227.2	1.18	0.534	0.641
STANDARD DEV:	23.9	0.17	0.130	0.086
F 2				
NUMBER IN GROUP:	47	42	42	42
MEAN:	235.5	1.30	0.567	0.691
STANDARD DEV:	19.0	0.29	0.168	0.151
F 3				
NUMBER IN GROUP:	45	40	40	40
MEAN:	238.5	1.16	0.492	0.623
STANDARD DEV:	16.3	0.10	0.051	0.054
F 4				
NUMBER IN GROUP:	42	36	36	36
MEAN:	233.6	1.23	0.548	0.660
STANDARD DEV:	24.4	0.26	0.188	0.145

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LUNG

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 5				
NUMBER IN GROUP:	40	34	34	34
MEAN:	296.7	1.60	0.553*	0.784
STANDARD DEV:	29.9	0.23	0.130	0.117
M 6				
NUMBER IN GROUP:	40	35	35	35
MEAN:	322.9	1.78	0.573	0.871*
STANDARD DEV:	31.8	0.49	0.215	0.227

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 5				
NUMBER IN GROUP:	40	35	35	35
MEAN:	208.0	1.21	0.594	0.645
STANDARD DEV:	15.5	0.18	0.103	0.096
F 6				
NUMBER IN GROUP:	38	34	34	34
MEAN:	222.0	1.22	0.556	0.662
STANDARD DEV:	20.1	0.17	0.097	0.093

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

UTERUS

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 1				
NUMBER IN GROUP:	45			
MEAN:	331.4			
STANDARD DEV:	26.0			
M 2				
NUMBER IN GROUP:	40			
MEAN:	333.6			
STANDARD DEV:	24.1			
M 3				
NUMBER IN GROUP:	43			
MEAN:	325.9			
STANDARD DEV:	28.7			
M 4				
NUMBER IN GROUP:	38			
MEAN:	321.2			
STANDARD DEV:	23.5			
F 1				
NUMBER IN GROUP:	45	40	40	40
MEAN:	227.2	0.99	0.434	0.532
STANDARD DEV:	23.9	1.09	0.442	0.568
F 2				
NUMBER IN GROUP:	47	41	41	41
MEAN:	235.5	1.46	0.629	0.766
STANDARD DEV:	19.0	3.03	1.310	1.577
F 3				
NUMBER IN GROUP:	45	40	40	40
MEAN:	238.5	0.93	0.409	0.499
STANDARD DEV:	16.3	1.24	0.633	0.675
F 4				
NUMBER IN GROUP:	42	37	37	37
MEAN:	233.6	1.02	0.462	0.544
STANDARD DEV:	24.4	1.05	0.538	0.550

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

UTERUS

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 5				
NUMBER IN GROUP:	40			
MEAN:	296.7			
STANDARD DEV:	29.9			
M 6				
NUMBER IN GROUP:	40			
MEAN:	322.9			
STANDARD DEV:	31.8			
F 5				
NUMBER IN GROUP:	40	35	35	35
MEAN:	208.0	0.90	0.437	0.477
STANDARD DEV:	15.5	0.63	0.297	0.333
F 6				
NUMBER IN GROUP:	38	34	34	34
MEAN:	222.0	1.33	0.628	0.728
STANDARD DEV:	20.1	1.44	0.731	0.808

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

BRAIN W/STEM

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 1				
NUMBER IN GROUP:	45	39	39	39
MEAN:	331.4	2.06	0.629	1.000
STANDARD DEV:	26.0	0.07	0.058	0.000
M 2				
NUMBER IN GROUP:	40	35	35	35
MEAN:	333.6	2.04	0.616	1.000
STANDARD DEV:	24.1	0.08	0.043	0.000
M 3				
NUMBER IN GROUP:	43	38	38	38
MEAN:	325.9	2.03	0.633	1.000
STANDARD DEV:	28.7	0.07	0.055	0.000
M 4				
NUMBER IN GROUP:	38	33	33	33
MEAN:	321.2	2.06	0.648	1.000
STANDARD DEV:	23.5	0.09	0.046	0.000
F 1				
NUMBER IN GROUP:	45	40	40	40
MEAN:	227.2	1.84	0.828	1.000
STANDARD DEV:	23.9	0.09	0.092	0.000
F 2				
NUMBER IN GROUP:	47	42	42	42
MEAN:	235.5	1.89*	0.813	1.000
STANDARD DEV:	19.0	0.07	0.078	0.000
F 3				
NUMBER IN GROUP:	45	40	40	40
MEAN:	238.5	1.86	0.790	1.000
STANDARD DEV:	16.3	0.06	0.058	0.000
F 4				
NUMBER IN GROUP:	42	37	37	37
MEAN:	233.6	1.87	0.821	1.000
STANDARD DEV:	24.4	0.06	0.092	0.000

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

BRAIN W/STEM

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 5				
NUMBER IN GROUP:	40	35	35	35
MEAN:	296.7	2.04	0.705*	1.000
STANDARD DEV:	29.9	0.07	0.078	0.000
M 6				
NUMBER IN GROUP:	40	35	35	35
MEAN:	322.9	2.04	0.645	1.000
STANDARD DEV:	31.8	0.09	0.069	0.000

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 5				
NUMBER IN GROUP:	40	35	35	35
MEAN:	208.0	1.88	0.919*	1.000
STANDARD DEV:	15.5	0.06	0.057	0.000
F 6				
NUMBER IN GROUP:	38	34	34	34
MEAN:	222.0	1.84	0.840	1.000
STANDARD DEV:	20.1	0.06	0.085	0.000

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

SPLEEN

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g) R	ORGAN-TO-BODY WT (%) R	ORGAN-TO-BRAIN WT RATIO R
M 1				
NUMBER IN GROUP:	45	39	39	39
MEAN:	331.4	1.18	0.359	0.573
STANDARD DEV:	26.0	0.48	0.146	0.236
M 2				
NUMBER IN GROUP:	40	35	35	35
MEAN:	333.6	1.37	0.414	0.672
STANDARD DEV:	24.1	1.42	0.435	0.679
M 3				
NUMBER IN GROUP:	43	38	38	38
MEAN:	325.9	1.98	0.625	0.970
STANDARD DEV:	28.7	2.66	0.859	1.285
M 4				
NUMBER IN GROUP:	38	33	33	33
MEAN:	321.2	2.59	0.841	1.265
STANDARD DEV:	23.5	3.80	1.265	1.884

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g) R	ORGAN-TO-BODY WT (%) 1/X	ORGAN-TO-BRAIN WT RATIO R
F 1				
NUMBER IN GROUP:	45	40	40	40
MEAN:	227.2	0.87	0.423	0.469
STANDARD DEV:	23.9	1.33	0.811	0.700
F 2				
NUMBER IN GROUP:	47	42	42	42
MEAN:	235.5	1.12	0.518	0.594
STANDARD DEV:	19.0	1.52	0.862	0.802
F 3				
NUMBER IN GROUP:	45	40	40	40
MEAN:	238.5	0.60	0.254	0.326
STANDARD DEV:	16.3	0.44	0.176	0.253
F 4				
NUMBER IN GROUP:	42	37	37	37
MEAN:	233.6	1.10	0.536	0.591
STANDARD DEV:	24.4	1.41	0.817	0.773

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

SPLEEN

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g) R	ORGAN-TO-BODY WT (%) R	ORGAN-TO-BRAIN WT RATIO R
M 5				
NUMBER IN GROUP:	40	35	35	35
MEAN:	296.7	1.70	0.649	0.832
STANDARD DEV:	29.9	2.33	1.131	1.152
M 6				
NUMBER IN GROUP:	40	35	35	35
MEAN:	322.9	2.86	0.972	1.399
STANDARD DEV:	31.8	3.32	1.257	1.631

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g) R	ORGAN-TO-BODY WT (%) 1/X	ORGAN-TO-BRAIN WT RATIO R
F 5				
NUMBER IN GROUP:	40	35	35	35
MEAN:	208.0	1.37	0.680	0.731
STANDARD DEV:	15.5	2.46	1.218	1.308
F 6				
NUMBER IN GROUP:	38	34	34	34
MEAN:	222.0	1.18	0.541	0.644
STANDARD DEV:	20.1	1.24	0.574	0.690

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

KIDNEY

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 1				
NUMBER IN GROUP:	45	39	39	39
MEAN:	331.4	2.52	0.768	1.224
STANDARD DEV:	26.0	0.20	0.056	0.093
M 2				
NUMBER IN GROUP:	40	35	35	35
MEAN:	333.6	2.54	0.767	1.247
STANDARD DEV:	24.1	0.19	0.045	0.084
M 3				
NUMBER IN GROUP:	43	38	38	38
MEAN:	325.9	2.53	0.792	1.250
STANDARD DEV:	28.7	0.20	0.107	0.087
M 4				
NUMBER IN GROUP:	38	33	33	33
MEAN:	321.2	2.68*	0.843*	1.302*
STANDARD DEV:	23.5	0.26	0.087	0.122

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 1				
NUMBER IN GROUP:	45	40	40	40
MEAN:	227.2	1.78	0.803	0.968
STANDARD DEV:	23.9	0.11	0.124	0.066
F 2				
NUMBER IN GROUP:	47	42	42	42
MEAN:	235.5	1.84	0.796	0.978
STANDARD DEV:	19.0	0.17	0.107	0.089
F 3				
NUMBER IN GROUP:	45	40	40	40
MEAN:	238.5	1.79	0.758	0.962
STANDARD DEV:	16.3	0.12	0.052	0.063
F 4				
NUMBER IN GROUP:	42	37	37	37
MEAN:	233.6	1.84	0.812	0.989
STANDARD DEV:	24.4	0.12	0.110	0.057

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

KIDNEY

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 5				
NUMBER IN GROUP:	40	35	35	35
MEAN:	296.7	2.84*	0.975*	1.391*
STANDARD DEV:	29.9	0.25	0.088	0.119
M 6				
NUMBER IN GROUP:	40	35	35	35
MEAN:	322.9	2.70*	0.854*	1.323*
STANDARD DEV:	31.8	0.26	0.120	0.110

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 5				
NUMBER IN GROUP:	40	35	35	35
MEAN:	208.0	1.91*	0.934*	1.018*
STANDARD DEV:	15.5	0.11	0.062	0.052
F 6				
NUMBER IN GROUP:	38	34	34	34
MEAN:	222.0	1.86	0.847	1.009
STANDARD DEV:	20.1	0.18	0.126	0.105

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LIVER

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
		LOG10	R	R
M 1				
NUMBER IN GROUP:	45	44	44	39
MEAN:	331.4	8.96	2.701	4.235
STANDARD DEV:	26.0	1.19	0.295	0.429
M 2				
NUMBER IN GROUP:	40	40	40	35
MEAN:	333.6	9.13	2.737	4.333
STANDARD DEV:	24.1	1.36	0.357	0.465
M 3				
NUMBER IN GROUP:	43	43	43	38
MEAN:	325.9	9.87	3.086	4.738
STANDARD DEV:	28.7	2.84	1.273	1.461
M 4				
NUMBER IN GROUP:	38	37	37	32
MEAN:	321.2	11.11*	3.462*	5.140*
STANDARD DEV:	23.5	2.43	0.716	0.862

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
		R	LOG10	R
F 1				
NUMBER IN GROUP:	45	45	45	40
MEAN:	227.2	6.54	2.908	3.495
STANDARD DEV:	23.9	0.70	0.444	0.346
F 2				
NUMBER IN GROUP:	47	47	47	42
MEAN:	235.5	7.03	3.001	3.681
STANDARD DEV:	19.0	1.09	0.568	0.588
F 3				
NUMBER IN GROUP:	45	45	45	40
MEAN:	238.5	6.80	2.851	3.571
STANDARD DEV:	16.3	0.87	0.303	0.457
F 4				
NUMBER IN GROUP:	42	42	42	37
MEAN:	233.6	8.27*	3.575*	4.330*
STANDARD DEV:	24.4	1.43	0.795	0.776

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LIVER

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
		LOG10	R	R
M 5				
NUMBER IN GROUP:	40	40	40	35
MEAN:	296.7	14.64*	4.947*	6.996*
STANDARD DEV:	29.9	2.76	0.874	1.332
M 6				
NUMBER IN GROUP:	40	40	40	35
MEAN:	322.9	9.90	3.095	4.724*
STANDARD DEV:	31.8	2.23	0.766	1.086

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
		R	LOG10	R
F 5				
NUMBER IN GROUP:	40	40	40	35
MEAN:	208.0	10.84*	5.227*	5.704*
STANDARD DEV:	15.5	1.93	0.981	1.058
F 6				
NUMBER IN GROUP:	38	38	38	34
MEAN:	222.0	7.22*	3.293*	3.889
STANDARD DEV:	20.1	1.44	0.883	0.820

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

TESTIS/EPIDID

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g) LOG10	ORGAN-TO-BODY WT (%) LOG10	ORGAN-TO-BRAIN WT RATIO LOG10
M 1				
NUMBER IN GROUP:	45	39	39	39
MEAN:	331.4	5.92	1.812	2.873
STANDARD DEV:	26.0	1.90	0.596	0.896
M 2				
NUMBER IN GROUP:	40	35	35	35
MEAN:	333.6	6.05	1.830	2.973
STANDARD DEV:	24.1	1.79	0.556	0.872
M 3				
NUMBER IN GROUP:	43	38	38	38
MEAN:	325.9	5.77	1.782	2.851
STANDARD DEV:	28.7	1.67	0.507	0.852
M 4				
NUMBER IN GROUP:	38	33	33	33
MEAN:	321.2	6.28	1.957	3.048
STANDARD DEV:	23.5	2.38	0.692	1.168

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 1				
NUMBER IN GROUP:	45			
MEAN:	227.2			
STANDARD DEV:	23.9			
F 2				
NUMBER IN GROUP:	47			
MEAN:	235.5			
STANDARD DEV:	19.0			
F 3				
NUMBER IN GROUP:	45			
MEAN:	238.5			
STANDARD DEV:	16.3			
F 4				
NUMBER IN GROUP:	42			
MEAN:	233.6			
STANDARD DEV:	24.4			

TABLE 9C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
ORGAN WEIGHT DATA

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

TESTIS/EPIDID

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g) LOG10	ORGAN-TO-BODY WT (%) LOG10	ORGAN-TO-BRAIN WT RATIO LOG10
M 5				
NUMBER IN GROUP:	40	35	35	35
MEAN:	296.7	2.19*	0.741*	1.067*
STANDARD DEV:	29.9	1.15	0.369	0.560
M 6				
NUMBER IN GROUP:	40	35	35	35
MEAN:	322.9	2.81*	0.893*	1.376*
STANDARD DEV:	31.8	1.90	0.632	0.930

SEX DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F 5				
NUMBER IN GROUP:	40			
MEAN:	208.0			
STANDARD DEV:	15.5			
F 6				
NUMBER IN GROUP:	38			
MEAN:	222.0			
STANDARD DEV:	20.1			

* Significantly different from the control group (Gp. 1), $p \leq 0.05$.

Table 10A
Histopathology Incidence Summary - Unscheduled Deaths
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Note: Dose levels were measured in ppm.

Key to Histopathology Incidence Summary

Symbols Prefacing Neoplastic Findings

B- = Primary, benign neoplasm
M- = Primary, malignant neoplasm
N- = Metastatic neoplasm
I- = Locally invasive neoplasm
X- = Other neoplasm (see Comment)

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	15	12	17	15	15	0
** TOP OF LIST **								
LIVER (LI)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--B-HEPATOCELLULAR ADENOMA		0	1	1	1	2	2	0
--M-HEPATOCELLULAR CARCINOMA		0	0	0	2	3	0	0
--LEUKEMIA ASSOCIATED HEPATOPATHY		7	7	6	13	11	9	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		8	7	6	13	12	9	0
--PIGMENT IN KUPFFER CELLS/HEPATOCYTES		0	0	0	0	2	3	0
--INCREASED CYTOPLASMIC EOSINOPHILIA		0	0	0	0	3	0	0
--DIFFUSE HEPATOCELLULAR ENLARGEMENT		0	0	0	1	2	1	0
--CONGESTION		4	7	5	8	6	5	0
--FOCAL HEMORRHAGE		0	0	0	1	1	0	0
--INFLAMMATION, CHRONIC		0	0	3	1	1	2	0
--FOCAL MONONUCLEAR INFILTRATION		0	1	0	0	0	0	0
--BILE DUCT, HYPERPLASIA		3	8	6	4	3	6	0
--BILE DUCT, INFLAMMATION, CHRONIC		2	8	6	4	3	4	0
--BILE DUCT, FIBROSIS		2	8	5	3	0	3	0
--CELLULAR ALTERATION, BASOPHILIC		2	5	5	3	0	3	0
--CELLULAR ALTERATION, EOSINOPHILIC		0	2	0	0	0	2	0
--FOCAL VACUOLIZATION		0	1	0	0	0	0	0
--DIFFUSE VACUOLIZATION		1	1	0	0	0	0	0
--INDIVIDUAL CELL DEGENERATION/NECROSIS		0	0	0	1	0	1	0
--FOCAL NECROSIS		1	1	2	0	0	4	0
--CENTRILOBULAR DEGENERATION/NECROSIS		0	1	0	1	0	0	0
--SPONGIOSIS HEPATIS		0	1	0	1	0	1	0
SPLEEN (SP)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	2	3	3	2	3	5	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		8	7	6	13	12	9	0
--CONTRACTED		0	0	2	0	0	0	0
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED		0	3	1	2	0	1	0
--FIBROSIS		2	1	0	0	0	1	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **								
SPLEEN (SP)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	2	3	3	2	3	5	0
--INFARCT		0	1	0	0	1	1	0
--INCREASED PIGMENT		0	1	0	0	0	0	0
--N-OSTEOSARCOMA		0	0	1	0	0	0	0
KIDNEY (KD)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--RENAL PAPILLA, MINERALIZATION		3	6	10	10	9	13	0
--NEPHROPATHY, CHRONIC PROGRESSIVE		10	14	12	16	15	15	0
--TUBULE, MICROCONCRETION		10	15	12	16	15	15	0
--TUBULE CELLS, PIGMENT		8	14	12	17	15	15	0
--TUBULE, NECROSIS		1	0	1	1	1	0	0
--PAPILLA, NECROSIS		0	0	0	0	1	0	0
--PELVIS, DILATATION		0	0	0	0	1	0	0
--PELVIS, INFLAMMATION		0	0	0	0	0	1	0
--CONGESTION		5	7	7	5	4	3	0
--CORTEX, DIFFUSE MINERALIZATION		0	0	0	0	1	0	0
--MICROCALCULI IN RENAL PELVIS		2	5	2	0	4	1	0
--TRANSITIONAL CELL HYPERPLASIA		0	3	1	0	4	1	0
--BACTERIAL COLONIES		0	1	1	1	3	0	0
--INFLAMMATION, SUPPURATIVE		0	1	1	0	1	0	0
--M-MALIGNANT TUBULE CELL CARCINOMA		1	0	0	0	0	0	0
--M-MALIGNANT MESENCHYMAL TUMOR		0	1	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		6	5	5	10	8	9	0
TESTIS (TE)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--HYPERPLASIA, INTERSTITIAL CELL		2	6	5	5	1	0	0
--B-BENIGN INTERSTITIAL CELL TUMOR		9	11	7	13	5	6	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **		-=-	-=-	-=-	-=-	-=-	-=-	-=-
TESTIS (TE)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--HYPOSPERMIA, UNILATERAL		1	6	2	2	0	0	0
--HYPOSPERMIA, BILATERAL		0	2	4	4	0	0	0
--ASPERMATOGENESIS, UNILATERAL		2	5	4	1	0	0	0
--ASPERMATOGENESIS, BILATERAL		5	4	5	10	15	15	0
--ARTERITIS/PERIARTERITIS		1	0	0	0	0	1	0
--I-HEMANGIOSARCOMA		0	0	0	1	0	0	0
--M-MESOTHELIOMA		0	0	0	1	1	0	0
--N-OSTEOSARCOMA		0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	1	2	3	2	0	0
EPIDIDYMIS (EP)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	1	2	0	0	0	0	0
--IMMATURE/ABNORMAL SPERM FORMS		3	9	6	6	0	0	0
--HYPOSPERMIA		7	11	10	12	15	15	0
--ARTERITIS/PERIARTERITIS		0	1	0	0	0	0	0
--N-OSTEOSARCOMA		0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	1	0	0	0	0	0
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
BRAIN W/STEM (BR)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	5	7	6	8	7	9	0
--CONGESTION		0	2	1	0	1	0	0
--FOCAL HEMORRHAGE		4	2	3	4	4	3	0
--ENCEPHALOMALACIA		0	1	0	0	0	0	0
--COMPRESSION, VENTRAL		1	3	2	3	0	3	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **								
BRAIN W/STEM (BR)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	5	7	6	8	7	9	0
--VENTRICLE, DILATATION		0	1	1	1	0	2	0
--COMPRESSION, DORSAL		0	0	0	0	1	0	0
--M-MALIGNANT ASTROCYTOMA		0	1	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		4	3	4	6	8	3	0
CORD, CERVICAL (CS)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	8	13	11	13	12	12	0
--HEMORRHAGE		2	1	1	3	1	2	0
--GLIOSIS		0	0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	2	1	4	3	2	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	8	14	12	15	12	14	0
--HEMORRHAGE		2	0	0	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	0	2	3	1	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	8	14	12	15	12	14	0
--HEMORRHAGE		1	0	0	1	1	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	1	0	2	3	1	0
PITUITARY (PI)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	2	1	2	7	5	3	0
--INCREASED CASTRATION CELLS		1	0	0	1	5	3	0
--CONGESTION/HEMORRHAGE		1	5	3	2	2	1	0
--MICROCYST(S)		1	1	0	0	2	2	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **								
PITUITARY (PI)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	2	1	2	7	5	3	0
--ANGIECTASIS/SINUSOID ECTASIA		4	4	4	5	3	3	0
--FOCAL HYPERTROPHY		0	2	2	2	1	3	0
--FOCAL HYPERPLASIA		1	3	0	0	3	0	0
--B-ADENOMA		2	6	6	5	2	5	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		3	4	2	4	4	5	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	0	1	2	2	1	1	0
--UNILATERALLY EXAMINED		0	1	1	0	0	0	0
--CONGESTION		6	7	5	6	6	5	0
--ANGIECTASIS/SINUSOID ECTASIA		1	0	0	1	0	1	0
--FOCAL HYPERTROPHY		4	4	1	0	2	2	0
--FOCAL VACUOLIZATION		5	4	2	2	2	6	0
--DIFFUSE VACUOLIZATION		1	5	3	5	5	10	0
--NECROSIS		0	0	0	1	1	0	0
--FOCAL HYPERPLASIA		0	0	2	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		7	6	5	12	9	8	0
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	6	7	5	7	7	7	0
--UNILATERALLY EXAMINED		0	1	1	0	0	0	0
--HYPERPLASIA		3	5	3	5	2	5	0
--B-BENIGN PHEOCHROMOCYTOMA		0	0	0	0	2	2	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	4	3	5	4	4	0

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	15	12	17	15	15	0
		-=-	-=-	-=-	-=-	-=-	-=-	-=-
THYROID (TY)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	3	4	5	8	9	5	0
--CONGESTION		3	4	3	2	3	3	0
--HEMORRHAGE		1	0	0	0	0	0	0
--FOLLICLE, CYST		0	1	0	0	0	1	0
--HYPERPLASIA, "C" CELL		2	3	2	4	1	6	0
--B-"C" CELL ADENOMA		1	2	1	2	0	1	0
--M-"C" CELL CARCINOMA		0	1	1	0	0	0	0
--B-FOLLICULAR CELL ADENOMA		1	0	0	1	1	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	1	3	1	0
PARATHYROID (PT)	NUMBER EXAMINED:	10	15	10	17	14	15	0
	NOT REMARKABLE:	10	15	10	17	14	15	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
TRACHEA (TR)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	10	15	12	17	15	15	0
LUNG (LU)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--CONGESTION		5	6	6	8	5	7	0
--HEMORRHAGE		0	0	0	0	1	0	0
--PERIBRONCHIAL/PERIVASCULAR, INFILTRATION, LYMPHOID		8	12	11	12	13	11	0
--MINERALIZATION		0	0	0	0	1	0	0
--ALVEOLUS, MACROPHAGES, VACUOLATED		0	3	0	1	1	1	0
--LEUKOCYTOSIS		0	3	1	2	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **								
LUNG (LU)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--FOCAL PNEUMONITIS		1	1	1	0	0	0	0
--DIFFUSE PNEUMONITIS		0	0	0	0	1	1	0
--N-OSTEOSARCOMA		0	0	0	0	1	0	0
--N-RENAL TUBULE CELL CARCINOMA		1	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		8	7	6	13	12	9	0
HEART (HT)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	0	0	0	1	0	0	0
--CARDIOMYOPATHY, DEGENERATIVE		9	13	10	15	15	14	0
--VALVE, THROMBOSIS		0	1	1	3	2	1	0
--ATRIUM, THROMBOSIS		0	3	0	1	0	2	0
--INFLAMMATION, SUPPURATIVE		0	1	2	2	2	0	0
--MINERALIZATION OF CORONARY ARTERIES		1	0	0	0	1	2	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		5	3	3	8	6	6	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	13	7	14	12	6	0
--HYPERPLASIA		1	2	4	3	2	5	0
--EROSION		0	1	2	0	0	2	0
--ULCER		0	0	1	1	1	4	0
--EDEMA		0	0	1	1	0	3	0
--MINERALIZATION		0	0	0	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	1	0	0	1	0
STOMACH, GL (ST)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	2	5	6	8	7	9	0
--CONGESTION		0	1	1	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---						
SEX:	----------MALE----------						
GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **							
STOMACH, GL (ST) ..... NUMBER EXAMINED:	10	15	12	17	15	15	0
NOT REMARKABLE:	2	5	6	8	7	9	0
--FOCAL HEMORRHAGE	2	0	0	2	0	1	0
--EROSION	4	7	4	9	7	4	0
--ULCER	1	0	0	0	0	2	0
--EDEMA	0	0	0	1	0	0	0
--MINERALIZATION	0	0	1	0	1	0	0
--INFLAMMATION, SUPPURATIVE	0	1	1	0	0	0	0
--ARTERITIS/PERIARTERITIS	0	1	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	3	1	1	1	2	1	0
DUODENUM (DU) ..... NUMBER EXAMINED:	10	15	12	17	15	15	0
NOT REMARKABLE:	8	15	12	16	13	13	0
--EROSION	0	0	0	0	1	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	2	0	0	1	1	2	0
JEJUNUM (JE) ..... NUMBER EXAMINED:	10	15	10	17	15	14	0
NOT REMARKABLE:	8	14	10	15	14	12	0
--M-LEIOMYOSARCOMA	0	1	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	2	0	0	2	1	2	0
ILEUM (IL) ..... NUMBER EXAMINED:	10	15	12	17	15	15	0
NOT REMARKABLE:	7	14	11	16	14	13	0
--INTUSSUSCEPTION	0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	3	1	0	1	1	2	0

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	15	12	17	15	15	0
		-=-	-=-	-=-	-=-	-=-	-=-	-=-
PANCREAS (PA)	NUMBER EXAMINED:	10	15	12	17	14	15	0
	NOT REMARKABLE:	1	7	8	10	10	3	0
--EDEMA		0	2	0	1	0	4	0
--INFLAMMATION, CHRONIC		2	1	0	1	1	1	0
--FOCAL ACINAR ATROPHY		1	2	1	2	0	5	0
--ECTOPIC SPLENIC TISSUE		1	0	0	0	0	0	0
--B-ISLET CELL ADENOMA		1	0	0	1	0	1	0
--M-ISLET CELL CARCINOMA		0	0	0	0	0	1	0
--FOCAL ACINAR CELL HYPERPLASIA		0	0	0	0	1	2	0
--N-RENAL TUBULE CARCINOMA		1	0	0	0	0	0	0
--N-OSTEOSARCOMA		0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		3	3	2	2	3	1	0
CECUM (CE)	NUMBER EXAMINED:	10	15	12	17	14	15	0
	NOT REMARKABLE:	8	12	9	11	12	8	0
--CONGESTION		0	1	2	0	0	1	0
--HEMORRHAGE		0	0	0	2	0	0	0
--EDEMA		0	1	1	2	1	3	0
--NEMATODE PARASITE(S)		0	1	0	1	1	0	0
--INFLAMMATION, ACUTE		0	2	2	0	1	0	0
--M-LEIOMYOSARCOMA		0	0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	0	0	1	0	2	0
COLON (CO)	NUMBER EXAMINED:	10	15	12	17	14	15	0
	NOT REMARKABLE:	8	13	9	14	12	11	0
--NEMATODE PARASITE(S)		1	0	2	1	1	0	0
--INFLAMMATION, ACUTE		0	1	0	0	0	0	0
--EDEMA		0	0	0	1	0	2	0
--ULCERATION		0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	0	1	1	2	0

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	MALE						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	15	12	17	15	15	0
RECTUM (RE)	NUMBER EXAMINED:	10	15	12	17	14	15	0
	NOT REMARKABLE:	9	15	11	14	14	14	0
--NEMATODE PARASITE(S)		0	0	1	2	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	1	0	0	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	10	14	12	17	14	15	0
	NOT REMARKABLE:	3	4	5	10	7	8	0
--CONGESTION		1	1	1	0	1	3	0
--FIBROSIS		1	1	0	0	0	0	0
--LYMPHANGIECTASIS		0	1	0	1	0	1	0
--HYPERPLASIA, LYMPHORETICULAR		0	1	0	0	0	2	0
--N-OSTEOSARCOMA		0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		6	6	5	6	6	4	0
PROSTATE (PR)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	4	3	0	7	5	6	0
--INFLAMMATION, CHRONIC ACTIVE		5	12	11	10	6	9	0
--INFLAMMATION, ACUTE		0	0	0	0	2	0	0
--HEMORRHAGE		0	0	0	0	1	0	0
--EDEMA		0	1	0	0	0	0	0
--HYPERPLASIA		0	2	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	1	1	2	1	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	1	2	2	3	2	2	0
--DECREASED SECRETION		8	12	10	14	11	12	0
--HEMORRHAGE		0	0	0	0	1	0	0
--INFLAMMATION, ACUTE		0	0	0	0	1	0	0
--N-OSTEOSARCOMA		0	0	1	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **								
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	1	2	2	3	2	2	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	4	1	1	2	1	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	8	12	11	16	11	13	0
--HEMORRHAGE		0	0	0	1	1	1	0
--MINERALIZATION		0	0	0	0	1	0	0
--INFLAMMATION, ACUTE		0	0	0	0	1	1	0
--INFLAMMATION, CHRONIC		0	0	0	0	1	0	0
--INFLAMMATION, CHRONIC ACTIVE		0	1	0	0	0	0	0
--HYPERPLASIA		0	1	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	2	1	1	2	2	0
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	15	11	17	15	13	0
--EDEMA		0	0	0	0	0	1	0
--SCHWANNOMA		0	0	1	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **								
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	15	11	17	15	13	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	0	0	1	0
THYMUS (TH)	NUMBER EXAMINED:	10	14	10	14	11	12	0
	NOT REMARKABLE:	3	7	6	8	2	6	0
--CONGESTION		2	3	3	3	5	4	0
--HEMORRHAGE		0	0	0	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		6	5	2	4	5	4	0
--MICROCYST(S)		0	1	0	0	1	0	0
AORTA, THORACIC (AO)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	13	11	16	12	15	0
--MEDIA, MINERALIZATION		0	0	0	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	2	1	1	2	0	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	9	14	10	16	14	14	0
--DEGENERATION		1	1	2	1	1	1	0
^DEATH COMMENT (DC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--MONONUCLEAR CELL LEUKEMIA		8	7	6	13	12	9	0
--PITUITARY NEOPLASM		1	3	2	2	0	3	0
--HEPATOCELLULAR NEOPLASM		0	0	0	0	1	0	0
--ISLET CELL CARCINOMA		0	0	0	0	0	1	0
--ASTROCYTOMA		0	1	0	0	0	0	0
--RENAL CARCINOMA		1	0	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **								
^DEATH COMMENT (DC)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--RENAL MESENCHYMAL TUMOR		0	1	0	0	0	0	0
--FIBROSARCOMA		0	0	1	0	0	0	0
--LEIOMYOSARCOMA		0	1	0	0	0	1	0
--HEMANGIOSARCOMA		0	0	0	1	0	0	0
--OSTEOSARCOMA		0	0	1	0	0	0	0
--SCHWANNOMA		0	0	1	0	0	0	0
--SQUAMOUS CELL CARCINOMA		0	1	0	1	0	0	0
--ZYMBAL'S GLAND CARCINOMA		0	0	0	0	0	1	0
--GENITOURINARY INFLAMMATION		0	0	0	0	1	0	0
--NERVE DEGENERATION (RADICULONEUROPATHY)		0	0	1	0	0	0	0
--ATRIAL THROMBOSIS		0	1	0	0	0	0	0
--ACCIDENTAL		0	1	0	1	0	0	0
--UNDETERMINED		0	0	0	0	1	0	0
HEMATO NEOPLASIA (HN)	NUMBER EXAMINED:	10	15	12	17	15	15	0
	NOT REMARKABLE:	2	8	6	4	3	6	0
--M-MALIGNANT LEUKEMIA, MONONUCLEAR CELL		8	7	6	13	12	9	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	4	3	0	3	1	0	0
	NOT REMARKABLE:	0	1	0	0	0	0	0
--TAIL-CHRONIC ACTIVE INFLAMMATION		3	0	0	2	1	0	0
--FOOT/PAW-PODODERMATITIS		1	1	0	0	0	0	0
--TAIL-NECROSIS		2	0	0	1	0	0	0
--M-SQUAMOUS CELL CARCINOMA		0	1	0	1	0	0	0

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
	NUMBER:	10	15	12	17	15	15	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	0	1	3	1	0	1	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--N-SCHWANNOMA		0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	1	2	1	0	1	0
LN, OTHER (LN)	NUMBER EXAMINED:	5	5	2	1	5	4	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--CONGESTION		0	1	1	0	2	3	0
--N-RENAL TUBULE CARCINOMA		1	0	0	0	0	0	0
--N-OSTEOSARCOMA		0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		4	4	1	1	5	4	0
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	1	0	2	2	1	0	0
	NOT REMARKABLE:	0	0	0	1	0	0	0
--HEMORRHAGE		0	0	0	0	1	0	0
--B-FIBROMA		1	0	0	0	0	0	0
--M-FIBROSARCOMA		0	0	1	0	0	0	0
--M-HEMANGIOSARCOMA		0	0	0	1	0	0	0
--N-SCHWANNOMA		0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0
EYE (EY)	NUMBER EXAMINED:	1	1	2	3	0	4	0
	NOT REMARKABLE:	1	0	0	0	0	0	0
--GLOBE RUPTURED, UNILATERAL		0	0	0	0	0	1	0
--KERATITIS		0	0	0	0	0	1	0
--HYPOPYON		0	0	0	0	0	1	0
--CORNEA, MINERALIZATION		0	0	1	3	0	3	0
--SCLERA, MINERALIZATION		0	1	2	2	0	1	0
--LENS, DEGENERATION		0	1	2	3	0	2	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	15	12	17	15	15	0
** FROM PREVIOUS PAGE **								
EYE (EY)	NUMBER EXAMINED:	1	1	2	3	0	4	0
	NOT REMARKABLE:	1	0	0	0	0	0	0
--RETINA, DEGENERATION		0	1	2	3	0	2	0
PENIS (PE)	NUMBER EXAMINED:	1	1	0	0	1	1	0
	NOT REMARKABLE:	0	0	0	0	1	0	0
--INFLAMMATION, ACUTE		1	1	0	0	0	1	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	1	3	2	2	1	1	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--CIRCUMSCRIBED FAT NECROSIS		0	1	0	2	0	0	0
--INFLAMMATION, CHRONIC ACTIVE		0	1	0	0	0	0	0
--MINERALIZATION OF MESENTERIC ARTERIES		0	0	0	0	1	0	0
--M-OSTEOSARCOMA		0	0	1	0	0	0	0
--N-MESOTHELIOMA		0	0	0	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	1	2	0	1	0
BONE, OTHER (OB)	NUMBER EXAMINED:	0	1	0	0	1	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--FRACTURE		0	1	0	0	0	0	0
--M-OSTEOSARCOMA		0	0	0	0	1	0	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	0	0	1	2	0	0	0
	NOT REMARKABLE:	0	0	1	0	0	0	0
--GALACTOCELE		0	0	0	1	0	0	0
--ACTIVE MAMMARY TISSUE		0	0	0	1	0	0	0
--B-FIBROADENOMA		0	0	0	1	0	0	0

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---						
	SEX:	----------MALE----------						
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-7-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	15	12	17	15	15	0
SCROTUM (SC)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
PREPUTIAL GLAND (PG)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	0	0	0	1	0	1	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
--M-ZYMBAL'S GLAND CARCINOMA		0	0	0	1	0	1	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
CLITORAL GLAND (CL)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0

** END OF LIST **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	8	10	13	15	17
** TOP OF LIST **							
LIVER (LI)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	0	0	0	0	0	0
--B-HEPATOCELLULAR ADENOMA		0	0	0	1	4	1
--M-HEPATOCELLULAR CARCINOMA		0	0	0	0	1	1
--LEUKEMIA ASSOCIATED HEPATOPATHY		5	3	5	7	6	9
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		5	4	6	7	7	9
--PIGMENT IN KUPFFER CELLS/HEPATOCYTES		0	0	0	0	2	2
--INCREASED CYTOPLASMIC EOSINOPHILIA		0	0	0	0	9	0
--DIFFUSE HEPATOCELLULAR ENLARGEMENT		0	0	0	1	7	2
--CONGESTION		2	2	1	4	2	3
--INFLAMMATION, CHRONIC		5	4	2	2	3	4
--BILE DUCT, HYPERPLASIA		1	3	4	4	3	3
--BILE DUCT, INFLAMMATION, CHRONIC		2	4	4	5	4	5
--BILE DUCT, FIBROSIS		0	2	3	2	0	2
--CELLULAR ALTERATION, BASOPHILIC		2	2	3	0	1	1
--CELLULAR ALTERATION, EOSINOPHILIC		0	1	1	0	0	0
--CENTRILOBULAR TO MIDZONAL VACUOLIZATION		0	0	0	0	0	1
--FOCAL NECROSIS		0	0	0	2	0	0
--CENTRILOBULAR DEGENERATION/NECROSIS		0	1	0	2	1	3
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED		0	1	1	2	0	1
--SPONGIOSIS HEPATIS		0	0	0	0	1	0
--N-MESOTHELIOMA		0	0	0	0	1	0
SPLEEN (SP)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	4	2	2	1	4	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		5	4	6	7	7	9
--CONTRACTED		0	0	0	0	1	1
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED		0	0	1	4	3	4
--FIBROSIS		0	0	0	0	0	1
--N-MESOTHELIOMA		0	0	0	0	1	0
--INCREASED PIGMENT		1	2	1	1	0	2

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	8	10	13	15	17
** FROM PREVIOUS PAGE **							
SPLEEN (SP)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	4	2	2	1	4	1
--ACCESSORY SPLEEN TISSUE		0	0	0	0	0	1
KIDNEY (KD)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	0	0	0	0	0	0
--RENAL PAPILLA, MINERALIZATION		4	3	2	3	4	11
--NEPHROPATHY, CHRONIC PROGRESSIVE		9	7	8	11	14	16
--TUBULE, MICROCONCRETION		10	7	9	11	15	16
--TUBULE CELLS, PIGMENT		10	8	9	13	15	17
--TUBULE, NECROSIS		0	0	0	1	1	1
--PAPILLA, NECROSIS		0	0	1	0	0	0
--PELVIS, DILATATION		0	0	1	0	1	0
--PELVIS, INFLAMMATION		0	0	1	0	0	0
--CONGESTION		3	1	1	3	2	3
--CORTEX, DIFFUSE MINERALIZATION		0	1	0	0	0	0
--MICROCALCULI IN RENAL PELVIS		4	4	6	10	0	6
--TRANSITIONAL CELL HYPERPLASIA		1	1	3	5	3	5
--CYST		0	0	0	0	0	1
--BACTERIAL COLONIES		0	0	1	0	0	2
--INFLAMMATION, SUPPURATIVE		0	0	0	0	1	1
--M-MALIGNANT NEPHROBLASTOMA		0	1	0	0	0	0
--N-MESOTHELIOMA		0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		3	2	6	6	5	6
TESTIS (TE)	NUMBER EXAMINED:	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	8	10	13	15	17
EPIDIDYMIS (EP)	NUMBER EXAMINED:	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0
UTERUS (UT)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	6	6	5	3	5	11
--DILATATION		2	2	5	10	7	3
--HYPERPLASIA, CYSTIC ENDOMETRIAL		2	0	1	3	3	3
--THROMBOSIS		0	0	0	0	1	0
--INFLAMMATION, SUPPURATIVE		0	0	1	0	0	0
--B-ENDOMETRIAL STROMAL POLYP		0	0	5	2	3	1
--M-CARCINOMA		0	0	0	1	0	0
--M-ENDOMETRIAL STROMAL SARCOMA		0	0	0	0	0	2
--M-LEIOMYOSARCOMA		0	0	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	1	2	2	0
BRAIN W/STEM (BR)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	1	3	6	9	9	9
--CONGESTION		0	0	0	1	1	1
--FOCAL HEMORRHAGE		2	1	2	1	2	6
--FOCAL GLIOSIS		1	0	0	0	0	0
--COMPRESSION, VENTRAL		4	4	0	3	3	3
--VENTRICLE, DILATATION		0	3	0	0	3	1
--M-MALIGNANT ASTROCYTOMA		1	0	0	0	0	0
--I-PITUITARY CARCINOMA		1	1	1	2	1	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	1	3	1	1	3
CORD, CERVICAL (CS)	NUMBER EXAMINED:	10	7	10	13	15	17
	NOT REMARKABLE:	10	7	9	13	14	17
--HEMORRHAGE		0	0	1	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	10	8	10	13	15	17
** FROM PREVIOUS PAGE **							
CORD, CERVICAL (CS)	NUMBER EXAMINED:	10	7	10	13	15	17
	NOT REMARKABLE:	10	7	9	13	14	17
--FOCAL MALACIA		0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	10	7	10	13	15	17
	NOT REMARKABLE:	10	7	10	13	15	16
--HEMORRHAGE		0	0	0	0	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	1
CORD, LUMBAR (LC)	NUMBER EXAMINED:	10	7	10	13	15	17
	NOT REMARKABLE:	10	7	9	13	15	17
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0
PITUITARY (PI)	NUMBER EXAMINED:	9	8	10	12	15	16
	NOT REMARKABLE:	2	2	2	3	4	2
--CONGESTION/HEMORRHAGE		3	1	0	2	3	5
--MICROCYST(S)		2	2	2	3	3	3
--ANGIECTASIS/SINUSOID ECTASIA		5	5	4	6	7	8
--FOCAL HYPERTROPHY		1	1	1	0	0	2
--FOCAL HYPERPLASIA		0	0	1	2	0	2
--B-ADENOMA		4	3	4	1	6	5
--M-CARCINOMA		1	1	1	2	1	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	0	1	2	1	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	2	2	0	2	1	3
--CONGESTION		4	3	5	7	6	9

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	8	10	13	15	17
** FROM PREVIOUS PAGE **							
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	2	2	0	2	1	3
--ANGIECTASIS/SINUSOID ECTASIA		2	2	6	5	6	4
--FOCAL HYPERTROPHY		1	2	5	3	1	1
--FOCAL VACUOLIZATION		3	3	4	2	3	2
--DIFFUSE VACUOLIZATION		0	1	4	3	2	7
--NECROSIS		0	0	1	1	0	1
--FOCAL HYPERPLASIA		1	0	0	0	1	0
--THROMBOSIS		0	0	1	0	1	0
--N-MESOTHELIOMA		0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		3	3	6	7	5	6
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	8	8	5	11	14	10
--HYPERPLASIA		0	0	2	0	1	3
--B-BENIGN PHEOCHROMOCYTOMA		1	0	0	1	0	0
--M-MALIGNANT PHEOCHROMOCYTOMA		0	0	0	0	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	4	1	0	3
THYROID (TY)	NUMBER EXAMINED:	10	8	10	13	14	17
	NOT REMARKABLE:	3	3	2	8	10	8
--CONGESTION		1	0	0	1	1	1
--HYPERPLASIA, "C" CELL		6	5	6	4	3	7
--B-"C" CELL ADENOMA		0	0	2	0	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0
PARATHYROID (PT)	NUMBER EXAMINED:	10	8	10	12	14	17
	NOT REMARKABLE:	10	8	10	12	14	17

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	10	8	10	13	15	17
ESOPHAGUS (ES)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	10	8	10	13	15	17
TRACHEA (TR)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	10	8	10	13	15	16
--INFLAMMATION, ACUTE		0	0	0	0	0	1
LUNG (LU)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	0	1	0	0	0	0
--CONGESTION		2	1	1	4	3	3
--HEMORRHAGE		0	0	1	2	0	0
--PERIBRONCHIAL/PERIVASCULAR, INFILTRATION, LYMPHOID		9	5	9	11	8	12
--ALVEOLUS, MACROPHAGES, VACUOLATED		0	1	1	3	2	1
--LEUKOCYTOSIS		0	0	1	1	1	1
--FOCAL PNEUMONITIS		0	1	0	0	2	0
--DIFFUSE PNEUMONITIS		0	0	0	0	1	3
--ALVEOLUS/BRONCHUS EPITHELIAL HYPERPLASIA		0	0	0	1	0	0
--N-OSTEOSARCOMA		0	0	0	0	0	1
--N-NEPHROBLASTOMA		0	1	0	0	0	0
--N-MESOTHELIOMA		0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		5	3	6	7	7	9
HEART (HT)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	2	1	0	1	3	2
--CARDIOMYOPATHY, DEGENERATIVE		6	6	8	12	12	11
--VALVE, THROMBOSIS		0	0	1	1	0	0
--ATRIUM, THROMBOSIS		1	0	1	2	0	3
--INFLAMMATION, SUPPURATIVE		0	0	1	0	1	2
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		4	1	4	5	2	4

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	8	10	13	15	17
STOMACH, NONGL (SU)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	8	8	6	9	12	12
--HYPERPLASIA		2	0	3	3	3	4
--EROSION		1	0	1	0	0	0
--ULCER		0	0	1	2	1	3
--EDEMA		0	0	0	3	2	2
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	2	0
STOMACH, GL (ST)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	6	5	3	5	6	6
--CONGESTION		0	0	0	1	0	0
--FOCAL HEMORRHAGE		2	0	0	2	0	1
--EROSION		4	3	5	7	7	9
--ULCER		0	0	0	1	1	3
--EDEMA		1	0	2	1	0	1
--MINERALIZATION		0	0	0	0	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	0	2	2	2	0
DUODENUM (DU)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	9	8	9	12	13	17
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	1	1	2	0
JEJUNUM (JE)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	9	8	9	13	15	17
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	1	0	0	0

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	10	8	10	13	15	17
ILEUM (IL)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	10	8	10	10	14	17
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	3	1	0
PANCREAS (PA)	NUMBER EXAMINED:	10	7	10	13	15	17
	NOT REMARKABLE:	7	6	4	6	8	12
--EDEMA		3	0	1	4	2	3
--INFLAMMATION, CHRONIC		0	0	3	1	2	0
--FOCAL ACINAR ATROPHY		0	0	1	0	0	2
--BASOPHILIC FOCUS		0	0	1	0	1	0
--M-ISLET CELL CARCINOMA		0	0	1	0	0	0
--M-ACINAR CELL CARCINOMA		0	0	0	0	1	0
--N-NEPHROBLASTOMA		0	1	0	0	0	0
--N-MESOTHELIOMA		0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	2	3	2	1
CECUM (CE)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	7	7	7	10	12	14
--CONGESTION		0	0	0	1	0	0
--HEMORRHAGE		0	0	0	1	0	0
--EDEMA		2	1	3	2	2	3
--NEMATODE PARASITE(S)		1	0	0	0	1	0
--INFLAMMATION, ACUTE		1	0	2	0	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	3	0	0
COLON (CO)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	9	8	9	10	11	15
--NEMATODE PARASITE(S)		1	0	1	3	3	1
--EDEMA		0	0	0	0	0	1

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	10	8	10	13	15	17
** FROM PREVIOUS PAGE **							
COLON (CO)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	9	8	9	10	11	15
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	1	1	0
RECTUM (RE)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	10	7	10	13	14	17
--NEMATODE PARASITE(S)		0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	7	5	5	8	6	11
--CONGESTION		1	1	1	1	4	5
--FIBROSIS		0	0	0	0	1	0
--LYMPHANGIECTASIS		0	0	0	1	0	1
--HYPERPLASIA, LYMPHORETICULAR		0	0	1	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		3	2	4	5	4	3
PROSTATE (PR)	NUMBER EXAMINED:	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	8	8	8	12	14	17
--M-TRANSITIONAL CELL CARCINOMA		0	0	1	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	0	1	1	1	0

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	8	10	13	15	17
OVARY (OV)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	3	3	3	3	6	9
--CONGESTION		1	1	1	2	3	1
--MEDULLARY TUBULE HYPERPLASIA		3	3	5	4	2	5
--FOLLICLE, CYST		0	1	1	0	0	0
--BURSA, CYST		0	0	0	1	1	0
--INFLAMMATION, CHRONIC		0	0	0	0	1	1
--B-BENIGN GRANULOSA/THECA CELL TUMOR		0	0	0	0	1	0
--N-MESOTHELIOMA		0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		3	1	3	4	3	3
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	9	7	10	10	10	15
--B-LEIOMYOMA		0	0	0	0	1	0
--M-MALIGNANT SCHWANNOMA		0	0	0	1	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	0	2	3	2
VAGINA (VA)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	9	8	10	12	13	17
--PROLAPSE		0	0	0	1	0	0
--I-MALIGNANT SCHWANNOMA		0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	0	1	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	10	8	10	13	15	16
	NOT REMARKABLE:	9	8	10	12	14	16
--EDEMA		0	0	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	0	1	0

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	8	10	13	15	17
THYMUS (TH)	NUMBER EXAMINED:	8	7	8	12	11	12
	NOT REMARKABLE:	3	4	5	5	7	8
--CONGESTION		1	0	0	3	2	2
--HEMORRHAGE		0	0	0	0	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	3	3	4	2	1
--MICROCYST(S)		3	1	1	0	1	1
AORTA, THORACIC (AO)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	9	7	10	12	14	16
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	0	1	1	1
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	9	8	10	13	15	17
	NOT REMARKABLE:	9	8	9	13	14	17
--DEGENERATION		0	0	1	0	1	0
^DEATH COMMENT (DC)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	0	0	0	0	0	0
--MONONUCLEAR CELL LEUKEMIA		5	3	6	7	7	9
--PITUITARY NEOPLASM		4	4	1	3	3	2
--MAMMARY FIBROADENOMA		0	0	2	0	1	0
--PHEOCHROMOCYTOMA		0	0	0	0	0	1
--ASTROCYTOMA		1	0	0	0	0	0
--NEPHROBLASTOMA		0	1	0	0	0	0
--TRANSITIONAL CELL CARCINOMA		0	0	1	0	0	0
--MESOTHELIOMA		0	0	0	0	1	0
--OSTEOSARCOMA		0	0	0	0	0	1
--SCHWANNOMA		0	0	0	1	1	0
--ENDOMETRIAL STROMAL SARCOMA		0	0	0	0	0	1
--UTERINE CARCINOMA		0	0	0	1	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	8	10	13	15	17
** FROM PREVIOUS PAGE **							
^DEATH COMMENT (DC)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	0	0	0	0	0	0
--SEPTICEMIA		0	0	0	0	0	1
--VAGINAL PROLAPSE		0	0	0	1	0	0
--TRAUMA		0	0	0	0	1	0
--ATRIAL THROMBOSIS		0	0	0	0	0	1
--ACCIDENTAL		0	1	0	1	0	0
--UNDETERMINED		0	0	0	0	1	1
HEMATO NEOPLASIA (HN)	NUMBER EXAMINED:	10	8	10	13	15	17
	NOT REMARKABLE:	5	4	4	6	8	8
--M-MALIGNANT LEUKEMIA, MONONUCLEAR CELL		5	4	6	7	7	9
SKIN, OTHER (SS)	NUMBER EXAMINED:	1	1	0	1	2	0
	NOT REMARKABLE:	0	0	0	0	0	0
--TAIL-CHRONIC ACTIVE INFLAMMATION		0	1	0	1	0	0
--M-FIBROSARCOMA		1	0	0	0	0	0
--TAIL-NECROSIS		0	0	0	1	2	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	0	0	1	0	2	0
	NOT REMARKABLE:	0	0	0	0	0	0
--HYPERPLASIA, LYMPHORETICULAR		0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	1	0
LN, OTHER (LN)	NUMBER EXAMINED:	3	0	3	3	3	1
	NOT REMARKABLE:	0	0	0	0	0	0
--CONGESTION		1	0	0	1	0	1
--HYPERPLASIA, LYMPHORETICULAR		0	0	1	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	10	8	10	13	15	17
** FROM PREVIOUS PAGE **							
LN, OTHER (LN)	NUMBER EXAMINED:	3	0	3	3	3	1
	NOT REMARKABLE:	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		3	0	2	3	3	1
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	0	0	0	0	0	1
	NOT REMARKABLE:	0	0	0	0	0	0
--M-OSTEOSARCOMA		0	0	0	0	0	1
EYE (EY)	NUMBER EXAMINED:	1	1	1	1	0	4
	NOT REMARKABLE:	0	0	0	0	0	0
--CORNEA, MINERALIZATION		0	0	1	1	0	3
--SCLERA, MINERALIZATION		0	1	0	1	0	2
--LENS, DEGENERATION		1	1	0	1	0	4
--RETINA, DEGENERATION		1	1	0	1	0	4
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	1
PENIS (PE)	NUMBER EXAMINED:	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	3	1	0	3	3	1
	NOT REMARKABLE:	0	0	0	0	0	0
--CIRCUMSCRIBED FAT NECROSIS		0	0	0	1	0	0
--FIBROUS ADHESIONS		2	0	0	0	0	0
--M-MESOTHELIOMA		0	0	0	0	1	0
--N-NEPHROBLASTOMA		0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	2	2	1

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	10	8	10	13	15	17
BONE, OTHER (OB)	NUMBER EXAMINED:	0	0	0	0	1	0
	NOT REMARKABLE:	0	0	0	0	0	0
--FRACTURE		0	0	0	0	1	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0
SCROTUM (SC)	NUMBER EXAMINED:	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0
PREPUTIAL GLAND (PG)	NUMBER EXAMINED:	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	1	0	3	2	1	1
	NOT REMARKABLE:	0	0	0	0	0	0
--GALACTOCELE		1	0	0	0	0	0
--INFLAMMATION, CHRONIC		1	0	0	0	0	0
--ACTIVE MAMMARY TISSUE		1	0	0	0	0	0
--B-FIBROADENOMA		0	0	3	1	1	1
--M-CARCINOMA		0	0	0	1	0	0
CLITORAL GLAND (CL)	NUMBER EXAMINED:	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0

TABLE 10A
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---					
	SEX:	----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	10	8	10	13	15	17
		-=-	-=-	-=-	-=-	-=-	-=-
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	0	0	0	0	0	1
	NOT REMARKABLE:	0	0	0	0	0	0
--N-OSTEOSARCOMA		0	0	0	0	0	1
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0

** END OF LIST **

Table 10B
Histopathology Incidence Summary - Interim Sacrifices - Weeks 1, 2, 13, and 79
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Notes: DEATH = 1 = WEEK 1 SACRIFICE
DEATH = 2 = WEEK 2 SACRIFICE
DEATH = 3 = WEEK 13 SACRIFICE
DEATH = 4 = WEEK 79 SACRIFICE

Dose levels were measured in ppm.

Key to Histopathology Incidence Summary

Symbols Prefacing Neoplastic Findings

B- = Primary, benign neoplasm
M- = Primary, malignant neoplasm
X- = Other neoplasm (see Comment)

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,7;WEEKS=ALL
DEATH=1;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	----------MALE----------						----------FEMALE----------					
GROUP:	-1-	-2-	-3-	-4-	-5-	-7-	-1-	-2-	-3-	-4-	-5-	-7-
NUMBER:	5	5	5	5	5	5	5	5	5	5	5	0
** TOP OF LIST **												
LIVER (LI) ..... NUMBER EXAMINED:	5	0	0	0	5	5	5	0	0	0	5	0
NOT REMARKABLE:	1	0	0	0	0	0	0	0	0	0	0	0
--FOCAL MONONUCLEAR INFILTRATION	4	0	0	0	5	5	5	0	0	0	4	0
--INCREASED MITOTIC FIGURES	0	0	0	0	5	5	0	0	0	0	5	0
--FOCAL NECROSIS	1	0	0	0	0	0	1	0	0	0	0	0
--ARTIFACTUAL DISTORTION	0	0	0	0	0	0	1	0	0	0	0	0
--INDIVIDUAL CELL DEGENERATION/NECROSIS	0	0	0	0	0	4	0	0	0	0	0	0

** END OF LIST **

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,7;WEEKS=ALL
DEATH=2;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	MALE						FEMALE					
GROUP:	-1-	-2-	-3-	-4-	-5-	-7-	-1-	-2-	-3-	-4-	-5-	-7-
NUMBER:	5	5	5	5	5	5	5	5	5	5	5	0
** TOP OF LIST **												
LIVER (LI) ..... NUMBER EXAMINED:	5	0	0	0	5	5	5	0	0	0	5	0
NOT REMARKABLE:	0	0	0	0	0	0	1	0	0	0	0	0
--INCREASED CYTOPLASMIC EOSINOPHILIA	0	0	0	0	5	5	0	0	0	0	4	0
--DIFFUSE HEPATOCELLULAR ENLARGEMENT	0	0	0	0	5	5	0	0	0	0	5	0
--FOCAL MONONUCLEAR INFILTRATION	5	0	0	0	5	5	4	0	0	0	2	0
--INDIVIDUAL CELL DEGENERATION/NECROSIS	0	0	0	0	0	4	0	0	0	0	1	0
--FOCAL NECROSIS	0	0	0	0	3	4	0	0	0	0	0	0

** END OF LIST **

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,7;WEEKS=ALL
DEATH=3;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	MALE						FEMALE					
GROUP:	-1-	-2-	-3-	-4-	-5-	-7-	-1-	-2-	-3-	-4-	-5-	-7-
NUMBER:	5	5	5	5	5	5	5	5	5	5	5	0
** TOP OF LIST **												
LIVER (LI) ..... NUMBER EXAMINED:	5	0	0	0	5	5	5	0	0	0	5	0
NOT REMARKABLE:	2	0	0	0	0	0	1	0	0	0	0	0
--INCREASED CYTOPLASMIC EOSINOPHILIA	0	0	0	0	5	5	0	0	0	0	5	0
--DIFFUSE HEPATOCELLULAR ENLARGEMENT	0	0	0	0	5	5	0	0	0	0	5	0
--FOCAL HEMORRHAGE	1	0	0	0	0	0	0	0	0	0	0	0
--FOCAL MONONUCLEAR INFILTRATION	3	0	0	0	5	5	4	0	0	0	4	0
--INDIVIDUAL CELL DEGENERATION/NECROSIS	0	0	0	0	0	5	0	0	0	0	1	0
--FOCAL NECROSIS	0	0	0	0	2	0	0	0	0	0	0	0
--ARTIFACTUAL DISTORTION	1	0	0	0	0	0	0	0	0	0	0	0
--PIGMENT IN KUPFFER CELLS/HEPATOCYTES	0	0	0	0	0	0	5	0	0	0	0	0
--CELLULAR ALTERATION, EOSINOPHILIC	0	0	0	0	0	0	2	0	0	0	0	0

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=4;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	15	0	0	15	15	0	15	0	0	15	15	0
** TOP OF LIST **													
LIVER (LI)	NUMBER EXAMINED:	10	0	0	10	10	0	10	0	0	10	10	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--B-HEPATOCELLULAR ADENOMA		0	0	0	1	1	0	0	0	0	0	1	0
--M-HEPATOCELLULAR CARCINOMA		0	0	0	0	4	0	0	0	0	0	2	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	1	0	0	1	0	0
--PIGMENT IN KUPFFER CELLS/HEPATOCYTES		0	0	0	0	9	0	0	0	0	1	7	0
--INCREASED CYTOPLASMIC EOSINOPHILIA		0	0	0	0	10	0	0	0	0	0	10	0
--DIFFUSE HEPATOCELLULAR ENLARGEMENT		0	0	0	0	10	0	0	0	0	0	10	0
--INFLAMMATION, CHRONIC		7	0	0	9	4	0	8	0	0	9	10	0
--FOCAL MONONUCLEAR INFILTRATION		0	0	0	0	1	0	0	0	0	0	0	0
--BILE DUCT, HYPERPLASIA		10	0	0	10	7	0	8	0	0	9	1	0
--BILE DUCT, INFLAMMATION, CHRONIC		10	0	0	10	10	0	8	0	0	9	6	0
--BILE DUCT, FIBROSIS		10	0	0	9	4	0	3	0	0	7	0	0
--CHOLANGIECTASIS		1	0	0	0	0	0	0	0	0	0	0	0
--CELLULAR ALTERATION, BASOPHILIC		9	0	0	4	3	0	6	0	0	4	1	0
--CELLULAR ALTERATION, EOSINOPHILIC		5	0	0	3	8	0	1	0	0	1	0	0
--FOCAL VACUOLIZATION		1	0	0	0	1	0	0	0	0	0	0	0
--FOCAL NECROSIS		0	0	0	1	1	0	0	0	0	0	0	0
--PROTRUSION OF HEPATIC PARENCHYMA (HERNIA)		2	0	0	0	0	0	0	0	0	0	0	0
--SINUSOID ECTASIA/ANGIECTASIS		0	0	0	0	0	0	0	0	0	2	0	0
SPLEEN (SP)	NUMBER EXAMINED:	10	0	0	10	10	0	10	0	0	10	10	0
	NOT REMARKABLE:	10	0	0	10	9	0	8	0	0	9	9	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	1	0	0	1	0	0
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED		0	0	0	0	0	0	1	0	0	0	1	0
KIDNEY (KD)	NUMBER EXAMINED:	10	0	0	10	10	0	10	0	0	10	10	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--RENAL PAPILLA, MINERALIZATION		2	0	0	3	5	0	0	0	0	1	2	0
--NEPHROPATHY, CHRONIC PROGRESSIVE		10	0	0	10	10	0	4	0	0	6	5	0

** CONTINUED ON NEXT PAGE **

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=4;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	15	0	0	15	15	0	15	0	0	15	15	0
** FROM PREVIOUS PAGE **													
KIDNEY (KD)	NUMBER EXAMINED:	10	0	0	10	10	0	10	0	0	10	10	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--TUBULE, MICROCONCRETION		10	0	0	10	10	0	10	0	0	10	9	0
--TUBULE CELLS, PIGMENT		10	0	0	10	10	0	10	0	0	10	10	0
TESTIS (TE)	NUMBER EXAMINED:	10	0	0	10	10	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--HYPERPLASIA, INTERSTITIAL CELL		10	0	0	10	1	0	0	0	0	0	0	0
--B-BENIGN INTERSTITIAL CELL TUMOR		9	0	0	10	3	0	0	0	0	0	0	0
--HYPOSPERMIA, UNILATERAL		4	0	0	4	0	0	0	0	0	0	0	0
--HYPOSPERMIA, BILATERAL		0	0	0	1	0	0	0	0	0	0	0	0
--ASPERMATOGENESIS, UNILATERAL		4	0	0	3	0	0	0	0	0	0	0	0
--ASPERMATOGENESIS, BILATERAL		0	0	0	0	10	0	0	0	0	0	0	0
EPIDIDYMIS (EP)	NUMBER EXAMINED:	10	0	0	10	10	0	0	0	0	0	0	0
	NOT REMARKABLE:	3	0	0	1	0	0	0	0	0	0	0	0
--IMMATURE/ABNORMAL SPERM FORMS		4	0	0	7	0	0	0	0	0	0	0	0
--HYPOSPERMIA		4	0	0	3	10	0	0	0	0	0	0	0
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	0	0	10	0	0	10	10	0
	NOT REMARKABLE:	0	0	0	0	0	0	7	0	0	4	3	0
--DILATATION		0	0	0	0	0	0	0	0	0	2	6	0
--HYPERPLASIA, CYSTIC ENDOMETRIAL		0	0	0	0	0	0	2	0	0	3	2	0
--B-ENDOMETRIAL STROMAL POLYP		0	0	0	0	0	0	2	0	0	2	2	0
BRAIN W/STEM (BR)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=4;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	15	0	0	15	15	0	15	0	0	15	15	0
		-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-
CORD, CERVICAL (CS)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0
PITUITARY (PI)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	1	10	0
	NOT REMARKABLE:	3	0	0	0	2	0	5	0	0	0	6	0
--INCREASED CASTRATION CELLS		0	0	0	0	7	0	0	0	0	0	0	0
--MICROCYST(S)		0	0	0	0	0	0	0	0	0	0	1	0
--ANGIECTASIS/SINUSOID ECTASIA		2	0	0	0	2	0	3	0	0	1	3	0
--FOCAL HYPERTROPHY		4	0	0	0	4	0	0	0	0	0	2	0
--FOCAL HYPERPLASIA		2	0	0	0	3	0	0	0	0	0	0	0
--B-ADENOMA		3	0	0	0	1	0	4	0	0	1	1	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	7	0	0	0	7	0	8	0	0	0	9	0
--FOCAL HYPERTROPHY		1	0	0	0	1	0	1	0	0	0	0	0
--FOCAL VACUOLIZATION		2	0	0	0	2	0	1	0	0	0	1	0
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	9	0	0	0	10	0	10	0	0	0	9	0
--UNILATERALLY EXAMINED		0	0	0	0	0	0	0	0	0	0	1	0
--HYPERPLASIA		1	0	0	0	0	0	0	0	0	0	0	0

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=4;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	15	0	0	15	15	0	15	0	0	15	15	0
THYROID (TY)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	4	0	0	0	7	0	5	0	0	0	6	0
--CONGESTION		0	0	0	0	1	0	0	0	0	0	0	0
--HYPERPLASIA, "C" CELL		6	0	0	0	2	0	4	0	0	0	4	0
--B-"C" CELL ADENOMA		0	0	0	0	0	0	1	0	0	0	0	0
PARATHYROID (PT)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0
TRACHEA (TR)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0
LUNG (LU)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	0	0	0	0	1	0	0	0	0	0	0	0
--PERIBRONCHIAL/PERIVASCULAR, INFILTRATION, LYMPHOID		10	0	0	0	9	0	10	0	0	0	10	0
--ALVEOLUS, MACROPHAGES, VACUOLATED		0	0	0	0	0	0	0	0	0	0	1	0
--ALVEOLUS/BRONCHUS EPITHELIAL HYPERPLASIA		0	0	0	0	1	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0	0	0	0	0
HEART (HT)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	1	0	0	0	3	0	3	0	0	0	5	0
--CARDIOMYOPATHY, DEGENERATIVE		9	0	0	0	7	0	7	0	0	0	5	0

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=4;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	MALE						FEMALE					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	15	0	0	15	15	0	15	0	0	15	15	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0
STOMACH, GL (ST)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	7	0
--EROSION		0	0	0	0	0	0	0	0	0	0	3	0
--EDEMA		0	0	0	0	0	0	0	0	0	0	1	0
DUODENUM (DU)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0
JEJUNUM (JE)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0
ILEUM (IL)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0
PANCREAS (PA)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	4	0	0	0	4	0	4	0	0	0	8	0
--INFLAMMATION, CHRONIC		4	0	0	0	1	0	5	0	0	0	2	0
--FOCAL ACINAR ATROPHY		3	0	0	0	1	0	3	0	0	0	0	0
--BASOPHILIC FOCUS		0	0	0	0	1	0	0	0	0	0	0	0
--ISLET CELL, HYPERPLASIA		1	0	0	0	0	0	0	0	0	0	0	0
--FOCAL ACINAR CELL HYPERPLASIA		0	0	0	0	3	0	0	0	0	0	0	0
--B-ACINAR CELL ADENOMA		0	0	0	0	1	0	0	0	0	0	0	0

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=4;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	MALE						FEMALE					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	15	0	0	15	15	0	15	0	0	15	15	0
CECUM (CE)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	9	0	10	0	0	0	10	0
--CONGESTION		0	0	0	0	1	0	0	0	0	0	0	0
COLON (CO)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	7	0	0	0	10	0	10	0	0	0	8	0
--NEMATODE PARASITE(S)		3	0	0	0	0	0	0	0	0	0	2	0
RECTUM (RE)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	7	0	0	0	8	0	8	0	0	0	8	0
--NEMATODE PARASITE(S)		3	0	0	0	2	0	2	0	0	0	2	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	9	0	0	0	10	0
--CONGESTION		0	0	0	0	0	0	1	0	0	0	0	0
PROSTATE (PR)	NUMBER EXAMINED:	10	0	0	0	10	0	0	0	0	0	0	0
	NOT REMARKABLE:	6	0	0	0	3	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC ACTIVE		4	0	0	0	7	0	0	0	0	0	0	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	10	0	0	1	10	0	0	0	0	0	0	0
	NOT REMARKABLE:	10	0	0	0	9	0	0	0	0	0	0	0
--DECREASED SECRETION		0	0	0	1	1	0	0	0	0	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=4;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	15	0	0	15	15	0	15	0	0	15	15	0
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	0	0	10	0	0	1	10	0
	NOT REMARKABLE:	0	0	0	0	0	0	10	0	0	0	10	0
--BURSA, CYST		0	0	0	0	0	0	0	0	0	1	0	0
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	0	0	10	0	0	0	10	0
	NOT REMARKABLE:	0	0	0	0	0	0	10	0	0	0	10	0
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	0	0	10	0	0	0	10	0
	NOT REMARKABLE:	0	0	0	0	0	0	10	0	0	0	10	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	10	0	0	0	9	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	9	0	10	0	0	0	10	0
THYMUS (TH)	NUMBER EXAMINED:	9	0	0	0	8	0	9	0	0	0	10	0
	NOT REMARKABLE:	8	0	0	0	7	0	8	0	0	0	9	0
--CONGESTION		1	0	0	0	0	0	0	0	0	0	0	0
--HYPERPLASIA, LYMPHORETICULAR		0	0	0	0	1	0	0	0	0	0	0	0
--MICROCYST(S)		0	0	0	0	0	0	1	0	0	0	1	0
AORTA, THORACIC (AO)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	10	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	10	0	0	0	10	0	10	0	0	0	10	0
	NOT REMARKABLE:	10	0	0	0	10	0	10	0	0	0	9	0
--DEGENERATION		0	0	0	0	0	0	0	0	0	0	1	0

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=4;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	15	0	0	15	15	0	15	0	0	15	15	0
^DEATH COMMENT (DC)	NUMBER EXAMINED:	15	0	0	15	15	0	15	0	0	15	15	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--SCHEDULED SACRIFICE		15	0	0	15	15	0	15	0	0	15	15	0
HEMATO NEOPLASIA (HN)	NUMBER EXAMINED:	10	0	0	10	10	0	10	0	0	10	10	0
	NOT REMARKABLE:	10	0	0	10	9	0	9	0	0	9	10	0
--M-MALIGNANT LEUKEMIA, MONONUCLEAR CELL		0	0	0	0	1	0	1	0	0	1	0	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	2	0	0	0	1	0	0	0	0	0	1	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--TAIL-CHRONIC ACTIVE INFLAMMATION		1	0	0	0	1	0	0	0	0	0	1	0
--M-FIBROSARCOMA		1	0	0	0	0	0	0	0	0	0	0	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
LN, OTHER (LN)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
EYE (EY)	NUMBER EXAMINED:	0	0	0	0	0	0	1	0	0	3	1	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--CORNEA, MINERALIZATION		0	0	0	0	0	0	0	0	0	1	0	0
--LENS, DEGENERATION		0	0	0	0	0	0	1	0	0	3	1	0

** CONTINUED ON NEXT PAGE **

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=4;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	15	0	0	15	15	0	15	0	0	15	15	0
** FROM PREVIOUS PAGE **													
EYE (EY)	NUMBER EXAMINED:	0	0	0	0	0	0	1	0	0	3	1	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--RETINA, DEGENERATION		0	0	0	0	0	0	1	0	0	3	1	0
PENIS (PE)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
BONE, OTHER (OB)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
SCROTUM (SC)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
PREPUTIAL GLAND (PG)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 10B
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=4;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	15	0	0	15	15	0	15	0	0	15	15	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
CLITORAL GLAND (CL)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0

** END OF LIST **

Table 10C
Histopathology Incidence Summary - Terminal Sacrifice
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Note: Dose level measured in ppm.

Key to Histopathology Incidence Summary

Symbols Prefacing Neoplastic Findings

B- = Primary, benign neoplasm
M- = Primary, malignant neoplasm
N- = Metastatic neoplasm
I- = Locally invasive neoplasm
X- = Other neoplasm (see Comment)

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	----------MALE----------						----------FEMALE----------					
GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-
** TOP OF LIST **												
LIVER (LI) ..... NUMBER EXAMINED:	45	35	43	38	40	40	45	42	45	42	40	38
NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--B-HEPATOCELLULAR ADENOMA	4	4	2	6	18	10	0	3	1	1	3	5
--M-HEPATOCELLULAR CARCINOMA	1	0	1	1	17	7	0	1	0	1	11	3
--LEUKEMIA ASSOCIATED HEPATOPATHY	1	1	6	12	5	11	4	7	2	5	5	5
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	7	6	10	19	14	20	9	13	5	8	10	9
--PIGMENT IN KUPFFER CELLS/HEPATOCYTES	0	0	0	1	33	8	0	0	0	0	15	1
--INCREASED CYTOPLASMIC EOSINOPHILIA	0	0	0	0	24	0	0	0	0	0	34	0
--DIFFUSE HEPATOCELLULAR ENLARGEMENT	0	0	0	0	23	0	0	0	0	0	31	0
--CONGESTION	0	0	0	0	0	0	0	1	0	0	1	0
--FOCAL HEMORRHAGE	1	1	1	0	2	0	0	0	0	2	1	0
--INFLAMMATION, CHRONIC	17	18	17	15	14	16	38	31	41	30	18	29
--FOCAL MONONUCLEAR INFILTRATION	0	2	0	3	2	2	1	0	0	0	0	0
--BILE DUCT, HYPERPLASIA	44	34	37	26	34	28	35	26	39	32	11	16
--BILE DUCT, INFLAMMATION, CHRONIC	44	34	37	25	35	28	39	30	40	34	25	31
--BILE DUCT, FIBROSIS	44	34	36	21	17	16	14	12	20	14	4	4
--CHOLANGIECTASIS	1	0	0	0	0	0	0	0	0	0	0	0
--CELLULAR ALTERATION, BASOPHILIC	44	33	37	23	22	23	38	35	39	24	4	11
--CELLULAR ALTERATION, EOSINOPHILIC	29	22	18	12	25	22	8	11	13	3	4	5
--FOCAL VACUOLIZATION	6	3	1	0	0	8	4	3	2	0	1	1
--INCREASED MITOTIC FIGURES	1	0	0	0	0	0	0	0	0	0	0	0
--INDIVIDUAL CELL DEGENERATION/NECROSIS	0	0	0	0	0	0	1	0	0	0	1	0
--FOCAL NECROSIS	1	1	3	2	3	2	4	4	2	6	5	1
--CENTRILOBULAR DEGENERATION/NECROSIS	0	0	0	0	0	0	0	0	0	1	0	0
--ARTIFACTUAL DISTORTION	0	1	1	0	0	0	0	0	0	0	0	0
--PROTRUSION OF HEPATIC PARENCHYMA (HERNIA)	1	1	2	3	0	1	1	2	1	3	3	0
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED	0	0	0	1	0	0	0	3	0	1	0	1
--SINUSOID ECTASIA/ANGIECTASIS	0	1	1	3	0	0	2	3	3	0	1	1
--SPONGIOSIS HEPATIS	3	2	3	10	11	2	0	0	0	1	0	1
--BILE DUCT, CYST	0	0	0	1	0	0	0	0	0	0	0	1
--N-MESOTHELIOMA	0	1	1	0	0	0	0	0	0	0	0	0
--ARTERITIS/PERIARTERITIS	0	0	0	0	0	0	0	1	0	0	0	0

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
SPLEEN (SP)	NUMBER EXAMINED:	40	35	39	35	35	36	40	42	41	37	34	33
	NOT REMARKABLE:	32	27	28	19	21	16	31	23	28	22	25	22
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		5	6	10	16	12	18	7	10	3	7	8	9
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED		3	0	1	1	2	2	1	5	0	3	0	1
--FIBROSIS		0	0	0	2	0	1	0	0	2	0	0	0
--INFARCT		0	0	0	3	1	0	0	0	0	0	1	0
--N-MESOTHELIOMA		0	2	1	1	0	0	0	0	0	0	0	0
--HYPERPLASIA, RETICULOENDOTHELIAL		0	0	0	1	0	0	1	0	1	0	0	0
--INCREASED PIGMENT		0	0	0	0	0	0	1	4	8	5	1	1
--M-HEMANGIOSARCOMA		0	0	0	0	0	0	1	0	0	0	0	0
KIDNEY (KD)	NUMBER EXAMINED:	40	35	39	35	37	36	40	42	40	37	36	35
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--RENAL PAPILLA, MINERALIZATION		7	13	17	18	31	32	13	12	13	9	14	13
--NEPHROPATHY, CHRONIC PROGRESSIVE		40	35	39	34	37	36	40	40	40	37	36	35
--TUBULE, MICROCONCRETION		40	35	39	33	37	35	39	41	40	37	34	35
--TUBULE CELLS, PIGMENT		40	35	39	35	37	36	40	42	40	37	36	35
--PELVIS, DILATATION		0	0	0	1	0	0	1	0	0	0	1	0
--PELVIS, INFLAMMATION		1	1	0	0	0	0	0	0	0	0	0	0
--CONGESTION		1	0	1	0	1	0	1	0	0	1	0	0
--MICROCALCULI IN RENAL PELVIS		11	16	12	15	9	10	25	32	22	26	16	8
--TRANSITIONAL CELL HYPERPLASIA		8	5	7	8	7	2	14	28	22	25	16	11
--CYST		0	1	1	0	0	2	0	0	2	0	0	1
--THROMBOSIS		1	0	0	0	0	0	0	0	0	0	0	0
--ARTERITIS		0	0	0	0	0	0	0	1	0	0	0	0
--INFLAMMATION, SUPPURATIVE		0	0	0	0	0	0	0	0	0	0	0	1
--TUBULE, SIMPLE HYPERPLASIA		1	0	0	0	0	0	0	0	0	0	0	0
--M-MALIGNANT MESENCHYMAL TUMOR		1	0	0	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA		0	0	1	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	1	5	4	2	4	1	3	0	4	1	2

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
TESTIS (TE)	NUMBER EXAMINED:	44	35	43	38	39	38	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--UNILATERALLY EXAMINED		0	0	0	0	1	0	0	0	0	0	0	0
--HYPERPLASIA, INTERSTITIAL CELL		2	1	2	1	2	0	0	0	0	0	0	0
--B-BENIGN INTERSTITIAL CELL TUMOR		41	34	43	37	12	11	0	0	0	0	0	0
--HYPOSPERMIA, UNILATERAL		8	2	3	0	0	0	0	0	0	0	0	0
--HYPOSPERMIA, BILATERAL		3	2	1	0	0	0	0	0	0	0	0	0
--ASPERMATOGENESIS, UNILATERAL		7	2	4	0	1	0	0	0	0	0	0	0
--ASPERMATOGENESIS, BILATERAL		32	30	38	38	37	38	0	0	0	0	0	0
--ARTERITIS/PERIARTERITIS		1	0	0	1	7	10	0	0	0	0	0	0
--NECROSIS		0	0	1	0	0	0	0	0	0	0	0	0
--M-MESOTHELIOMA		3	2	2	1	2	2	0	0	0	0	0	0
EPIDIDYMIS (EP)	NUMBER EXAMINED:	44	35	43	37	38	37	0	0	0	0	0	0
	NOT REMARKABLE:	3	2	0	0	0	0	0	0	0	0	0	0
--UNILATERALLY EXAMINED		0	0	0	0	1	0	0	0	0	0	0	0
--IMMATURE/ABNORMAL SPERM FORMS		7	2	3	0	0	0	0	0	0	0	0	0
--HYPOSPERMIA		39	33	42	37	38	37	0	0	0	0	0	0
--INFLAMMATION, CHRONIC		1	0	0	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA		1	1	2	1	2	2	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0	0	0	0	0
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	0	0	40	42	42	38	35	36
	NOT REMARKABLE:	0	0	0	0	0	0	13	9	10	11	8	7
--DILATATION		0	0	0	0	0	0	17	28	22	21	16	21
--HYPERPLASIA, CYSTIC ENDOMETRIAL		0	0	0	0	0	0	21	13	25	14	16	21
--INFLAMMATION, SUPPURATIVE		0	0	0	0	0	0	0	1	0	0	0	0
--FOCAL GLANDULAR HYPERPLASIA		0	0	0	0	0	0	0	0	0	0	1	0
--DECIDUOMA		0	0	0	0	0	0	0	0	0	0	1	0
--B-ENDOMETRIAL STROMAL POLYP		0	0	0	0	0	0	4	13	8	7	10	9

** CONTINUED ON NEXT PAGE **

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
** FROM PREVIOUS PAGE **													
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	0	0	40	42	42	38	35	36
	NOT REMARKABLE:	0	0	0	0	0	0	13	9	10	11	8	7
--M-CARCINOMA		0	0	0	0	0	0	0	2	1	0	0	0
--M-LEIOMYOSARCOMA		0	0	0	0	0	0	1	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	1	0	0	2	0	0
BRAIN W/STEM (BR)	NUMBER EXAMINED:	40	2	2	2	35	1	40	4	4	1	35	4
	NOT REMARKABLE:	38	0	0	0	31	0	36	0	0	0	28	1
--FOCAL HEMORRHAGE		0	0	0	0	1	0	0	0	0	0	0	0
--ENCEPHALOMALACIA		0	0	0	0	0	0	0	0	0	0	1	0
--COMPRESSION, VENTRAL		2	2	2	2	3	1	3	4	4	1	6	3
--VENTRICLE, DILATATION		0	0	0	0	0	0	3	2	0	0	1	1
--I-PITUITARY CARCINOMA		0	0	0	0	0	1	0	1	1	0	0	0
CORD, CERVICAL (CS)	NUMBER EXAMINED:	40	0	0	0	35	0	40	0	0	0	35	0
	NOT REMARKABLE:	40	0	0	0	35	0	40	0	0	0	35	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	40	0	0	0	35	0	40	0	0	0	35	0
	NOT REMARKABLE:	40	0	0	0	35	0	40	0	0	0	35	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	40	0	0	0	35	0	39	0	0	0	35	0
	NOT REMARKABLE:	40	0	0	0	34	0	38	0	0	0	35	0
--EPIDERMAL INCLUSION CYST		0	0	0	0	1	0	1	0	0	0	0	0
PITUITARY (PI)	NUMBER EXAMINED:	40	35	39	35	35	33	39	21	17	17	35	14
	NOT REMARKABLE:	10	13	14	10	3	3	5	1	0	0	8	0
--INCREASED CASTRATION CELLS		0	0	0	0	18	17	0	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
** FROM PREVIOUS PAGE **													
PITUITARY (PI)	NUMBER EXAMINED:	40	35	39	35	35	33	39	21	17	17	35	14
	NOT REMARKABLE:	10	13	14	10	3	3	5	1	0	0	8	0
--CONGESTION/HEMORRHAGE		2	1	0	4	0	3	0	2	0	2	2	0
--MICROCYST(S)		1	7	4	3	1	7	14	5	3	6	11	2
--ANGIECTASIS/SINUSOID ECTASIA		16	14	13	11	15	12	16	18	17	17	15	14
--FOCAL HYPERTROPHY		7	3	4	5	11	12	2	0	0	0	1	0
--FOCAL HYPERPLASIA		7	2	3	5	3	11	11	4	0	2	4	1
--B-ADENOMA		18	14	16	13	15	10	17	15	15	12	13	13
--M-CARCINOMA		0	0	0	0	0	1	0	1	1	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	1	2	1	0	0	0	1	0	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	40	1	3	1	36	0	40	1	2	1	35	0
	NOT REMARKABLE:	17	0	0	0	11	0	3	0	0	0	5	0
--CONGESTION		2	0	2	0	0	0	1	0	1	0	4	0
--ANGIECTASIS/SINUSOID ECTASIA		4	0	1	0	2	0	22	1	2	1	27	0
--FOCAL HYPERTROPHY		12	0	1	0	10	0	22	1	1	0	9	0
--FOCAL VACUOLIZATION		17	0	1	1	16	0	23	1	2	0	9	0
--DIFFUSE VACUOLIZATION		0	1	0	0	7	0	1	0	0	0	0	0
--ATROPHY, UNILATERAL		0	0	0	0	0	0	0	1	0	0	0	0
--FOCAL HYPERPLASIA		6	0	0	0	5	0	6	0	0	0	3	0
--CYST		0	0	0	0	2	0	0	0	0	0	0	0
--THROMBOSIS		0	0	0	0	0	0	0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	3	0	1	0	0	0	3	0
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	40	1	3	1	36	0	40	2	2	1	35	0
	NOT REMARKABLE:	19	0	2	1	27	0	39	2	1	0	34	0
--UNILATERALLY EXAMINED		0	0	0	0	1	0	0	0	0	0	0	0
--HYPERPLASIA		17	0	0	0	5	0	1	0	0	0	1	0
--B-BENIGN PHEOCHROMOCYTOMA		4	1	1	0	1	0	0	0	1	0	1	0
--M-MALIGNANT PHEOCHROMOCYTOMA		1	0	0	0	0	0	0	0	0	1	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	MALE						FEMALE					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
** FROM PREVIOUS PAGE **													
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	40	1	3	1	36	0	40	2	2	1	35	0
	NOT REMARKABLE:	19	0	2	1	27	0	39	2	1	0	34	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	2	0	0	0	0	0	0	0
THYROID (TY)	NUMBER EXAMINED:	40	0	0	0	35	1	39	2	0	0	35	2
	NOT REMARKABLE:	17	0	0	0	10	0	6	1	0	0	7	0
--CONGESTION		0	0	0	0	0	0	0	0	0	0	1	0
--FOLLICLE, CYST		2	0	0	0	1	0	2	0	0	0	5	0
--HYPERPLASIA, "C" CELL		16	0	0	0	14	1	28	0	0	0	22	1
--B-"C" CELL ADENOMA		7	0	0	0	9	0	4	0	0	0	4	0
--M-"C" CELL CARCINOMA		1	0	0	0	1	0	2	1	0	0	0	1
--B-FOLLICULAR CELL ADENOMA		0	0	0	0	4	0	0	0	0	0	1	0
--M-FOLLICULAR CELL CARCINOMA		0	0	0	0	0	1	0	0	0	0	0	1
PARATHYROID (PT)	NUMBER EXAMINED:	39	0	0	0	35	1	39	1	0	0	34	1
	NOT REMARKABLE:	39	0	0	0	35	1	39	1	0	0	33	1
--B-ADENOMA		0	0	0	0	0	0	0	0	0	0	1	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	40	0	0	0	35	0	39	0	0	0	35	0
	NOT REMARKABLE:	40	0	0	0	35	0	39	0	0	0	34	0
--INFLAMMATION, CHRONIC		0	0	0	0	0	0	0	0	0	0	1	0
TRACHEA (TR)	NUMBER EXAMINED:	40	0	0	0	35	0	39	0	0	0	35	0
	NOT REMARKABLE:	40	0	0	0	34	0	39	0	0	0	35	0
--INFLAMMATION, CHRONIC		0	0	0	0	1	0	0	0	0	0	0	0

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
LUNG (LU)	NUMBER EXAMINED:	40	0	1	3	35	6	40	0	0	2	35	0
	NOT REMARKABLE:	0	0	0	0	1	0	1	0	0	0	1	0
--CONGESTION		0	0	0	0	0	0	0	0	0	1	1	0
--HEMORRHAGE		0	0	0	2	0	1	2	0	0	0	0	0
--PERIBRONCHIAL/PERIVASCULAR, INFILTRATION, LYMPHOID		40	0	1	3	32	5	39	0	0	1	31	0
--ALVEOLUS, MACROPHAGES, VACUOLATED		1	0	0	0	2	1	4	0	0	1	11	0
--FOCAL PNEUMONITIS		1	0	0	2	1	2	3	0	0	1	2	0
--ALVEOLUS/BRONCHUS EPITHELIAL HYPERPLASIA		0	0	0	0	0	0	0	0	0	1	0	0
--B-ALVEOLAR/BRONCHIOLAR ADENOMA		1	0	0	0	0	0	1	0	0	0	0	0
--M-ALVEOLAR/BRONCHIOLAR CARCINOMA		2	0	0	0	0	0	0	0	0	0	0	0
--N-"C" CELL CARCINOMA		1	0	0	0	1	0	0	0	0	0	0	0
--N-HEPATOCELLULAR CARCINOMA		0	0	0	0	0	1	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		6	0	1	3	13	5	7	0	0	1	7	0
HEART (HT)	NUMBER EXAMINED:	40	0	0	0	35	1	39	0	0	0	35	0
	NOT REMARKABLE:	0	0	0	0	0	0	1	0	0	0	2	0
--CARDIOMYOPATHY, DEGENERATIVE		40	0	0	0	35	1	38	0	0	0	33	0
--ATRIUM, THROMBOSIS		0	0	0	0	0	1	0	0	0	0	0	0
--MINERALIZATION OF CORONARY ARTERIES		0	0	0	0	1	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	3	1	0	0	0	0	1	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	40	1	2	0	35	1	40	2	0	4	35	0
	NOT REMARKABLE:	38	1	2	0	33	1	36	2	0	2	34	0
--HYPERPLASIA		2	0	0	0	0	0	4	0	0	2	1	0
--EROSION		0	0	0	0	1	0	0	0	0	0	1	0
--ULCER		0	0	0	0	0	0	0	0	0	2	0	0
--EDEMA		0	0	0	0	1	0	0	0	0	2	1	0
--MINERALIZATION		0	0	0	0	1	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	0	0	0	1	0	0

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
STOMACH, GL (ST)	NUMBER EXAMINED:	40	1	2	0	35	1	40	2	0	4	35	0
	NOT REMARKABLE:	40	1	2	0	28	0	39	1	0	2	34	0
--FOCAL HEMORRHAGE		0	0	0	0	0	0	0	0	0	1	0	0
--EROSION		0	0	0	0	5	1	1	1	0	2	1	0
--EDEMA		0	0	0	0	1	0	0	0	0	1	0	0
--MINERALIZATION		0	0	0	0	1	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	0	0	0	1	0	0
DUODENUM (DU)	NUMBER EXAMINED:	44	0	7	5	40	5	45	0	5	5	40	4
	NOT REMARKABLE:	44	0	6	5	40	5	45	0	5	5	40	4
--INFLAMMATION, CHRONIC		0	0	1	0	0	0	0	0	0	0	0	0
JEJUNUM (JE)	NUMBER EXAMINED:	40	0	1	1	35	0	40	0	0	0	35	0
	NOT REMARKABLE:	40	0	1	0	35	0	40	0	0	0	35	0
--N-MESOTHELIOMA		0	0	0	1	0	0	0	0	0	0	0	0
ILEUM (IL)	NUMBER EXAMINED:	40	0	1	1	35	0	40	0	0	0	34	0
	NOT REMARKABLE:	40	0	1	0	35	0	40	0	0	0	34	0
--N-MESOTHELIOMA		0	0	0	1	0	0	0	0	0	0	0	0
PANCREAS (PA)	NUMBER EXAMINED:	40	2	2	1	35	0	40	0	0	1	35	0
	NOT REMARKABLE:	22	0	0	0	11	0	21	0	0	1	19	0
--EDEMA		0	0	0	0	0	0	1	0	0	0	1	0
--INFLAMMATION, CHRONIC		10	0	0	0	7	0	8	0	0	0	5	0
--FOCAL ACINAR ATROPHY		13	0	0	0	6	0	9	0	0	0	5	0
--BASOPHILIC FOCUS		0	0	0	0	4	0	1	0	0	0	5	0
--MICROCYST(S)		0	0	0	0	1	0	0	0	0	0	0	0
--ISLET CELL, HYPERPLASIA		0	0	0	0	1	0	0	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
** FROM PREVIOUS PAGE **													
PANCREAS (PA)	NUMBER EXAMINED:	40	2	2	1	35	0	40	0	0	1	35	0
	NOT REMARKABLE:	22	0	0	0	11	0	21	0	0	1	19	0
--B-ISLET CELL ADENOMA		2	0	0	0	5	0	1	0	0	0	0	0
--M-ISLET CELL CARCINOMA		0	0	1	0	0	0	0	0	0	0	0	0
--FOCAL ACINAR CELL HYPERPLASIA		1	1	0	0	5	0	0	0	0	0	1	0
--B-ACINAR CELL ADENOMA		0	0	0	0	4	0	0	0	0	0	2	0
--N-MESOTHELIOMA		0	2	1	1	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	3	0	0	0	0	0	0	0
CECUM (CE)	NUMBER EXAMINED:	40	0	1	0	35	0	40	0	0	0	35	0
	NOT REMARKABLE:	39	0	1	0	33	0	39	0	0	0	35	0
--HEMORRHAGE		0	0	0	0	1	0	0	0	0	0	0	0
--EDEMA		0	0	0	0	1	0	0	0	0	0	0	0
--NEMATODE PARASITE(S)		1	0	0	0	0	0	0	0	0	0	0	0
--INFLAMMATION, ACUTE		0	0	0	0	0	0	1	0	0	0	0	0
COLON (CO)	NUMBER EXAMINED:	40	0	1	0	35	0	40	0	0	0	34	0
	NOT REMARKABLE:	37	0	1	0	31	0	33	0	0	0	34	0
--NEMATODE PARASITE(S)		3	0	0	0	4	0	7	0	0	0	0	0
RECTUM (RE)	NUMBER EXAMINED:	40	0	0	0	35	0	40	0	0	0	35	0
	NOT REMARKABLE:	27	0	0	0	29	0	37	0	0	0	30	0
--NEMATODE PARASITE(S)		13	0	0	0	6	0	3	0	0	0	5	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	39	0	0	1	34	0	40	0	0	2	35	0
	NOT REMARKABLE:	38	0	0	1	32	0	37	0	0	0	29	0
--CONGESTION		0	0	0	0	0	0	1	0	0	1	0	0
--LYMPHANGIECTASIS		1	0	0	0	0	0	0	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
** FROM PREVIOUS PAGE **													
LN, MESENTERIC (MS)	NUMBER EXAMINED:	39	0	0	1	34	0	40	0	0	2	35	0
	NOT REMARKABLE:	38	0	0	1	32	0	37	0	0	0	29	0
--HYPERPLASIA, LYMPHORETICULAR		0	0	0	0	0	0	1	0	0	0	4	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	2	0	2	0	0	2	2	0
PROSTATE (PR)	NUMBER EXAMINED:	39	0	0	0	35	0	0	0	0	0	0	0
	NOT REMARKABLE:	11	0	0	0	9	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC ACTIVE		27	0	0	0	26	0	0	0	0	0	0	0
--HYPERPLASIA		1	0	0	0	3	0	0	0	0	0	0	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	41	25	30	24	36	10	0	0	0	0	0	0
	NOT REMARKABLE:	10	2	1	0	22	1	0	0	0	0	0	0
--DECREASED SECRETION		31	22	29	24	14	9	0	0	0	0	0	0
--INCREASED SECRETION		0	1	0	0	0	0	0	0	0	0	0	0
--FOCAL HYPERPLASIA		0	1	0	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA		0	0	1	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	1	0	0	1	1	0	0	0	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	39	0	0	0	35	0	40	0	0	0	35	0
	NOT REMARKABLE:	39	0	0	0	35	0	40	0	0	0	35	0
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	0	0	40	3	3	6	35	6
	NOT REMARKABLE:	0	0	0	0	0	0	10	0	0	1	13	0
--CONGESTION		0	0	0	0	0	0	0	0	0	1	0	0
--MEDULLARY TUBULE HYPERPLASIA		0	0	0	0	0	0	25	2	3	4	16	3
--FOLLICLE, CYST		0	0	0	0	0	0	5	1	1	1	1	1
--BURSA, CYST		0	0	0	0	0	0	3	1	1	3	4	2
--INFLAMMATION, CHRONIC		0	0	0	0	0	0	1	0	0	1	2	0

** CONTINUED ON NEXT PAGE **

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
** FROM PREVIOUS PAGE **													
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	0	0	40	3	3	6	35	6
	NOT REMARKABLE:	0	0	0	0	0	0	10	0	0	1	13	0
--ABSCESS		0	0	0	0	0	0	0	0	0	0	0	1
--B-BENIGN GRANULOSA/THECA CELL TUMOR		0	0	0	0	0	0	2	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	1	0	0	1	2	0
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	0	0	40	6	4	4	35	3
	NOT REMARKABLE:	0	0	0	0	0	0	39	5	4	4	34	3
--FIBROSIS		0	0	0	0	0	0	1	0	0	0	1	0
--M-MALIGNANT SCHWANNOMA		0	0	0	0	0	0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	1	0	0	0	0	0
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	0	0	40	1	2	0	35	0
	NOT REMARKABLE:	0	0	0	0	0	0	40	1	1	0	35	0
--HEMORRHAGE		0	0	0	0	0	0	0	0	1	0	0	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	40	0	0	0	35	0	40	0	0	0	35	0
	NOT REMARKABLE:	40	0	0	0	34	0	40	0	0	0	34	0
--EDEMA		0	0	0	0	1	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC		0	0	0	0	0	0	0	0	0	0	1	0
THYMUS (TH)	NUMBER EXAMINED:	32	0	0	0	27	1	31	0	0	2	20	0
	NOT REMARKABLE:	27	0	0	0	25	0	25	0	0	0	19	0
--CONGESTION		0	0	0	0	0	0	1	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	1	1	0	0	2	0	0
--MICROCYST(S)		5	0	0	0	1	0	5	0	0	0	1	0

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	MALE						FEMALE					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
AORTA, THORACIC (AO)	NUMBER EXAMINED:	40	0	0	0	34	0	40	0	0	0	35	0
	NOT REMARKABLE:	40	0	0	0	33	0	40	0	0	0	34	0
--MEDIA, MINERALIZATION		0	0	0	0	1	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	0	0	0	0	1	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	40	0	0	0	34	0	40	0	0	0	35	0
	NOT REMARKABLE:	36	0	0	0	28	0	38	0	0	0	32	0
--DEGENERATION		4	0	0	0	6	0	2	0	0	0	3	0
^DEATH COMMENT (DC)	NUMBER EXAMINED:	45	40	43	38	40	40	45	47	45	42	40	38
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--SCHEDULED SACRIFICE		45	40	43	38	40	40	45	47	45	42	40	38
HEMATO NEOPLASIA (HN)	NUMBER EXAMINED:	45	35	43	38	40	40	45	42	45	42	40	38
	NOT REMARKABLE:	38	29	33	19	25	20	36	29	40	34	30	29
--M-MALIGNANT LEUKEMIA, MONONUCLEAR CELL		7	6	10	19	14	20	8	13	5	8	10	9
--M-HISTIOCYTIC SARCOMA		0	0	0	0	1	0	1	0	0	0	0	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	10	13	13	12	9	12	1	1	4	1	4	5
	NOT REMARKABLE:	0	1	1	1	0	1	0	0	1	0	0	0
--TAIL-CHRONIC ACTIVE INFLAMMATION		8	7	8	9	9	8	0	0	1	0	4	4
--FOOT/PAW-PODODERMATITIS		2	0	2	0	0	0	0	0	0	0	0	0
--M-FIBROSARCOMA		0	0	0	0	0	0	0	1	0	0	0	0
--TAIL-NECROSIS		0	0	1	0	0	0	0	0	0	0	0	0
--B-KERATOACANTHOMA		0	1	0	0	0	0	0	0	0	0	0	1
--EPIDERMAL CYST		1	0	0	1	0	0	0	0	1	0	0	0
--B-BASAL CELL ADENOMA		1	0	0	0	0	0	0	0	0	0	0	0
--B-SQUAMOUS CELL PAPILLOMA		0	1	0	1	0	1	0	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	MALE						FEMALE					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
** FROM PREVIOUS PAGE **													
SKIN, OTHER (SS)	NUMBER EXAMINED:	10	13	13	12	9	12	1	1	4	1	4	5
	NOT REMARKABLE:	0	1	1	1	0	1	0	0	1	0	0	0
--INFLAMMATION, CHRONIC ACTIVE		0	1	1	0	0	1	0	0	0	0	0	0
--ACANTHOSIS		0	1	1	0	0	1	0	0	0	0	0	0
--M-SCHWANNOMA		0	1	0	0	0	0	0	0	0	0	0	0
--ULCER		0	0	0	0	0	1	0	0	0	0	0	0
--M-BASAL CELL CARCINOMA		0	0	0	0	0	0	1	0	1	0	0	0
--ABSCESS		0	0	0	0	0	0	0	0	0	1	0	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	0	0	0	0	0	0	1	0	0	1	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--HYPERPLASIA, LYMPHORETICULAR		0	0	0	0	0	0	0	0	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	1	0	0	0	0	0
LN, OTHER (LN)	NUMBER EXAMINED:	0	0	0	0	1	1	1	0	0	1	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--CONGESTION		0	0	0	0	0	0	1	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	1	1	0	0	1	0	0
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	2	0	1	0	2	4	1	0	0	2	1	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--EDEMA		0	0	0	0	0	0	0	0	0	1	0	0
--ABSCESS		1	0	0	0	0	0	0	0	0	0	0	0
--B-LIPOMA		0	0	0	0	1	0	0	0	0	0	1	0
--B-FIBROMA		1	0	1	0	0	3	0	0	0	0	0	0
--M-FIBROSARCOMA		0	0	0	0	0	1	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	1	0	0	2	0	0

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
EYE (EY)	NUMBER EXAMINED:	5	8	8	5	7	8	4	6	10	6	4	7
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--UNILATERALLY EXAMINED		0	0	0	1	0	0	0	0	0	0	0	0
--GLOBE RUPTURED, UNILATERAL		0	0	3	0	1	0	0	1	1	0	3	1
--HEMORRHAGE		0	0	0	0	0	0	0	0	0	1	0	0
--KERATITIS		0	2	2	0	3	7	2	0	2	0	0	4
--HYPOPYON		0	0	0	1	0	0	0	0	0	0	0	0
--CORNEA, MINERALIZATION		2	6	5	2	4	7	4	4	8	3	3	6
--SCLERA, MINERALIZATION		3	5	7	3	2	4	1	5	6	2	1	2
--LENS, DEGENERATION		5	7	4	4	5	8	4	1	5	2	0	4
--RETINA, DEGENERATION		5	6	5	4	5	7	4	1	5	2	0	5
--PANOPHTHALMITIS, UNILATERAL		0	0	1	0	0	0	0	1	0	0	2	0
PENIS (PE)	NUMBER EXAMINED:	0	0	0	0	1	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	1	0	0	0	0	0	0	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	1	2	1	1	3	0	0	0	0	1	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--CIRCUMSCRIBED FAT NECROSIS		0	0	0	0	1	0	0	0	0	1	0	0
--N-NEPHROBLASTOMA		0	1	0	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA		1	1	1	1	1	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0	0	1	0	0
BONE, OTHER (OB)	NUMBER EXAMINED:	0	0	0	0	0	0	0	1	0	0	0	1
	NOT REMARKABLE:	0	0	0	0	0	0	0	1	0	0	0	1

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
MAMMARY, MALE (MM)	NUMBER EXAMINED:	4	1	1	1	1	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	1	1	0	0	0	0	0	0	0	0	0
--GALACTOCELE		2	0	0	1	0	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC		1	0	0	0	0	0	0	0	0	0	0	0
--B-FIBROADENOMA		2	0	0	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0	0	0	0	0
SCROTUM (SC)	NUMBER EXAMINED:	0	2	0	1	1	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA		0	2	0	1	1	0	0	0	0	0	0	0
PREPUTIAL GLAND (PG)	NUMBER EXAMINED:	1	0	1	0	0	1	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC ACTIVE		1	0	0	0	0	1	0	0	0	0	0	0
--B-ADENOMA		0	0	0	0	0	1	0	0	0	0	0	0
--M-CARCINOMA		0	0	1	0	0	0	0	0	0	0	0	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	0	0	0	0	0	0	0	2	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--M-ZYMBAL'S GLAND CARCINOMA		0	0	0	0	0	0	0	1	0	0	0	0
--M-SQUAMOUS CELL CARCINOMA		0	0	0	0	0	0	0	1	0	0	0	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	0	0	4	12	7	8	2	3
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	1	1	1
--GALACTOCELE		0	0	0	0	0	0	3	7	4	1	0	0
--INFLAMMATION, CHRONIC		0	0	0	0	0	0	1	1	0	0	0	0
--ACTIVE MAMMARY TISSUE		0	0	0	0	0	0	0	6	4	0	0	1
HYPERPLASIA		0	0	0	0	0	0	1	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10C
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	MALE						FEMALE					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	45	40	43	38	40	40	45	47	45	42	40	38
** FROM PREVIOUS PAGE **													
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	0	0	4	12	7	8	2	3
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	1	1	1
--B-FIBROADENOMA		0	0	0	0	0	0	0	3	2	6	1	1
--M-CARCINOMA		0	0	0	0	0	0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	1	0	0	0	0	0
CLITORAL GLAND (CL)	NUMBER EXAMINED:	0	0	0	0	0	0	3	0	1	1	0	1
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--ABSCESS		0	0	0	0	0	0	2	0	0	0	0	0
--B-ADENOMA		0	0	0	0	0	0	0	0	1	0	0	0
--M-CARCINOMA		0	0	0	0	0	0	1	0	0	1	0	1
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	1	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC ACTIVE		0	0	0	0	0	0	0	0	1	0	0	0
** END OF LIST **													

Table 10D
Expanded Histopathology Incidence Summary - Liver, Kidney, and Pituitary
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Note: Dose levels were measured in ppm.

Key to Expanded Histopathology Incidence Summary

Symbols Prefacing Neoplastic Findings

B- = Primary, benign neoplasm
M- = Primary, malignant neoplasm
N- = Metastatic neoplasm
I- = Locally invasive neoplasm
X- = Other neoplasm (see Comment)

Symbols Used in Expanded Table

-> = Finding not present
P> = Finding present
+> = Neoplastic finding present
1> = Minimal
2> = Slight
3> = Moderate
4> = Moderately severe
5> = Severe
TL> = Total
MN> = Mean of graded findings

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

ORGAN/TISSUE EXAMINED		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
		-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-
** TOP OF LIST **													
LIVER (LI)	NUMBER EXAMINED:	80	50	55	65	80	55	80	50	55	65	80	55
	NOT REMARKABLE:	3	0	0	0	0	0	2	0	0	0	0	0
--B-HEPATOCELLULAR ADENOMA	->	76	45	52	57	59	43	80	47	54	63	72	49
	+>	4	5	3	8	21	12	0	3	1	2	8	6
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
--M-HEPATOCELLULAR CARCINOMA	->	79	50	54	62	56	48	80	49	55	64	66	51
	+>	1	0	1	3	24	7	0	1	0	1	14	4
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
--LEUKEMIA ASSOCIATED HEPATOPATHY	->	72	42	43	40	64	35	71	40	48	52	69	41
	P>	8	8	12	25	16	20	9	10	7	12	11	14
	TL>	80	50	55	65	80	55	80	50	55	64	80	55
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	->	65	37	39	33	53	26	65	33	44	49	63	37
	+>	15	13	16	32	27	29	15	17	11	16	17	18
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
--PIGMENT IN KUPFFER CELLS/HEPATOCYTES	->	80	50	55	64	36	44	80	50	55	64	56	52
	1>	0	0	0	1	16	9	0	0	0	1	24	2
	2>	0	0	0	0	28	2	0	0	0	0	0	1
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.0	0.0	0.0	0.0	0.9	0.2	0.0	0.0	0.0	0.0	0.3	0.1
--INCREASED CYTOPLASMIC EOSINOPHILIA	->	80	50	55	65	33	55	80	50	55	65	18	55
	P>	0	0	0	0	47	0	0	0	0	0	62	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

ORGAN/TISSUE EXAMINED		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
LIVER (LI)	NUMBER EXAMINED:	80	50	55	65	80	55	80	50	55	65	80	55
	NOT REMARKABLE:	3	0	0	0	0	0	2	0	0	0	0	0
--DIFFUSE HEPATOCELLULAR ENLARGEMENT	->	80	50	55	64	35	54	80	50	55	64	22	53
	1>	0	0	0	0	0	0	0	0	0	0	2	0
	2>	0	0	0	1	29	0	0	0	0	0	41	0
	3>	0	0	0	0	16	1	0	0	0	1	15	2
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.0	0.0	0.0	0.0	1.3	0.1	0.0	0.0	0.0	0.0	1.6	0.1
--CENTRILOBULAR TO MIDZONAL HEPATOCELLULAR ENLARGEMENT	->	80	50	55	65	80	55	80	50	55	65	80	55
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
--CONGESTION	->	76	43	50	57	74	50	78	47	54	61	77	52
	P>	4	7	5	8	6	5	2	3	1	4	3	3
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
--FOCAL HEMORRHAGE	->	78	49	54	64	77	55	80	50	55	63	79	55
	P>	2	1	1	1	3	0	0	0	0	2	1	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
--INFLAMMATION, CHRONIC	->	56	32	35	40	61	37	29	15	12	24	49	22
	1>	21	13	17	20	15	11	32	19	27	23	27	24
	2>	3	4	3	5	3	6	18	16	14	17	4	7
	3>	0	1	0	0	0	1	1	0	2	1	0	2
	4>	0	0	0	0	1	0	0	0	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.3	0.5	0.4	0.5	0.3	0.5	0.9	1.0	1.1	0.9	0.4	0.8

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

ORGAN/TISSUE EXAMINED		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
		-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-
** FROM PREVIOUS PAGE **													
LIVER (LI)	NUMBER EXAMINED:	80	50	55	65	80	55	80	50	55	65	80	55
	NOT REMARKABLE:	3	0	0	0	0	0	2	0	0	0	0	0
--FOCAL MONONUCLEAR INFILTRATION	->	68	47	55	62	62	53	66	50	55	65	70	55
	1>	12	3	0	3	17	2	14	0	0	0	10	0
	2>	0	0	0	0	1	0	0	0	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.2	0.1	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.1	0.0
--BILE DUCT, HYPERPLASIA	->	23	8	12	25	36	21	36	21	12	20	65	36
	1>	2	0	1	18	40	28	39	23	33	33	13	17
	2>	46	35	41	22	4	6	5	6	10	12	2	2
	3>	9	7	1	0	0	0	0	0	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	1.5	1.8	1.6	1.0	0.6	0.7	0.6	0.7	1.0	0.9	0.2	0.4
--BILE DUCT, INFLAMMATION, CHRONIC	->	24	8	12	26	32	23	31	16	11	17	45	19
	1>	6	5	5	23	41	28	41	31	32	33	32	30
	2>	50	37	38	16	7	4	8	3	12	15	3	6
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	1.3	1.6	1.5	0.8	0.7	0.7	0.7	0.7	1.0	1.0	0.5	0.8
--BILE DUCT, FIBROSIS	->	24	8	14	32	59	36	63	36	32	42	76	49
	1>	15	10	11	30	21	19	15	12	18	20	4	5
	2>	41	30	30	3	0	0	2	2	5	3	0	1
	3>	0	2	0	0	0	0	0	0	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	1.2	1.5	1.3	0.6	0.3	0.3	0.2	0.3	0.5	0.4	0.1	0.1

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN/TISSUE EXAMINED	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
LIVER (LI)	NUMBER EXAMINED:	80	50	55	65	80	55	80	50	55	65	80	55
	NOT REMARKABLE:	3	0	0	0	0	0	2	0	0	0	0	0
--CHOLANGIECTASIS	->	78	50	55	65	80	55	80	50	55	65	80	55
	1>	1	0	0	0	0	0	0	0	0	0	0	0
	2>	1	0	0	0	0	0	0	0	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
--CELLULAR ALTERATION, BASOPHILIC	->	25	12	13	35	55	29	34	13	13	37	74	43
	1>	12	4	9	16	16	19	22	15	21	15	6	10
	2>	37	29	30	13	8	6	20	21	18	12	0	1
	3>	6	5	3	1	1	1	4	1	3	1	0	1
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	1.3	1.5	1.4	0.7	0.4	0.6	0.9	1.2	1.2	0.6	0.1	0.3
--CELLULAR ALTERATION, EOSINOPHILIC	->	46	26	37	50	47	31	71	38	41	61	76	50
	1>	23	14	14	12	24	11	4	5	11	3	2	4
	2>	8	9	4	2	8	8	4	6	3	1	2	1
	3>	3	1	0	1	0	5	1	1	0	0	0	0
	4>	0	0	0	0	1	0	0	0	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.6	0.7	0.4	0.3	0.6	0.8	0.2	0.4	0.3	0.1	0.1	0.1
--FOCAL VACUOLIZATION	->	73	46	54	65	79	47	76	47	53	65	79	54
	1>	6	4	1	0	1	7	1	2	1	0	0	0
	2>	1	0	0	0	0	1	2	1	1	0	1	1
	3>	0	0	0	0	0	0	1	0	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.1	0.1	0.0	0.0	0.0	0.2	0.1	0.1	0.1	0.0	0.0	0.0

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

ORGAN/TISSUE EXAMINED		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
LIVER (LI)	NUMBER EXAMINED:	80	50	55	65	80	55	80	50	55	65	80	55
	NOT REMARKABLE:	3	0	0	0	0	0	2	0	0	0	0	0
--CENTRILOBULAR TO MIDZONAL VACUOLIZATION	->	80	50	55	65	80	55	80	50	55	65	80	54
	3>	0	0	0	0	0	0	0	0	0	0	0	1
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
--DIFFUSE VACUOLIZATION	->	79	49	55	65	80	55	80	50	55	65	80	55
	1>	0	1	0	0	0	0	0	0	0	0	0	0
	2>	1	0	0	0	0	0	0	0	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
--INCREASED MITOTIC FIGURES	->	79	50	55	65	75	55	80	50	55	65	75	55
	1>	1	0	0	0	1	0	0	0	0	0	2	0
	2>	0	0	0	0	4	0	0	0	0	0	3	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0
--INDIVIDUAL CELL DEGENERATION/NECROSIS	->	80	50	55	64	80	54	79	50	55	65	77	55
	1>	0	0	0	0	0	1	0	0	0	0	3	0
	2>	0	0	0	1	0	0	1	0	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
--FOCAL NECROSIS	->	77	48	50	62	71	49	75	46	53	57	75	54
	1>	3	0	4	3	7	3	4	3	1	6	3	1
	2>	0	1	1	0	2	2	1	1	1	2	2	0
	4>	0	1	0	0	0	1	0	0	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.0	0.1	0.1	0.0	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.0

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

ORGAN/TISSUE EXAMINED	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	MALE						FEMALE					
GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **												
LIVER (LI) NUMBER EXAMINED:	80	50	55	65	80	55	80	50	55	65	80	55
NOT REMARKABLE:	3	0	0	0	0	0	2	0	0	0	0	0
--CENTRILOBULAR DEGENERATION/NECROSIS ->	80	49	55	64	80	55	80	49	55	62	79	52
3>	0	1	0	1	0	0	0	1	0	1	0	2
4>	0	0	0	0	0	0	0	0	0	1	0	1
5>	0	0	0	0	0	0	0	0	0	1	1	0
TL>	80	50	55	65	80	55	80	50	55	65	80	55
MN>	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.1	0.2
--ARTIFACTUAL DISTORTION ->	79	49	54	65	80	55	79	50	55	65	80	55
P>	1	1	1	0	0	0	1	0	0	0	0	0
TL>	80	50	55	65	80	55	80	50	55	65	80	55
--PROTRUSION OF HEPATIC PARENCHYMA (HERNIA) ->	77	49	53	62	80	54	79	48	54	62	77	55
P>	3	1	2	3	0	1	1	2	1	3	3	0
TL>	80	50	55	65	80	55	80	50	55	65	80	55
--INFARCTED LOBE/PROCESS ->	80	50	55	65	80	55	80	50	55	65	80	55
TL>	80	50	55	65	80	55	80	50	55	65	80	55
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED ->	80	50	55	64	80	55	80	46	54	62	80	53
1>	0	0	0	1	0	0	0	3	1	1	0	1
2>	0	0	0	0	0	0	0	1	0	2	0	1
TL>	80	50	55	65	80	55	80	50	55	65	80	55
MN>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1
--SINUSOID ECTASIA/ANGIECTASIS ->	80	49	54	62	80	55	78	47	52	63	79	54
P>	0	1	1	3	0	0	2	3	3	2	1	1
TL>	80	50	55	65	80	55	80	50	55	65	80	55

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN/TISSUE EXAMINED	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
LIVER (LI)	NUMBER EXAMINED:	80	50	55	65	80	55	80	50	55	65	80	55
	NOT REMARKABLE:	3	0	0	0	0	0	2	0	0	0	0	0
--SPONGIOSIS HEPATIS	->	77	47	52	54	69	52	80	50	55	64	79	54
	1>	2	0	1	7	7	2	0	0	0	1	1	1
	2>	1	3	2	4	4	1	0	0	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
	MN>	0.1	0.1	0.1	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0
--BILE DUCT, CYST	->	80	50	55	64	80	55	80	50	55	65	80	54
	P>	0	0	0	1	0	0	0	0	0	0	0	1
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
--N-MESOTHELIOMA	->	80	49	54	65	80	55	80	50	55	65	79	55
	+>	0	1	1	0	0	0	0	0	0	0	1	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
--ARTERITIS/PERIARTERITIS	->	80	50	55	65	80	55	80	49	55	65	80	55
	P>	0	0	0	0	0	0	0	1	0	0	0	0
	TL>	80	50	55	65	80	55	80	50	55	65	80	55
KIDNEY (KD)	NUMBER EXAMINED:	60	50	51	62	62	51	60	50	50	60	61	52
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--RENAL PAPILLA, MINERALIZATION	->	48	31	24	31	17	6	43	35	35	47	41	28
	1>	12	18	26	29	31	31	17	15	15	13	20	24
	2>	0	1	1	2	14	14	0	0	0	0	0	0
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
	MN>	0.2	0.4	0.5	0.5	1.0	1.2	0.3	0.3	0.3	0.2	0.3	0.5

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	55								
KIDNEY (KD)	NUMBER EXAMINED:	60	50	51	62	62	51	60	50	50	60	61	52
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--RENAL PAPILLA, MINERALIZATION	->	48	31	24	31	17	6	43	35	35	47	41	28
	1>	12	18	26	29	31	31	17	15	15	13	20	24
	2>	0	1	1	2	14	14	0	0	0	0	0	0
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
	MN>	0.2	0.4	0.5	0.5	1.0	1.2	0.3	0.3	0.3	0.2	0.3	0.5

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

ORGAN/TISSUE EXAMINED	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	----------MALE----------						----------FEMALE----------					
GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-
** FROM PREVIOUS PAGE **												
KIDNEY (KD) ..... NUMBER EXAMINED:	60	50	51	62	62	51	60	50	50	60	61	52
NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--NEPHROPATHY, CHRONIC PROGRESSIVE ->	0	1	0	2	0	0	7	3	2	6	6	1
1>	21	20	26	29	6	2	42	37	41	50	42	25
2>	34	28	21	28	40	32	10	8	7	4	13	24
3>	5	1	3	2	16	14	1	2	0	0	0	1
4>	0	0	1	1	0	2	0	0	0	0	0	0
5>	0	0	0	0	0	1	0	0	0	0	0	1
TL>	60	50	51	62	62	51	60	50	50	60	61	52
MN>	1.7	1.6	1.6	1.5	2.2	2.4	1.1	1.2	1.1	1.0	1.1	1.6
--TUBULE, MICROCONCRETION ->	0	0	0	3	0	1	1	2	1	2	3	1
1>	1	4	8	4	11	12	19	18	13	19	29	20
2>	59	45	43	55	51	38	40	30	36	39	29	31
4>	0	1	0	0	0	0	0	0	0	0	0	0
TL>	60	50	51	62	62	51	60	50	50	60	61	52
MN>	2.0	2.0	1.8	1.8	1.8	1.7	1.7	1.6	1.7	1.6	1.4	1.6
--TUBULE CELLS, PIGMENT ->	2	1	0	0	0	0	0	0	1	0	0	0
1>	53	39	36	31	0	7	41	36	38	40	0	15
2>	3	7	10	20	43	35	16	11	9	12	48	32
3>	1	2	2	3	17	2	2	2	1	6	11	4
4>	1	1	2	6	2	6	1	1	1	2	1	1
5>	0	0	1	2	0	1	0	0	0	0	1	0
TL>	60	50	51	62	62	51	60	50	50	60	61	52
MN>	1.1	1.3	1.5	1.8	2.3	2.2	1.4	1.4	1.3	1.5	2.3	1.8

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN/TISSUE EXAMINED	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
KIDNEY (KD)	NUMBER EXAMINED:	60	50	51	62	62	51	60	50	50	60	61	52
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--TUBULE, NECROSIS	->	59	50	50	61	61	51	60	50	50	59	60	51
	2>	0	0	0	0	1	0	0	0	0	0	1	0
	3>	1	0	1	1	0	0	0	0	0	1	0	1
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
	MN>	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1
--PAPILLA, NECROSIS	->	60	50	51	62	61	51	60	50	49	60	61	52
	P>	0	0	0	0	1	0	0	0	1	0	0	0
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
--PELVIS, DILATATION	->	60	50	51	61	61	51	59	50	49	60	59	52
	2>	0	0	0	1	0	0	1	0	0	0	1	0
	3>	0	0	0	0	1	0	0	0	0	0	1	0
	4>	0	0	0	0	0	0	0	0	1	0	0	0
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
	MN>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0
--PELVIS, INFLAMMATION	->	59	49	51	62	62	50	60	50	49	60	61	52
	2>	0	0	0	0	0	1	0	0	0	0	0	0
	3>	1	1	0	0	0	0	0	0	1	0	0	0
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
	MN>	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
--CONGESTION	->	54	43	43	57	57	48	56	49	49	56	59	49
	P>	6	7	8	5	5	3	4	1	1	4	2	3
	TL>	60	50	51	62	62	51	60	50	50	60	61	52

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN/TISSUE EXAMINED	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
KIDNEY (KD)	NUMBER EXAMINED:	60	50	51	62	62	51	60	50	50	60	61	52
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--CORTEX, DIFFUSE MINERALIZATION	->	60	50	51	62	61	51	60	49	50	60	61	52
	P>	0	0	0	0	1	0	0	1	0	0	0	0
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
--MICROCALCULI IN RENAL PELVIS	->	47	29	37	47	49	40	31	14	22	24	45	38
	P>	13	21	14	15	13	11	29	36	28	36	16	14
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
--TRANSITIONAL CELL HYPERPLASIA	->	52	42	43	54	51	48	45	21	25	30	42	36
	1>	0	0	0	0	0	0	0	0	1	0	0	0
	2>	8	8	7	8	10	3	15	29	24	30	19	16
	3>	0	0	1	0	1	0	0	0	0	0	0	0
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
	MN>	0.3	0.3	0.3	0.3	0.4	0.1	0.5	1.2	1.0	1.0	0.6	0.6
--CYST	->	60	49	50	62	62	49	60	50	48	60	61	50
	P>	0	1	1	0	0	2	0	0	2	0	0	2
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
--THROMBOSIS	->	59	50	51	62	62	51	60	50	50	60	61	52
	P>	1	0	0	0	0	0	0	0	0	0	0	0
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
--ARTERITIS	->	60	50	51	62	62	51	60	49	50	60	61	52
	P>	0	0	0	0	0	0	0	1	0	0	0	0
	TL>	60	50	51	62	62	51	60	50	50	60	61	52

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

ORGAN/TISSUE EXAMINED	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	MALE						FEMALE					
GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **												
KIDNEY (KD) ..... NUMBER EXAMINED:	60	50	51	62	62	51	60	50	50	60	61	52
NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--BACTERIAL COLONIES ->	60	49	50	61	59	51	60	50	49	60	61	50
P>	0	1	1	1	3	0	0	0	1	0	0	2
TL>	60	50	51	62	62	51	60	50	50	60	61	52
--INFLAMMATION, SUPPURATIVE ->	60	49	50	62	61	51	60	50	50	60	60	50
2>	0	0	0	0	1	0	0	0	0	0	1	2
3>	0	1	1	0	0	0	0	0	0	0	0	0
TL>	60	50	51	62	62	51	60	50	50	60	61	52
MN>	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
--TUBULE, SIMPLE HYPERPLASIA ->	59	50	51	62	62	51	60	50	50	60	61	52
1>	1	0	0	0	0	0	0	0	0	0	0	0
TL>	60	50	51	62	62	51	60	50	50	60	61	52
MN>	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
--M-MALIGNANT TUBULE CELL CARCINOMA ->	59	50	51	62	62	51	60	50	50	60	61	52
+>	1	0	0	0	0	0	0	0	0	0	0	0
TL>	60	50	51	62	62	51	60	50	50	60	61	52
--M-MALIGNANT MESENCHYMAL TUMOR ->	59	49	51	62	62	51	60	50	50	60	61	52
+>	1	1	0	0	0	0	0	0	0	0	0	0
TL>	60	50	51	62	62	51	60	50	50	60	61	52
--M-MALIGNANT NEPHROBLASTOMA ->	60	50	51	62	62	51	60	49	50	60	61	52
+>	0	0	0	0	0	0	0	1	0	0	0	0
TL>	60	50	51	62	62	51	60	50	50	60	61	52

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN/TISSUE EXAMINED	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
KIDNEY (KD)	NUMBER EXAMINED:	60	50	51	62	62	51	60	50	50	60	61	52
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA	->	60	50	50	62	62	51	60	50	50	60	60	52
	+>	0	0	1	0	0	0	0	0	0	0	1	0
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	->	54	44	41	48	52	38	56	45	44	50	55	44
	+>	6	6	10	14	10	13	4	5	6	10	6	8
	TL>	60	50	51	62	62	51	60	50	50	60	61	52
PITUITARY (PI)	NUMBER EXAMINED:	60	50	51	52	60	48	58	29	27	30	60	30
	NOT REMARKABLE:	15	14	16	17	10	6	12	3	2	3	18	2
--INCREASED CASTRATION CELLS	->	59	50	51	51	30	28	58	29	27	30	60	30
	1>	1	0	0	0	1	7	0	0	0	0	0	0
	2>	0	0	0	1	23	12	0	0	0	0	0	0
	3>	0	0	0	0	6	1	0	0	0	0	0	0
	TL>	60	50	51	52	60	48	58	29	27	30	60	30
	MN>	0.0	0.0	0.0	0.0	1.1	0.7	0.0	0.0	0.0	0.0	0.0	0.0
--CONGESTION/HEMORRHAGE	->	57	44	48	46	58	44	55	26	27	26	55	25
	P>	3	6	3	6	2	4	3	3	0	4	5	5
	TL>	60	50	51	52	60	48	58	29	27	30	60	30
--MICROCYST(S)	->	58	42	47	49	57	39	42	22	22	21	45	25
	P>	2	8	4	3	3	9	16	7	5	9	15	5
	TL>	60	50	51	52	60	48	58	29	27	30	60	30
--ANGIECTASIS/SINUSOID ECTASIA	->	38	32	34	36	40	33	34	6	6	6	35	8
	P>	22	18	17	16	20	15	24	23	21	24	25	22
	TL>	60	50	51	52	60	48	58	29	27	30	60	30

** CONTINUED ON NEXT PAGE **

TABLE 10D
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
EXPANDED HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=T

ORGAN/TISSUE EXAMINED		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	MALE						FEMALE					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
PITUITARY (PI)	NUMBER EXAMINED:	60	50	51	52	60	48	58	29	27	30	60	30
	NOT REMARKABLE:	15	14	16	17	10	6	12	3	2	3	18	2
--FOCAL HYPERTROPHY	->	49	45	45	45	44	33	55	28	26	30	57	28
	1>	3	4	0	2	1	1	1	0	0	0	1	0
	2>	8	1	6	5	10	13	1	1	1	0	2	2
	3>	0	0	0	0	5	1	1	0	0	0	0	0
	TL>	60	50	51	52	60	48	58	29	27	30	60	30
	MN>	0.3	0.1	0.2	0.2	0.6	0.6	0.1	0.1	0.1	0.0	0.1	0.1
--FOCAL HYPERPLASIA	->	50	45	48	47	51	37	47	25	26	26	56	27
	1>	3	0	1	3	1	2	2	0	0	0	0	0
	2>	6	3	2	2	7	7	7	2	1	3	4	2
	3>	1	2	0	0	1	2	2	2	0	1	0	1
	TL>	60	50	51	52	60	48	58	29	27	30	60	30
	MN>	0.3	0.2	0.1	0.1	0.3	0.5	0.4	0.3	0.1	0.3	0.1	0.2
--B-ADENOMA	->	37	30	29	34	42	33	33	11	8	16	40	12
	+>	23	20	22	18	18	15	25	18	19	14	20	18
	TL>	60	50	51	52	60	48	58	29	27	30	60	30
--M-CARCINOMA	->	60	50	51	52	60	47	57	27	25	28	59	29
	+>	0	0	0	0	0	1	1	2	2	2	1	1
	TL>	60	50	51	52	60	48	58	29	27	30	60	30
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	->	57	46	48	47	54	42	56	29	26	27	59	30
	+>	3	4	3	5	6	6	2	0	1	3	1	0
	TL>	60	50	51	52	60	48	58	29	27	30	60	30

** END OF LIST **

Table 10E
Histopathology Incidence Summary - All Deaths
Oncogenicity Study in Rats with Di(2-ethylhexyl)phthalate Including
Ancillary Hepatocellular Proliferation and Biochemical Analyses

Note: Dose levels were measured in ppm.

Key to Histopathology Incidence Summary

Symbols Prefacing Neoplastic Findings

B- = Primary, benign neoplasm
M- = Primary, malignant neoplasm
N- = Metastatic neoplasm
I- = Locally invasive neoplasm
X- = Other neoplasm (see Comment)

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	----------MALE----------						----------FEMALE----------					
GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** TOP OF LIST **												
LIVER (LI) ..... NUMBER EXAMINED:	80	50	55	65	80	55	80	50	55	65	80	55
NOT REMARKABLE:	3	0	0	0	0	0	2	0	0	0	0	0
--B-HEPATOCELLULAR ADENOMA	4	5	3	8	21	12	0	3	1	2	8	6
--M-HEPATOCELLULAR CARCINOMA	1	0	1	3	24	7	0	1	0	1	14	4
--LEUKEMIA ASSOCIATED HEPATOPATHY	8	8	12	25	16	20	9	10	7	12	11	14
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	15	13	16	32	27	29	15	17	11	16	17	18
--PIGMENT IN KUPFFER CELLS/HEPATOCYTES	0	0	0	1	44	11	0	0	0	1	24	3
--INCREASED CYTOPLASMIC EOSINOPHILIA	0	0	0	0	47	0	0	0	0	0	62	0
--DIFFUSE HEPATOCELLULAR ENLARGEMENT	0	0	0	1	45	1	0	0	0	1	58	2
--CONGESTION	4	7	5	8	6	5	2	3	1	4	3	3
--FOCAL HEMORRHAGE	2	1	1	1	3	0	0	0	0	2	1	0
--INFLAMMATION, CHRONIC	24	18	20	25	19	18	51	35	43	41	31	33
--FOCAL MONONUCLEAR INFILTRATION	12	3	0	3	18	2	14	0	0	0	10	0
--BILE DUCT, HYPERPLASIA	57	42	43	40	44	34	44	29	43	45	15	19
--BILE DUCT, INFLAMMATION, CHRONIC	56	42	43	39	48	32	49	34	44	48	35	36
--BILE DUCT, FIBROSIS	56	42	41	33	21	19	17	14	23	23	4	6
--CHOLANGIECTASIS	2	0	0	0	0	0	0	0	0	0	0	0
--CELLULAR ALTERATION, BASOPHILIC	55	38	42	30	25	26	46	37	42	28	6	12
--CELLULAR ALTERATION, EOSINOPHILIC	34	24	18	15	33	24	9	12	14	4	4	5
--FOCAL VACUOLIZATION	7	4	1	0	1	8	4	3	2	0	1	1
--CENTRILOBULAR TO MIDZONAL VACUOLIZATION	0	0	0	0	0	0	0	0	0	0	0	1
--DIFFUSE VACUOLIZATION	1	1	0	0	0	0	0	0	0	0	0	0
--INCREASED MITOTIC FIGURES	1	0	0	0	5	0	0	0	0	0	5	0
--INDIVIDUAL CELL DEGENERATION/NECROSIS	0	0	0	1	0	1	1	0	0	0	3	0
--FOCAL NECROSIS	3	2	5	3	9	6	5	4	2	8	5	1
--CENTRILOBULAR DEGENERATION/NECROSIS	0	1	0	1	0	0	0	1	0	3	1	3
--ARTIFACTUAL DISTORTION	1	1	1	0	0	0	1	0	0	0	0	0
--PROTRUSION OF HEPATIC PARENCHYMA (HERNIA)	3	1	2	3	0	1	1	2	1	3	3	0
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED	0	0	0	1	0	0	0	4	1	3	0	2
--SINUSOID ECTASIA/ANGIECTASIS	0	1	1	3	0	0	2	3	3	2	1	1
--SPONGIOSIS HEPATIS	3	3	3	11	11	3	0	0	0	1	1	1
--BILE DUCT, CYST	0	0	0	1	0	0	0	0	0	0	0	1

** CONTINUED ON NEXT PAGE **

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	----------MALE----------						----------FEMALE----------					
GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **												
LIVER (LI) ..... NUMBER EXAMINED:	80	50	55	65	80	55	80	50	55	65	80	55
NOT REMARKABLE:	3	0	0	0	0	0	2	0	0	0	0	0
--N-MESOTHELIOMA	0	1	1	0	0	0	0	0	0	0	1	0
--ARTERITIS/PERIARTERITIS	0	0	0	0	0	0	0	1	0	0	0	0
SPLEEN (SP) ..... NUMBER EXAMINED:	60	50	51	62	60	51	60	50	51	60	59	50
NOT REMARKABLE:	44	30	31	31	33	21	43	25	30	32	38	23
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	13	13	16	29	25	27	13	14	9	15	15	18
--CONTRACTED	0	0	2	0	0	0	0	0	0	0	1	1
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED	3	3	2	3	2	3	2	5	1	7	4	5
--FIBROSIS	2	1	0	2	0	2	0	0	2	0	0	1
--INFARCT	0	1	0	3	2	1	0	0	0	0	1	0
--N-MESOTHELIOMA	0	2	1	1	0	0	0	0	0	0	1	0
--HYPERPLASIA, RETICULOENDOTHELIAL	0	0	0	1	0	0	1	0	1	0	0	0
--INCREASED PIGMENT	0	1	0	0	0	0	2	6	9	6	1	3
--N-OSTEOSARCOMA	0	0	1	0	0	0	0	0	0	0	0	0
--M-HEMANGIOSARCOMA	0	0	0	0	0	0	1	0	0	0	0	0
--ACCESSORY SPLEEN TISSUE	0	0	0	0	0	0	0	0	0	0	0	1
KIDNEY (KD) ..... NUMBER EXAMINED:	60	50	51	62	62	51	60	50	50	60	61	52
NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--RENAL PAPILLA, MINERALIZATION	12	19	27	31	45	45	17	15	15	13	20	24
--NEPHROPATHY, CHRONIC PROGRESSIVE	60	49	51	60	62	51	53	47	48	54	55	51
--TUBULE, MICROCONCRETION	60	50	51	59	62	50	59	48	49	58	58	51
--TUBULE CELLS, PIGMENT	58	49	51	62	62	51	60	50	49	60	61	52
--TUBULE, NECROSIS	1	0	1	1	1	0	0	0	0	1	1	1
--PAPILLA, NECROSIS	0	0	0	0	1	0	0	0	1	0	0	0
--PELVIS, DILATATION	0	0	0	1	1	0	1	0	1	0	2	0
--PELVIS, INFLAMMATION	1	1	0	0	0	1	0	0	1	0	0	0
--CONGESTION	6	7	8	5	5	3	4	1	1	4	2	3

** CONTINUED ON NEXT PAGE **

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	----------MALE----------						----------FEMALE----------					
GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-
** FROM PREVIOUS PAGE **												
KIDNEY (KD) ..... NUMBER EXAMINED:	60	50	51	62	62	51	60	50	50	60	61	52
NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--CORTEX, DIFFUSE MINERALIZATION	0	0	0	0	1	0	0	1	0	0	0	0
--MICROCALCULI IN RENAL PELVIS	13	21	14	15	13	11	29	36	28	36	16	14
--TRANSITIONAL CELL HYPERPLASIA	8	8	8	8	11	3	15	29	25	30	19	16
--CYST	0	1	1	0	0	2	0	0	2	0	0	2
--THROMBOSIS	1	0	0	0	0	0	0	0	0	0	0	0
--ARTERITIS	0	0	0	0	0	0	0	1	0	0	0	0
--BACTERIAL COLONIES	0	1	1	1	3	0	0	0	1	0	0	2
--INFLAMMATION, SUPPURATIVE	0	1	1	0	1	0	0	0	0	0	1	2
--TUBULE, SIMPLE HYPERPLASIA	1	0	0	0	0	0	0	0	0	0	0	0
--M-MALIGNANT TUBULE CELL CARCINOMA	1	0	0	0	0	0	0	0	0	0	0	0
--M-MALIGNANT MESENCHYMAL TUMOR	1	1	0	0	0	0	0	0	0	0	0	0
--M-MALIGNANT NEPHROBLASTOMA	0	0	0	0	0	0	0	1	0	0	0	0
--N-MESOTHELIOMA	0	0	1	0	0	0	0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	6	6	10	14	10	13	4	5	6	10	6	8
TESTIS (TE) ..... NUMBER EXAMINED:	64	50	55	65	64	53	0	0	0	0	0	0
NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--UNILATERALLY EXAMINED	0	0	0	0	1	0	0	0	0	0	0	0
--HYPERPLASIA, INTERSTITIAL CELL	14	7	7	16	4	0	0	0	0	0	0	0
--B-BENIGN INTERSTITIAL CELL TUMOR	59	45	50	60	20	17	0	0	0	0	0	0
--HYPOSPERMIA, UNILATERAL	13	8	5	6	0	0	0	0	0	0	0	0
--HYPOSPERMIA, BILATERAL	3	4	5	5	0	0	0	0	0	0	0	0
--ASPERMATOGENESIS, UNILATERAL	13	7	8	4	1	0	0	0	0	0	0	0
--ASPERMATOGENESIS, BILATERAL	37	34	43	48	62	53	0	0	0	0	0	0
--ARTERITIS/PERIARTERITIS	2	0	0	1	7	11	0	0	0	0	0	0
--NECROSIS	0	0	1	0	0	0	0	0	0	0	0	0
--I-HEMANGIOSARCOMA	0	0	0	1	0	0	0	0	0	0	0	0
--M-MESOTHELIOMA	3	2	2	2	3	2	0	0	0	0	0	0
--N-OSTEOSARCOMA	0	0	1	0	0	0	0	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	MALE						FEMALE					
GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **												
TESTIS (TE) ..... NUMBER EXAMINED:	64	50	55	65	64	53	0	0	0	0	0	0
NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	2	1	2	3	2	0	0	0	0	0	0	0
EPIDIDYMIS (EP) ..... NUMBER EXAMINED:	64	50	55	64	63	52	0	0	0	0	0	0
NOT REMARKABLE:	7	4	0	1	0	0	0	0	0	0	0	0
--UNILATERALLY EXAMINED	0	0	0	0	1	0	0	0	0	0	0	0
--IMMATURE/ABNORMAL SPERM FORMS	14	11	9	13	0	0	0	0	0	0	0	0
--HYPOSPERMIA	50	44	52	52	63	52	0	0	0	0	0	0
--INFLAMMATION, CHRONIC	1	0	0	0	0	0	0	0	0	0	0	0
--ARTERITIS/PERIARTERITIS	0	1	0	0	0	0	0	0	0	0	0	0
--N-OSTEOSARCOMA	0	0	1	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA	1	1	2	1	2	2	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	2	1	1	0	0	0	0	0	0	0	0	0
UTERUS (UT) ..... NUMBER EXAMINED:	0	0	0	0	0	0	60	50	52	61	60	53
NOT REMARKABLE:	0	0	0	0	0	0	26	15	15	18	16	18
--DILATATION	0	0	0	0	0	0	19	30	27	33	29	24
--HYPERPLASIA, CYSTIC ENDOMETRIAL	0	0	0	0	0	0	25	13	26	20	21	24
--THROMBOSIS	0	0	0	0	0	0	0	0	0	0	1	0
--INFLAMMATION, SUPPURATIVE	0	0	0	0	0	0	0	1	1	0	0	0
--FOCAL GLANDULAR HYPERPLASIA	0	0	0	0	0	0	0	0	0	0	1	0
--DECIDUOMA	0	0	0	0	0	0	0	0	0	0	1	0
--B-ENDOMETRIAL STROMAL POLYP	0	0	0	0	0	0	6	13	13	11	15	10
--M-CARCINOMA	0	0	0	0	0	0	0	2	1	1	0	0
--M-ENDOMETRIAL STROMAL SARCOMA	0	0	0	0	0	0	0	0	0	0	0	2
--M-LEIOMYOSARCOMA	0	0	0	0	0	0	1	0	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	0	0	0	0	0	0	2	1	1	4	2	0

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
BRAIN W/STEM (BR)	NUMBER EXAMINED:	60	17	14	19	60	16	60	12	14	14	60	21
	NOT REMARKABLE:	53	7	6	8	48	9	47	3	6	9	47	10
--CONGESTION		0	2	1	0	1	0	0	0	0	1	1	1
--FOCAL HEMORRHAGE		4	2	3	4	5	3	2	1	2	1	2	6
--ENCEPHALOMALACIA		0	1	0	0	0	0	0	0	0	0	1	0
--FOCAL GLIOSIS		0	0	0	0	0	0	1	0	0	0	0	0
--COMPRESSION, VENTRAL		3	5	4	5	3	4	7	8	4	4	9	6
--VENTRICLE, DILATATION		0	1	1	1	0	2	3	5	0	0	4	2
--COMPRESSION, DORSAL		0	0	0	0	1	0	0	0	0	0	0	0
--M-MALIGNANT ASTROCYTOMA		0	1	0	0	0	0	1	0	0	0	0	0
--I-PITUITARY CARCINOMA		0	0	0	0	0	1	1	2	2	2	1	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		4	3	4	6	8	3	2	1	3	1	1	3
CORD, CERVICAL (CS)	NUMBER EXAMINED:	60	15	12	17	60	15	60	7	10	13	60	17
	NOT REMARKABLE:	58	13	11	13	57	12	60	7	9	13	59	17
--HEMORRHAGE		2	1	1	3	1	2	0	0	1	0	0	0
--GLIOSIS		0	0	0	0	0	1	0	0	0	0	0	0
--FOCAL MALACIA		0	0	0	0	0	0	0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	2	1	4	3	2	0	0	1	0	0	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	60	15	12	17	60	15	60	7	10	13	60	17
	NOT REMARKABLE:	58	14	12	15	57	14	60	7	10	13	60	16
--HEMORRHAGE		2	0	0	0	1	0	0	0	0	0	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	0	2	3	1	0	0	0	0	0	1
CORD, LUMBAR (LC)	NUMBER EXAMINED:	60	15	12	17	60	15	59	7	10	13	60	17
	NOT REMARKABLE:	58	14	12	15	56	14	58	7	9	13	60	17
--HEMORRHAGE		1	0	0	1	1	1	0	0	0	0	0	0
--EPIDERMAL INCLUSION CYST		0	0	0	0	1	0	1	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
CORD, LUMBAR (LC)	NUMBER EXAMINED:	60	15	12	17	60	15	59	7	10	13	60	17
	NOT REMARKABLE:	58	14	12	15	56	14	58	7	9	13	60	17
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	1	0	2	3	1	0	0	1	0	0	0
PITUITARY (PI)	NUMBER EXAMINED:	60	50	51	52	60	48	58	29	27	30	60	30
	NOT REMARKABLE:	15	14	16	17	10	6	12	3	2	3	18	2
--INCREASED CASTRATION CELLS		1	0	0	1	30	20	0	0	0	0	0	0
--CONGESTION/HEMORRHAGE		3	6	3	6	2	4	3	3	0	4	5	5
--MICROCYST(S)		2	8	4	3	3	9	16	7	5	9	15	5
--ANGIECTASIS/SINUSOID ECTASIA		22	18	17	16	20	15	24	23	21	24	25	22
--FOCAL HYPERTROPHY		11	5	6	7	16	15	3	1	1	0	3	2
--FOCAL HYPERPLASIA		10	5	3	5	9	11	11	4	1	4	4	3
--B-ADENOMA		23	20	22	18	18	15	25	18	19	14	20	18
--M-CARCINOMA		0	0	0	0	0	1	1	2	2	2	1	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		3	4	3	5	6	6	2	0	1	3	1	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	60	16	15	18	61	15	60	9	12	14	60	17
	NOT REMARKABLE:	24	1	2	2	19	1	13	2	0	2	15	3
--UNILATERALLY EXAMINED		0	1	1	0	0	0	0	0	0	0	0	0
--CONGESTION		8	7	7	6	6	5	5	3	6	7	10	9
--ANGIECTASIS/SINUSOID ECTASIA		5	0	1	1	2	1	24	3	8	6	33	4
--FOCAL HYPERTROPHY		17	4	2	0	13	2	24	3	6	3	10	1
--FOCAL VACUOLIZATION		24	4	3	3	20	6	27	4	6	2	13	2
--DIFFUSE VACUOLIZATION		1	6	3	5	12	10	1	1	4	3	2	7
--NECROSIS		0	0	0	1	1	0	0	0	1	1	0	1
--ATROPHY, UNILATERAL		0	0	0	0	0	0	0	1	0	0	0	0
--FOCAL HYPERPLASIA		6	0	2	0	5	0	7	0	0	0	4	0
--CYST		0	0	0	0	2	0	0	0	0	0	0	0
--THROMBOSIS		0	0	0	0	0	0	0	0	1	0	2	0
--N-MESOTHELIOMA		0	0	0	0	0	0	0	0	0	0	1	0

** CONTINUED ON NEXT PAGE **

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
		-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-	-=-
** FROM PREVIOUS PAGE **													
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	60	16	15	18	61	15	60	9	12	14	60	17
	NOT REMARKABLE:	24	1	2	2	19	1	13	2	0	2	15	3
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		7	6	5	12	12	8	4	3	6	7	8	6
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	60	16	15	18	61	15	60	10	12	14	60	17
	NOT REMARKABLE:	34	7	7	8	44	7	57	10	6	11	57	10
--UNILATERALLY EXAMINED		0	1	1	0	1	0	0	0	0	0	1	0
--HYPERPLASIA		21	5	3	5	7	5	1	0	2	0	2	3
--B-BENIGN PHEOCHROMOCYTOMA		4	1	1	0	3	2	1	0	1	1	1	0
--M-MALIGNANT PHEOCHROMOCYTOMA		1	0	0	0	0	0	0	0	0	1	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	4	3	5	6	4	1	0	4	1	0	3
THYROID (TY)	NUMBER EXAMINED:	60	15	12	17	60	16	59	10	10	13	59	19
	NOT REMARKABLE:	24	4	5	8	26	5	14	4	2	8	23	8
--CONGESTION		3	4	3	2	4	3	1	0	0	1	2	1
--HEMORRHAGE		1	0	0	0	0	0	0	0	0	0	0	0
--FOLLICLE, CYST		2	1	0	0	1	1	2	0	0	0	5	0
--HYPERPLASIA, "C" CELL		24	3	2	4	17	7	38	5	6	4	29	8
--B-"C" CELL ADENOMA		8	2	1	2	9	1	5	0	2	0	4	1
--M-"C" CELL CARCINOMA		1	1	1	0	1	0	2	1	0	0	0	1
--B-FOLLICULAR CELL ADENOMA		1	0	0	1	5	1	0	0	0	0	1	0
--M-FOLLICULAR CELL CARCINOMA		0	0	0	0	0	1	0	0	0	0	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	1	3	1	0	0	1	0	0	0
PARATHYROID (PT)	NUMBER EXAMINED:	59	15	10	17	59	16	59	9	10	12	58	18
	NOT REMARKABLE:	59	15	10	17	59	16	59	9	10	12	57	18
--B-ADENOMA		0	0	0	0	0	0	0	0	0	0	1	0

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
ESOPHAGUS (ES)	NUMBER EXAMINED:	60	15	12	17	60	15	59	8	10	13	60	17
	NOT REMARKABLE:	60	15	12	17	60	15	59	8	10	13	59	17
--INFLAMMATION, CHRONIC		0	0	0	0	0	0	0	0	0	0	1	0
TRACHEA (TR)	NUMBER EXAMINED:	60	15	12	17	60	15	59	8	10	13	60	17
	NOT REMARKABLE:	60	15	12	17	59	15	59	8	10	13	60	16
--INFLAMMATION, CHRONIC		0	0	0	0	1	0	0	0	0	0	0	0
--INFLAMMATION, ACUTE		0	0	0	0	0	0	0	0	0	0	0	1
LUNG (LU)	NUMBER EXAMINED:	60	15	13	20	60	21	60	8	10	15	60	17
	NOT REMARKABLE:	0	0	0	0	2	0	1	1	0	0	1	0
--CONGESTION		5	6	6	8	5	7	2	1	1	5	4	3
--HEMORRHAGE		0	0	0	2	1	1	2	0	1	2	0	0
--PERIBRONCHIAL/PERIVASCULAR, INFILTRATION, LYMPHOID		58	12	12	15	54	16	58	5	9	12	49	12
--MINERALIZATION		0	0	0	0	1	0	0	0	0	0	0	0
--ALVEOLUS, MACROPHAGES, VACUOLATED		1	3	0	1	3	2	4	1	1	4	14	1
--LEUKOCYTOSIS		0	3	1	2	0	0	0	0	1	1	1	1
--FOCAL PNEUMONITIS		2	1	1	2	1	2	3	1	0	1	4	0
--DIFFUSE PNEUMONITIS		0	0	0	0	1	1	0	0	0	0	1	3
--ALVEOLUS/BRONCHUS EPITHELIAL HYPERPLASIA		0	0	0	0	1	0	0	0	0	2	0	0
--B-ALVEOLAR/BRONCHIOLAR ADENOMA		1	0	0	0	0	0	1	0	0	0	0	0
--M-ALVEOLAR/BRONCHIOLAR CARCINOMA		2	0	0	0	0	0	0	0	0	0	0	0
--N-OSTEOSARCOMA		0	0	0	0	1	0	0	0	0	0	0	1
--N-"C" CELL CARCINOMA		1	0	0	0	1	0	0	0	0	0	0	0
--N-NEPHROBLASTOMA		0	0	0	0	0	0	0	1	0	0	0	0
--N-RENAL TUBULE CELL CARCINOMA		1	0	0	0	0	0	0	0	0	0	0	0
--N-HEPATOCELLULAR CARCINOMA		0	0	0	0	0	1	0	0	0	0	0	0
--N-MESOTHELIOMA		0	0	0	0	0	0	0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		14	7	7	16	26	14	12	3	6	8	14	9

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	--- NUMBER-OF-ANIMALS-AFFECTED ---											
SEX:	MALE						FEMALE					
GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
HEART (HT) NUMBER EXAMINED:	60	15	12	17	60	16	59	8	10	13	60	17
NOT REMARKABLE:	1	0	0	1	3	0	6	1	0	1	10	2
--CARDIOMYOPATHY, DEGENERATIVE	58	13	10	15	57	15	51	6	8	12	50	11
--VALVE, THROMBOSIS	0	1	1	3	2	1	0	0	1	1	0	0
--ATRIUM, THROMBOSIS	0	3	0	1	0	3	1	0	1	2	0	3
--INFLAMMATION, SUPPURATIVE	0	1	2	2	2	0	0	0	1	0	1	2
--MINERALIZATION OF CORONARY ARTERIES	1	0	0	0	2	2	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	5	3	3	8	9	7	4	1	4	5	3	4
STOMACH, NONGL (SU) NUMBER EXAMINED:	60	16	14	17	60	16	60	10	10	17	60	17
NOT REMARKABLE:	57	14	9	14	55	7	54	10	6	11	56	12
--HYPERPLASIA	3	2	4	3	2	5	6	0	3	5	4	4
--EROSION	0	1	2	0	1	2	1	0	1	0	1	0
--ULCER	0	0	1	1	1	4	0	0	1	4	1	3
--EDEMA	0	0	1	1	1	3	0	0	0	5	3	2
--MINERALIZATION	0	0	0	0	2	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	1	0	1	0	0	1	0	0	1	1	2	0
STOMACH, GL (ST) NUMBER EXAMINED:	60	16	14	17	60	16	60	10	10	17	60	17
NOT REMARKABLE:	52	6	8	8	45	9	55	6	3	7	47	6
--CONGESTION	0	1	1	0	0	0	0	0	0	1	0	0
--FOCAL HEMORRHAGE	2	0	0	2	0	1	2	0	0	3	0	1
--EROSION	4	7	4	9	12	5	5	4	5	9	11	9
--ULCER	1	0	0	0	0	2	0	0	0	1	1	3
--EDEMA	0	0	0	1	1	0	1	0	2	2	1	1
--MINERALIZATION	0	0	1	0	2	0	0	0	0	0	0	1
--INFLAMMATION, SUPPURATIVE	0	1	1	0	0	0	0	0	0	0	0	0
--ARTERITIS/PERIARTERITIS	0	1	0	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)	3	1	1	1	2	1	2	0	2	3	2	0

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
DUODENUM (DU)	NUMBER EXAMINED:	79	15	19	22	80	20	80	8	15	18	80	21
	NOT REMARKABLE:	77	15	18	21	78	18	79	8	14	17	78	21
--INFLAMMATION, CHRONIC		0	0	1	0	0	0	0	0	0	0	0	0
--EROSION		0	0	0	0	1	1	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	0	0	1	1	2	1	0	1	1	2	0
JEJUNUM (JE)	NUMBER EXAMINED:	60	15	11	18	60	14	60	8	10	13	60	17
	NOT REMARKABLE:	58	14	11	15	59	12	59	8	9	13	60	17
--M-LEIOMYOSARCOMA		0	1	0	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA		0	0	0	1	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	0	0	2	1	2	1	0	1	0	0	0
ILEUM (IL)	NUMBER EXAMINED:	60	15	13	18	60	15	60	8	10	13	59	17
	NOT REMARKABLE:	57	14	12	16	59	13	60	8	10	10	58	17
--INTUSSUSCEPTION		0	0	1	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA		0	0	0	1	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		3	1	0	1	1	2	0	0	0	3	1	0
PANCREAS (PA)	NUMBER EXAMINED:	60	17	14	18	59	15	60	7	10	14	60	17
	NOT REMARKABLE:	27	7	8	10	25	3	32	6	4	7	35	12
--EDEMA		0	2	0	1	0	4	4	0	1	4	3	3
--INFLAMMATION, CHRONIC		16	1	0	1	9	1	13	0	3	1	9	0
--FOCAL ACINAR ATROPHY		17	2	1	2	7	5	12	0	1	0	5	2
--BASOPHILIC FOCUS		0	0	0	0	5	0	1	0	1	0	6	0
--ECTOPIC SPLENIC TISSUE		1	0	0	0	0	0	0	0	0	0	0	0
--MICROCYST(S)		0	0	0	0	1	0	0	0	0	0	0	0
--ISLET CELL, HYPERPLASIA		1	0	0	0	1	0	0	0	0	0	0	0
--B-ISLET CELL ADENOMA		3	0	0	1	5	1	1	0	0	0	0	0
--M-ISLET CELL CARCINOMA		0	0	1	0	0	1	0	0	1	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
PANCREAS (PA)	NUMBER EXAMINED:	60	17	14	18	59	15	60	7	10	14	60	17
	NOT REMARKABLE:	27	7	8	10	25	3	32	6	4	7	35	12
--FOCAL ACINAR CELL HYPERPLASIA		1	1	0	0	9	2	0	0	0	0	1	0
--B-ACINAR CELL ADENOMA		0	0	0	0	5	0	0	0	0	0	2	0
--M-ACINAR CELL CARCINOMA		0	0	0	0	0	0	0	0	0	0	1	0
--N-NEPHROBLASTOMA		0	0	0	0	0	0	0	1	0	0	0	0
--N-RENAL TUBULE CARCINOMA		1	0	0	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA		0	2	1	1	0	0	0	0	0	0	1	0
--N-OSTEOSARCOMA		0	0	1	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		3	3	2	2	6	1	1	0	2	3	2	1
CECUM (CE)	NUMBER EXAMINED:	60	15	13	17	59	15	60	8	10	13	60	17
	NOT REMARKABLE:	57	12	10	11	54	8	56	7	7	10	57	14
--CONGESTION		0	1	2	0	1	1	0	0	0	1	0	0
--HEMORRHAGE		0	0	0	2	1	0	0	0	0	1	0	0
--EDEMA		0	1	1	2	2	3	2	1	3	2	2	3
--NEMATODE PARASITE(S)		1	1	0	1	1	0	1	0	0	0	1	0
--INFLAMMATION, ACUTE		0	2	2	0	1	0	2	0	2	0	0	1
--M-LEIOMYOSARCOMA		0	0	0	0	0	1	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	0	0	1	0	2	0	0	1	3	0	0
COLON (CO)	NUMBER EXAMINED:	60	15	13	17	59	15	60	8	10	13	59	17
	NOT REMARKABLE:	52	13	10	14	53	11	52	8	9	10	53	15
--NEMATODE PARASITE(S)		7	0	2	1	5	0	8	0	1	3	5	1
--INFLAMMATION, ACUTE		0	1	0	0	0	0	0	0	0	0	0	0
--EDEMA		0	0	0	1	0	2	0	0	0	0	0	1
--ULCERATION		0	0	1	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	0	1	1	2	0	0	0	1	1	0

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
RECTUM (RE)	NUMBER EXAMINED:	60	15	12	17	59	15	60	8	10	13	60	17
	NOT REMARKABLE:	43	15	11	14	51	14	55	7	10	13	52	17
--NEMATODE PARASITE(S)		16	0	1	2	8	1	5	1	0	0	7	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	1	0	0	0	0	0	0	1	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	59	14	12	18	58	15	60	8	10	15	60	17
	NOT REMARKABLE:	51	4	5	11	49	8	53	5	5	8	45	11
--CONGESTION		1	1	1	0	1	3	3	1	1	2	4	5
--FIBROSIS		1	1	0	0	0	0	0	0	0	0	1	0
--LYMPHANGIECTASIS		1	1	0	1	0	1	0	0	0	1	0	1
--HYPERPLASIA, LYMPHORETICULAR		0	1	0	0	0	2	1	0	1	0	5	0
--N-OSTEOSARCOMA		0	0	1	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		6	6	5	6	8	4	5	2	4	7	6	3
PROSTATE (PR)	NUMBER EXAMINED:	59	15	12	17	60	15	0	0	0	0	0	0
	NOT REMARKABLE:	21	3	0	7	17	6	0	0	0	0	0	0
--INFLAMMATION, CHRONIC ACTIVE		36	12	11	10	39	9	0	0	0	0	0	0
--INFLAMMATION, ACUTE		0	0	0	0	2	0	0	0	0	0	0	0
--HEMORRHAGE		0	0	0	0	1	0	0	0	0	0	0	0
--EDEMA		0	1	0	0	0	0	0	0	0	0	0	0
--HYPERPLASIA		1	2	0	0	3	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	1	1	2	1	0	0	0	0	0	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	61	40	42	42	61	25	0	0	0	0	0	0
	NOT REMARKABLE:	21	4	3	3	33	3	0	0	0	0	0	0
--DECREASED SECRETION		39	34	39	39	26	21	0	0	0	0	0	0
--HEMORRHAGE		0	0	0	0	1	0	0	0	0	0	0	0
--INFLAMMATION, ACUTE		0	0	0	0	1	0	0	0	0	0	0	0
--INCREASED SECRETION		0	1	0	0	0	0	0	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	61	40	42	42	61	25	0	0	0	0	0	0
	NOT REMARKABLE:	21	4	3	3	33	3	0	0	0	0	0	0
--FOCAL HYPERPLASIA		0	1	0	0	0	0	0	0	0	0	0	0
--N-OSTEOSARCOMA		0	0	1	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA		0	0	1	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	5	1	1	3	2	0	0	0	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	59	15	12	17	60	15	60	8	10	13	60	17
	NOT REMARKABLE:	57	12	11	16	56	13	58	8	8	12	59	17
--HEMORRHAGE		0	0	0	1	1	1	0	0	0	0	0	0
--MINERALIZATION		0	0	0	0	1	0	0	0	0	0	0	0
--INFLAMMATION, ACUTE		0	0	0	0	1	1	0	0	0	0	0	0
--INFLAMMATION, CHRONIC		0	0	0	0	1	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC ACTIVE		0	1	0	0	0	0	0	0	0	0	0	0
--HYPERPLASIA		0	1	0	0	0	0	0	0	0	0	0	0
--M-TRANSITIONAL CELL CARCINOMA		0	0	0	0	0	0	0	0	1	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	2	1	1	2	2	2	0	1	1	1	0
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	0	0	60	11	13	20	60	23
	NOT REMARKABLE:	0	0	0	0	0	0	23	3	3	4	29	9
--CONGESTION		0	0	0	0	0	0	1	1	1	3	3	1
--MEDULLARY TUBULE HYPERPLASIA		0	0	0	0	0	0	28	5	8	8	18	8
--FOLLICLE, CYST		0	0	0	0	0	0	5	2	2	1	1	1
--BURSA, CYST		0	0	0	0	0	0	3	1	1	5	5	2
--INFLAMMATION, CHRONIC		0	0	0	0	0	0	1	0	0	1	3	1
--ABSCESS		0	0	0	0	0	0	0	0	0	0	0	1
--B-BENIGN GRANULOSA/THECA CELL TUMOR		0	0	0	0	0	0	2	1	0	0	1	0
--N-MESOTHELIOMA		0	0	0	0	0	0	0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	4	1	3	5	5	3

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	0	0	60	14	14	17	60	20
	NOT REMARKABLE:	0	0	0	0	0	0	58	12	14	14	54	18
--FIBROSIS		0	0	0	0	0	0	1	0	0	0	1	0
--B-LEIOMYOMA		0	0	0	0	0	0	0	0	0	0	1	0
--M-MALIGNANT SCHWANNOMA		0	0	0	0	0	0	0	1	0	1	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	2	1	0	2	3	2
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	0	0	60	9	12	13	60	17
	NOT REMARKABLE:	0	0	0	0	0	0	59	9	11	12	58	17
--HEMORRHAGE		0	0	0	0	0	0	0	0	1	0	0	0
--PROLAPSE		0	0	0	0	0	0	0	0	0	1	0	0
--I-MALIGNANT SCHWANNOMA		0	0	0	0	0	0	0	0	0	0	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	1	0	0	0	1	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	60	15	12	17	59	15	60	8	10	13	60	16
	NOT REMARKABLE:	59	15	11	17	58	13	59	8	10	12	58	16
--EDEMA		0	0	0	0	1	1	0	0	0	1	0	0
--INFLAMMATION, CHRONIC		0	0	0	0	0	0	0	0	0	0	1	0
--M-SCHWANNOMA		0	0	1	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	0	0	1	1	0	0	0	1	0
THYMUS (TH)	NUMBER EXAMINED:	51	14	10	14	46	13	48	7	8	14	41	12
	NOT REMARKABLE:	38	7	6	8	34	6	36	4	5	5	35	8
--CONGESTION		3	3	3	3	5	4	2	0	0	3	2	2
--HEMORRHAGE		0	0	0	0	1	0	0	0	0	0	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		6	5	2	4	6	5	3	3	3	6	2	1
--HYPERPLASIA, LYMPHORETICULAR		0	0	0	0	1	0	0	0	0	0	0	0
--MICROCYST(S)		5	1	0	0	2	0	9	1	1	0	3	1

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
AORTA, THORACIC (AO)	NUMBER EXAMINED:	60	15	12	17	59	15	60	8	10	13	60	17
	NOT REMARKABLE:	59	13	11	16	55	15	59	7	10	12	58	16
--MEDIA, MINERALIZATION		0	0	0	0	2	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	2	1	1	2	0	1	1	0	1	2	1
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	60	15	12	17	59	15	59	8	10	13	60	17
	NOT REMARKABLE:	55	14	10	16	52	14	57	8	9	13	55	17
--DEGENERATION		5	1	2	1	7	1	2	0	1	0	5	0
^DEATH COMMENT (DC)	NUMBER EXAMINED:	85	70	70	85	85	55	85	70	70	85	85	55
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--SCHEDULED SACRIFICE		75	55	58	68	70	40	75	62	60	72	70	38
--MONONUCLEAR CELL LEUKEMIA		8	7	6	13	12	9	5	3	6	7	7	9
--PITUITARY NEOPLASM		1	3	2	2	0	3	4	4	1	3	3	2
--MAMMARY FIBROADENOMA		0	0	0	0	0	0	0	0	2	0	1	0
--HEPATOCELLULAR NEOPLASM		0	0	0	0	1	0	0	0	0	0	0	0
--ISLET CELL CARCINOMA		0	0	0	0	0	1	0	0	0	0	0	0
--PHEOCHROMOCYTOMA		0	0	0	0	0	0	0	0	0	0	0	1
--ASTROCYTOMA		0	1	0	0	0	0	1	0	0	0	0	0
--RENAL CARCINOMA		1	0	0	0	0	0	0	0	0	0	0	0
--NEPHROBLASTOMA		0	0	0	0	0	0	0	1	0	0	0	0
--RENAL MESENCHYMAL TUMOR		0	1	0	0	0	0	0	0	0	0	0	0
--TRANSITIONAL CELL CARCINOMA		0	0	0	0	0	0	0	0	1	0	0	0
--FIBROSARCOMA		0	0	1	0	0	0	0	0	0	0	0	0
--LEIOMYOSARCOMA		0	1	0	0	0	1	0	0	0	0	0	0
--HEMANGIOSARCOMA		0	0	0	1	0	0	0	0	0	0	0	0
--MESOTHELIOMA		0	0	0	0	0	0	0	0	0	0	1	0
--OSTEOSARCOMA		0	0	1	0	0	0	0	0	0	0	0	1
--SCHWANNOMA		0	0	1	0	0	0	0	0	0	1	1	0
--ENDOMETRIAL STROMAL SARCOMA		0	0	0	0	0	0	0	0	0	0	0	1

** CONTINUED ON NEXT PAGE **

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
^DEATH COMMENT (DC)	NUMBER EXAMINED:	85	70	70	85	85	55	85	70	70	85	85	55
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--UTERINE CARCINOMA		0	0	0	0	0	0	0	0	0	1	0	0
--SQUAMOUS CELL CARCINOMA		0	1	0	1	0	0	0	0	0	0	0	0
--ZYMBAL'S GLAND CARCINOMA		0	0	0	0	0	1	0	0	0	0	0	0
--SEPTICEMIA		0	0	0	0	0	0	0	0	0	0	0	1
--GENITOURINARY INFLAMMATION		0	0	0	0	1	0	0	0	0	0	0	0
--VAGINAL PROLAPSE		0	0	0	0	0	0	0	0	0	1	0	0
--TRAUMA		0	0	0	0	0	0	0	0	0	0	1	0
--NERVE DEGENERATION (RADICULONEUROPATHY)		0	0	1	0	0	0	0	0	0	0	0	0
--ATRIAL THROMBOSIS		0	1	0	0	0	0	0	0	0	0	0	1
--ACCIDENTAL		0	1	0	1	0	0	0	1	0	1	0	0
--UNDETERMINED		0	0	0	0	1	0	0	0	0	0	1	1
HEMATO NEOPLASIA (HN)	NUMBER EXAMINED:	65	50	55	65	65	55	65	50	55	65	65	55
	NOT REMARKABLE:	50	37	39	33	37	26	50	33	44	49	48	37
--M-MALIGNANT LEUKEMIA, MONONUCLEAR CELL		15	13	16	32	27	29	14	17	11	16	17	18
--M-HISTIOCYTIC SARCOMA		0	0	0	0	1	0	1	0	0	0	0	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	16	16	13	15	11	12	2	2	4	2	7	5
	NOT REMARKABLE:	0	2	1	1	0	1	0	0	1	0	0	0
--TAIL-CHRONIC ACTIVE INFLAMMATION		12	7	8	11	11	8	0	1	1	1	5	4
--FOOT/PAW-PODODERMATITIS		3	1	2	0	0	0	0	0	0	0	0	0
--M-FIBROSARCOMA		1	0	0	0	0	0	1	1	0	0	0	0
--TAIL-NECROSIS		2	0	1	1	0	0	0	0	0	1	2	0
--B-KERATOACANTHOMA		0	1	0	0	0	0	0	0	0	0	0	1
--EPIDERMAL CYST		1	0	0	1	0	0	0	0	1	0	0	0
--B-BASAL CELL ADENOMA		1	0	0	0	0	0	0	0	0	0	0	0
--B-SQUAMOUS CELL PAPILLOMA		0	1	0	1	0	1	0	0	0	0	0	0
--M-SQUAMOUS CELL CARCINOMA		0	1	0	1	0	0	0	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
SKIN, OTHER (SS)	NUMBER EXAMINED:	16	16	13	15	11	12	2	2	4	2	7	5
	NOT REMARKABLE:	0	2	1	1	0	1	0	0	1	0	0	0
--INFLAMMATION, CHRONIC ACTIVE		0	1	1	0	0	1	0	0	0	0	0	0
--ACANTHOSIS		0	1	1	0	0	1	0	0	0	0	0	0
--M-SCHWANNOMA		0	1	0	0	0	0	0	0	0	0	0	0
--ULCER		0	0	0	0	0	1	0	0	0	0	0	0
--M-BASAL CELL CARCINOMA		0	0	0	0	0	0	1	0	1	0	0	0
--ABSCESS		0	0	0	0	0	0	0	0	0	1	0	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	0	1	3	1	0	1	1	0	1	1	2	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--HYPERPLASIA, LYMPHORETICULAR		0	0	0	0	0	0	0	0	0	1	1	0
--N-SCHWANNOMA		0	0	1	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	1	2	1	0	1	1	0	1	0	1	0
LN, OTHER (LN)	NUMBER EXAMINED:	5	5	2	1	6	5	4	0	3	4	3	1
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--CONGESTION		0	1	1	0	2	3	2	0	0	1	0	1
--HYPERPLASIA, LYMPHORETICULAR		0	0	0	0	0	0	0	0	1	0	0	0
--N-RENAL TUBULE CARCINOMA		1	0	0	0	0	0	0	0	0	0	0	0
--N-OSTEOSARCOMA		0	0	1	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		4	4	1	1	6	5	4	0	2	4	3	1
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	3	0	3	2	3	4	1	0	0	2	1	1
	NOT REMARKABLE:	0	0	0	1	0	0	0	0	0	0	0	0
--HEMORRHAGE		0	0	0	0	1	0	0	0	0	0	0	0
--EDEMA		0	0	0	0	0	0	0	0	0	1	0	0
--ABSCESS		1	0	0	0	0	0	0	0	0	0	0	0
--B-LIPOMA		0	0	0	0	1	0	0	0	0	0	1	0

** CONTINUED ON NEXT PAGE **

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	MALE						FEMALE					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
** FROM PREVIOUS PAGE **													
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	3	0	3	2	3	4	1	0	0	2	1	1
	NOT REMARKABLE:	0	0	0	1	0	0	0	0	0	0	0	0
--B-FIBROMA		2	0	1	0	0	3	0	0	0	0	0	0
--M-FIBROSARCOMA		0	0	1	0	0	1	0	0	0	0	0	0
--M-HEMANGIOSARCOMA		0	0	0	1	0	0	0	0	0	0	0	0
--M-OSTEOSARCOMA		0	0	0	0	0	0	0	0	0	0	0	1
--N-SCHWANNOMA		0	0	1	0	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	2	0	1	0	0	2	0	0
EYE (EY)	NUMBER EXAMINED:	6	9	10	8	7	12	6	7	11	10	5	11
	NOT REMARKABLE:	1	0	0	0	0	0	0	0	0	0	0	0
--UNILATERALLY EXAMINED		0	0	0	1	0	0	0	0	0	0	0	0
--GLOBE RUPTURED, UNILATERAL		0	0	3	0	1	1	0	1	1	0	3	1
--HEMORRHAGE		0	0	0	0	0	0	0	0	0	1	0	0
--KERATITIS		0	2	2	0	3	8	2	0	2	0	0	4
--HYPOPYON		0	0	0	1	0	1	0	0	0	0	0	0
--CORNEA, MINERALIZATION		2	6	6	5	4	10	4	4	9	5	3	9
--SCLERA, MINERALIZATION		3	6	9	5	2	5	1	6	6	3	1	4
--LENS, DEGENERATION		5	8	6	7	5	10	6	2	5	6	1	8
--RETINA, DEGENERATION		5	7	7	7	5	9	6	2	5	6	1	9
--PANOPHTHALMITIS, UNILATERAL		0	0	1	0	0	0	0	1	0	0	2	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	0	0	0	0	0	1
PENIS (PE)	NUMBER EXAMINED:	1	1	0	0	2	1	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	2	0	0	0	0	0	0	0
--INFLAMMATION, ACUTE		1	1	0	0	0	1	0	0	0	0	0	0

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	2	5	3	3	4	1	3	1	0	4	3	1
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--CIRCUMSCRIBED FAT NECROSIS		0	1	0	2	1	0	0	0	0	2	0	0
--INFLAMMATION, CHRONIC ACTIVE		0	1	0	0	0	0	0	0	0	0	0	0
--FIBROUS ADHESIONS		0	0	0	0	0	0	2	0	0	0	0	0
--MINERALIZATION OF MESENTERIC ARTERIES		0	0	0	0	1	0	0	0	0	0	0	0
--M-OSTEOSARCOMA		0	0	1	0	0	0	0	0	0	0	0	0
--M-MESOTHELIOMA		0	0	0	0	0	0	0	0	0	0	1	0
--N-NEPHROBLASTOMA		0	1	0	0	0	0	0	1	0	0	0	0
--N-MESOTHELIOMA		1	1	1	1	2	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	1	2	1	1	1	0	0	3	2	1
BONE, OTHER (OB)	NUMBER EXAMINED:	0	1	0	0	1	0	0	1	0	0	1	1
	NOT REMARKABLE:	0	0	0	0	0	0	0	1	0	0	0	1
--FRACTURE		0	1	0	0	0	0	0	0	0	0	1	0
--M-OSTEOSARCOMA		0	0	0	0	1	0	0	0	0	0	0	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	4	1	2	3	1	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	1	2	0	0	0	0	0	0	0	0	0
--GALACTOCELE		2	0	0	2	0	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC		1	0	0	0	0	0	0	0	0	0	0	0
--ACTIVE MAMMARY TISSUE		0	0	0	1	0	0	0	0	0	0	0	0
--B-FIBROADENOMA		2	0	0	1	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0	0	0	0	0
SCROTUM (SC)	NUMBER EXAMINED:	0	2	0	1	1	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--N-MESOTHELIOMA		0	2	0	1	1	0	0	0	0	0	0	0

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
PREPUTIAL GLAND (PG)	NUMBER EXAMINED:	1	0	1	0	0	1	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC ACTIVE		1	0	0	0	0	1	0	0	0	0	0	0
--B-ADENOMA		0	0	0	0	0	1	0	0	0	0	0	0
--M-CARCINOMA		0	0	1	0	0	0	0	0	0	0	0	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	0	0	0	1	0	1	0	2	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--M-ZYMBAL'S GLAND CARCINOMA		0	0	0	1	0	1	0	1	0	0	0	0
--M-SQUAMOUS CELL CARCINOMA		0	0	0	0	0	0	0	1	0	0	0	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	0	0	5	12	10	10	3	4
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	1	1	1
--GALACTOCELE		0	0	0	0	0	0	4	7	4	1	0	0
--INFLAMMATION, CHRONIC		0	0	0	0	0	0	2	1	0	0	0	0
--ACTIVE MAMMARY TISSUE		0	0	0	0	0	0	1	6	4	0	0	1
--HYPERPLASIA		0	0	0	0	0	0	1	0	0	0	0	0
--B-FIBROADENOMA		0	0	0	0	0	0	0	3	5	7	2	2
--M-CARCINOMA		0	0	0	0	0	0	0	1	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	0	1	0	0	0	0	0
CLITORAL GLAND (CL)	NUMBER EXAMINED:	0	0	0	0	0	0	3	0	1	1	0	1
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--ABSCESS		0	0	0	0	0	0	2	0	0	0	0	0
--B-ADENOMA		0	0	0	0	0	0	0	0	1	0	0	0
--M-CARCINOMA		0	0	0	0	0	0	1	0	0	1	0	1

TABLE 10E
ONCOGENICITY STUDY IN RATS WITH DI(2-ETHYLHEXYL)PHTHALATE
(NECROPSY/PATHOLOGY)
HISTOPATHOLOGY INCIDENCE SUMMARY

TABLE INCLUDES:
SEX=ALL;GROUP=1,2,3,4,5,6;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---											
	SEX:	----------MALE----------						----------FEMALE----------					
	GROUP:	-1-	-2-	-3-	-4-	-5-	-6-	-1-	-2-	-3-	-4-	-5-	-6-
ORGAN AND FINDING DESCRIPTION	NUMBER:	85	70	70	85	85	55	85	70	70	85	85	55
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	0	0	0	1
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--N-OSTEOSARCOMA		0	0	0	0	0	0	0	0	0	0	0	1
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0	1	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC ACTIVE		0	0	0	0	0	0	0	0	1	0	0	0

** END OF LIST **

TRIAGE of 8(e) Submissions

Date sent to triage: 3/4/97

NON-CAP CAP

Submission number: 13805A

TSCA Inventory: Y N D

STUDY TYPE (circle appropriate):

Ernest Falke (E605C)
ATOX SBTOX SEN CARC

Gordon Cash (E425)
ECO AQUATO

Katherine Anitole (E613B)
RTOX/DTOX

Daljit Sawhney (E611A)
CTOX STOX

Deborah Norris (E606)
NEUR

Elizabeth Margosches (E613C)
EPI

Michael Cimino (E611D)
GTOX

Leonard Keifer (E611C)
Metabolism/Pharmacokinetics

OTHER: _____

NOTES:

CECATS\TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA:
Submission # 8EHQ: 1196-13805 SEQ. A

TYPE: (INT.) SUPP FLWP

SUBMITTER NAME:
Eastman Chemical Co.

INFORMATION REQUESTED: FLWP DATE:
0501 NO INFO REQUESTED
0502 INFO REQUESTED (TECH)
0503 INFO REQUESTED (VOL ACTIONS)
0504 INFO REQUESTED (REPORTING RATIONALE)

DISPOSITION:
(0639) REFER TO CHEMICAL SCREENING
0678 CAP NOTICE

VOLUNTARY ACTIONS:
(0401) NO ACTION REPORTED
0402 STUDIES PLANNED/UNDERWAY
0403 NOTIFICATION OF WORKERS/USERS
0404 LABEL/MSDS CHANGES
0405 PROCESS/HANDLING CHANGES
0406 APP/USE DISCONTINUED
0407 PRODUCTION DISCONTINUED
0408 CONFIDENTIAL

SUB. DATE: 11-18-96 OTS DATE: 11-22-96 CSRAD DATE: 1-27-97

CHEMICAL NAME: CAS#
1,2-benzenedicarboxylic acid, bis(2-ethylhexyl) ester 117-81-7
(DOP)
(DEHP)

INFORMATION TYPE:		P F C	INFORMATION TYPE:		P F C	INFORMATION TYPE:		P F C
0201	ONCO (HUMAN)	01 02 04	0216	EPI/CLIN	01 02 04	0241	IMMUNO (ANIMAL)	01 02 04
(0202)	ONCO (ANIMAL)	01 (02) 04	0217	HUMAN EXPOS (PROD CONTAM)	01 02 04	0242	IMMUNO (HUMAN)	01 02 04
0203	CELL TRANS (IN VITRO)	01 02 04	0218	HUMAN EXPOS (ACCIDENTAL)	01 02 04	0243	CHEM/PHYS PROP	01 02 04
0204	MUTA (IN VITRO)	01 02 04	0219	HUMAN EXPOS (MONITORING)	01 02 04	0244	CLASTO (IN VITRO)	01 02 04
0205	MUTA (IN VIVO)	01 02 04	0220	ECO/AQUA TOX	01 02 04	0245	CLASTO (ANIMAL)	01 02 04
0206	REPRO/TERATO (HUMAN)	01 02 04	0221	ENV. OCCC/REL/FATE	01 02 04	0246	CLASTO (HUMAN)	01 02 04
0207	REPRO/TERATO (ANIMAL)	01 02 04	0222	EMER INCI OF ENV CONTAM	01 02 04	0247	DNA DAM/REPAIR	01 02 04
0208	NEURO (HUMAN)	01 02 04	0223	RESPONSE REQEST DELAY	01 02 04	0248	PROD/USE/PROC	01 02 04
0209	NEURO (ANIMAL)	01 02 04	0224	PROD/COMP/CHEM ID	01 02 04	0251	MSDS	01 02 04
0210	ACUTE TOX. (HUMAN)	01 02 04	0225	REPORTING RATIONALE	01 02 04	0299	OTHER	01 02 04
0211	CHR. TOX. (HUMAN)	01 02 04	0226	CONFIDENTIAL	01 02 04			
0212	ACUTE TOX. (ANIMAL)	01 02 04	0227	ALLERG (HUMAN)	01 02 04			
0213	SUB ACUTE TOX (ANIMAL)	01 02 04	0228	ALLERG (ANIMAL)	01 02 04			
0214	SUB CHRONIC TOX (ANIMAL)	01 02 04	0239	METAB/PHARMACO (ANIMAL)	01 02 04			
(0215)	CHRONIC TOX (ANIMAL)	01 (02) 04	0240	METAB/PHARMACO (HUMAN)	01 02 04			

TRIAGE DATA:	NON-CBI INVENTORY	ONGOING REVIEW	SPECIES	TOXICOLOGICAL CONCERN:	USE:	PRODUCTION
CAS SR	(YES)	YES (DROP/REFER)	Rat	(LOW)	—	
	NO	NO (CONTINUE)		MED		
	DETERMINI	REFER		HIGH		

COMMENTS

"13805A"="L"="CARCINOGENITY IN F-344 RATS BY THE ORAL ROUTE IS OF LOW CONCERN. DEHP WAS ADMINISTERED DAILY TO MALES AND FEMALES IN THE DIET FOR AT LEAST 104 WEEKS AT CONCENTRATIONS OF 0, 100, 500, 2500, OR 12500 PPM (0, 5.8, 28.9, 146.6, OR 789.0 MG/KG/DAY FOR MALES OR 0, 7.3, 36.1, 181.7, OR 938.5 MG/KG/DAY FOR FEMALES). A RECOVERY GROUP WAS ADMINISTERED 679.3 MG/KG (MALES) OR 808.2 MG/KG (FEMALES) FOR 78 WEEKS FOLLOWED BY A 26 WEEK RECOVERY PERIOD DURING WHICH THEY WERE FED THE BASAL DIET ALONE. STATISTICAL EVALUATION REVEALED NO DIFFERENCE IN SURVIVAL BETWEEN TREATED AND CONTROL RATS. TOTAL INCIDENCES OF RATS WITH HEPATOCELLULAR ADENOMAS AND/OR CARCINOMAS WERE 6, 10, 7, 17, AND 43% IN MALES AT 0, 5.8, 28.9, 146.6, AND 789 MG/KG, RESPECTIVELY, AND 0,8, 0, 5, AND 26% IN FEMALES AT 0, 7.3, 36.1, 181.7, AND 938.5 MG/KG, RESPECTIVELY. NO STATISTICAL ANALYSIS OF INCIDENCE WAS AVAILABLE. CARCINOGENIC EFFECTS WERE OBSERVED ONLY IN THE LIVER. OTHER TREATMENT-RELATED EFFECTS IN THE LIVER INCLUDED SIGNIFICANTLY INCREASED ABSOLUTE AND RELATIVE WEIGHT; INCREASED INCIDENCES OF SPONGIOSIS HEPATIS, PIGMENTED KUPFFER CELLS, DIFFUSE HEPATOCELLULAR ENLARGEMENT, AND CYTOPLASMIC EOSINOPHILIA; AND SUSTAINED INCREASES IN PERIOXISOME PROLIFERATION. A 6 MONTH CESSATION OF DEHP RESULTED IN REVERSAL OF HEPATOMEGALY, NO DETECTABLE LEVELS OF PEROXISOMAL PROLIFERATION, AND DECREASED NEOPLASMS. ABSOLUTE AND RELATIVE KIDNEY WEIGHTS AS WELL AS THE INCIDENCE AND SEVERITY OF MINERALIZATION OF RENAL PAPILLA AND PIGMENTED RENAL TUBULE CELLS WERE INCREASED; THERE WAS NO INDICATION THAT THESE CHANGES WERE REVERSIBLE UPON CESSATION OF TEST SUBSTANCE. DECREASED ABSOLUTE AND RELATIVE TESTES WEIGHTS, INCREASED INCIDENCES OF BILATERAL ASPERMATOGENESIS, AND DECREASED INCIDENCES OF INTERSTITIAL CELL NEOPLASMS WERE OBSERVED AND DID NOT SEEM REVERSIBLE. INCREASED INCIDENCES OF MONOCELLULAR LEUKEMIA IN MALES AT 146.6 AND 789 MG/KG AND INCREASED PITUITARY CASTRATION CELLS AT 789 MG/KG WERE CONSIDERED TO BE TREATMENT RELATED."